

Exercise-Induced Bronchoconstriction and Asthma

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. HHS-2007-10021-I

Prepared by:

University of Alberta Evidence-based Practice Center, Edmonton, AB, Canada

Investigators

Donna M. Dryden, Ph.D.
Carol H. Spooner, B.Sc.N., M.Sc.
Michael K. Stickland, Ph.D.
Ben Vandermeer, M.Sc.
Lisa Tjosvold, B.A., M.L.I.S.
Liza Bialy, B.Sc.
Kai Wong, B.Sc.
Brian H. Rowe, M.D., M.Sc., C.C.F.P. (E.M.)

AHRQ Publication No. 10-E001
January 2010 (Web site posting)
Revised March 2010

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Suggested Citation:

Dryden DM, Spooner CH, Stickland MK, Vandermeer B, Tjosvold L, Bialy L, Wong K, Rowe BH. Exercise-Induced Bronchoconstriction and Asthma. Evidence Report/Technology Assessment No. 189 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021-I) AHRQ Publication No. 10-E001. Rockville, MD: Agency for Healthcare Research and Quality. January 2010 (Web site posting); revised March 2010.

No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in this report.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.

We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to epc@ahrq.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Beth A. Collins Sharp, R.N., Ph.D.
Director, EPC Program
Agency for Healthcare Research and Quality

Capt. Karen Lohmann Siegel, P.T., M.A.
EPC Program Task Order Officer
Agency for Healthcare Research and Quality

Acknowledgments

We are grateful to members of the technical expert panel, Dr. Louis-Philippe Boulet (Université Laval, Sainte-Foy, QC), Dr. Robert Cowie (University of Calgary, AB), Dr. Andrew Gregory (Vanderbilt University Medical Center, Nashville, TN), Dr. Cynthia LaBella (Children's Memorial Hospital, Chicago, IL), Dr. Darcy Marciniuk (University of Saskatoon, SK), Dr. Kenneth Rundell (Marywood University, Scranton, PA), Dr. John Weiler (American Academy of Asthma Allergy and Immunology) and Karen Siegel (Agency for Healthcare Research and Quality), who provided direction for the scope and content of the review. We thank the Cochrane Airways Group for their assistance and providing access to their database of articles. We also thank all the individuals at AHRQ, the Scientific Resource Center, and the peer reviewers for their comments and suggestions.

We thank Jennifer Seida for her work in developing the protocol, Mohammad Karkhaneh and Kate O'Gorman for assistance with data extraction and preparation of the appendices, Ken Bond for copyediting, and Simon Bow and Annabritt Chisholm for their assistance with literature retrieval.

Structured Abstract

Objectives: The objectives are: (1) to assess diagnostic test characteristics of six alternative index tests compared with the selected reference standard—a standardized exercise challenge test (ECT) in patients with suspected exercise-induced bronchoconstriction or asthma (EIB/EIA); (2) to determine the efficacy of a single prophylactic dose of four pharmacologic and one nonpharmacologic interventions versus placebo to attenuate EIB/EIA in patients with diagnosed EIB/EIA; and (3) to determine if regular daily treatment with short-acting or long-acting beta-agonists (SABA or LABA) causes patients with EIA to develop tachyphylaxis when additional prophylactic doses are used pre-exercise.

Data Sources: A systematic and comprehensive literature search was conducted in 14 electronic databases (Diagnosis) and the Cochrane Airways Register (Therapy).

Review Methods: Study selection, quality assessment, and data extraction were conducted independently by two reviewers. The primary outcome was the maximum percent fall in the post-exercise forced expiratory volume in 1 second (percent fall FEV₁). The diagnostic threshold for a positive ECT was a percent fall FEV₁ of 10 percent or more. Sensitivity (SN) and specificity (SP) were calculated. For therapy, mean differences (MD) in the percent fall FEV₁ and 95 percent confidence intervals (CI) (random effects model) were calculated. A positive MD indicates the intervention works better than the control.

Results: For the diagnostic reviews, 5,318 citations yielded 28 relevant studies; for the therapy reviews, 1,634 citations yielded 109 relevant RCTs

Diagnostic test results versus ECT: self-reported history (2 studies) SN=36–89 percent, SP=85–86 percent; methacholine challenge (16 studies) SN=0–100 percent, SP=0–100 percent; sport specific challenges (5 studies) SN=0–100 percent, SP=0–100 percent; eucapnic voluntary hyperpnea (7 studies) SN=25–90 percent, SP=0–71 percent; free running asthma screening test (3 studies) SN=60–67 percent, SP=47–67 percent; mannitol (3 studies) SN=58–96 percent, SP=65–78 percent. All SN and SP calculations indicated substantial heterogeneity that could not be explained by sensitivity or subgroup analyses.

Therapy results: SABA offered greater protection than mast cell stabilizers (MCS) (12 studies); MD=6.8 (95 percent CI: 4.5, 9.2) but combining them offered no additional benefit; SABA versus MCS plus SABA (5 studies) MD=1.3 (95 percent CI: -6.3, 8.9). Leukotriene receptor antagonists (LTRA), MCS, ipratropium bromide, and interval warmup routines provided statistically significant attenuation of EIA when compared with placebo; inhaled corticosteroids (ICS) and other warmup routines did not. Single-dose intervention versus placebo results are: LTRA (9 studies) MD=8.9 (95 percent CI: 6.9, 11.0); MCS (nedocromil sodium) (17 studies) MD=15.6 (95 percent CI: 13.2, 18.2); interval warmup versus no warmup (4 studies) MD=10.6 (95 percent CI: 6.5, 14.7); ICS (4 studies) MD=5.0 (95 percent CI: 0.0, 9.9); continuous low intensity warmup versus no warmup (3 studies) MD=12.6 (95 percent CI: -1.5, 26.7); continuous high intensity warmup versus no warmup (2 studies) MD=9.8 (95 percent CI: -6.4, 26.0).

After daily LABA (salmeterol) use for 3 to 4 weeks (4 studies), the percent fall FEV₁ following an ECT at 2 and 4 weeks was greater than at day 1 in the LABA arm indicating that tachyphylaxis to prophylactic LABA use occurred. Daily SABA use for 1 week (1 study) also

indicated development of tachyphylaxis. However, both LABA and SABA continued to have an attenuating effect on EIA.

Conclusions: Given the small number of studies comparing EIB/EIA diagnostic tests, the heterogeneity of the study populations, and the varied study methodologies, there is no clear evidence that any of the index tests are a suitable replacement for a standardized ECT to diagnose EIB/EIA in the general population.

All bronchodilator agents and most anti-inflammatory agents when used as pre-treatment are somewhat effective in attenuating the percent fall FEV₁ associated with EIA. There is evidence that the protective effect of LABA and SABA decreases with the daily use of these drugs. There is no evidence of an attenuating benefit following single-dose pre-treatment with ICS. There is a role for LTRA and MCS; however, the attenuation appears less than with bronchodilator agents. Finally, pre-exercise interval warmup appears to be effective in attenuating the FEV₁ falls associated with EIA.

UPDATE: The following section was added on 3/15/2010:

On February 18, 2010 the Food and Drug Administration issued a drug safety communication requiring changes to use of Long-Acting Beta-Agonists (LABAs) in the treatment of asthma. These changes are based on FDA's analyses of studies showing an increased risk of severe exacerbation of asthma symptoms in some patients using LABAs for the treatment of asthma. The FDA cautioned that LABAs should only be used long-term in patients whose asthma cannot be adequately controlled on asthma controller medications and then, LABAs should be used only in combination with these other medications.

The Exercise-Induced Bronchoconstriction and Asthma (EIB/EIA) Evidence Report was conducted prior to the FDA warning and focused on studies that examined whether individuals using LABAs develop a tolerance (tachyphylaxis) to long term regular use of the drugs. The evidence suggests that the protective effect of LABA drugs decrease if they are used daily rather than “as needed” before exercising. These conclusions reflect a different focus than the FDA analysis; however, the conclusions for EIB/EIA do not conflict with the FDA concerns about daily use of LABAs.

Contents

Executive Summary.....	1
Evidence Report.....	21
Chapter 1. Introduction.....	23
What is Exercise-Induced Bronchoconstriction and Asthma?.....	23
Magnitude and Importance of the Condition.....	25
Diagnosis of Exercise-Induced Bronchoconstriction and Asthma.....	26
Treatment of Exercise-Induced Bronchoconstriction and Asthma.....	27
Objective of this Evidence Report.....	27
The Key Questions.....	28
Chapter 2. Methods.....	29
Literature Search and Retrieval.....	29
Study Selection.....	30
Assessment of Methodological Quality.....	31
Grading the Body of Evidence.....	32
Data Extraction.....	32
Data Analysis.....	32
Diagnostic Test Accuracy Review.....	33
Therapy Review.....	33
Peer Review.....	33
Chapter 3. Results.....	35
Diagnostic Test Accuracy Review.....	35
Literature Search.....	35
Key Question D–1: Self-Reported History or Symptoms Diary.....	37
Description of Included Studies.....	37
Methodological Quality of the Included Studies.....	37
Quantitative Results.....	37
Key Question D–2: Methacholine Challenge.....	40
Description of Included Studies.....	40
Methodological Quality of Included Studies.....	40
Quantitative Results.....	40
Key Question D–3: Sport or Venue Specific Exercise Challenges.....	51
Description of Included Studies.....	51
Methodological Quality of the Included Studies.....	52
Quantitative Results.....	52
Key Question D–4: Eucapnic Voluntary Hyperpnea.....	56
Description of Included Studies.....	56
Methodological Quality of Included Studies.....	56
Quantitative Results.....	56
Key Question D–5: Free Running Asthma Screening Test.....	63
Description of Included Studies.....	63

Methodological Quality of the Included Studies	63
Quantitative Results	63
Key Question D–6: Mannitol Challenge.....	67
Description of Included Studies.....	67
Methodological Quality of Included Studies	67
Quantitative Results	67
Therapy Review	72
Literature Search.....	72
Key Question T–1: Tachyphylaxis to Short-Acting or Long-Acting Beta-Agonists.....	74
Description of Included Studies.....	74
Methodological Quality of Included Studies	74
Quantitative Results: SABA	74
Quantitative Results: LABA	76
Key Question T–2: Leukotriene Receptor Antagonist Therapy	87
Description of Included Studies.....	87
Methodological Quality of Included Studies	87
Quantitative Results	87
Key Question T–3: Inhaled Corticosteroid Therapy.....	95
Description of Included Studies.....	95
Methodological Quality of Included Studies	95
Quantitative Results	95
Key Question T–4: Mast Cell Stabilizers	99
Background.....	99
NCS versus Placebo Review.....	99
NCS versus SCG Review.....	100
MCS to Prevent EIA Review	102
Key Question T–5: Anticholinergic Agents	107
Description of Included Studies.....	107
Methodological Quality of Included Studies	107
Quantitative Results	107
Key Question T–6: Refractory Period (10 to 15 Minute Warmup and/or Cooldown).....	118
Description of Included Studies.....	118
Methodological Quality of Included Studies	118
Quantitative Results	118
Chapter 4. Discussion	127
Diagnostic Test Accuracy Review.....	127
Limitations	133
Conclusions.....	133
Therapy Review	135
Pharmacologic Interventions	137
Bronchodilating Agents	137
Anti-inflammatory Agents.....	138
Nonpharmacologic Interventions.....	140
Limitations	141
Conclusions.....	142

Reccomendations for Future Research	143
References and Included Studies	145
Abbreviations	152

Tables

Table 1. Summary of sensitivity and specificity for the diagnostic test accuracy review	20
Table 2. Prophylactic therapy for EIA: Pulmonary function results	21
Table 3. Factors that may influence the severity of EIB/EIA.....	24
Table 4. Inclusion and exclusion criteria for the diagnostic test accuracy review	30
Table 5. Inclusion and exclusion criteria for the therapy review.....	31
Table 6. Description of studies in the diagnostic test accuracy review: Self-report vs. ECT.....	38
Table 7. Description of participants in the diagnostic test accuracy review: Self-report vs. ECT	38
Table 8. Methodological quality of the studies in the diagnostic test accuracy review: Self-report vs. ECT	39
Table 9. Description of studies in the diagnostic test accuracy review: Methacholine vs. ECT ..	44
Table 10. Description of participants in the diagnostic test accuracy review: Methacholine vs. ECT	47
Table 11. Methodological quality of studies in the diagnostic test accuracy review: Methacholine vs. ECT	50
Table 12. Description of studies in the diagnostic test accuracy review: Sport specific vs. ECT.....	53
Table 13. Description of participants in the diagnostic test accuracy review: Sport specific vs. ECT	54
Table 14. Methodological quality of studies in the diagnostic test accuracy review: Sport specific vs. ECT	55
Table 15. Description of studies in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT.....	59
Table 16. Description of participants in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT	61
Table 17. Methodological quality of studies in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT	62
Table 18. Description of studies in the diagnostic test accuracy review: FRAST vs. ECT.....	65
Table 19. Description of participants in the diagnostic test accuracy review: FRAST vs. ECT ..	66
Table 20. Methodological quality of studies in the diagnostic test accuracy review: FRAST vs. ECT	66
Table 21. Description of studies in the diagnostic test accuracy review: Mannitol vs. ECT	69
Table 22. Description of participants in the diagnostic test accuracy review: Mannitol vs. ECT	70
Table 23. Methodological quality of studies in the diagnostic test accuracy review: Mannitol vs. ECT	71
Table 24a. Description of trials in the therapy review: Tachyphylaxis to LABA	81
Table 24b. Description of trials in the therapy review: Tachyphylaxis to SABA	83

Table 25a. Baseline characteristics of patients in trials in the therapy review: Tachyphylaxis to LABA.....	84
Table 25b. Baseline characteristics of patients in trials in the therapy review: Tachyphylaxis to SABA.....	85
Table 26. Quality assessment of trials in the therapy review: Tachyphylaxis to LABA and SABA.....	86
Table 27. Description of trials in the therapy review: LTRA.....	90
Table 28. Baseline characteristics of patients in trials in the therapy review: LTRA.....	93
Table 29. Quality assessment of trials in the therapy review: LTRA.....	94
Table 30. Description of trials in the therapy review: Inhaled corticosteroids.....	97
Table 31. Baseline characteristics of patients in trials in the therapy review: Inhaled corticosteroids.....	98
Table 32. Quality assessment of trials in the therapy review: Inhaled corticosteroids.....	98
Table 33. Description of trials included in the Cochrane reviews of mast cell stabilizers.....	104
Table 34. Baseline characteristics of patients in trials included in the Cochrane reviews of mast cell stabilizers.....	106
Table 35. Description of trials in the therapy review: Anticholinergic therapy.....	111
Table 36. Baseline characteristics of patients in trials in the therapy review: Anticholinergic therapy.....	115
Table 37. Quality assessment of trials in the therapy review: Anticholinergic therapy.....	117
Table 38. Description of trials in the therapy review: Refractory period.....	121
Table 39. Baseline characteristics of patients in trials in the therapy review: Refractory period.....	124
Table 40. Quality assessment of trials in the therapy review: Refractory period.....	125
Table 41. Summary of sensitivity and specificity for the diagnostic test accuracy review.....	132
Table 42. Prophylactic therapy for EIA: Pulmonary function results.....	136

Figures

Figure 1. Diagnosis of EIB/EIA: Flow diagram for study retrieval and selection.....	36
Figure 2. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT (PC ₂₀ MCH less than 8 mg/ml; FEV ₁ fall index 10 percent or more for ECT).....	41
Figure 3. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT (PC ₂₀ MCH less than 16 mg/ml; FEV ₁ fall index 10 percent or more for ECT).....	41
Figure 4. ROC curve plotting sensitivity vs. specificity: Methacholine challenge vs. ECT (PC ₂₀ MCH less than 8 mg/ml; FEV ₁ fall index 10 percent or more for ECT).....	42
Figure 5. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT in studies in which all patients had asthma (PC ₂₀ MCH less than 8 mg/ml; FEV ₁ fall index 10 percent or more for ECT).....	42
Figure 6. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT in studies in which less than 50 percent of patients had asthma (PC ₂₀ MCH less than 8mg/ml; FEV ₁ fall index 10 percent or more for ECT).....	43
Figure 7. Forest plot of sensitivity and specificity: Sport specific challenges vs. ECT (FEV ₁ fall index 10 percent or more).....	52
Figure 8. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (participants with no history of EIB/EIA; FEV ₁ fall index 10 percent or more for ECT and EVH).....	57

Figure 9. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (participants with a history of EIB/EIA; FEV ₁ fall index 10 percent or more for ECT and EVH).....	57
Figure 10. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (all participants; threshold for a positive test is a FEV ₁ fall index 10 percent or more for ECT and 15 percent or more for EVH).....	58
Figure 11. Forest plot of sensitivity and specificity: FRAST vs. ECT (FEV ₁ fall index $\geq 10\%$)..	64
Figure 12. Forest plot of sensitivity and specificity: Mannitol vs. ECT (FEV ₁ fall index $\geq 10\%$ for ECT and $\geq 15\%$ for mannitol).....	68
Figure 13. Therapy for EIB/EIA: Flow diagram for study retrieval and selection.....	73
Figure 14. Effectiveness of LABA vs. placebo: Change from day 1 to week 3–4 weeks after the first ECT (MD in the maximum percent fall FEV ₁).....	77
Figure 15. Effects over time of LABA and placebo on the maximum percent fall in FEV ₁ for the first ECT.....	78
Figure 16. Effectiveness of LABA vs. placebo: Change from day 1 after the second ECT (MD in the maximum percent fall FEV ₁).....	79
Figure 17. Effectiveness of LABA vs. LTRA: Change from day 1 to week 8 (MD in the maximum percent fall FEV ₁).....	80
Figure 18. LTRA vs. placebo in pre-exercise treatment of EIB/EIA: Maximum decrease in FEV ₁	88
Figure 19. LTRA vs. placebo in pre-exercise treatment of EIB/EIA: Achievement of complete protection (maximum percent fall FEV ₁ is less than 10 percent).....	89
Figure 20. Inhaled corticosteroids vs. placebo in pre-exercise treatment of EIA: MD in maximum percent fall in FEV ₁ or peak expiratory flow.....	96
Figure 21. Ipratropium vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV ₁ or peak expiratory flow.....	108
Figure 22. Atropine vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV ₁ or peak expiratory flow.....	108
Figure 23. Oxitropium vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV ₁ or peak expiratory flow.....	108
Figure 24. Ipratropium vs. placebo in pre-exercise treatment of EIA: Achievement of complete protection (maximum fall FEV ₁ less than 10 percent).....	109
Figure 25. Oxitropium bromide vs. placebo in pre-exercise treatment of EIA: Achievement of complete protection (maximum fall FEV ₁ is less than 10 percent).....	109
Figure 26. Ipratropium vs. placebo in pre-exercise treatment of EIA: Achievement of clinical protection (50 percent or greater improvement over placebo in FEV ₁).....	110
Figure 27. Warmup vs. no warmup in pre-exercise treatment of EIB/EIA: maximum percent decrease in FEV ₁ or peak expiratory flow.....	120
Figure 28. Mean difference in the maximum percent decrease in FEV ₁ following ECT with prophylactic therapy relative to placebo.....	140

Appendixes

- Appendix A. Technical Expert Panel and Peer Reviewers
- Appendix B. Literature Search Strings
- Appendix C. Forms
- Appendix D. Excluded Studies
- Appendix E. Studies Investigating Mast Cell Stabilizing Agents

Appendixes cited in this report are provided electronically at
<http://www.ahrq.gov/downloads/pub/evidence/pdf/eibeia/eibeia.pdf>

Executive Summary

Introduction

Vigorous physical exercise can be followed by *transient* clinical signs and symptoms similar to an asthma attack and are due to post-exercise bronchoconstriction (i.e., a narrowing of the airways). Clinical symptoms include coughing, wheezing, shortness of breath, excessive mucus production, chest tightness, chest pain, or an ‘itching or scratching sensation’ in the chest. Though it is more common in people with asthma, it also occurs in people without asthma.

For the purposes of this evidence report, we defined exercise-induced bronchoconstriction (EIB) as “the airway obstruction that occurs in association with exercise without regard to the presence of chronic asthma”¹ and we defined exercise-induced asthma (EIA) as “the condition in which exercise induces symptoms of asthma in patients who have asthma.”¹ Research is ongoing to determine if the pathogenesis of the phenomenon is the same in non-asthmatics and asthmatics. In this report EIB and EIA were analyzed and discussed separately when the populations and data were specifically identified by authors of the primary studies as one or the other. When it was not clear or studies included patients with and without asthma, we referred to them as EIB/EIA.

The acute bronchoconstriction associated with EIB/EIA peaks rapidly, 3 to 15 minutes after exercise stops, then remits spontaneously within 20 to 60 minutes.² It does not cause a persistent deterioration in lung function. Following recovery, a refractory period of 40 minutes to 3 hours has been reported. During this time repeat exercise causes less bronchoconstriction.³

Two of the most common pulmonary function measures used to quantify the degree of bronchoconstriction are the forced expiratory volume in 1 second (FEV₁) and the peak expiratory flow (PEF), with FEV₁ considered the more reliable and valid. Both measures will decrease from baseline pre-exercise values in susceptible individuals. It is proposed that the increase in minute ventilation caused by vigorous exercise triggers the airway narrowing.^{3,4} Some episodes are severe enough that the person will require an inhaled bronchodilator agent to reverse the bronchoconstriction.

Approximately 20.5 million people in the United States (7 percent) have asthma.⁵ Between 60 and 90 percent of people with asthma experience EIA and consider exercise a major trigger of asthma symptoms.^{6,7} Prevalence of EIB is lower (6 to 13 percent) in populations with no history of asthma or allergy.^{8,9} Among elite athletes the prevalence is reported to range from 10 to 50 percent.⁷

The signs and symptoms of EIB/EIA often go unrecognized or are blamed on lack of conditioning. Some people will avoid exercise and some parents, teachers, and coaches of children with asthma may impose restrictions on which activities will be allowed.¹⁰ With a proper diagnosis and treatment, children and adults have successfully competed at all levels of physical activity.

Key Questions

The objective of this report was to synthesize the evidence for six key questions on diagnostic test accuracy for EIB/EIA and six key questions on therapy for EIB/EIA (five involving pharmaceutical interventions and one on a nonpharmacologic intervention).

- D-1. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a self-reported history/symptoms diary for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-2. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a methacholine challenge (MCH) for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-3. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of sport/venue specific exercise challenges for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-4. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of eucapnic voluntary hyperpnea (EVH) for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-5. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a free running asthma screening test (FRAST) for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-6. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of mannitol for diagnosing EIB/EIA compared with a standardized exercise challenge?
- T-1. In patients with confirmed EIB/EIA, do patients using short- or long-acting beta-agonists (SABA or LABA) therapy develop tachyphylaxis to treatment and, if so, at what frequency, compared with standard comparator treatments and/or placebo?
- T-2. In patients with confirmed EIB/EIA, does pre-exercise treatment with leukotriene receptor antagonist therapy (LTRA) reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-3. In patients with confirmed EIB/EIA, does pre-exercise treatment with inhaled corticosteroid therapy (ICS) reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-4. In patients with confirmed EIB/EIA, does pre-exercise treatment with mast cell stabilizers (sodium cromoglycate or nedocromil; MCS) therapy reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-5. In patients with confirmed EIB/EIA, does pre-exercise treatment with anticholinergic therapy (SAAC) reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-6. In patients with confirmed EIB/EIA, does a refractory period (10 to 15 minute warmup and/or cooldown) reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?

Methods

For questions involving diagnostic test accuracy, we searched MEDLINE[®], EMBASE, EBM Reviews - Cochrane Central Register of Controlled Trials, AMED, PsycINFO, PASCAL, CINAHL[®], SPORTDiscus with Full Text, Academic Search Elite, Web of Science[®], BIOSIS Previews[®], PubMed, Scopus[®], the Medion Database of Diagnostic Reviews - University of Maastricht, and Proquest Dissertations and Theses. For questions involving EIB/EIA therapy we searched the Cochrane Airways Register. This Register contains references to randomized controlled trials (RCTs) from the Cochrane Central Register of Controlled Trials, MEDLINE[®], EMBASE, CINAHL[®], AMED, PsycINFO, as well as results from handsearches of respiratory

journals and meeting abstracts. For all questions, we handsearched conference proceedings from key scientific meetings and reference lists of included studies.

Two reviewers independently screened the search results (titles and abstracts) to determine if an article met broad inclusion criteria. The full-text of potentially relevant articles was retrieved and two reviewers independently assessed each study using a standard inclusion/exclusion form. Disagreements were resolved by discussion or through third party adjudication, as needed.

Two reviewers independently assessed the methodological quality of individual diagnostic test accuracy studies using the Quality Assessment of Studies of Diagnostic Accuracy (QUADAS) tool¹¹ and the methodological quality of RCTs in the therapy reviews using the Jadad¹² scale and Schulz's criteria to assess allocation concealment.^{13,14}

Two reviewers also independently assessed the strength of evidence for each key question. For the diagnostic test reviews, we used the GRADE system for rating the quality of evidence and strength of recommendations for diagnostic tests.¹⁵ We assessed the strength of the study designs, the quantity and quality of individual studies, the indirectness of evidence, and the consistency and precision of the results. For all studies, the outcomes were measures of test accuracy (i.e., true positive, true negative, false positive, false negative), which are surrogates for patient-important outcomes. For each key question the quality of evidence was graded as high, moderate, low or very low. For therapy reviews, the strength of evidence for the primary outcome (maximum percent fall in FEV₁) was assessed using the EPC approach to grading the strength of a body of evidence.¹⁶ A grade of high, moderate, low, or insufficient was based on four domains: risk of bias, consistency, directness, and precision. Disagreements were resolved by discussion or through third party adjudication, as needed.

Data analysis

The primary outcome used to determine the presence or absence of EIB/EIA was the maximum percent fall in FEV₁ post-exercise challenge calculated using the following formula:

$$\frac{FEV_1 / PEF_{pre-exercise} - \text{minimum } FEV_1 / PEF_{post-exercise}}{FEV_1 / PEF_{pre-exercise}} \times 100$$

The peak expiratory flow (PEF) was used if that was the only pulmonary function measure reported. In the case of missing data, some assumptions and imputations were necessary to transform reported data into the form required for analysis. Data from graphs were extracted using CorelDRAW[®] 9.0 (Corel Corp., Ottawa, Canada). Means were approximated by medians, and 95 percent empirical intervals were used to calculate approximate standard deviations. In the therapy reviews the majority of studies used a crossover design, therefore, standard errors of mean differences were either computed exactly using individual patient data, or imputed using an estimated within-patient correlation of 0.5. Meta-analyses were conducted using the random effects model where appropriate. The I² statistic was used to assess heterogeneity.¹⁷ Planned subgroup analyses included age (children [less than 18 years old] versus adult [18 years and older]), severity of EIB/EIA as defined by the percent fall index on placebo (mild [less than 30 percent] versus moderate-severe [30 percent or more]), and patients with EIB versus EIA. All data pooling was performed using Review Manager 5.0 (The Cochrane Collaboration, Copenhagen, Denmark).

Therapy reviews

For each study the maximum percent fall in FEV₁ on the placebo ECT was subtracted from the maximum percent fall on the treatment ECT to obtain the difference. For each comparison a mean difference (MD) and 95 percent confidence interval (CI) were calculated using all included studies weighted according to sample size. There were two secondary outcomes of interest: (1) the proportion of people who received complete protection from EIB/EIA with treatment compared with placebo, for which a risk ratio (RR) and 95percent CI were calculated; and (2) the degree of protection received over placebo, known as the “clinical protection index,” which was calculated using the following formula:

$$\frac{\text{maximum \% fall } FEV_{1(\text{placebo})} - \text{maximum \% fall } FEV_{1(\text{treatment})}}{\text{maximum \% fall } FEV_{1(\text{placebo})}} \times 100$$

Results – Diagnostic Test Accuracy Review

In addition to a history of symptoms suggesting EIB/EIA following exercise, objective diagnostic testing is necessary to confirm a diagnosis. A fall in the FEV₁ of 10 percent or more after a challenge test is the recommended diagnostic threshold to objectively diagnose EIB/EIA.¹⁸ Testing can be done using either direct or indirect methods. Currently, there is no universally accepted gold standard test to confirm a diagnosis of EIB or EIA. In the absence of a gold standard, a standardized exercise challenge test (ECT) on a treadmill or bicycle ergometer conducted according to the American Thoracic Society guidelines¹⁸ is the best defined reference standard that is available and was used as the reference test in this report. The index tests that were assessed included a self reported history/symptoms diary, one direct challenge, and four indirect challenge tests. Methacholine (MCH) is considered a direct challenge as it acts directly on smooth muscle receptors to cause constriction independent of airway inflammation.¹⁹ The indirect challenges included two alternative exercise protocols (sport/venue-specific and free running asthma screening test [FRAST]), eucapnic voluntary hyperpnea (EVH), and inhaled mannitol. The indirect challenges are thought to cause inflammatory cells to release mediators such as leukotrienes, prostaglandin, and histamine which provoke smooth muscle constriction.²⁰

Sensitivity and specificity are two measures of diagnostic test characteristics. Sensitivity is the probability of testing positive if EIB/EIA is really present. Specificity is the probability of testing negative if EIB/EIA is truly absent. As the sensitivity of the test under investigation (index test) increases, the number of persons with EIB/EIA who are missed (false negatives) will decrease. As the specificity of the index test increases, the number of persons without EIB/EIA who are incorrectly classified (false positives) will decrease. To avoid the risk of spectrum bias, diagnostic test accuracy studies should include a broad spectrum of participants who range from high to low likelihood of EIB/EIA.

Twenty-eight studies met the inclusion criteria for the questions relating to diagnostic test accuracy: self-reported history/symptoms diary^{21,22} (n=2), MCH²³⁻³⁷ (n=15), sport or venue specific challenges^{34,38-41} (n=5), EVH^{34,38,39,42-45} (n=7), FRAST^{36,40,46} (n=3), and mannitol^{23,47} (n=2).

Table 1 and the following summaries provide an overview of the results of the diagnostic test accuracy review. Sensitivity and specificity are reported for individual studies but data were not pooled due to substantial heterogeneity.

Key Question D–1. Self-Reported History or Symptoms Diary

Many people with potential EIB/EIA present with complaints of symptoms such as shortness of breath, cough, wheeze, and chest pain, associated with exercise¹⁸ and these symptoms have been used to diagnose EIB/EIA. There is a concern that self-report alone leads to an unacceptably high rate of false positive and false negative decisions.⁴

Results. Two studies^{21,22} met the inclusion criteria for the diagnostic test accuracy of self-reported history/symptoms diary compared with a standardized ECT.

Frobese et al.²¹ matched 20 teenage athletes who answered “yes” to the question “do you experience cough after exercise” to 20 who responded “no.” All participants performed a treadmill ECT. The authors used a fall in FEV₁ of 10 percent or more to define a positive ECT. They reported a sensitivity of 89 percent (95 percent CI: 67, 99); a specificity of 86 percent (95 percent CI: 64, 97).

Rupp et al.,²² gave 166 teenage athletes a questionnaire with two questions relevant to EIB/EIA (“Do you have trouble breathing after running 1 mile and resting?” “Do you have to stop when running for ½ mile?”). Twenty-nine percent were identified as being at risk of EIB/EIA. All took a treadmill ECT. At a threshold of 15 percent or more, the authors reported a sensitivity of 36 percent (95 percent CI: 17, 59); a specificity of 85 percent (95 percent CI: 78, 90).

Methodological quality. Neither study included a representative spectrum of participants or defined their selection criteria and neither study blinded assessors to the results of the other challenge. It is unclear whether the ECTs met the ATS guideline recommendations.¹⁸ Furthermore, the number of “unclear” responses for both studies using the QUADAS tool raises questions regarding bias and generalizability.

Discussion. Despite extensive searching, only two studies addressed this question. The results of one study²¹ suggest that exercise-induced cough may be a predictor of EIB/EIA. Self-reported history and symptoms may be a starting point for further investigations but on their own are not sufficient to confirm a diagnosis of EIB/EIA.

Conclusion: There is insufficient evidence to conclude that self-report of symptoms is a reliable diagnostic tool for EIB/EIA. The quality of evidence is classified as “very low.” The initial grade based on study design was low and there are serious limitations related to study quality. The diagnostic thresholds differed and the sensitivity estimates are inconsistent and imprecise.

Key Question D–2. Methacholine Challenge

MCH is considered a direct challenge. Once inhaled into the lungs, it acts on smooth muscle acetylcholine receptors causing contraction and airway narrowing.²³ It has been noted that airway responsiveness to pharmacological agents such as MCH is different from hyper-responsiveness to osmotic agents or to hyper-responsiveness following exercise.¹⁸

The threshold for a positive ECT was a maximum fall in FEV₁ of 10 percent or more from a pre-exercise baseline.¹⁸ The threshold for a positive MCH challenge was a fall in FEV₁ of 20 percent or more at a provocative concentration of less than 8 mg/ml (PC₂₀).¹⁸ We also looked at a threshold PC₂₀ of less than 16 mg/ml.

Results. Fifteen studies²³⁻³⁷ met the inclusion criteria for the diagnostic test accuracy review of a MCH challenge compared with a standardized ECT. The number of participants ranged

from 12 to 375. Considerable heterogeneity was observed across the studies. Overall, 331 participants (57 percent) had a positive ECT and 416 (71 percent) had a positive MCH at the 8 mg/ml threshold. Both sensitivity and specificity ranged from 0 to 100 percent. Using the 16 mg/ml threshold, 420 participants (53 percent) had a positive ECT and 498 (63 percent) had a positive MCH. Sensitivity ranged from 55 to 100 percent and specificity 0 to 100 percent. To explore heterogeneity, we conducted a post hoc subgroup analysis on studies where all participants had mild to moderate stable asthma^{24-26,28,29,32,33,35,36} and studies^{27,30,34,37} that reported fewer than 50 percent of participants had confirmed asthma. The heterogeneity was reduced somewhat. Among studies in which all participants had asthma, the sensitivity ranged from 66 to 100, specificity 0 to 100 percent; in 4 studies reporting fewer than 50 percent had asthma sensitivity ranged from 0 to 50 percent and specificity 42 to 84 percent.

There was no reduction in heterogeneity when we explored the effects of age (child versus adult), MCH method (5 breath dosimeter versus 2 minute tidal breathing), or ECT parameters (air temperature and humidity, or treadmill versus bicycle ergometer).

Methodological quality. There are several methodological issues in this group of studies. Of concern is the risk of spectrum bias. Most studies did not report how participants were recruited into the study, nor did they describe the inclusion criteria; three studies recruited volunteers.^{26,30,34} Blinding of the ECT results to the results of the MCH challenge was not reported. It is unclear whether eight of the ECTs met the ATS guideline recommendations.¹⁸

Discussion. Across these 15 studies, there was considerable heterogeneity in estimates for sensitivity and specificity although sensitivity estimates varied less when examining patients with a confirmed diagnosis of asthma. Unlike ECTs, a positive airway response to MCH does not imply the presence of inflammatory cells or their mediators that are known to be present in EIB/EIA;²⁰ therefore, it is not surprising that MCH shows variable sensitivity and specificity to detect EIB/EIA. It has been suggested¹⁸ that a positive MCH test should not be used to infer EIB/EIA and likewise, a negative MCH should not be used to *exclude* EIB/EIA.

Conclusion. Based on the available evidence we cannot conclude that the MCH challenge is a reliable test to diagnose EIB/EIA in those with confirmed asthma or in populations with mixed asthma prevalence. The quality of evidence is classified as “moderate.” The initial grading based on study design was high; however, there are serious limitations to quality of individual studies. Sensitivity estimates are reasonably consistent but are imprecise in the participants with EIA. Specificity estimates are inconsistent and imprecise.

Key Question D–3. Sport or Venue Specific Exercise Challenge

Sport/venue specific challenges are advantageous in that the athlete can exercise in the conditions where they become symptomatic and the tests are reasonably inexpensive. In comparing sport/venue specific challenges with an ECT, coordinating the timing of the two tests and ensuring good quality control on the sport challenges can be problematic. The environmental conditions, level of intensity, and increase in minute ventilation reached during both challenges may be hard to match.

The threshold for a positive ECT or a sport specific challenge was a maximum fall in FEV₁ of 10 percent or more from a pre-exercise baseline.¹⁸

Results. Five studies^{34,38-41} met inclusion criteria for the diagnostic test accuracy review of sport or venue specific exercise challenges compared with a standardized ECT. Three focused on swimming challenges^{34,38,40} and two assessed cold weather sport challenges.^{39,41} Rundell et al.⁴¹

only included athletes who tested positive on a sport specific challenge. The sensitivity of the swimming challenge tests ranged from 0 to 50 percent; specificity from 83 to 100 percent. In total 11 (19 percent) participants were positive on the ECT and 5 (9 percent) were positive on the swim challenge. In the two studies involving winter athletes, Dickensen et al.³⁹ had no true positives but a specificity of 79 percent, and Rundell et al.⁴¹ sensitivity of 100 percent but had no true negatives and a specificity of 0 percent.

Methodological quality. In these five studies there are some methodological weaknesses. None of the studies had a representative patient spectrum which suggests the possibility of spectrum bias. Blinding of ECT results to the results of the index test was not reported. It is unclear whether two of the ECTs met the ATS guideline recommendations.¹⁸

Discussion. These studies compared challenges in the specific sport the athletes practiced (e.g., biathlon) or at the venue of activity (e.g., skating arena, swimming pool) to a laboratory ECT. The estimates of sensitivity and specificity both, ranged from 0 to 100 percent. Sport specific challenges are one of the recommended challenges for diagnosing EIB/EIA in elite athletes;³⁴ however, in total only seven athletes were positive in their own field of competition while 16 were positive on a standardized ECT. It is not clear why this occurred, although it is possible that the level of minute ventilation and differences in environmental conditions played a role.

Conclusion. Sport specific challenges may be useful in identifying athletes who do *not* have EIB/EIA but other testing such as a standardized ECT may also be required. The quality of evidence is classified as “low.” The initial grading based on study design was high; however, there are serious limitations related to study quality. The sensitivity estimates are inconsistent and imprecise. Specificity estimates are also inconsistent and imprecise.

Key Question D–4. Eucapnic Voluntary Hyperpnea

Eucapnic voluntary hyperpnea (EVH) is a test based on the premise that the increased minute ventilation with exercise is responsible for bronchoconstriction in susceptible subjects.⁴⁸ The EVH challenge requires the person to increase their minute ventilation up to 80-85 percent of the maximum minute ventilation for 5-6 minutes, which approximates the minute ventilation obtained during vigorous exercise. EVH was developed as a surrogate for exercise to identify EIB⁴⁹ and currently, it is the challenge recommended by the International Olympic Committee Medical Commission to identify EIB/EIA among Olympic athletes.¹⁹

The threshold for a positive ECT or EVH challenge was a maximum fall in FEV₁ of 10 percent or more from a pre-exercise baseline.¹⁸

Results. Seven studies^{34,38,39,42-45} met inclusion criteria for the diagnostic test accuracy review of EVH compared with a standardized ECT. The number of participants ranged from 10 to 33. Substantial heterogeneity was identified. Forty-two (30 percent) participants had a positive ECT and 74 (54 percent) had a positive EVH. Sensitivity estimates ranged from 25 to 90 percent and specificity from 0 to 71. A post hoc subgroup analysis of studies in which participants did not have known EIB/EIA^{34,38,39,42} explained some of the heterogeneity. In this population, the sensitivity ranged from 25 to 75 percent and specificity from 29 to 71 percent. Among studies in which all participants had EIB/EIA,⁴²⁻⁴⁵ the sensitivity of EVH was high, ranging from 71 to 90 percent; however, one study had no true positive cases⁴² and three had no true negative cases.

Methodological quality. As a group, there are methodological weaknesses that limit the interpretation and generalizability of the results. Of greatest concern is the risk of spectrum bias

in all studies. Either the participants recruited into the studies were volunteers,^{34,38,39,42,44} or the recruitment source and methods were not reported.^{43,45} In some studies all participants had a history of EIB/EIA⁴³⁻⁴⁵ and therefore are not representative of the spectrum of patients who might be tested for EIB/EIA. Blinding of the ECT results to the results of the EVH challenge was not reported. It is unclear whether the ECTs met the ATS guideline recommendations.¹⁸

Discussion. Overall, both the sensitivity and specificity of EVH compared to an ECT showed substantial heterogeneity and no trend was observed. It is unclear whether an EVH challenge is identifying the same people that experience a fall in FEV₁ of 10 percent or more on an ECT, particularly in a population of athletes with an unclear history of asthma. The EVH challenge resulted in a higher proportion of false positives (FP) (i.e., negative on the ECT but positive on EVH) among participants with no or unknown history of EIB/EIA. The proportion of FP ranged from 25 to 71 percent. The participants included both elite athletes (n=63) and those with unknown activity levels (n=20). Based on the available evidence, it is unclear if the EVH challenge is more sensitive to EIB/EIA, or if the mechanism that triggers the bronchoconstriction is different from that for the ECT, or if level of minute ventilation achieved on an ECT according to ATS recommendations is less than the level achieved in an EVH challenge particularly in athletes. Among participants with a history of EIB/EIA, the proportion of FPs ranged from 0 to 5 percent in participants with unknown activity levels. Among athletes, the proportion with a FP result was 27 percent. Further research is needed to determine if the EVH challenge would be an appropriate add-on test to an ECT in athletes with symptoms of EIB/EIA.

Conclusion. Based on the available data, we cannot conclude that an EVH challenge is a reliable diagnostic test for EIB/EIA. The quality of evidence is classified as “low.” The initial grading based on study design was high; however, there are serious limitations related to study quality. Furthermore, the sensitivity and specificity estimates are inconsistent and imprecise.

Key Question D–5. Free Running Asthma Screening Test (FRAST)

Free running has often been used in screening large groups for EIB/EIA because the test is relatively easy to perform, requires limited equipment, and multiple subjects can be tested at the same time.⁴⁸ The threshold for a positive ECT or FRAST was a maximum fall in FEV₁ of 10 percent or more from a pre-exercise baseline.¹⁸

Results. Three studies^{36,40,46} met inclusion criteria for the diagnostic test accuracy review of FRAST compared with a standardized ECT. Participants were children under 15 years, and all free running tests took place indoors. In two studies^{36,40} the threshold for a positive FRAST was a fall in FEV₁ of 10 percent or more. In these 34 participants, 13 (38 percent) had a positive ECT and 18 (41 percent) had a positive FRAST. The sensitivities were 60 and 67 percent; specificities were 47 and 67 percent. The remaining study⁴⁶ used a threshold of a fall in FEV₁ of 16.5 percent or more for the FRAST and 20 percent or more for the ECT. Based on these thresholds the sensitivity was 53 percent (95 percent CI: 34, 72); specificity was 100 percent (94 percent CI: 88, 100).

Methodological quality. Overall, there were concerns about the methodological quality of the studies. Generalizing the results to a target population of people with suspected EIB/EIA may be limited as none of the studies had representative spectrum of participants. Blinding of results of the ECT to the results of the FRAST was not reported. It is unclear whether two of the ECTs met the ATS guideline recommendations.¹⁸

Discussion. Sensitivity and specificity of FRAST were modest (60 to 67 percent and 47 to 67 percent, respectively). While the FRAST may be easy to perform, there is insufficient evidence to conclude that it accurately identifies people with EIB/EIA compared with a standardized ECT. Furthermore, in a FRAST challenge there is an overall lack of control in terms of exercise intensity and therefore stimulus (i.e., minute ventilation).

Conclusion. There is insufficient evidence to conclude that FRAST is a reliable diagnostic test for EIB/EIA. The quality of evidence is classified as “very low.” The initial grading based on study design was moderate; however, there are serious limitations related to study quality. The sensitivity and specificity estimates are consistent but imprecise.

Key Questions D–6. Mannitol Challenge

Recently, a mannitol provocation test has been developed to examine airway hyper-responsiveness. Like exercise, mannitol is thought to cause airway narrowing indirectly through increasing the osmolarity of the airway surface, leading to the release of endogenous mediators such as prostaglandin, leukotrienes and histamine, and resulting in smooth muscle contraction.^{50,51} Mannitol has the advantage that it can be performed with minimal equipment (i.e., a metered-dose inhaler and spirometer).

The threshold for a positive ECT was a maximum fall in FEV₁ of 10 percent or more. The threshold for a positive mannitol challenge was a 15 percent drop in FEV₁ at less than 635mg or a drop of 10 percent between consecutive doses.²³

Results. Three studies^{23,47,52} met the inclusion criteria for the diagnostic test accuracy review of mannitol compared with a standardized ECT. All participants in Brannan et al.⁴⁷ and Kersten et al.⁵² had diagnosed asthma. In these 58 participants, 39 (67 percent) had a positive ECT test, 35 (67 percent) had a positive mannitol challenge. The sensitivity was 69 and 96 percent, respectively. Specificity was 78 percent in the Kersten et al.⁵² study. Anderson et al.²³ included those with suspected but not confirmed asthma and reported a sensitivity of 58 percent (95 percent CI: 50, 66) and a specificity of 65 percent (95 percent CI: 58, 72).

Methodological quality. Concern regarding the risk of spectrum bias in the studies by Brannan et al.⁴⁷ and Kersten et al. limits the conclusions that can be drawn.⁵² Participants were volunteers who had a history of EIA and are not representative of the spectrum of patients who might be tested for EIB/EIA. Blinding of the results of the ECT and the index test was not reported. All three of the ECTs met the ATS guideline recommendations.¹⁸

Discussion. Both mannitol and ECT are considered indirect tests, acting through a similar mechanism of increasing osmolarity of the airway surface. The advantage of mannitol is that exercise is not a requirement, and the test can be conducted in a physician’s office with minimal equipment. Among adults and children with a history of EIA or suspected asthma, the diagnostic test characteristics for mannitol compared to an ECT hold promise. Its role as a screening or diagnostic tool requires further study.

Conclusion. Based on these data, it is difficult to conclude that the mannitol provocation test is a reliable diagnostic test for EIB/EIA. The quality of evidence is classified as “moderate.” The initial grading based on study design was high; however, there are concerns regarding the limitations related to study quality. The sensitivity and specificity estimates are reasonably consistent but are imprecise.

Results – Therapy Reviews

The primary objective of therapy is to prevent EIB/EIA from occurring or, short of that, to at least attenuate the degree of bronchoconstriction. Pharmacologic effect is assessed by taking a single dose of an inhaled agent prior to an ECT that meets intensity and ventilation standards. FEV₁ or PEF is measured immediately following the challenge and at 5 minute intervals until lung function begins to improve. The maximum fall in FEV₁ is expressed as a percent of the baseline measure taken immediately prior to the ECT. The greater the percent fall, the worse the EIB/EIA or, conversely, the less the percent fall the more effective the therapy. This report conducted systematic reviews of randomized controlled trials (RCTs) involving four categories of prophylactic agents compared with a placebo: inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA), mast-cell stabilizers (MCS), and short-acting anticholinergics (SAAC). We conducted two additional reviews. The first was to determine if using short- or long-acting beta agonists (SABA or LABA) on a daily basis caused people to develop a tolerance, or tachyphylaxis, to these agents thus reducing the prophylactic effect on EIB/EIA. If the post-exercise drop in FEV₁ increases after prolonged use of SABA or LABA, it is an indication of tachyphylaxis. The second review investigated whether engaging in a specific warmup routine prior to an ECT caused a refractory period during which time the EIB/EIA response was prevented or attenuated on a subsequent ECT.

The primary outcome for these six reviews was the mean difference (MD) between the mean maximum percent fall in FEV₁ on drug or warmup and the mean maximum percent fall in FEV₁ with placebo or no warmup. In this executive summary, we report the absolute MD in order to phrase the results using positive numbers. In the forest plots in the main report, a negative MD that falls to the left of the null line indicates the drug performed better than the placebo and, by extension, a larger difference indicates a greater drug effect. The 95 percent CIs relate to whether or not the result represents a statistically significant improvement.

Overall, 109 studies were included in the therapy reviews. The included studies addressed the following research questions: tachyphylaxis to SABA and LABA⁵³⁻⁶³ (n=11), LTRA^{44,64-71} (n=9), ICS⁷²⁻⁷⁵ (n=4), MCS (n=3 Cochrane reviews and publications⁷⁶⁻⁷⁸), SAAC⁷⁹⁻⁹⁶ (n=18), and a refractory period⁹⁷⁻¹⁰³ (n=7).

Table 2 and the following summaries provide an overview of the results. The pharmacological treatments were further divided into *bronchodilating* and *anti-inflammatory* agents.

Pharmacological Interventions: Bronchodilating Agents

T–1. Tachyphylaxis to SABA or LABA Therapy

β₂-Receptors on the airway smooth muscle are responsible for bronchodilation; beta-agonist agents attach to these receptors and are effective bronchodilators and improve breathing. SABA agents have been the mainstay of EIB/EIA treatment for many years. With the development and availability of LABA agents, more research has been applied to the effectiveness of these agents in preventing EIB/EIA. It has been reported in the literature that some people develop a tolerance

(tachyphylaxis) to long term regular use of beta-agonist drugs and they lose some of their effectiveness and protective effect.^{57,59}

Seven studies met inclusion criteria to address the question of whether people with EIB/EIA develop tachyphylaxis to LABA agents⁵³⁻⁶¹ and two met the inclusion criteria for SABA agents.^{62,63} Overall, the quality of the trials was high. All were randomized, double-blind trials that described the withdrawals and dropouts. Five described an adequate process to ensure double-blinding.

SABA. Data from the two SABA crossover studies could not be combined and are therefore described individually. Both studies involved asthmatics who took 1 week of regular (four times per day) SABA or placebo prior to exercise challenges and measured the baseline FEV₁ at the end of the treatment weeks. In one study⁶³ there was a statistically significant 230 ml difference (p=0.02) in the measure of FEV₁ after the treatment weeks that favored placebo. In the second study,⁶² there was no significant difference between the mean FEV₁ after the placebo week compared with the salbutamol week (2.8L versus 2.8L).

Only the study by Inman and O'Byrne⁶³ assessed prophylaxis. When the 10 adults took a single dose of placebo prior to an ECT on day 8, the mean fall in FEV₁ was positive for EIA in both groups; however, the fall was slightly greater after the SABA week (29.4 ± 4.7 percent versus 24.9 ± 4.4; p=0.12). On day 9 following pre-treatment with a SABA, all received total protection from EIA; however, the fall in FEV₁ was greater after the SABA week (5.1 ± 2.0 percent versus 1.1 ± 0.8; p=0.05) and remained lower throughout the recovery period. Adverse events were not reported. Hancox⁶² randomized 8 women with EIA and following a week of study drug performed an ECT with no pretreatment but gave SABA 5, 10, and 15 minutes post ECT. The fall in FEV₁ was greater in the SABA treated group (p=0.001).

LABA. Four crossover trials^{55,57-59} randomized groups to 3 to 4 weeks of salmeterol^{55,57} once a day,⁵⁹ or every other day⁵⁸ or to a matching placebo. The average fall in FEV₁ after the first ECT on day 1 was 3.7 percent in the LABA arms compared with 26.9 percent in the placebo arms. The absolute MD was 25.1 percent (95 percent CI: 18.0, 32.3) In the individual studies the percent fall in FEV₁ following an ECT at both 2 weeks and 4 weeks was of a greater magnitude in the LABA arms than at day 1, indicating a greater degree of EIA and less protection from salmeterol. The fall in FEV₁ in the placebo arms remained unchanged or showed a small decrease. After 4 weeks of daily LABA use, the average fall in FEV₁ after an ECT (3 studies) increased to 11.4 percent in the LABA arms compared with a decrease to 21.3 percent in the placebo arms. The pooled MD was 10.5 percent (95 percent CI: 14.7, 6.4). Three headaches were attributed to salmeterol; one exacerbation and one complaint of chest tightness were attributed to placebo.

The study by Garcia et al.⁵⁴ compared daily formoterol with placebo and also concluded that twice daily LABA over 4 weeks caused a significant reduction in bronchoprotection against EIA. Though the LABA was still effective, tachyphylaxis was evident by day 14. Adverse events were not reported.

Two studies compared regular use of salmeterol versus a LTRA (montelukast) once in the evening for 8 weeks.^{53,60} Both drugs attenuated the EIA response after 3 days of treatment to a similar degree. The mean fall in FEV₁ on LABA was 19.8 percent compared with 18.2 percent on LTRA (MD=1.01; 95 percent CI: -2.2, 4.2). Montelukast maintained its effectiveness at 4 and 8 weeks compared with a slight decrease in effect with regular use of salmeterol. At 8 weeks the mean fall in FEV₁ on LABA increased to 23.0 percent compared with a slight decrease to 17.1 percent on LTRA. The pooled MD was 5.4 (95 percent CI: 2.2, 8.7). This evidence, although

indirect, provides additional support for the concept of tachyphylaxis following regular use of LABA agents in patients with EIA. Adverse events were infrequent, mild and occurred more or less equally between therapies.

Discussion. Based on the results of one study,⁶³ SABA agents were found to have a prophylactic effect on EIA. The day 1 data from the LABA tachyphylaxis review also show that LABA is effective for attenuating the drop in FEV₁ post exercise. However, the evidence indicates tachyphylaxis is associated with the regular use of both SABA and LABA agents. The results of this review demonstrated that the percent fall in FEV₁ following an ECT after 1 to 4 weeks of use was greater (i.e., drugs were becoming less effective) in the SABA and LABA arms than in the placebo arms. Notwithstanding the tachyphylaxis, a prophylactic effect for SABA and LABA was still observed.

Conclusion. Given the consistency of results, the magnitude of effect and concordance with clinical consensus, the evidence indicates that prophylactic use of SABA and LABA agents is safe and effective for episodic prophylaxis of EIA. The evidence suggests that tachyphylaxis develops if these agents are used daily. The body of evidence comparing SABA/LABA to placebo was graded as “moderate”; evidence comparing LABA to LTRA was graded as “low.”

Pharmacological Interventions: Anti-Inflammatory Agents

T-2. Leukotriene Receptor Antagonist Therapy

Leukotrienes are produced by the cysteinyl leukotriene pathway and are implicated in both bronchoconstriction and in the inflammatory cascade leading to worsening asthma. LTRAs are relatively new agents available for the management of chronic and acute asthma which block this pathway.

Nine crossover trials^{44,64-71} met the inclusion criteria for the single prophylactic use of LTRA compared with placebo in the pre-treatment of EIA. Overall, the methodological quality of the trials was good. All were randomized, eight were double-blind trials and six described an adequate process to ensure double-blinding. Seven described the withdrawals and dropouts; however, none described the method of randomization and only one had adequate allocation concealment. All trials recruited people with asthma and confirmed EIA and all recorded the mean fall in FEV₁ up to 2 hours after drug administration. The pooled results showed that LTRA was more effective than placebo in preventing EIA. The average fall in FEV₁ in the LTRA arms after the first ECT ranged from 7.6 to 13.3 percent (average 10.9) compared with 15.0 to 23.2 percent (average 18.5) on the placebo challenges. The absolute MD was 8.3 percent (95 percent CI: 6.9, 11.0; I²=65 percent) and represented clinical protection of approximately 45 percent over placebo. Three trials^{68,70,71} recorded the mean maximum fall in FEV₁ 24 hours after drug administration. The average fall in the placebo arms was 13.8 percent (range 10.7 to 16.9) compared with 8.7 percent (range 8.3 to 10) in the LTRA arms. The pooled results showed that LTRA remained more effective than placebo in preventing EIA (MD=4.9; 95 percent CI: 1.8 to 8.0; I²=76 percent). Adverse events were infrequent, mild and occurred more or less equally between LTRA and placebo groups.

Discussion. We identified nine trials of LTRA compared with placebo in the pre-treatment of EIA. The methodological quality of the studies was high and the pooled results demonstrated a consistent benefit associated with prophylactic use. LTRAs reduced the maximum percent fall in

FEV₁ at the earliest measurement by approximately nine percent compared with placebo (Table 2).

Conclusion. From the available evidence, it appears that LTRAs are effective and safe as pre-exercise treatment for patients with mild to moderate stable asthma and EIA. The strength of the body of evidence is “moderate.”

T-3. Inhaled Corticosteroid Therapy

The main inhaled anti-inflammatory agents used for chronic and acute asthma are ICS agents. The search and selection methods employed for this review identified trials involving single prophylactic ICS use compared with placebo in the pre-treatment of EIA.

Four crossover trials⁷²⁻⁷⁵ met the inclusion criteria. Overall the quality of the trials was good. All were randomized and double-blind; two described an adequate process to ensure double-blinding. All described the withdrawals and dropouts; however, none described the method of randomization and one had inadequate allocation concealment. All trials recruited people with stable asthma and confirmed EIA. The pooled results showed no significant difference between ICS and placebo (absolute MD=5.0 percent; 95 percent CI 0.0, 10.0; I²=0 percent). None of the studies reported adverse events.

Discussion. The pooled results failed to produce a statistically significant or clinically important reduction in the percent fall in FEV₁ compared with placebo.

Conclusion. From the available evidence, we cannot conclude that a pre-exercise single-dose of an ICS agent will attenuate EIA. The strength of the body of evidence is “moderate.”

T-4. Mast Cell Stabilizers

Three systematic reviews were identified that synthesized the evidence for MCS. One review compared nedocromil sodium (NCS) versus placebo for preventing EIA^{76,104} and one compared NCS versus sodium cromoglycate (SCG).⁷⁷ The third review⁷⁸ compared the effects of a prophylactic dose of either NCS or SCG (collectively called MCS) to that of atropine, ipratropium or oxitropium bromide (collectively called SAAC agents) and to SABA. The review also compared the effects of a combination of a SABA plus a MCS to a SABA alone. Our search strategy located no additional RCTs that would add to these reviews. In the three reviews, all trials recruited people with stable asthma and confirmed EIA.

Twenty-one RCTs were included in the NCS versus placebo review.^{76,104} NCS provided a statistically and clinically significant attenuation of EIA. The average fall in FEV₁/PEF was 15.2 percent (range 10.0 to 29.8) in the NCS arms compared with 31.5 percent (range 17.5 to 47.2) in the placebo arms (absolute MD=15.6 percent; 95 percent CI: 13.2, 18.1; I²=20 percent). This represents a clinical protection index of approximately 51 percent over placebo. In those that had more severe EIA (i.e., a percent fall index 30 percent or more), the effect of NCS appeared more pronounced (absolute MD=21.4 percent; 95 percent CI: 25.5, 17.2).

There were nine RCTs included in the NCS versus SCG review.⁷⁷ No significant differences between NCS and SCG were identified (absolute MD=0.88; CI: -4.5, 2.7; I²=0 percent).

There were 24 RCTs included in the review comparing MCS to other agents. Overall, the maximum fall on MCS was reduced to 7.1 percent compared with 13.8 percent on SAAC agents (MD=6.7 percent; 95 percent CI: 3.3, 10.0; I²=0 percent). When compared with SABA, MCS were not as effective at preventing EIA. The mean percent fall in FEV₁ using MCS was 11.2

percent compared with 4.3 percent on SABA (MD=6.8 percent; 95 percent CI: 4.5, 9.2; $I^2=0$ percent). Combining MCS with a SABA did not produce significant advantages to pulmonary function over SABA alone (MD=1.8 percent; 95 percent CI: -1.1, 4.6; $I^2=0$ percent). Few trials reported adverse events due to MCS; those that did reported bad taste, throat irritation and cough.

Discussion. MCS stabilize the mast cell membranes and prevent the release of inflammatory mediators; they are used as weak anti-inflammatory agents in mild to moderate chronic asthma. Examining existing Cochrane reviews, this report highlights the efficacy (approximately 51 percent improvement in the post-exercise FEV₁ compared with placebo) for NCS. An analysis failed to demonstrate a difference between NCS and SCG and further comparative analyses suggest that MCS are more effective than SAAC agents but less effective than SABA agents (Table 2).

Conclusion. From the available evidence, it appears that MCS agents are effective and safe as pre-exercise treatment for patients with stable asthma and EIA. No significant differences were identified between NCS and SCG on pulmonary function or degree of protection afforded to patients. MCS agents were somewhat more effective than SAAC agents but not as effective as SABA agents. The combination of SABA and MCS agents did not provide significant advantages over a SABA alone. The strength of the body of evidence is “moderate.”

T-5. Anticholinergic Therapy

SAAC agents are used in respiratory conditions to decrease mucus production and as weak bronchodilators. The original anticholinergic agent used in asthma was atropine; however, ipratropium bromide (IB) is now the most commonly used agent in this class. Long-acting anticholinergic agents such as tiotropium bromide are also now available. The search and selection methods employed for this review trials involving single prophylactic SAAC use compared with placebo in the pre-treatment of EIA.

Eighteen crossover trials^{79,96} met the inclusion criteria. Overall, the methodological quality was low. Though all were randomized, seven were not double-blind trials and only one described an adequate process to ensure double-blinding. Seventeen trials described the withdrawals and dropouts; however, none described the method of randomization and all had unclear allocation concealment.

All trials recruited people with stable asthma and confirmed EIA. The mean fall in FEV₁/PEF on the placebo challenges ranged from 14 to 41 percent (average 32). Seven of the placebo groups^{79,83,85,88,90,93,96} had a mean fall in FEV₁/PEF greater than 30 percent indicating moderate to severe EIA. The average fall in FEV₁/PEF in the SAAC arms ranged from 10 to 33 percent (average 21). The pooled results showed that IB was more effective than placebo in preventing EIA (absolute MD=8.8 percent; 95 percent CI: 5.0, 14.6; $I^2=76$ percent). Four trials compared atropine to placebo.^{80,84,86,91} The pooled results showed that atropine was more effective than placebo in preventing EIA (absolute MD=16.0; 95 percent CI: 10.2, 21.7; $I^2=0$ percent). Two trials compared oxitropium bromide to placebo.^{88,89} The pooled results showed that oxitropium bromide was more effective than placebo in preventing EIA (absolute MD=13.8; 95 percent CI: 6.0, 21.6; $I^2=0$ percent). Few trials reported adverse events; those that did reported dry mouth or thirst, bitter taste, and slight tremor.

Discussion. The pooled results demonstrated a modest but consistent benefit associated with the pre-exercise use of IB in EIA. IB reduced airway narrowing at the earliest measurement by

34 percent over placebo; however, the results should be viewed cautiously due to the presence of heterogeneity. Complete protection was achieved 4.5 times more often with IB than placebo.

Conclusion. The evidence suggests that when used as a pre-treatment, SAAC agents are effective and safe for patients with EIA and can offer a clinically relevant protective effect to some people. The strength of the body of evidence is “moderate.”

Nonpharmacologic Interventions

T–6. Refractory Period (10 to 15 Minute Warmup and/or Cooldown)

As an alternative, or in addition to using medications to attenuate EIB/EIA, many athletes, trainers and researchers advocate specific warmup routines as a method to trigger a refractory period. A refractory period is the time after the warmup routine during which further vigorous exercise will evoke significantly less severe or no EIB/EIA.

Seven trials⁹⁷⁻¹⁰³ met the inclusion criteria. Overall, the methodological quality was low. All were randomized, but none were double-blind trials. Six described the withdrawals and dropouts; however, none described the method of randomization and all had unclear allocation concealment. Six of the seven trials reported participants had stable asthma and confirmed EIA.

The effect of a warmup routine on EIA prior to a standard exercise challenge was examined for the following subgroups.

Interval protocol. Four trials compared an interval warmup to no warmup^{97,99,100,103} prior to an ECT. The MD in the percent fall FEV₁ on the ECT ranged from an improvement of 4.8 to 16.1 percent over the fall after no warmup. The pooled results showed that a series of short intense sprints attenuated the EIA response by a mean of 10.6 percent (95 percent CI: 6.5, 14.7; I²=15 percent).

Continuous low intensity protocol. Three trials compared a continuous low intensity warmup that ranged from 3 minutes¹⁰¹ to 30 minutes¹⁰² to no warmup prior to an ECT. The mean difference in the percent fall in FEV₁ on the ECT ranged from an improvement of 0 to 20.6 percent over the fall after no warmup. The pooled results failed to demonstrate statistically significant evidence that the low intensity warmup attenuated the EIA response (absolute MD=12.6 percent; 95 percent CI: -1.5, 26.7; I²=90 percent).

Continuous high intensity protocol. Two trials compared a continuous high intensity warmup that was identical to the ECT with no warmup prior to the ECT.^{102,103} The mean difference in the maximum percent fall in FEV₁ on the ECT ranged from an improvement of 1.0 to 17.6 percent over the fall after no warmup. The pooled results failed to demonstrate statistically significant evidence that a continuous high intensity warmup attenuated the EIA response. (absolute MD=9.8 percent; 95 percent CI: -6.4, 26.0; I²=89 percent).

Discussion. Seven RCTs compared either different warmup routines with each other or with no warmup prior to an ECT. The evidence suggests that compared with no warmup, pre-treatment of EIA with interval warmup exercise offers a statistically significant and homogeneous attenuating benefit of approximately 11 percent improvement in the percent fall FEV₁ index (Table 2). For both high and low intensity continuous warmup protocols, the evidence is less clear. Combinations of interval and continuous warmup protocols compared within one study identified no differences and all protocols provided similar protection against EIA in the 10 to 11 percent range.

Conclusion. From the available evidence, it appears that certain warmup protocols are effective in reducing the degree of airway obstruction associated with EIA. Combination warmups show promise; however, it is unclear whether continuous warmups are effective in this condition. The strength of the body of evidence is “low.”

Gaps in Evidence and Recommendations for Future Research

Methodological Limitations of the Reviews

This review has methodological and logistic limitations. Some of the important limitations are listed below.

Diagnostic test accuracy reviews. Since there is no universally accepted gold standard to diagnose EIB/EIA, we used the standardized ECT based on ATS guidelines as our reference standard. Not all studies performed the ECT according to the ATS guidelines, however, and the variations in ECT protocol among studies may have affected the pulmonary response to the challenge and underestimated the number of positive results. Specifically, there were variations in environmental conditions (percent humidity and temperature of inspired air); restrictions on nose breathing; speed, grade, intensity and duration of the challenge; and target heart rate and minute ventilation achieved during the ECT. All of these have the potential to influence the stimulus for triggering EIB/EIA. These variations may have contributed to the heterogeneity in sensitivity and specificity observed with all the index tests.

Another concern is that many studies suffered from a potential spectrum bias. Ideally, studies should have a sample of participants who are representative of the population being examined for EIB/EIA. That is, studies should have sufficient subjects that span the range from high to low likelihood of EIB/EIA. In this review, many studies purposely recruited volunteers who either had known EIB/EIA, or definitely did not have it. In several studies no information on baseline likelihood was reported. The lack of a representative patient spectrum limits the generalizability of the results to a target population of people with suspected EIB/EIA and makes estimates of sensitivity and specificity unreliable.

A further limitation is that not all potentially relevant studies reported sufficient data to generate a 2x2 table comparing the reference standard result with an index test result based on one or more diagnostic thresholds.

Finally, poor reporting of study methods, challenge criteria, or participant characteristics meant we were not able to perform important subgroup analyses to provide more useful evidence summaries.

Therapy reviews. A double-blind RCT is considered the highest quality study design for assessing drug therapy. A short-coming of many of the included trials was a lack of disclosure on the methods used to generate and conceal the randomization code from investigators and participants as well as the adequacy of the blinding process.

Concerns regarding crossover trials, even though randomized, center on three factors: drug carryover effects, period effects, and statistical issues. Ideally, results should be reported for each treatment period and the test sequence reported so analyses can confirm the presence or absence of a carryover or period effect. No study reported data in such a manner and all merged the results from the treatment and placebo periods as though it were a parallel study.

Studies did not always provide sufficient quantitative data (e.g., measures of variance, mean endpoint estimates, statistical test results) needed to pool the individual trial results and to judge the treatment-related between group outcome differences.

In studies assessing the effect of a refractory period, the warmup protocols were not standardized. We categorized the warmup interventions into three groups, but still within each group the warmup approaches varied from each other.

Studies varied in the presentation of FEV₁ and PEF data. Our primary outcome was the maximum percent fall in FEV₁ from baseline. When possible we transformed data to this measure. The ATS convention is to accept a 10 percent maximum fall in FEV₁ following ECT as the diagnostic cutpoint for EIB/EIA and the majority of studies used this. However, other cutpoints were used and it was not always possible to obtain data at the 10 percent level. The review provided data on 15 and 20 percent cutpoints when available. While outcome reporting mainly included detailed pulmonary function measures, data on the proportion obtaining clinical and complete protection were not always reported nor was it standardized (Table 2).

Side effect profiles were also poorly reported. While side effects were likely uncommon, better reporting and the use of patient treatment preference may have provided more robust assessments of the effectiveness of various treatment options. Finally, most studies relied exclusively on pulmonary function outcomes to assess effectiveness; symptom control and exercise performance data were not available.

Recommendations for Future Research

Efforts are needed to improve the overall quality of reporting of primary studies of diagnostic test accuracy. The STARD checklist¹⁰⁵ details 25 items that address the level of detail that should be specified within such studies including descriptions of participants, tests methods, statistical methods, and results. This could be considered as a guide for authors reporting studies that evaluate diagnostic tests and for journals that publish EIB/EIA-related research.

Studies designed to more carefully examine the methodology of the standard ATS ECT test are needed. Specifically, guidelines state that the inspired air temperature must be less than 25°C, and less than 50 percent relative humidity. Studies have used inspired air as cold as -18°C and many have used medical compressed air, which has a relative humidity of 0 percent as the air leaves the tank. Colder, drier air would result in the greatest increase in osmolarity of the airway surface and thus most likely cause EIB/EIA. Additional studies are needed to more thoroughly examine how inspired air affects EIB/EIA so that a more standardized ECT guideline can be developed.

Future purposely designed studies to compare the diagnostic characteristics of different diagnostic methods are needed. New tests such as mannitol are encouraging; however, currently there are insufficient data to allow for a strong recommendation of this test. Particular attention in future studies must be given to including a representative sample of participants with suspected EIB/EIA. Studies that prospectively recruit participants and blind the reference standard results to those who interpret the index test results are needed.

To determine if the response to diagnostic tests differs in those with EIB versus EIA, those with atopy or no atopy, or other potentially defining characteristics, appropriate populations need to be included, adequate baseline data reported, and comparative analyses by the characteristics of interest performed and reported.

With regard to the systematic review of therapy for EIA, there are several issues with respect to methodological quality, populations, interventions, outcome assessments, and controls that require discussion.

Efforts are needed to improve the quality of reporting primary studies (i.e., randomized controlled trials). The CONSORT Statement¹⁰⁶ could be considered as a guide for authors reporting trials and journals that publish EIB/EIA-related research. Most trials in this review used a crossover design. Concerns regarding crossover trials center on three factors: drug carryover effects, period effects, and statistical issues. Data should be reported in a manner that allows analyses to confirm the presence or absence of a carryover effect. Future studies should focus on complete reporting of results by period and sequence to assure readers that these concerns have been accounted for.

Population: The populations involved in the therapy trials all had stable asthma and confirmed EIA. Athletic status was not reported. This finding, coupled with the small number of studies investigating some interventions, precluded more detailed subgroup analysis of the issue of EIB/EIA in elite athletes. Additional investigations of treatment effects in patient subgroups defined by asthma severity, age, and activity level are clearly indicated.

More trials in clinically homogenous groups of patients with EIB and patients with EIA are needed to better explore and characterize differences in the efficacy of interventions between these two conditions.

Intervention: The nonpharmacologic interventions were not standardized. Although the warmup interventions were divided into similar groups, each warmup approach varied from the others. Future research exploring different standardized warmup approaches is clearly indicated.

Control: Many of the patients in the pharmacological studies were administered placebo agents as the control treatment. These agents were often similar in appearance or delivered in similar appearing devices (inhaler agents) to the active treatment; however, it may have been possible for patients to detect differences among treatments, especially the bronchodilators such as SABA, LABA and SAAC agents. It is impossible to determine how frequently this occurred since most studies did not report the patient's perception of treatment received. In addition, it was not possible to blind the participants to the warmup programs in the refractory studies. When the participant cannot be blinded, it is particularly important that the outcome assessor be blinded to all information that could bias the outcome measure or assessment (e.g., other test results, intervention given, challenge performed).

Outcome: The pulmonary function outcomes reported varied and studies used different diagnostic cutpoints ranging from a fall index of 10 to 20 percent. The ATS convention is to accept a 10 percent maximum fall in FEV₁. While outcome reporting included detailed pulmonary function measures, the format was not standardized. Data on the proportion obtaining clinical and complete protection were often missing (Table 2).

Side effect profiles were also poorly reported. While there is evidence for the safety of many of these agents from the chronic asthma literature, it would be prudent for future research to capture adverse effects in the EIB/EIA population. Future trials of interventions to prevent or attenuate EIB/EIA should include clinically relevant secondary outcomes such as patient preferences, symptom scores, and sport performance effects (e.g., changes in athletic performance or endurance). More robust outcome reporting would further inform decision-making by athletes, physicians, and sporting bodies.

Conclusion

Despite exhaustive efforts to identify evidence regarding the diagnostic test characteristics of self-reported history, MCH, sport or venue specific challenges, EVH, FRAST, or mannitol to diagnose patients with EIB/EIA, few studies were found that compared these diagnostic tests to a standardized ECT. The studies that were identified suffered from spectrum bias and considerable variability in test methodology and reported data.

Based on the available data as summarized in this review, none of the six tests provide the diagnostic test characteristics to make them individually attractive as an exclusive alternative to a standardized ECT. There is no clear evidence to suggest that any are equivalent to, or better than, a standardized ECT to diagnose EIB/EIA. More important, given the difference in response by a single individual to multiple challenges, a single negative test should not be used to exclude EIB/EIA. A specificity ranging from 79 to 100 percent in sport specific challenges may indicate they are useful in identifying athletes who do not have EIB/EIA.

Despite exhaustive efforts to locate randomized trials that compared the therapeutic effectiveness of six different interventions for EIB/EIA against placebo, only a small number of studies were identified for each question. The studies that were included suffered from several potential biases; however, this summary represents the most comprehensive review of therapies for EIB/EIA ever reported.

On the basis of this review, we can conclude that the bronchodilator agents examined (SABA, LABA, LTRA, and SAAC) are effective to varying degrees at attenuating or eliminating the drop in FEV₁ associated with EIA. There is evidence of the development of tachyphylaxis associated with 1 to 4 weeks of regular use of SABA and LABA agents but it was not enough to negate their usefulness altogether.

On the basis of this review, we can conclude that the anti-inflammatory agents examined provide mixed results. The evidence suggests that MCS agents are effective in attenuating or eliminating the FEV₁ drop associated with EIA. There is some role for LTRA agents in the treatment of EIA; however, the attenuation appears less than with other bronchodilator agents. There is limited evidence that a single prophylactic dose of ICS is of clinical benefit in preventing EIA. The long-term benefit of ICS agents in asthma is well known, and it is possible that better control of chronic airway inflammation may benefit patients with EIA specifically.¹⁰⁷

Finally, from the available evidence, it appears that certain warmup protocols are effective at reducing the degree of airway obstruction associated with EIA. Combination warmups show promise; however, it is unclear whether continuous warmups are effective for this condition.

Table 1. Summary of sensitivity and specificity for the diagnostic test accuracy review

Index test	# studies, sample size	ECT type (# studies) Definition of EIB/EIA (# studies)	Sensitivity point estimate or range mean % (95% CI)	Specificity point estimate or range mean % (95% CI)	ECT +ve ($\geq 10\%$ fall FEV ₁)	Index test +ve	Evidence Grade
					N (%)	N (%)	
Self-report	2, N=206	Treadmill (2) $\geq 10\%$ fall FEV ₁ (1) $\geq 15\%$ fall FEV ₁ (1)	89% (67, 99) 36% (17, 59)	86% (64, 97) 85% (78, 90)	19 (48) 20 (13)	20 (50) 30 (18)	Very low
Methacholine	16, N=1,048	Treadmill (10) Bicycle ergometer (6) ECT: $\geq 8\%$ fall FEV ₁ (1), $\geq 10\%$ fall FEV ₁ (6), $\geq 15\%$ fall FEV ₁ (2), $\geq 18\%$ fall FEV ₁ (1), $\geq 20\%$ fall FEV ₁ (5) MCH: $\geq 20\%$ fall FEV ₁ at various doses MCH	$\geq 10\%$ fall FEV ₁ 0-100%; (MCH _{PC20} <8mg/ml) 55-100% (MCH _{PC20} <16mg/ml)	0-100% 0-100%	331 (57) 420 (53)	416 (71) 498 (63)	Moderate
Sport specific challenge	5, N=95	Treadmill (3), bicycle ergometer (2) $\geq 10\%$ fall FEV ₁ (4) $\geq 20\%$ fall FEV ₁ (1)	$\geq 10\%$ fall FEV ₁ Swim challenge 0-50% Winter sports n=37 100% (48, 100) (1 study)	83-100% 79% (49, 95) (1 study)	11 (19) 5 (14)	5 (9) 26 (70)	Low
Eucapnic voluntary hyperpnea	7, N=138	Treadmill (4), bicycle ergometer (3) ECT: $\geq 10\%$ fall FEV ₁ (4), $\geq 20\%$ fall FEV ₁ (1) NR (2) EVH: $\geq 10\%$ fall FEV ₁ (4), NR (3)	$\geq 10\%$ fall FEV ₁ 25-90%	0-71%	42 (30)	74 (54)	Low
FRAST	3, N=99	Treadmill (1), bicycle ergometer (2) $\geq 10\%$ fall FEV ₁ (1) $\geq 20\%$ fall FEV ₁ (2)	$\geq 10\%$ fall FEV ₁ : 60-67% $\geq 20\%$ fall FEV ₁ : 53%	47-67% 100%	13 (38) 30 (50)	18 (53) 16 (27)	Very low
Mannitol	3, N=423	Treadmill (2), bicycle ergometer (1) ECT: $\geq 10\%$ fall FEV ₁ (3) Mannitol: $\geq 15\%$ fall FEV ₁ (3)	$\geq 10\%$ fall FEV ₁ 58-96%	($\geq 10\%$ fall FEV ₁) 65-78%	202 (48)	203 (48)	Moderate

ECT = exercise challenge test; EVH = eucapnic voluntary hyperpnea; FEV₁ = forced expiratory volume in 1 second; FRAST = free running asthma screening test; MCH = methacholine; PC = provocative concentration; +ve=positive

Table 2. Prophylactic therapy for EIA: Pulmonary function results

Comparisons Intervention vs. control	N trials (SS_i vs. SS_c) MD % fall FEV₁/PEF (95% CI)*	Clinical protection ≥50% N trials (SS_i vs. SS_c) RR (95% CI) †	Mean % protection of intervention over control (95% CI)	Complete protection N trials (SS_i vs. SS_c) RR (95% CI) †	Evidence Grade
Leukotriene receptor antagonists vs. placebo	N=9 (267 vs. 267) 8.9 (6.9, 11.0)	NR	NR	≤10% fall FEV ₁ N=4 (124 vs. 123) 1.87 (0.77, 4.56)	Moderate
Inhaled corticosteroids vs. placebo	N=4 (50 vs. 50) 5.0 (0.0, 9.9)	NR	BV 6%; BUD 17%; FP 49%	NR	Moderate
MCS (Nedocromil sodium) vs. placebo	N=17 (240 vs. 240) 15.6 (13.2, 18.2)	NR	51 (46, 55)	NR	Moderate
Nedocromil sodium vs. sodium cromoglycate	N=7 (97 vs. 97) 0.9 (-2.7, 4.5)	N=6 (78 vs. 78) 1.12 (0.89, 1.40)	NR	≤10% fall FEV ₁ N=6 (78 vs. 78) 1.0 (0.7, 1.4)	Moderate
MCS vs. anticholinergics	N=8 (183 vs. 175) 6.7 (3.3, 10.0)	N=5 (56 vs. 48) 1.35 (1.00, 1.83)	11.2 (2.4, 20.0)	≤15% fall FEV ₁ N=8 (177 vs. 169) 1.3 (1.1, 1.6)	Moderate
SABA vs. MCS	N=12 (271 vs. 272) 6.8 (4.5, 9.2)	N=6 (77 vs. 77) 1.4 (1.1, 1.7)	22.7 (11.9, 33.4)	≤15% fall FEV ₁ N=9 (225 vs. 226) 1.4 (1.2, 1.8)	Moderate
SABA + MCS vs. SABA	N=5 (40 vs. 40) 1.3 (-6.3, 8.9)	N=3 (37 vs. 37) 0.9 (0.7, 1.1)	10.3 (-27.0, 6.5)	≤15% fall FEV ₁ N=4 (44 vs. 44) 0.9 (0.5, 1.4)	Moderate
LABA vs. placebo	N=4 (55 vs. 55) 25.1 (18.0, 32.3)	NR	86%	NR	Moderate
Anticholinergics (Ipratropium bromide) vs. placebo	N=11 (142 vs. 142) 9.8 (5.0, 19.5)	N=6 % achieved=60 (48, 72)	NR	≤10% fall FEV ₁ N=7 (74 vs. 74) 4.5 (1.2, 10.9)	Moderate
Interval warmup vs. no warmup	N=4 (56 vs. 56) 10.6 (6.5, 14.7)	NR	NR	≤15% fall FEV ₁ N=1 1/12 (8.3%)	Low
Continuous low intensity warmup vs. no warmup	N=3 (37 vs. 37) 12.6 (-1.5, 26.7)	NR	NR	≤15% fall FEV ₁ N=1 6/12 (50%)	Low
Continuous high intensity warmup vs. no warmup	N=2 (13 vs. 13) 9.8 (-6.4, 26.0)	NR	NR	NR	Low

BUD = budesonide; BV = Betamethasone valerate; FEV₁ = forced expiratory flow in 1 second; FP=fluticasone ICS = Inhaled corticosteroid; LTRA = leukotriene receptor antagonist; MCS = mast cell stabilizers; MD = mean difference; NR = not reported; PEF = peak expiratory flow; RR = risk ratio; SABA = short-acting beta-agonist; SS_i = sample size intervention; SS_c = sample size comparison.

*a positive MD indicates intervention is better; † RR>1 indicates intervention is better

Evidence Report

Chapter 1. Introduction

What is Exercise-induced Bronchoconstriction and Asthma?

Vigorous physical exercise can be followed by *transient* clinical signs and symptoms of asthma due to airway narrowing. The phenomenon was first recorded around 150 AD by Aretaeus of Cappodocia.¹⁰⁸ Airway obstruction following exercise was first observed among individuals with underlying asthma from which the term *exercise-induced asthma* (EIA) was derived. Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role, and it is associated with bronchial (or airway) hyper-responsiveness.¹⁰⁹ Similar post-exercise asthma-like symptoms have been observed in persons without the presence of co-existing asthma, particularly in athletes. In this population the phenomenon has been referred to as *exercise-induced bronchoconstriction* (EIB).¹ In this report we define EIB as “the airway obstruction that occurs in association with exercise without regard to the presence of chronic asthma.” We define EIA as “the condition in which exercise induces symptoms of asthma in patients who have asthma.”¹ (The two conditions will be discussed separately when the populations are specifically identified; otherwise, for the sake of brevity, they are collectively referred to as EIB/EIA.

The underlying mechanisms of EIB and EIA are multifactorial and complex. Whether the two phenomena have the same pathogenesis is still unknown and continues to be explored.^{110,111} In the early 1970s, Chan-Yeung et al.¹¹² recognized that the severity of the airway constriction was associated with the level of ventilation. In normal nasal breathing, inspired air is heated to body temperature and is completely saturated with water in the first few generations of the airways. There is a marked increase in minute ventilation during and following strenuous exercise and, as a result, the nose is unable to condition the increased volume of air. The added burden on the lower airways, down to the tenth generation and beyond, to warm and humidify the large volume of air triggers osmotic and thermal changes.^{20,113,114} Loss of water in the periciliary fluid layer of the airway produces a hyperosmotic environment that may stimulate degranulation of pulmonary mucosa mast cells with subsequent release of several inflammatory mediators such as histamine, leukotrienes, prostaglandin, platelet activating factors, and neuropeptides from sensory nerves.¹¹⁵ Theorists propose that the released mediators stimulate bronchial smooth muscle spasm¹¹⁶ and rapid rewarming leads to increased bronchial circulation and engorged capillary beds (or airway edema) that may intensify the obstruction.^{114,117,118}

The hallmark of EIB/EIA is that the acute airflow obstruction (measured by the forced expiratory volume in 1 second [FEV₁]) peaks rapidly 3 to 15 minutes after exercise stops and then remits spontaneously within 20 to 60 minutes.² It does not cause a prolonged deterioration in lung function. The nature and severity of episodes vary widely within and among individuals and can be influenced by multiple factors (Table 3). Common clinical symptoms include coughing, wheezing, shortness of breath, excessive mucus production, chest tightness, chest pain or an itching or scratching sensation in the chest. Less common symptoms include stomach pain, nausea;¹¹⁹ and near-death experiences.¹²⁰ EIB/EIA has been shown to appear during prolonged exercise causing a lack of endurance despite conditioning. It may influence athletic performance^{120,121} and often results in a prolonged recovery time following exercise.¹¹⁹ A small subset of individuals experience a second, late-phase constriction 4 to 12 hours after the initial activity. This constriction is generally less severe than the first, but the magnitude of the two episodes are

significantly correlated.¹⁰⁸ No single factor predicts who will experience a late response, and these responses do not happen consistently in the same individuals.^{108,122}

Approximately 40 to 50 percent of individuals who have an initial episode of EIB/EIA experience a refractory period that is defined as “a period of diminished responsiveness when a second period of exercise follows in 1 to 4 hours.”⁸ During this time the magnitude of the EIB/EIA response to an identical exercise task may be less than 50 percent of the initial response.¹²³ This phenomenon is somewhat elusive as it can be present at some times but not at others. The cause is not fully understood but it has been suggested that depletion of catecholamines, increased circulation of prostaglandin, and degranulation of mast cell mediators play a role.

Table 3. Factors that may influence the severity of EIB/EIA

Factor	Decrease EIB/EIA	Increase EIB/EIA
Environmental conditions	Warm temperatures (34-37° C) ¹²⁴ High humidity (100%) Absence of allergens Low air pollution	Cold temperatures, dry air ^{124,125} Airborne particles and pollutants, allergens, moulds, dust Irritants: automobile exhaust, sulphur dioxide, nitrogen dioxide, smoke, ozone, ¹²⁶ chlorine ¹²⁷
Type, intensity, duration of exercise	Short episodes of fast/slow running with brief rests ¹²⁸ VO ₂ max <40% predicted ¹²⁹ <3 minutes continuous exercise	Continuous activities that require near maximum aerobic capacity VO ₂ max ≥60% predicted 6-8 minutes continuous exercise
Overall control of underlying asthma and BHR	Good control: FEV ₁ >70% predicted Fall in BHR ¹³⁰	Poor control: FEV ₁ <65% predicted Increase in BHR ¹³⁰
Physical conditioning	Good physical conditioning Warmup and cooldown sessions	Poor physical conditioning Sudden burst of activity Fatigue ¹²⁶ Emotional stress ¹²⁶ Athletic overtraining ¹²⁶
Respiratory tract infections, especially viral	No respiratory tract infections	Presence of respiratory tract infections ¹²⁶ Sinusitis ¹³⁰ Rhinitis
Time since last exercise	If within 40-90 min may benefit from refractory period ¹³⁰	>2-3 hr
Concurrent medications	Maintenance anti-inflammatory bronchodilator medication	Salicylates, NSAIDS, β-blockers ¹³⁰
Pre-exercise foods eaten	None	Peanuts, celery, shrimp, grain, carrots, bananas ¹³⁰

BHR = bronchial hyperresponsiveness

Magnitude and Importance of the Condition

According to National Center for Health Statistics estimates, approximately 20.5 million Americans (seven percent) have asthma.⁵ Asthma is reported to have resulted in 4,099 deaths in 2003 and 1.8 million emergency department visits in 2004.^{5,131,132} Between 60 to 90 percent of people with asthma experience EIA and consider exercise a major trigger of their asthma symptoms.¹³³ Some claim that all asthmatics will experience EIA if ventilation is sufficiently high.⁶ Prevalence of EIB is lower (six to 13 percent) in a population with no history of asthma or allergy.^{8,9}

EIB/EIA gained considerable attention following the 1972 Olympic Games when a gold medalist swimmer, Rick Demont, had his medal rescinded because he took oral ephedrine prior to the race to control his EIB/EIA. Since then, several studies conducted among athletes have reported the prevalence of EIB/EIA to range from 11 to 50 percent.⁷ Helenius and Haahtela⁹ estimated that the prevalence in summer sport athletes was between 3.7 to 22.8 percent, whereas among winter sport athletes the estimate ranged from 2.8 to 54.8 percent.¹³⁴ High level endurance training in sports such as cross-country skiing, swimming, and long distance running may increase bronchial hyper-responsiveness (BHR) and cause inflammation in the airways because these athletes are repeatedly exposed to cold air, inhaled irritants, and allergens.¹³⁵

Asthma is known to have a negative impact on health-related quality of life.¹³⁶ The threat of an asthma attack may result in withdrawal from physical and social activities, which can lead to deconditioning, weight gain, and to an altered sense of self-esteem.¹³⁷ Both recreational and elite athletes tend to minimize or deny symptoms due to embarrassment, fear of repercussions, or lack of understanding of what they are experiencing.^{8,138} EIB/EIA and asthma have an impact on quality of life. The fear of sudden breathlessness creates a sense of panic, which may prevent children and adults from participating in sports and cause parents of children with asthma to impose restrictions.¹⁰ Fear of failure and sub-optimal performance in sports may lead many individuals suffering from EIB/EIA to opt for sedentary activities.¹²⁰

Unrecognized EIB/EIA can result in serious public health consequences. Data compiled from coroners reports for deaths between 1993 to 2000 indicated that, among 61 asthma-related deaths occurring in close relation to physical activity, about 80 percent occurred in individuals younger than 21 years of age. More than half of all asthma-related deaths occurred in individuals who were considered to be elite or competitive athletes, nearly 10 percent of which occurred in individuals with no known history of asthma.¹³⁹

Diagnosis of Exercise-Induced Bronchoconstriction and Asthma

Potential EIB/EIA can be detected by taking a thorough medical history. EIB/EIA is suspected when individuals, who otherwise have good lung function, complain of recurrent shortness of breath and symptoms of cough, wheeze, chest pain, or prolonged recovery time following exercise. These symptoms are independent of a person's conditioning level. If symptoms are relieved by inhaling a short-acting beta-agonist (SABA) or if symptoms are prevented by taking a SABA before exercise, a diagnosis of EIB/EIA is strongly supported.¹¹⁸ The degree of airway constriction can be measured objectively by a spectrum of pulmonary function tests; however, most clinicians and laboratories use the FEV₁⁷ or, very occasionally, the peak expiratory flow (PEF).

When a patient's history suggests EIB/EIA, measuring the change in FEV₁ before and after a standardized exercise challenge test (ECT) on a treadmill or bicycle ergometer can assist in making the diagnosis. The American Thoracic Society (ATS) has published guidelines for conducting a standardized ECT,¹⁸ which include recommendations for environmental control, as well as the level and duration of intensity required to ensure a sufficiently vigorous challenge. Minute ventilation must reach the target level in the first 4 minutes of the challenge.

The standardized laboratory ECT has not always demonstrated sufficient sensitivity to identify EIB/EIA in elite athletes who perform in many venues and with widely varying intensity and duration, therefore, other surrogate tests have been recommended.¹⁴⁰ Some of the current options include sport specific challenges, the free running asthma screening test (FRAST), measures of direct bronchial responsiveness to methacholine (MCH) and indirect responsiveness to eucapnic voluntary hyperpnea (EVH) or mannitol.

In the general population, vigorous exercise should cause little to no prolonged decrease in airflow following exercise. A decrease of 10 percent from baseline has been shown to be a change greater than two standard deviations from the normal response.¹⁴¹ In 2001, prior to the Salt Lake City Olympics, the International Olympic Committee Medical Commission met to determine the parameters for EIB/EIA. They accepted a cutpoint of a fall of 10 percent or more in FEV₁, as suggested by the European Respiratory Society and ATS guidelines.^{18,142} This decision was supported by a study indicating a coefficient of variation of six percent for repeated maneuvers of FEV₁.¹⁴³ However, the cutpoint value is a subject of ongoing debate. Two investigators have suggested that a fall in FEV₁ of only 6.5 percent is appropriate.^{144,145} Anderson et al. claim that the 10 percent value is justified as this level of constriction could potentially limit exercise performance.^{140,145} A 10 percent fall is also supported by Hurwitz et al. who found this degree of constriction to have a specificity of 90 percent for identifying those with asthma.¹⁴⁶

By convention EIB/EIA is quantified using the maximum percent fall index, which is the maximum reduction in lung function post-exercise, expressed as a percent of the pre-exercise value. The index is calculated using the formula:

$$\frac{FEV_1 / PEF_{pre-exercise} - \text{minimum } FEV_1 / PEF_{post-exercise}}{FEV_1 / PEF_{pre-exercise}} \times 100$$

A fall of 10 percent or greater on an ECT indicates that the individual has EIB/EIA. The greater the reduction in FEV₁, the more severe the EIB/EIA episode is. If a person takes a

prophylactic dose of a medication to control EIB/EIA, “complete protection” is achieved if the percent fall index is less than 10 percent.¹⁴⁷

A significant placebo effect has been observed in randomized trials comparing an active pre-exercise treatment to placebo. Some participants have obtained either complete protection from EIB/EIA or significant attenuation of it with the placebo alone. Therefore, it is customary to subtract the fall in FEV₁ on the active drug from the fall experienced on placebo and calculate the “clinical protection index” (the degree of protection afforded by a drug expressed as a percent of that offered by placebo) using the following formula:

$$\frac{\text{maximum \% fall } FEV_{1(\text{placebo})} - \text{maximum \% fall } FEV_{1(\text{treatment})}}{\text{maximum \% fall } FEV_{1(\text{placebo})}} \times 100$$

A result of 50 percent or more is regarded as clinically significant.¹²²

Treatment of Exercise-Induced Bronchoconstriction and Asthma

The goal of treatment is to prevent or, at least, to reduce the severity of the bronchoconstriction and symptoms so that an individual can participate in any activity, regardless of its intensity and duration, without serious respiratory limitations. Through a combination of education, a commitment to fitness, pharmacologic intervention, and use of nonpharmacologic strategies, EIB/EIA can be successfully managed in the majority of cases. Different pharmaceutical agents that appear to operate on different phases of the response can provide at least partial relief from EIB/EIA.¹²⁵ The most commonly used agents are inhaled SABA and long-acting beta-agonist (LABA) agents. Other agents include mast cell stabilizing agents (MCS), short-acting anticholinergics (SAAC), leukotriene receptor antagonists (LTRA), and inhaled corticosteroids (ICS). Theophyllines,¹⁴⁸⁻¹⁵⁰ antihistamines,¹⁵¹⁻¹⁵³ calcium channel blockers,^{79,154} heparin,¹⁵⁵ and furosemide¹⁵⁵⁻¹⁵⁸ have also been shown to have some degree of effectiveness.

There are many unresolved issues with respect to the treatment of EIB/EIA with pharmaceutical agents. There is concern that the continuous use of the SABA and LABA agents to control asthma over the long term could lead to a decrease in efficacy when also used prophylactically to control EIA. A development of tolerance, or tachyphylaxis, to SABA or LABA agents may not only decrease their protective effect, but also shorten their duration of action.⁶² In the case of SABAs, a serious concern is that continuous use will decrease its impact as a rescue medication in the case of severe EIA.

Objective of this Evidence Report

The objective of this report was to synthesize the evidence to answer six key questions on diagnostic testing for EIB/EIA and six key questions on therapy for EIB/EIA (five involving pharmaceutical interventions and one a nonpharmacologic intervention).

The Key Questions

The key questions for the diagnostic test accuracy review were as follows:

- D-1. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a self-reported history/symptoms diary for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-2. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a methacholine challenge for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-3. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of sport/venue specific exercise challenges for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-4. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of eucapnic voluntary hyperpnea for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-5. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of a free running asthma screening test (FRAST) for diagnosing EIB/EIA compared with a standardized exercise challenge?
- D-6. In patients with suspected EIB/EIA, what are the diagnostic test characteristics of mannitol for diagnosing EIB/EIA compared with a standardized exercise challenge?

The key questions for the therapy review were as follows:

- T-1. In patients with confirmed EIB/EIA, do patients using SABA or LABA therapy develop tachyphylaxis to treatment and, if so, at what frequency, compared with standard comparator treatments and/or placebo?
- T-2. In patients with confirmed EIB/EIA, does pre-exercise treatment with leukotriene receptor antagonists therapy reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-3. In patients with confirmed EIB/EIA, does pre-exercise treatment with inhaled corticosteroid therapy reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-4. In patients with confirmed EIB/EIA, does pre-exercise treatment with mast cell stabilizers (sodium cromoglycate or nedocromil) therapy reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-5. In patients with confirmed EIB/EIA, does pre-exercise treatment with anticholinergics (ipratropium) therapy reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?
- T-6. In patients with confirmed EIB/EIA, does a refractory period (10 to 15 minute warmup and/or cooldown) reduce symptoms and prevent a 10 percent or more drop in FEV₁ compared with no treatment/placebo?

Chapter 2. Methods

In this chapter we document a prospectively developed protocol that was used to conduct this evidence report. A core research team was assembled by the University of Alberta Evidence-based Practice Center (UAEPC). In consultation with the Agency for Healthcare Research and Quality (AHRQ) Task Order Officer (TOO) and the American Academy of Asthma Allergy and Immunology (AAAAI) representative, a Technical Expert Panel (TEP) was assembled to provide content and methodological expertise in the development of this report (Appendix A).

Literature Search and Retrieval

The research librarian, in collaboration with the core research team and TEP, developed search strategies designed to identify evidence relevant to each key question of the report.

For questions relating to the diagnostic test accuracy reviews (Key Questions D–1 to D–6), we systematically searched the following electronic resources: MEDLINE[®], EMBASE, EBM Reviews - Cochrane Central Register of Controlled Trials, AMED, PsycINFO, PASCAL, CINAHL[®], SPORTDiscus with Full Text, Academic Search Elite, Web of Science[®], BIOSIS Previews[®], PubMed, Scopus[®], the Medion Database of Diagnostic Reviews - University of Maastricht, and Proquest Dissertations and Theses. The original searches were performed between November 5 and 28, 2008. On July 31, 2009, the searches were updated using the original search strategies in MEDLINE[®], EMBASE, Cochrane Central Register of Controlled Trials, PASCAL, SPORTDiscus with Full Text, Web of Science[®], BIOSIS Previews[®], PubMed, and Scopus[®].

Search terms were identified by reviewing search strategies of systematic reviews on similar topics and by looking at how potentially relevant studies were indexed in various databases. A combination of subject headings and text words was adapted for each electronic resource: (exerc* OR train* OR fitness OR physical OR athlete* OR sport*) AND (bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR “Respiratory Sounds” OR “Bronchial Spasm” OR bronchospas* OR “Bronchial Hyperreactivity” OR “Respiratory Hypersensitivity” OR (bronch* AND spasm*) OR (bronch* AND constrict*) OR (bronchial* OR respiratory OR airway* OR lung*) AND (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency)) OR EIB OR EIA. Terms used to limit the searches to diagnostic studies included: diagnos* or predict* or probability or accuracy or sensitivity or specificity. Searches were limited to English language. Date restrictions were not applied. (See Appendix B for exact search strings).

Handsearches were conducted to identify literature from symposia proceedings from the following scientific meetings: AAAAI Annual Meeting (2007–2008), American Thoracic Society (ATS) International Conference (2008), British Thoracic Society (BTS) Winter Meeting (2008), Chest Meeting (2008), and the European Respiratory Society (ERS) Annual Congress (2008). We also searched the last 3 years (2006–2008) of conference proceedings of the American College of Sports Medicine (ACSM) and the Canadian Society for Exercise Physiology (CSEP).

For questions relating to the therapy reviews (Key Questions T–1 to T–6), a comprehensive search was run in the Cochrane Airways Register. The Register contains references to randomized controlled trials (RCTs) from systematic searches of bibliographic databases including Cochrane Central Register of Controlled Trials, Medline[®], Embase, Cinahl[®], AMED,

Appendixes cited in this report are provided electronically at
<http://www.ahrq.gov/downloads/pub/evidence/pdf/eibeia/eibeia.pdf>

PsycINFO, as well as handsearching of respiratory journals and meeting abstracts. The original search was performed on November 5, 2008. On August 4, 2009, the search was updated using the original search strategy.

Search terms were identified by reviewing search strategies of systematic reviews on similar topics and by looking at how potentially relevant studies were indexed in various databases. A combination of subject headings and textwords were used: (exerc* OR train* OR fitness OR physical OR athlete* OR sport*) AND (bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR “Respiratory Sounds” OR “Bronchial Spasm” OR bronchospas* OR “Bronchial Hyperreactivity” OR “Respiratory Hypersensitivity” OR (bronch* AND spasm*) OR (bronch* AND constrict*) OR (bronchial* OR respiratory OR airway* OR lung*) AND (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency)) OR EIB OR EIA. We did not apply language or date restrictions. A study design filter was not required as all references in this database are RCTs. (Appendix B). The results from the literature searches were entered into a Reference Manager for Windows bibliographic database version 11.0 (© 2004-2005 Thomson ResearchSoft).

We handsearched abstracts for those years not yet available in the Cochrane Airways Register for the following conference proceedings: AAAAI (2007–2008), ATS International Conference (2008), BTS Winter Meeting (2008), Chest Meeting (2008), ERS Annual Congress (2008). We also searched the last 3 years (2006–2008) of conference proceedings of the ACSM and the CSEP.

To identify ongoing studies we searched ClinicalTrials.gov and ClinicalStudyResults.org. Studies were also identified by checking reference lists of included studies.

Study Selection

Our inclusion/exclusion criteria (Tables 4 and 5) were developed in consultation with the TEP.

Table 4. Inclusion and exclusion criteria for the diagnostic test accuracy review

Study design	Prospective or retrospective studies
Participants	Adults and children aged 6 years and older with suspected EIB/EIA. Recreational and elite athletes are eligible for inclusion.
Index tests	Self-reported history/symptoms diary; methacholine challenge; sport/venue specific exercise challenges; eucapnic voluntary hyperpnea; FRAST; mannitol
Reference standard	Standardized exercise challenge test (treadmill or cycle ergometer) with a drop in FEV ₁ of 10% or more from baseline
Outcomes	Studies should provide numeric data for the calculation of diagnostic test characteristics (sensitivity, specificity)

Table 5. Inclusion and exclusion criteria for the therapy review

Study design	Randomized controlled trials (parallel or crossover)
Participants	Adults and children aged 6 years and older with confirmed EIB/EIA. Recreational and elite athletes are eligible for inclusion.
Interventions	<i>Pre-exercise pharmacologic therapy:</i> For Key Question T-1: regular use (≥ 1 wk) SABA or LABA. For Key Questions T-2 to T-5: single-dose prophylactic use of leukotriene receptor antagonists, inhaled corticosteroids, mast cell stabilizers, short-acting anticholinergics <i>Nonpharmacologic therapy:</i> refractory period (pre-exercise warmup and/or cooldown)
Comparator	For Key Question T-1, any standard comparator treatments and/or placebo. For Key Questions T-2 to T-6, no treatment or placebo.
Outcomes	Maximum percent fall in FEV ₁ or PEF from pre-exercise baseline, symptoms, presence or absence of EIB/EIA (complete protection), clinical protection, adverse effects

We used a two-step process for article screening. First, two reviewers independently screened the titles and abstracts (when available) to determine if an article met broad inclusion criteria. Each article was rated as “include,” “exclude,” or “unclear.” The full-text of all articles classified as “include” or “unclear” were retrieved for formal review. Second, two reviewers independently assessed each study using a standard inclusion/exclusion form (Appendix C). Disagreements were resolved through discussion between the two reviewers or third party adjudication, as needed.

Assessment of Methodological Quality

We assessed the methodological quality of the diagnostic test accuracy studies using the Quality Assessment of Studies of Diagnostic Accuracy (QUADAS) tool.¹¹ This tool comprises 14 items that assess several common sources of bias in diagnostic studies, including spectrum bias, selection bias, information bias, verification bias, misclassification bias, disease progression bias, and excluded data. For the purpose of this review, we chose to include only 13 of the QUADAS items. A priori, we determined that the question regarding incorporation bias did not apply because none of the index tests under review were incorporated in the reference standard. Each item in the QUADAS tool is scored as “yes,” “no,” or “unclear.” In addition, the source of funding (e.g., industry, government, other) for each study was recorded.¹⁵⁹ Results of the quality assessment are presented in the text and a table for each of the individual key questions (D–1 to D–6).

We assessed the methodological quality of RCTs included in the therapy review using the Jadad¹² scale and Schulz’s criteria to assess allocation concealment.^{13,14} Components of the 5-point Jadad scale include randomization, double blinding, and reporting of withdrawals and dropouts. Allocation concealment was assessed and scored as “adequate,” “inadequate,” or “unclear.” In addition, the source of funding for each study (e.g., industry, government, other) was recorded.¹⁵⁹ Results are presented in the text and a table for each of the individual key questions (T–1 to T–6).

The methodological quality of included studies was assessed independently by two reviewers. Decision rules regarding application of the quality assessment tools were developed a priori (Appendix C). Discrepancies were resolved through discussion between the two reviewers or third party adjudication, as needed.

Grading the Body of Evidence

For the diagnostic test accuracy reviews, we graded the available evidence for each key question using the GRADE system for rating the quality of evidence and strength of recommendations for diagnostic tests.¹⁵ We assessed the strength of the study designs, the quantity and quality of individual studies, and the consistency and precision of the results. We also assessed the indirectness of evidence. For all studies, the outcomes were measures of test accuracy (i.e., true positive, true negative, false positive, false negative), which are surrogates for patient-important outcomes. We determined that true positive and true negative results would improve outcomes that are important to patients. True positive results will lead to administration of effective, safe prophylactic treatment for EIB/EIA; true negative results will spare patients unnecessary treatment or further testing for EIB/EIA. We identified uncertainty about the consequences of false positive results which could lead to unnecessary treatment for EIB/EIA and the potential exclusion of individuals from participating in sports or working in occupations requiring heavy physical demands. We also determined that there was uncertainty about directness for false negative results related to delayed access to prophylactic and/or rescue treatments, ongoing symptoms of EIB/EIA, underperformance in physical activity, and reduced quality of life leading to avoidance of physical activities and sports. This uncertainty about directness resulted in a reduction in the quality of evidence. For each key question the quality of evidence was graded as high, moderate, low or very low.

For the therapy reviews, the strength of evidence for the primary outcome (maximum percent fall in FEV₁ from baseline) was assessed for each key question using the EPC approach to grading the strength of a body of evidence.¹⁶ This approach assesses the evidence based on four domains: risk of bias, consistency, directness, and precision. We classified the strength of evidence as high, moderate, low, or insufficient.

Data Extraction

Data were extracted using standard forms (Appendix C) by one reviewer and checked for accuracy and completeness by a second reviewer. Data extracted for each study included details of study design and inclusion/exclusion criteria, details of the population, details of the index test and reference standard (for the diagnostic test accuracy reviews), intervention and comparator (for the therapy reviews), and results obtained for various outcomes. Reviewers resolved discrepancies in data extraction by consensus or in consultation with a third party.

Data Analysis

The following data assumptions were made and imputations performed to transform reported data into the form required for this report. Graph extraction was performed using CorelDRAW® 9.0 (Corel Corp., Ottawa, Canada). Means were approximated by medians, and 95 percent empirical intervals were used to calculate approximate standard deviations (SD). Because the majority of the included studies in the therapy reviews used a crossover design, standard errors of mean differences were either computed exactly using individual patient data (IPD) or imputed using an estimated within-patient correlation of 0.5.

Diagnostic Test Accuracy Review

Our reference standard was a standardized ECT- either using a treadmill or bicycle ergometer. Our threshold for a positive test on the ECT was a fall in FEV₁ of 10 percent or more from a pre-exercise baseline.¹⁸ Thresholds of 15 percent and 20 percent were examined in sensitivity analyses. The threshold for a positive test for the methacholine challenge was a 20 percent or more drop in FEV₁ at a provocative concentration of less than 8 mg/ml (PC₂₀).¹⁸ For mannitol the threshold was a 15 percent drop in FEV₁ at less than 635mg or a drop of 10 percent between consecutive doses.²³ The threshold for a positive test for EVH, FRAST and sport/venue specific challenges was a fall in FEV₁ of 10 percent or more. Where data were available we conducted sensitivity analyses using a different threshold dose for methacholine (less than 16 mg/ml). True positives, false positives, true negatives, and false negatives were recorded for each of the six index tests. These data were used to calculate sensitivity and specificity for each study. We present individual study results graphically by plotting the estimates of sensitivity and specificity and their 95 percent confidence intervals (95 percent CI) in forest plots. Where there were more than five studies, we plotted the sensitivity and specificity in receiver operating characteristic (ROC) space and present a summary ROC curve. Area under the curve (AUC) was estimated.

Because many of the studies presented IPD, we were able to use our thresholds for both reference and index tests for our primary and sensitivity analyses. Where no IPD were available and a different threshold was used by the study authors, we presented a qualitative summary of the results of the study.

Planned subgroup analyses included age (children [less than 18 years old] versus adult [18 years and older]), different thresholds for positive results, and patients with EIB versus EIA.

Therapy Review

For studies assessing therapy of the five treatments compared with a control or placebo, a mean difference (MD) was calculated for continuous variables and a risk ratio (RR) was calculated for dichotomous variables. Results are reported with accompanying 95 percent CI.

Meta-analyses were conducted using the random effects model where appropriate. The I² statistic was used to assess heterogeneity.¹⁷ Planned subgroup analyses included age (children [less than 18 years old] versus adult [18 years and older]), severity of EIB/EIA as defined by the percent fall index on placebo (mild [less than 30 percent] versus moderate-severe [30 percent or more]), and patients with EIB versus EIA.

Sensitivity analyses were conducted to assess the robustness of the findings across study quality.¹⁶⁰ When meta-analyses had sufficient studies, publication bias was tested visually using the funnel plot. All data pooling was performed using Review Manager 5.0 (The Cochrane Collaboration, Copenhagen, Denmark).

Peer Review

Eight experts in the field (Appendix A) agreed to peer review the draft report and provide comments. Reviewer comments were considered by the UAEPC in preparation of the final report. All peer reviewer comments and the UAEPC disposition of comments were submitted to AHRQ for assessment and approval.

Chapter 3. Results


Diagnostic Test Accuracy Review

Literature Search

The search strategy for the diagnosis of EIB/EIA identified 5,318 citations from electronic databases and six additional references by handsearching (Figure 1). Screening these titles and abstracts identified 434 potentially relevant references. Ten studies could not be retrieved (Appendix D). Most of these were abstracts that were only available in supplementary issues of journals; they were requested through interlibrary loan but did not arrive by the time this report was written. The search update identified an additional six studies for further evaluation. Overall 28 studies met the inclusion criteria for this report; 412 studies were excluded. The included studies addressed the following research questions: self-report (n=2),^{21,22} methacholine (MCH) challenge (n=15),²³⁻³⁷ sport/venue specific challenges (n=54),^{34,38-41} eucapnic voluntary hyperpnea (EVH; n=7),^{34,38,39,42-45} FRAST (n=3),^{36,40,46} and mannitol (n=3).^{23,47}

The main reasons for excluding studies were (1) the diagnostic technique did not assess EIB/EIA (n=158), (2) inappropriate study design (n=116), (3) there was no comparison group (n=46), (4) there were insufficient data to construct a 2x2 table (n=26), (5) the study assessed other diagnostic tests that were not included in this report (n=24), and (6) there was an inappropriate reference standard (n=21). Eleven studies were excluded for other reasons. The list of excluded studies and reasons for exclusion are identified in Appendix D.

Figure 1. Diagnosis of EIB/EIA: Flow diagram for study retrieval and selection



Key Question D–1: Self-Reported History or Symptoms Diary

Description of Included Studies

Two studies^{21,22} met the inclusion criteria for the diagnostic test accuracy review of self-reported history/symptoms diary compared with a standardized exercise challenge test (ECT). Tables 6 and 7 summarize the study and participant characteristics.

In the study by Frobase et al.²¹ 20 junior high school athletes (11 to 15 years) who responded “yes” to the question “do you experience cough after exercise?” were included. They were matched to 20 controls who responded “no” to the same question. All participants underwent a treadmill ECT. They ran for 6 minutes at an intensity of 85 to 90 percent of predicted maximum heart rate. No information about a history of asthma was provided.

In the study by Rupp et al.²² 166 high school athletes (12 to 18 years) completed a self-report questionnaire that included two questions relevant to EIB/EIA (“do you have trouble breathing after running 1 mile and resting?” and “do you have to stop when running for ½ mile?”). Forty-eight students (29 percent) were identified as being at risk for EIB/EIA based on baseline spirometry or by clinical history. All participants underwent a treadmill ECT. They ran for 6 minutes after reaching 80 percent of their predicted maximum heart rate.

Methodological Quality of the Included Studies

Table 8 summarizes the methodological quality of the included studies. The number of “unclear” responses for both studies raises questions regarding bias and generalizability. Neither study had a representative patient spectrum which suggests the possibility of spectrum bias. Blinding to the results of the ECT and the index test was not reported. There were no details about uninterpretable or indeterminate index test results. One study²² did not report their source of funding; one²¹ was supported by government grants. The body of evidence is classified as “low.”

Quantitative Results

The two studies used different thresholds to define a positive result on the ECT. Using a threshold of a maximum percent fall in FEV₁ of 10 percent or more, Frobase et al.²¹ reported a sensitivity of 89 percent (95 percent CI: 67, 99) and a specificity of 86 percent (95 percent CI: 64, 97). In the study group, 17 (85 percent) participants had a positive ECT; in the control group 2 (10 percent) had a positive ECT.

Using a threshold of 15 percent or more, Rupp et al.²² reported a sensitivity of 36 (95 percent CI: 17, 59) and specificity of 85 percent (95 percent CI: 78, 90). Twenty participants (13 percent) had a positive ECT; 30 (18 percent) were at risk of EIB/EIA based on the questionnaire.

Table 6. Description of studies in the diagnostic test accuracy review: Self-report vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (Self-report) Type; Description
Frobese ²¹ 1992	Case control (prospective); self-report first NR; NR NR NR	Treadmill; 6 85-90% max HR; NR PEF at 3 min intervals up to 15 min ≥10% fall FEV ₁	Do you experience cough after exercise?
Rupp ²² 1993	Cross sectional (prospective); self-report first NR; NR; all ECT completed in 1 mo period Aug-Sept 1990; back to back NR	Treadmill; 6 6 mph, 10% grade after HR reached 170 bpm; 45-55% RH, air conditioned 22-25°C After 1 min cooldown, 1, 10, 20, 30 min ≥15% fall FEV ₁	Determination of risk for EIB/EIA based on 3 components of pre-challenge evaluation: self-report questionnaire, physician interview, and resting PFT; participants categorized as 'at risk' if FEV ₁ or FVC ≤80% of predicted values or if FEV ₁ to FVC ratio ≤0.80

bpm = beats per minute; C = Celsius; ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; HR = heart rate; max = maximum; min = minute(s); mph = miles per hour; NR = not reported; PFT = pulmonary function test; RH = relative humidity

Table 7. Description of participants in the diagnostic test accuracy review: Self-report vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (range) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV₁) Baseline FEV₁ (% predicted)
Frobese ²¹ 1992	20; 20 11-15 NR	Junior high school students answering yes to "Do you cough after exercise?" U.S. NR	NR; NR NR NR NR	NR NR
Rupp ²² 1993	166; 166 12-18 121 (72.8)	High school (students in athletic program) U.S. High school athletes	NR; NR NR NR NR	NR NR

EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; NR = not reported

Table 8. Methodological quality of the studies in the diagnostic test accuracy review: Self-report vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Clinical data	Uninterpretable results reported	Withdrawals explained
Frobese ²¹ 1992	No	No	Yes	Yes	Yes	Yes	Yes	U	U	U	U	U	Yes
Rupp ²² 1993	U	U	Yes	Yes	Yes	Yes	U	Yes	U	U	U	U	Yes

U = unclear

Key Question D–2: Methacholine Challenge

Description of Included Studies

Fifteen studies²³⁻³⁷ met the inclusion criteria for the diagnostic test accuracy review of a methacholine (MCH) challenge compared with a standardized exercise challenge test (ECT). All studies were conducted prospectively. Twelve used a cross sectional study design,^{23-25,27-32,34-36} three^{26,33,37} used a case-control design. One was published as a meeting abstract;²⁴ fourteen were published in peer reviewed journals. The median year of publication was 1994 and ranged from 1973 to 2009. Studies were conducted in Europe,^{27,29-31,34,35,37} the United States,^{23,26,28} the Middle East,^{24,25} Asia,^{32,33} and South America.³⁶

The characteristics of the studies are summarized in Table 9. The standardized ECT was performed on a treadmill^{23-28,30,32-34} or a bicycle ergometer.^{29,31,35-37} A positive test was defined at five different cutpoints using the maximum percent fall in FEV₁ of 8 percent or greater,²⁵ 10 percent or greater,^{23,24,30,34,36,37} 15 percent or greater,^{27,31} 18 percent or greater,²⁸ and 20 percent or greater.^{26,29,32,33,35} Most studies reported the target workload as between 80 to 90 percent of maximum predicted heart rate. In one study the target workload was described as “to exhaustion”³⁴ and in another “target ventilation output of more than 60 percent of predicted maximum voluntary ventilation.”³⁷ For two studies, the target workload was not reported.^{24,25}

MCH challenges were based on the 2 minute tidal breathing method^{25,27,29,30,35} or the five breath dosimeter method.^{23,26,28,32-34,36,37} For the remaining studies, the protocol was either specific to the particular study group or was not clearly described.^{24,31}

The baseline characteristics of the participants are presented in Table 10. The number of participants in each study ranged from 12 to 375 (median=52; IQR 28, 59). Six studies involved adults,^{26,28,31,33,34,37} seven involved children,^{24,27,29,30,32,35,36} and two included both adults and children.^{23,25} One study focused on elite female swimmers³⁴ and one on endurance athletes.³⁷ The remaining studies did not report on the level of fitness or sports participation. Most studies included participants who had a history of asthma.^{23-26,28,29,31-33,35,36} Generally, asthma was mild to moderate and stable. For the studies that used a case-control design,^{26,33,37} the control group comprised healthy controls who had no history of asthma.

Methodological Quality of Included Studies


Table 11 summarizes the methodological quality of the included studies. There are several methodological issues in this group of studies. Of concern is the risk of spectrum bias. Most studies did not report how participants were recruited into the study, nor did they describe the inclusion criteria; three studies recruited volunteers.^{26,30,34} Blinding of results of the ECT to the results of the MCH challenge was not reported. Seven studies did not report their sources of funding.^{24,25,27-29,35,36} Four studies received funding support from industry,^{23,30-32} and six were supported by government and/or institution grants.^{26,30,31,33,34,37} The body of evidence is classified as “moderate.”

Quantitative Results

We analyzed the data using two concentration thresholds for MCH: PC₂₀ MCH less than 8 mg/ml and PC₂₀ MCH less than 16 mg/ml. Regardless of the threshold, there was considerable heterogeneity across the studies. Using the PC₂₀ MCH less than 8 mg/ml threshold 331 (57


percent) tested positive for EIB/EIA on the ECT; 416 (71 percent) were positive on the MCH challenge. Sensitivity and specificity both ranged from 0 to 100 percent. (Figure 2)

Figure 2. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT (PC₂₀ MCH less than 8 mg/ml; FEV₁ fall index 10 percent or more for ECT)




Using the PC₂₀ MCH less than 16 mg/ml threshold 420 (53 percent) tested positive for EIB/EIA on the ECT; 498 (63 percent) were positive on the MCH challenge. Heterogeneity in sensitivity estimates was reduced somewhat (range 55 to 100); specificity still ranged from 0 to 100 percent (Figure 3).

Figure 3. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT (PC₂₀ MCH less than 16 mg/ml; FEV₁ fall index 10 percent or more for ECT)




The area under the curve (AUC) of the ROC curve was marginally more than 0.5 using a 10 percent fall in FEV₁ for a positive ECT and a PC₂₀ MCH of less than 8 mg/ml (Figure 4) for a positive MCH. There was no improvement in the AUCs for any of the FEV₁ cutpoints (10, 15 or 20 percent) or the MCH threshold (data not shown).

Figure 4. ROC curve plotting sensitivity vs. specificity: Methacholine challenge vs. ECT (PC₂₀ MCH less than 8 mg/ml; FEV₁ fall index 10 percent or more for ECT)



To explore heterogeneity, we performed a subgroup analysis on studies in which all participants had a diagnosis of asthma.^{24-26,28,29,32,33,35,36} This analysis (Figure 5) reduced the heterogeneity in sensitivity somewhat (range from 66 to 100); however, specificities ranged from 0 to 100 percent. Among this group of participants, 277 (70 percent) tested positive for EIA on the ECT; 350 (88 percent) were positive to the MCH challenge.


Figure 5. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT in studies in which all patients had asthma (PC₂₀ MCH less than 8 mg/ml; FEV₁ fall index 10 percent or more for ECT)



In the subgroup of four studies in which fewer than 50 percent of participants had asthma^{27,30,34,37} heterogeneity remained (Figure 6). Sensitivity ranged from 0 to 50 percent and

specificity from 42 to 84 percent. Among this group of participants, 54 (29 percent) tested positive for EIB/EIA on the ECT; 66 (35 percent) were positive to the MCH challenge. Of note, the study by Pedersen et al.³⁴ focused on elite swimmers; when this study was excluded, sensitivity ranged from 38 to 50 percent and specificity from 42 to 76 percent.

Figure 6. Forest plot of sensitivity and specificity: Methacholine challenge vs. ECT in studies in which less than 50 percent of patients had asthma (PC₂₀ MCH less than 8mg/ml; FEV₁ fall index 10 percent or more for ECT)



We also explored the following possible sources of heterogeneity: adults versus children, treadmill versus bicycle ergometer ECT, the five breath dosimeter versus 2 minute tidal breathing method for the MCH challenge, and cold/dry air versus other conditions during the ECT. There was no improvement in heterogeneity for any of these subgroups.

Table 9. Description of studies in the diagnostic test accuracy review: Methacholine vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (MCH challenge) Type; Description Follow-up time points Author definition of EIB
Anderson ²³ 2009	Cross sectional (prospective); ECT first 5 visits; 1; ECT - MCH: 1-2 d; ECT - Mannitol: 1-2 d; MCH - Mannitol: 1 d NR	Treadmill; 6 80-90% max H; medical grade dry air from Douglas bag; 20-25°C Pre-ECT, 5, 10, 15, 30 min post ECT ≥10% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.0312–16 mg/ml; measured within 3 min after each concentration NR PC ₂₀ MCH ≤16 mg/ml
Avital ²⁴ 1989	Cross sectional (prospective); NR 2; 1; 2 within a 2 mo period NR	Treadmill; 6 6 km/hr at 10% slope RH and temp NR NR ≥10% fall FEV ₁	Steady state tidal breathing technique; concentrations and time NR NR PC ₂₀ MCH <8 mg/ml
Avital ²⁵ 2000	Cross sectional (prospective); MCH first Varied; 3; 85% within 7 d; 15% within 30 d Withheld: Bronchodilators ≥12 hr; SCG ≥20 hr; ICS continued unchanged	Treadmill; 6 (5 km/h, 10% slope) NR RH 48-56%; 22-26°C Pre-ECT, 1, 3, 5, 10, 15 min post ECT ≥8% fall FEV ₁	2 min tidal breathing method; increasing concentrations from 0.03–32 mg/ml measurements at 30, 90, 180 sec after each inhalation NR PC ₂₀ MCH <8 mg/ml
Chatham ²⁶ 1982	Case-control (prospective); MCH first 2; all within 48 hr; 24 hr Withheld: bronchodilators, methylxanthines, antihistamines x 72 hr	Treadmill; 6 90 max HR RH 40.1±13.3%; 22.3±1°C Pre-ECT, 5, 15, 30, 60 min post ECT ≥20% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.156–25 mg/ml in 7 increments NR PC ₂₀ MCH
Clough ²⁷ 1991	Cross sectional (prospective); Randomized order: half MCH first, half ECT first 2; 1; 24 hr Withheld: beta ₂ -agonists x 6 hr; all other med. x 24 hr	Treadmill; 6 4.8 km/hr, 15% slope; 90% max HR RH NR; air conditioned room Pre-ECT, 3, 5, 10 min post ECT ≥15% fall FEV ₁	2 min tidal breathing method; doubling concentrations from 0.025–6.4 μmol NR PC ₂₀ MCH <6.4 μmol

bpm = beats per minute; C = Celsius; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; hr = hour(s); HR = heart rate; km/hr = kilometers per hour; ICS = inhaled corticosteroids; m = meters; μmol = micromole; max = maximum; mcg = microgram; MCH = methacholine; med = medication(s); mg/ml = milligram per milliliter; min = minute(s); mo = month(s); mph = miles per hour; NR = not reported; PC₂₀ = provocative concentration causing a 20% fall in FEV₁; PEF = peak expiratory flow; PSI = pounds per square inch; RH = relative humidity; rpm = revolutions per minute; SABA = short-acting beta-agonist; SCG = sodium cromoglycate; SD = standard deviation; sec = seconds; temp = temperature; wk = week(s)

Table 9. Description of studies in the diagnostic test accuracy review: Methacholine vs. ECT (continued)

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (minutes) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST Type; Description Follow-up time points Author definition of EIB
Eggleston ²⁸ 1979	Cross sectional (prospective); ECT first NR; NR; <3 mo Withheld: SABA x 8 hr; LABA x 12 hr; SCG x 2 wk	Treadmill; 5 90% max HR RH and temp NR Pre-ECT, 1, 5, 10, 15, 20 min post ECT ≥18% fall FEV ₁	5 breath dosimeter method; concentrations NR; 1.5 and 3 min after each NR PC ₂₀ MCH
Foresi ²⁹ 1986	Cross sectional (prospective); MCH first 3; 1; 48 hr 19 on no drugs or SABA as necessary; 2 on SABA (200 mcg 4 /d); Withheld: amcg 2 hr SABA 200 mcg 4 /d	Bicycle ergometer; 6 Resistance of 2.0 - 3.5 watts/kg; workload=90% max HR RH ≤50%; 22°C Pre-ECT, immediately after, 5 min intervals x 30 min post ECT >20% fall FEV ₁	2 min tidal breathing method; doubling concentrations from 0.03 – 65 mg/ml; before, 0.5, 1.5, 3 min after each inhalation PC ₂₀ MCH
Henriksen ³⁰ 2002	Cross sectional (prospective); ECT first 2; 1; 2-7 d after d 1 NR	Treadmill; 6 to 8 5.5% incline; load increased during 1 st 2 min by increasing speed to HR of 180 bpm; load further increased to 90% max HR of 220 bpm minus age during last 4 min RH mean 34%, range 33-35%; mean 22°C, range 20-24°C Pre-ECT immediately after, 3, 6, 10, 15 min post ECT ≥10% fall FEV ₁	2 min tidal breathing method; cumulative dose of 2 mg MCH in 5 increments NR PC ₂₀ .MCH
Kiviloog ³¹ 1973	Cross sectional (prospective); MCH first 1; 2 (MCH in am; ECT in pm); at least 4 hr Withheld: steroids x 8 hr; bronchodilators, coffee, tea, antihistamines, anticholinergics x 24 hr	Bicycle ergometer; load increased every 6 min by 49 (males) or 33 watts (females) to exhaustion (80-102%); RH mean 41, range 15-66%; mean 19°C, range 18-25.5°C, no fan used 2, 6, 10, 15, 30 min post-exercise ≥15% fall in PEF for ECT within 10 min of termination	Concentrations of 0.025 (x5 inhalations), 0.25 (x5), 0.25 (x15), 2.5 (x5); inhale deeply for 2 sec at each breath NR Decrease in PEF by ≥15% below baseline within 3 min of termination of inhalation; MCH negative response decrease at 2.5% concentration

Table 9. Description of studies in the diagnostic test accuracy review: Methacholine vs. ECT (continued)

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST Type; Description Follow-up time points Author definition of EIB
Koh ³² 1996	Cross sectional (prospective); ECT first 2 consecutive d; 1; 17 hr (d1=MCH test at 4 pm; d2=ECT at 9 am) Withheld: no meds or caffeine on test day; ICS x 24 hr; cromolyn sodium x 7d	Treadmill; 6 80-90% max HR (slope/speed adjusted) RH NR; no variations in environmental temp, air conditioned, 3-10 min apart until 60 min post-ECT ≥20% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.075–150 mg/ml in 12 increments; measured 60-90 sec after inhalation NR PC ₂₀ MCH
Lin ³³ 1991	Case-control (prospective); ECT first 2; 1, then 4; MCH then ECT 1-3 wk later NR	Treadmill; 6 3 mph at 10% incline, adjusted until HR reached 90% predicted age max for 4 min RH and temp NR Pre-ECT, 5, 10, 15, 20, 25, 30 min post ECT ≥20% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.1–25.0 in 7 increments NR PC ₂₀ MCH
Pedersen ³⁴ 2008	Cross sectional (prospective); NR 4 visits; NR; at least 24 hr apart NA	Treadmill; 5±1.1 Ran until exhausted at constant speed with gradient increasing 2% every 2 min RH and temp NR Pre-ECT, 1, 3, 5, 10, 15, 20 min post ECT ≥10% fall FEV ₁	5 breath dosimeter method; concentrations NR; measured after each inhalation NR PC ₂₀ MCH ≤2µmol (~4 mg/ml)
Sekerel ³⁵ 1997	Cross sectional (prospective); randomized order of tests 3; 1; within 1 wk at same time of d Withheld: oral med x 24 hr; inhaled med x 12 hr	Bicycle ergometer; 6 90% max HR RH and temp NR 1, 5, 10, 15, 20 min post ECT ≥20% fall FEV ₁	2 min tidal breathing method; increasing concentrations starting at 0.03 mg/ml; measured at 0.5 and 1.5 min after each inhalation NR PC ₂₀ MCH
Souza ³⁶ 2005	Cross sectional (prospective); randomized order of tests 3; 1 (all 8-10 am); min 24 h to 10 d Withheld: coffee, tea, drinks with caffeine x 2 hr; SABA x 12 h; antihistamines x 48 hr (short-acting) x 5 d (long-acting)	Bicycle ergometer; 6 (nose clips) 80-90% max HR after 1-2 min warmup (target 178±7 bpm) compressed air RH ~50%; 21.1±1°C 3, 6, 10, 15, 20, 30 min post ECT ≥10% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.25–25 mg/ml in 6 increments NR PC ₂₀ MCH ≤6.6µ mol
Verges ³⁷ 2005	Case-control (prospective); MCH first 1; 6; mean interval of 6.2±1.5 hr (range=4-10 hr) between MCH and ECT Withheld: SABA x 48 hr; ICS x 3 wk	Bicycle ergometer; 12 at >60% max HR, voluntary ventilation (35 x FEV ₁) RH dry medical air; NR Pre-ECT, 1, 3, 5, 7, 10, 15 min post ECT ≥10% fall FEV ₁	5 breath dosimeter method; increasing concentrations from 0.0156–4 mg in 6 increments; measured 2 min after each inhalation NR PC ₂₀ MCH <4 mg

Table 10. Description of participants in the diagnostic test accuracy review: Methacholine vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS N (%) History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ L % predicted
Anderson ²³ 2009	510; 375 (performed all tests) 24.3±10.2; range 6-50 182 (48.2)	Clinic (referred for investigation of asthma-type symptoms) U.S. NR	Suspected asthma at ≥step 1 NAEPPII asthma severity grading; mild to stable NAEPPII score 1.2±0.5 293 (78) none within 4 wk prior to study NR	3.32±0.82 L 93.6%±10%
Avital ²⁴ 1989	70; 70 11.3; range 5-19 NR	NR Israel NR	Severe=14; moderate=22; mild=34 NR NR NR	NR NR
Avital ²⁵ 2000	135; 128 12.4±3.9; range 6-25 NR	Clinic (pediatric pulmonology) Israel NR	ATS criteria; mild=85 (63.0), moderate=50 (37.0) NR 38 (28.1) inhaled beclomethasone dipropionate NR	NR 86.1±10.1% All but 4 were above 70% predicted, these 4 had mean FEV ₁ 65.8±3.9% predicted
Chatham ²⁶ 1982	25; 25 All: 26.4±4.7, asthmatics: 26.5±4.6 All: 15 (60), asthmatics: 9 (60)	Clinic and newspaper advertising U.S. NR	15 (60); mild (all asymptomatic) 15 (60) 12/15 (80); none for 4 wk History of EIA in asthmatics 11/15 (73.3)	NR All: 78.0±3.0%; asthmatics: 76.6±2.7%
Clough ²⁷ 1991	60; 60 Range 7-8 38 (63.3)	Clinic (all registered to 86 general practitioner offices were sent questionnaire) United Kingdom NR	24 (40) physician Dx or receiving anti-asthma med or parent thought child had asthma NR All taking beta-agonists: 21 inhalation, 3 orally; 3 SCG; 1 oral theophylline Atopy 30 (50); ICS 2 (3.3) NR	NR NR

ATS = American Thoracic Society; BHR = bronchial hyper-responsiveness; CI = confidence interval; d = day(s); Dx = diagnosis; ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); Hx = history; ICS = inhaled corticosteroids; L = liters; MCH = methacholine; NAEPPII = National Asthma Education and Prevention Program; NR = not reported; prn = as needed; SABA = short-acting beta-agonist; SCG = sodium cromoglycate; SD = standard deviation; Tx = treatment; wk = week(s)

Table 10. Description of participants in the diagnostic test accuracy review: Methacholine vs. ECT (continued)

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ (% predicted)
Eggleston ²⁸ 1979	45; 45 21.1±3.1; range 16-30 27 (60)	NR U.S. NR	45 (100) defined by ATS; NR 42 (93.3) 5 (11.1) Most had history of EIA	NR 94.6±3.9%
Foresi ²⁹ 1986	25; 25 12.5±2.8; range 9-19 19(76)	NR Italy NR	25 (100) clinical Hx of asthma; all FEV ₁ >70% predicted, all stable in previous month; 25 (100) none on ICS NR	NR 91.9±9.1%
Henriksen ³⁰ 2002	74; 58 mean 17.9 (95% CI: 17.6, 18.3) 16 (25.4)	Adolescents with wheeze from previous phase of study Norway Physical activity hr/wk, mean (95% CI)=3.1 (2.8-3.5)	NR; beta-agonist=11(19) NR ICS=4(6.6) NR	NR Mean (95% CI)=104(100-107)
Kiviloog ³¹ 1973	57; 57 31; range 15-61 26(45.6)	Clinic (lung clinic outpatients) Sweden NR	57 (100) defined by ATS, NR extrinsic asthma 32 (56.1%) NR 47 (82.5%)	NR NR
Koh ³² 1996	56; 53 9.9±2.5; range 6-15 41(73.2)	NR South Korea NR	53 (100); mild, stable; beta-agonist prn, SCG 11/56 43 (76.8) NR NR	NR 97.7±13.6% (all ≥70% predicted)
Lin ³³ 1991	42 (22 asymptomatic asthma, 20 matched controls); 22 (only asthma pts analyzed) Range 20-40 12(60)	Authors selected subjects China NR	22 asthma patients; stable medicated NR NR NR	Before MCH=2.99±0.48 L, before ECT=2.97±0.45 L NR

Table 10. Description of participants in the diagnostic test accuracy review: Methacholine vs. ECT (continued)

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ % predicted
Pedersen ³⁴ 2008	21; 16 18.3±2.7 0	Elite swimmers (invited to participate) Denmark Athletic (4+ d per wk activity); elite swimmers 22.2±4 hr/wk	None 1 (6.3) NA NR	4.34±0.57 L 110.8±14.6%
Sekerel ³⁵ 1997	12; 12 9.83±1.8 7(58.3)	Clinic (allergy outpatient) Turkey NR	12 (100) confirmed by ATS criteria; stable, varying severity NR 6 (50) Baseline EIB median fall FEV ₁ =22% (range 4.0–35.0)	NR NR
Souza ³⁶ 2005	43; 30 11±3; range 6-15 14 (46.7)	Clinic (pulmonary outpatient) Brazil NR	Hx of ≥2 episodes dyspnea and/or wheezing relieved with bronchodilators; other Dx ruled out; stable at testing NR None NR	2.39±0.7 L 98±12 %
Verges ³⁷ 2005	39=competitive athletes, 13=controls Athletes=22.4±4.8, controls=27±7 Athletes=26(66.7), controls=7(53.8)	Competitive athletes and healthy sedentary subjects France 13 <2 hr physical activity per wk, 39 >12 hr/wk during 4 mo preceding study	NR; NR none had allergic asthma ICS: 2 athletes EIB: 4 athletes	Athletes=4.3±7.5 L, controls=4.24±1.08 L Athletes=106.0±12.1%, controls=110±19%

Table 11. Methodological quality of studies in the diagnostic test accuracy review: Methacholine vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Uninterpretable results reported	Withdrawals explained
Anderson ²³ 2009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	U	Yes	U	Yes
Avital ²⁴ 1989	U	No	U	U	Yes	Yes	No	No	U	U	U	Yes
Avital ²⁵ 2000	U	U	Yes	No	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Chatham ²⁶ 1982	No	U	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Clough ²⁷ 1991	U	U	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Eggleston ²⁸ 1979	U	No	Yes	U	Yes	Yes	Yes	U	U	U	U	Yes
Foresi ²⁹ 1986	U	U	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Henriksen ³⁰ 2002	No	No	Yes	Yes	U	U	U	Yes	U	U	No	No
Kiviloog ³¹ 1973	U	No	Yes	No	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Koh ³² 1996	U	No	U	U	Yes	Yes	Yes	Yes	U	U	U	Yes
Lin ³³ 1991	No	No	Yes	Yes	U	U	Yes	U	U	U	Yes	No
Pedersen ³⁴ 2008	No	No	U	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
Sekerel ³⁵ 1997	U	U	U	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
De Souza ³⁶ 2005	U	No	Yes	Yes	U	Yes	Yes	Yes	U	U	U	Yes
Verges ³⁷ 2005	U	No	U	No	Yes	Yes	Yes	Yes	U	U	Yes	Yes

U = unclear

Key Question D–3: Sport or Venue Specific Exercise Challenges

Description of Included Studies

Five studies^{34,38-41} met the inclusion criteria for the diagnostic test accuracy review of sport or venue specific exercise challenges compared with a standardized exercise challenge test (ECT). Three studies focused on swimming challenges,^{34,38,40} one assessed short track speed skating and biathlon field challenges,³⁹ and one assessed five cold weather sport challenges.⁴¹ Tables 12 and 13 summarize the study and participant characteristics.

Dickinson et al.³⁹ included elite winter athletes who were members of Great Britain's national teams for short track speed skating (n=10) and biathlon (n=4). The sport specific challenge for speed skaters involved indoor skating for 6 minutes at an 11 to 12 second pace per 250 meter lap. The sport specific challenge for biathletes was a 20 minute simulated race in Finland. The standardized ECT was performed on a treadmill for 8 minutes; the intensity level was more than 90 percent of maximum heart rate for the final 4 minutes. As part of this study, participants also completed an EVH challenge test (see Key Question D-4 for details). Two (14 percent) participants had a previous diagnosis of asthma and were taking asthma medication. Rundell et al.⁴¹ included 23 elite winter athletes who competed in a race or race simulation at their regular sport (biathlon, short-track speed skating, Nordic combined, cross country skiing, or kayaking) and demonstrated a drop in FEV₁ of 10 percent or more. Seven of the participants had been diagnosed with EIA as children but took no medications at the time of the study.

Castricum et al.³⁸ included 33 elite swimmers who were members of Australia's state, national or international teams. The swim challenge required participants to swim for 8 minutes at more than 85 percent of their predicted maximum heart rate in an indoor 50 meter pool. The standardized ECT was a bicycle ergometer test; participants cycled at more than 90 percent of their predicted maximum heart rate. As part of this study, participants also completed an EVH challenge test (see Key Question D-4 for details). Thirteen (39 percent) participants had a previous diagnosis of asthma; of these, 11 were taking asthma medication.

In the study by Pedersen et al.³⁴ 16 elite (national or international caliber) female swimmers from Denmark underwent four different challenge tests: swimming, MCH, EVH, and a standardized ECT performed on a treadmill (see also Key Questions D-2 and D-4). The swim challenge was carried out under race conditions at the National Danish Swimming Championships. The distances were 200 meters (n=11), 400 meters (n=3) and 800 meters (n=2). For the treadmill test, the participants were instructed to run until exhaustion. None of the swimmers had a previous diagnosis of asthma.

Reggiani et al.⁴⁰ assessed nine competitive swimmers from Italy; all had been involved in competitive swimming for at least 5 years. The swim challenge required participants to swim for 8 minutes at 80 percent of their maximum heart rate in an indoor 25 meter pool. The standardized ECT was a bicycle ergometer test; participants cycled at 80 percent of their maximum heart rate for 8 minutes. As part of this study, participants also completed a FRAST (see Key Question D-5 for details). All participants had a history of atopic diseases; they were asymptomatic at the time of the challenge tests.

Methodological Quality of the Included Studies

Table 14 summarizes the methodological quality of the included studies. There are several methodological issues. None had a representative patient spectrum which suggests the possibility of spectrum bias. Blinding of assessment of the ECT to the results of the index test was not reported. Two studies^{38,40} did not report their source of funding; one reported industry funding;³⁹ one was supported by government grants,³⁴ and one by the United States Olympic Committee.⁴¹ The body of evidence is classified as “low.”

Quantitative Results

In the study by Dickinson et al.³⁹ three (21 percent) athletes had a positive test on the sport specific challenge using a FEV₁ fall index of 10 percent or more. None of the participants had a positive test on the ECT; therefore, sensitivity could not be calculated. Specificity of the sport specific challenge was 79 percent (95 percent CI: 49, 95) indicating an 80 percent probability that for participants who do not have EIB/EIA, the sport challenge would correctly identify them as not having EIB/EIA. All of the athletes in the study by Rundell et al.⁴¹ were positive on a sport specific challenge. Five were also positive on an ECT at 95 percent of peak heart rate for 8 minutes. Sensitivity was 100 percent (95 percent CI: 48, 100). Overall, 5 (14 percent) of the cold weather athletes were positive for EIB/EIA on the ECT; 21 (57 percent) were positive for EIB/EIA on cold air challenges. None of the participants had a negative test on the sport specific challenge.

The sensitivity of the swimming challenge tests ranged from 0⁴⁰ to 50 percent³⁴ (Figure 7). The specificity ranged from 83 to 100 percent. Overall, 11 (19 percent) of the swimmers were positive for EIB/EIA on the ECT; 5 (9 percent) were positive for EIB/EIA on the swimming challenge.

Figure 7. Forest plot of sensitivity and specificity: Sport specific challenges vs. ECT (FEV₁ fall index 10 percent or more)




Table 12. Description of studies in the diagnostic test accuracy review: Sport specific vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (Sport specific challenge) Type; Description Follow-up time points Author definition of EIB
Castricum ³⁸ 2008	Cross sectional (prospective); randomized order of tests 3; 1; between 1 and 7 d Asthma med withheld for designated time	Bicycle ergometer; 8 91±4.8% max HR; RH 60.5±2.1%; 21±0.8°C 1, 3, 5, 7, 10 min post ECT ≥10% fall FEV ₁	Swimming: 50 m chlorine and ozone filtered indoor pool; temp: 30±2.7°C; pool temp: 27±0.3°C; RH: 82±4.58%; swim x 8 min to maintain >85% max HR 1, 3, 5, 7, 10 min post challenge ≥10% fall FEV ₁
Dickinson ³⁹ 2006	Cross sectional (prospective); randomized order of tests NR Asthma med withheld: ICS and LABA x 3 d; SABA x 1 d	Treadmill; 8 90% max HR; RH 56%; 18°C 3, 5, 10, 15 min post ECT ≥10% fall FEV ₁	Skating: indoor speed skating rink; 8°C, RH 35%; 6 min, Biathlon: simulated outdoor race x 20 min; temp 1-2°C; RH 31- 34% 3, 5, 10, 15 min post challenge ≥10% fall FEV ₁
Pedersen ³⁴ 2008	Cross sectional (prospective); NR 4 visits; NR; at least 24 hr apart NA	Treadmill: constant speed, incline increased every 2 min; 5±1.1 min; ran to exhaustion; RH and temp NR 0, 1, 3, 5, 10, 15, 20 min post ECT ≥10% fall FEV ₁	Swimming: Race conditions at national championships; swimmers chose favorite distance from 200 m to 800 m; 2 min at highest possible speed; temp and RH NR 1, 3, 5, 10, 15, 20 min post challenge ≥10% fall FEV ₁
Reggiani ⁴⁰ 1988	Cross sectional (prospective); NR 3; 1; ≥3 d to <1 wk None on ICS	Bicycle ergometer; 8 80% max HR; RH 76%; 22°C, in environmental chamber 5, 10, 15, min post ECT ≥20% fall FEV ₁	Swimming: 25 m indoor pool, pool temp 26°C; 8 min at 80% max HR 5, 10, 15 min post challenge ≥20% fall FEV ₁
Rundell 2000	Cross sectional (prospective); Sport specific first 2; 1 Different days None on asthma med	Treadmill: 8 (no warmup) 95% peak HR RH 60%; 21°C 5, 10, 15, min post ECT ≥10% fall FEV ₁	Biathlon, short-track speed skating, cross country skiing, Nordic combined, kyaking: followed usual warmup routine then performed in competition; duration from 1 min 20 sec for speed skaters to >1h for cross country skiers 5, 10, 15 min post competition ≥10% fall FEV ₁

C = Celsius; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroids; LABA = long-acting beta-agonist; m = meters; max = maximum; med = medication(s); min = minute(s); NA = not applicable; NR = not reported; RH = relative humidity; SABA = short-acting beta-agonist; temp = temperature; wk = week(s)

Table 13. Description of participants in the diagnostic test accuracy review: Sport specific vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ % predicted
Castricum ³⁸ 2008	33; 33 18.2±4.9 23 (69.7)	Competative athletes (swimmers; volunteers) Australia Athletic	13 (39.4); NR NR 3 ICS; 3 ICS+LABA; 1 MSC; 4 SABA prn; 2 no med; No	4.45±0.86 L 114.73±14.97%
Dickinson ³⁹ 2006	14; 14 22.6±5.7 NR	Competative athletes (speed skating, biathalon; volunteers) United Kingdom Athletic	2 (14); NR NR 2 (14) ICS or SABA No	4.4±0.4 L 105±11.8%
Pedersen ³⁴ 2008	21; 16; 18.3±2.7; range 15–25 0	Competative athletes (swimmers; invited) Denmark Athletic (4+ days per wk activity); elite swimmers 22.2±4 hr/wk	None 1 (6.3) NA NR	4.34±0.57 L 110.8±14.6%
Reggiani ⁴⁰ 1988	9; 9 15.1±2.0 7 (77.8)	Competitive athletes (swimmers; volunteers) Italy Athletic average 40 km/wk	NR; stable and asymptomatic at testing 9 (100) NR NR	4.18±1.16 L NR
Rundell ⁴¹ 2000	23; 23 20.0±4.5 14 (61)	Competitive athletes (biathlon, short-track speed skating, cross- country skiing, Nordic combined, kyaking; invited) United States Elite cold weather athletes	7 (30) EIA as children; NR None on oral/inhaled med 23 (100)	4.76±1.0 L All >100%

Dx = diagnosis; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); Hx = history; ICS = inhaled corticosteroids; km = kilometers; LABA = long-acting beta-agonist; L = liters; MCS= mast cell stabilizers; NA = not applicable; NR = not reported; prn = as needed; SABA = short-acting beta-agonist; SD = standard deviation; wk = week(s)

Table 14. Methodological quality of studies in the diagnostic test accuracy review: Sport specific vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Uninterpretable results reported	Withdrawals explained
Castricum ³⁸ 2008	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Dickinson ³⁹ 2006	No	No	Yes	U	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Pedersen ³⁴ 2008	No	No	U	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
Reggiani ⁴⁰ 1988	No	U	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Rundell ⁴¹ 2000	No	U	Yes	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes

U = unclear

Key Question D–4: Eucapnic Voluntary Hyperpnea

Description of Included Studies

Seven studies^{34,38,39,42-45} met the inclusion criteria for the diagnostic test accuracy review of eucapnic voluntary hyperpnea (EVH) compared with a standardized ECT. All seven studies were conducted prospectively. Six^{34,38,39,43-45} used a cross sectional design, and one⁴² used a case-control design with healthy controls. They were all published in peer reviewed journals. The median year of publication was 2005 and ranged from 1984 to 2008. Studies were conducted in Europe,^{34,39,45} Australia,³⁸ and the United States.⁴²⁻⁴⁴

The characteristics of the studies are summarized in Table 15. The standardized ECT was performed on a treadmill^{34,39,43,45} or a bicycle ergometer.^{38,42,44} A positive test was defined as a FEV₁ fall index of 10 percent or more,^{34,38,39,44} or 15 percent or more.⁴⁵ Two studies did not report their definitions of a positive ECT.^{42,43} The target workload was reported as 90 percent of maximum heart rate,^{38,39} pulse rate of greater than 170 after 2 minutes of running (equivalent to 80 percent of predicted maximum heart rate),⁴⁵ “until exhaustion,”³⁴ “until a symptom limited maximum exercise capacity,”⁴² and “highest intensity.”⁴⁴ One study⁴³ did not report the criteria for target workload.

Most studies used five percent CO₂ air content for the EVH challenge at room temperature. One study⁴² also tested participants with cold air. The duration of hyperpnea was either 5 minutes⁴² or 6 minutes.^{34,38,39,44,45} One study⁴³ did not report duration. During the EVH challenge, the target ventilation rate was set at 80 percent maximum voluntary ventilation (MVV),⁴² 85 percent MVV,^{38,44} a minimum ventilation of 30 times FEV₁ equivalent to MVV,³⁴ or 40 or more liters per minute.⁴³ Two studies^{39,45} did not specify the rate of target ventilation.

The baseline characteristics of the participants are presented in Table 16. The number of participants in each study ranged from 10 to 33. Three studies included adults only,^{39,42,44} one included children only,⁴⁵ two included both adults and children,^{34,38} and one⁴³ did not report the age of participants. Four studies^{34,38,39,44} focused on elite athletes; three^{42,43,45} did not report the level of fitness or sports participation. Fourteen³⁹ to 100 percent of participants^{43,45} had a diagnosis of asthma in the five studies that reported this. In three studies⁴³⁻⁴⁵ 100 percent of participants had a history of EIB/EIA.

Methodological Quality of Included Studies

Table 17 summarizes the methodological quality of the included studies. As a group, there are methodological issues that limit interpretation and generalizability of the results. Of concern is the risk of spectrum bias in all studies. Either the participants recruited into the studies were volunteers,^{34,38,39,42,44} or the recruitment source and methods were not reported.^{43,45} In some studies all participants had a history of EIB/EIA⁴³⁻⁴⁵ and therefore are not representative of the spectrum of patients who might be tested for EIB/EIA. Blinding of results of the ECT to the results of the EVH challenge was not reported. Four studies did not report their sources of funding.^{38,42,43,45} Two studies received funding support from industry,^{39,44} and one was supported by government and institution grants.³⁴ The body of evidence is classified as “low.”


Quantitative Results

A total of 138 participants were studied; 42 (30 percent) tested positive for EIB/EIA on the ECT and 74 (54 percent) were positive using EVH. Overall, the sensitivity and specificity of the

seven studies were heterogeneous with values ranging from 25 to 90 percent for sensitivity and 0 to 71 percent for specificity (data not shown).


To explore the heterogeneity, we conducted a post hoc subgroup analysis of participants who did not have a history of EIB/EIA. This included all participants from three studies^{34,38,39} and one group of participants from a fourth study.⁴² Among these 83 individuals, 10 (12 percent) tested positive on the ECT while 44 (53 percent) tested positive using EVH. Heterogeneity was somewhat reduced and the range of sensitivity and specificity was narrowed—25 to 75 percent and 29 to 67 percent, respectively (Figure 8). Of note, the studies by Castricum et al.,³⁸ Dickinson et al.,³⁹ and Pedersen et al.³⁴ focused on elite athletes (proportion with asthma 39, 14 and 0 percent, respectively).

Figure 8. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (participants with no history of EIB/EIA; FEV₁ fall index 10 percent or more for ECT and EVH)




For the three studies⁴³⁻⁴⁵ and one group⁴² in which all participants had a history of EIB/EIA the sensitivity of EVH was higher, ranging from 71 to 90 percent⁴³ (Figure 9). Among these 55 people, 32 (58 percent) tested positive for EIB/EIA using the ECT and 30 (55 percent) tested positive using EVH.

Figure 9. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (participants with a history of EIB/EIA; FEV₁ fall index 10 percent or more for ECT and EVH)



Subgroup and sensitivity analyses. Sensitivity analyses were performed using different thresholds for a positive EVH challenge. Using a threshold of a FEV₁ fall index of 15 percent or more for a positive EVH challenge, the sensitivity improved; however, there was still considerable heterogeneity (Figure 10). The results of the analyses using a threshold of 20 percent or more were not substantially different (data not shown). In a subgroup analysis on studies enrolling athletes the sensitivity ranged 25 to 88 percent; specificity ranged 0 to 67 percent (data not shown).

Figure 10. Forest plot of sensitivity and specificity: Eucapnic voluntary hyperpnea vs. ECT (all participants; threshold for a positive test is a FEV₁ fall index 10 percent or more for ECT and 15 percent or more for EVH)



Cold air versus warm air. In the study by Eliasson et al.⁴² participants performed EVH tests while inspiring air at room temperature or inspiring air cooled to minus 18°C to minus 26°C. Despite the increased conditioning of the air required during the cold air trial, there was no difference in post-EVH FEV₁ response between the cold versus room temperature challenges (data not shown).

Table 15. Description of studies in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (EVH) Type; Description Follow-up time points Author definition of EIB
Castricum ³⁸ 2008	Cross sectional (prospective); randomized order of tests 3; 1; between 1 and 7 d Asthma med withheld	Bicycle ergometer; 8 91±4.8% max HR RH 60.5±2.1%, 21±0.8°C 1, 3, 5, 7, 10 min post ECT ≥10% fall FEV ₁	Gas (dry) 5% CO ₂ , 21% O ₂ , 74% N ₂ ; 21±0.8°C, RH 60.5±2.1%; Load=85% MVV x 6 min 1, 3, 5, 7, 10 min post challenge ≥10% fall FEV ₁
Dickinson ³⁹ 2006	Cross sectional (prospective); randomized order of tests NR Asthma med withheld before tests (ICS x 3 d; LABA x 2 d, SABA x 1 d)	Treadmill; 8 90% max HR RH 56%, 18°C 3, 5, 10, 15 min post ECT ≥10% fall FEV ₁	Gas (dry) 5% CO ₂ , 21% O ₂ , N ₂ , 74%; 19.1°C, RH <2%; Load: hyperventilate x 6 min 1, 3, 5, 7, 10 min post challenge ≥10% fall FEV ₁
Eliasson ⁴² 1992	Case-control (prospective); randomized order of tests At least 4; 1; all challenges between 7-9 am No caffeine x 12 hr prior to tests SABA/LABA discontinued	Bicycle ergometer at 60 rpm with resistance increased by 25 watts/min; NR Symptom-limited max exercise capacity ambient indoor conditions 0, 5, 10, 15 min post ECT NR	1) Gas (dry) compressed air 5% CO ₂ x 5 min at 80% MVV; 2) Gas (cold air, -18 to -26°C) 5% CO ₂ x 5 min at 80% MVV 1 then 5 min intervals for 15 min post challenge NR
Pedersen ³⁴ 2008	Cross sectional (prospective); NR 4 visits; NR; at least 24 hr apart NA	Treadmill at constant speed; incline increased 2% every 2 min; 5±1.1 until exhaustion NR 0, 1, 3, 5, 10, 15, 20 min post ECT ≥10% fall FEV ₁	Gas (dry) 5% CO ₂ , 21% O ₂ , 74% N ₂ ; room temp x 6 min; Load: 85% MVV 0, 1, 3, 5, 10, 15, 20 min post challenge ≥10% fall FEV ₁
Rosenthal ⁴³ 1984	Cross sectional (prospective); NR 2; 1; >24 hr otherwise unspecified NR	Treadmill; NR; NR dry air, room temperature NR NR	Gas (dry) 5% CO ₂ , 21% O ₂ , 74% N ₂ ; room temp; Load: hyperventilate at ≥40 L/min NR NR
Rundell ⁴⁴ 2005	Cross sectional (prospective); randomized order of tests 4; 1; 48-72 hr NR	Bicycle ergometer; 6 Highest intensity RH 50%, -3°C 5, 10, 15 min post ECT ≥10% fall FEV ₁	Gas (dry) 5% CO ₂ , 21% O ₂ , 74% N ₂ ; 21°C, RH 40%; Load: 85% MVV 5, 10, 15 min post challenge ≥10% fall FEV ₁

bpm = beats per minute; C = Celsius; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroids; L/min = liters per minute; LABA = long-acting beta-agonist; m = meters; μmol = micromole; max = maximum; med = medication(s); mg/ml = milligram per milliliter; min = minute(s); MMV = maximal voluntary ventilation; NR = not reported; RH = relative humidity; PEF = peak expiratory flow; rpm = revolutions per minute; SABA = short-acting beta-agonist; temp = temperature

Table 15. Description of studies in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT (continued)

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (EVH) Type; Description Follow-up time points Author definition of EIB
Schmidt ⁴⁵ 1983	Cross sectional (prospective); randomized order of tests 2; 1; 24 hr All med x 8 hr prior to tests	Treadmill; 6; HR >170 bpm after 2 min running (~80% max HR) RH 40%, 21°C 0, 1, 3, 5, 10, 15 min post ECT ≥15% fall in PEF	Gas 5% CO ₂ , 21% O ₂ , 74% N ₂ ; 21°C, RH 40% ; Load: hyperventilate vigorously x 6 min NR >15% fall in PEF from baseline

Table 16. Description of participants in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%) History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ % predicted
Castricum ³⁸ 2008	33; 33 18.2±4.9 23 (69.7)	Athlete volunteers at state level or above Australia Athletic	13 (39.4); NR NR 3 ICS; 3 ICS+LABA; 1 mast; 4 SABA as needed; 2 no med NR	4.45±0.86 L 114.73±14.97%
Dickinson ³⁹ 2006	14; 14 22.6±5.7 NR	Athlete volunteers from Great Britain short track speed skating and biathlon teams United Kingdom Athletic	2 (14) Hx of asthma; NR NR 2 (14) treated with ICS or SABA NR	4.4±0.4 L 105±11.8%
Eliasson ⁴² 1992	40; 40 Range 22–42 33 (82.5)	Clinic (from pulmonary clinic with suspected EIB; healthy controls with no symptoms of EIB), volunteers U.S. NR	9 (23) family Hx of asthma; NR; 20 (50) self-report: post-exercise wheeze=13; dyspnea out of proportion to level of exertion=11; chest tightness=8 16 (40) seasonal allergies; 5 (13) food allergies None on ICS or NSAIDs 20 had EIB; 20 did not	NR EIB=100.1±11.7% Control=104.5±9.8%
Pedersen ³⁴ 2008	21; 16 18.3±2.7 0	Athletic team of elite swimmers (invited to participate) Denmark Athletic (4+ d/wk activity), elite swimmers 22.2±4 hr/wk	None; NA 1 (6.3) NA NR	4.34±0.57 L 110.8±14.6%
Rosenthal ⁴³ 1984	10; 10 NR NR	NR U.S. NR	10 (100); NR NR NR 10 (100)	NR NR
Rundell ⁴⁴ 2005	11; 11 22.8±6.8 8 (72.7)	11 volunteers, EIB positive, recreational and college athletes U.S. Athletic	4 (36); 4 mild NR NR 11 (100)	4.0±0.75 L 98.4±14.2%
Schmidt ⁴⁵ 1983	14; 14 11.6; range 8-14 NR	NR Denmark NR	14 (100); NR NR NR 14 (100)	NR NR

Dx = diagnosis; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; Hx = history; ICS = inhaled corticosteroids; LABA = long-acting beta-agonist; L = liters; med = medication(s); min = minute(s); NA = not applicable; NSAID=non-steroidal anti-inflammatory; NR = not reported; PEF = peak expiratory flow; SABA = short-acting beta-agonist; SD = standard deviation; wk = week(s); y = year

Table 17. Methodological quality of studies in the diagnostic test accuracy review: Eucapnic voluntary hyperpnea vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Uninterpretable results reported	Withdrawals explained
Castricum ³⁸ 2008	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Dickinson ³⁹ 2006	No	No	Yes	U	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Eliasson ⁴² 1992	U	Yes	U	Yes	Yes	Yes	U	Yes	U	U	Yes	Yes
Pedersen ³⁴ 2008	No	No	U	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
Rosenthal ⁴³ 1984	No	No	U	Yes	Yes	Yes	No	No	U	U	Yes	Yes
Rundell ⁴⁴ 2005	No	No	U	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
Schmidt ⁴⁵ 1983	No	No	U	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes

U = Unclear

Key Question D–5: Free Running Asthma Screening Test

Description of Included Studies

Three studies^{36,40,46} met the inclusion criteria for the diagnostic test accuracy review of a free running asthma screening test (FRAST) compared with a standardized exercise challenge test (ECT). All studies were conducted prospectively; two used a cross sectional design^{36,40} and one used a case-control design with healthy controls.⁴⁶ The studies were published in peer reviewed journals in 1988,⁴⁰ 2005³⁶ and 2008.⁴⁶ The studies were conducted in Europe^{40,46} and South America.³⁶

The standardized ECT was performed on a treadmill⁴⁶ and a bicycle ergometer.^{36,40} All free running tests took place indoors. Garcia de la Rubia et al.⁴⁶ defined a positive test as a FEV₁ fall index of 20 percent or more on the treadmill and a 16.5 percent or more for the FRAST. Among children with asthma the maximum heart rate ranged from 70 to 90 percent in treadmill running and 82 to 93 percent in free running. Results were not reported for the control group. Reggiani et al.⁴⁰ defined a positive test as a FEV₁ fall index of 20 percent or greater on the bicycle ergometer and the FRAST. The target workload was 80 percent of maximum heart rate for both tests. As part of the study the authors also assessed the diagnostic characteristics of a sport specific (swimming) challenge (see Key Question D-3 for details). Souza et al.³⁶ defined a positive test as a FEV₁ fall index of 10 percent or greater for both the ECT and FRAST. The target workload was between 80 and 90 percent of maximum heart rate for both tests. The characteristics of the studies are summarized in Table 18.

The baseline characteristics of the participants are presented in Table 19. Sixty people were enrolled in the study by Garcia de la Rubia et al.,⁴⁶ 30 had extrinsic asthma but were asymptomatic at testing. The 30 healthy controls had never presented with symptoms of asthma and had no history of allergy. The nine competitive swimmers who participated in the study by Reggiani et al.⁴⁰ all had a history of atopy but were asymptomatic at the time of testing. In the study by Souza et al.³⁶ the 30 participants analyzed had intermittent asthma defined as at least two episodes of dyspnea and/or wheezing relieved with the use of bronchodilators.


Methodological Quality of the Included Studies

Table 20 summarizes the methodological quality of the included studies. Overall there were concerns with the methodological quality of the studies. Generalizing the results to a target population of people with suspected EIB/EIA may be limited as none of the studies had representative spectrum of participants. Blinding of assessment of the ECT to the results of the FRAST was not reported. None of the studies reported their source of funding. The body of evidence is classified as “very low.”

Quantitative Results

For two studies^{36,40} the sensitivity and specificity could be calculated using a FEV₁ fall index of 10 percent or more on both challenges. The sensitivity of FRAST was 60 and 67 percent; specificity was 47 and 67 percent (Figure 11). Overall, 13 (38 percent) participants had a positive ECT; 18 (53 percent) had a positive FRAST.

Figure 11. Forest plot of sensitivity and specificity: FRAST vs. ECT (FEV₁ fall index ≥10%)



Garcia de la Rubia et al.⁴⁶ used a FEV₁ fall index of 20 percent or more as the threshold for a positive test for the ECT and 16.5 percent or more for the FRAST. Based on these thresholds the sensitivity was 53 percent (95 percent CI: 34, 72) and the specificity was 100 percent (94 percent CI: 88, 100). Thirty (50 percent) participants had a positive ECT; 16 (27 percent) had a positive FRAST.

Table 18. Description of studies in the diagnostic test accuracy review: FRAST vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (min) Load; Environmental conditions Follow-up time points Author definition of EIB	INDEX TEST (FRAST) Type; Description Follow-up time points Author definition of EIB
Garcia de la Rubia ⁴⁶ 1998	Case-control (prospective); NR 2; 1; within 7 d NR	Treadmill; 6-8 Variable speed/incline 5%; 70-90% max HR; RH 53.69±5.34%, 19.06±1.39°C 2, 5, 10, 15, 20 min post ECT ≥20% fall FEV ₁	Indoor sports center; 6-8 min; 82-93% max HR; RH 54.73±3.41%, 19.96±1.01°C NR ≥16.5% fall FEV ₁
Reggiani ⁴⁰ 1988	Cross sectional (prospective); NR 3; 1; ≥3 d to <1 wk None on ICS	Bicycle ergometer; 8 80% max HR; RH 76%, 22°C; in environmental chamber 5, 10, 15 min post ECT ≥20% fall FEV ₁	25 m indoor pool, 8 min at 80% max HR; RH NR; pool temp 26°C; 5, 10, 15 min post challenge; ≥20% fall FEV ₁
Souza ³⁶ 2005	Cross sectional (prospective); Randomized order of tests 3; 1 (all 8-10 am); min 24 hr to 10 d None; asthma med stopped based on guidelines	Bicycle ergometer; 6 90-100% max HR; RH 50%, 21.1±1°C, 3, 6, 10, 15, 20, 30 min post ECT ≥10% fall FEV ₁	Indoors along 50 m corridor; 6 min; 80-90% max HR; RH 50%, 22±2°C, wore nose clips 3, 6, 10, 15, 20, 30 min post challenge ≥10% fall FEV ₁

d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroids; m = meters; max = maximum; MCH = methacholine; med = medication(s); mg/ml = milligram per milliliter; min = minute(s); NR = not reported; RH = relative humidity; temp = temperature

Table 19. Description of participants in the diagnostic test accuracy review: FRAST vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ % predicted
Garcia de la Rubia ⁴⁶ 1998	60; 60 Asthma: 9.8±1.9, Control: 10.7±2.0 NR	University medical sports center Spain NR	Asthma group: 30 (100); stable 30 (100) NR NR	Asthma group: FVC ≥65% predicted NR
Reggiani ⁴⁰ 1988	9; 9 15.1±2.0 7 (77.8)	Competitive swimmers (volunteers) Italy Athletic average 40 km/wk	NR 9 (100); stable and asymptomatic at testing NR NR	4.18±1.16 L NR
Souza ³⁶ 2005	43; 30 11±3; range 6-15 14 (46.7)	Pulmonary outpatient clinic Brazil NR	30 (100); Intermittant NR 0 (0) NR	2.39±0.7 L 98±12%

EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroids; km/wk = kilometers per week; L = liters; NR = not reported; SD = standard deviation

Table 20. Methodological quality of studies in the diagnostic test accuracy review: FRAST vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Uninterpretable results reported	Withdrawals explained
Garcia de la Rubia ⁴⁶ 1998	U	No	U	Yes	Yes	Yes	Yes	Yes	U	U	Yes	U
Reggiani ⁴⁰ 1988	No	U	Yes	Yes	Yes	Yes	Yes	Yes	U	U	Yes	Yes
Souza ³⁶ 2005	U	No	Yes	Yes	U	Yes	Yes	Yes	U	U	U	Yes

U = unclear

Key Question D–6: Mannitol Challenge

Description of Included Studies

Three studies^{23,47,52} met the inclusion criteria for the diagnostic test accuracy review of Mannitol compared with a standardized exercise challenge test (ECT). All studies used a cross sectional design and all were conducted prospectively. The characteristics of the studies and the participants are summarized in Tables 21 and 22.

In the study by Anderson et al.²³ the standardized ECT was performed on a treadmill. The target workload was between 80 and 90 percent of maximum heart rate. A positive test was defined as a FEV₁ fall index of 10 percent or greater. A positive test for the mannitol challenge was defined as a FEV₁ fall index of 15 percent or more or a fall of 10 percent or more between consecutive doses. As part of the study the authors also compared the ECT to a MCH challenge (See Key Question D-2). In total, there were 510 participants enrolled, 375 underwent all three challenge tests and were included in the final analyses. Both children (26 percent) and adults (74 percent) were included in the study. Participants had symptoms suggestive of asthma but none had a confirmed diagnosis. Symptoms suggested mild, persistent asthma (i.e., symptoms two or more times per week; asymptomatic between exacerbations; exacerbations of only a few hours to a few days; night time symptoms two or more times per month).¹⁰⁹ Seventy-eight percent of participants were atopic.

Brannan et al.⁴⁷ used a standardized bicycle ergometer challenge. The target workload was between 90 and 100 percent of maximum heart rate. A positive test was defined as a FEV₁ fall index of 10 percent or greater. A positive test for the mannitol challenge was defined as a FEV₁ fall index of 15 percent or more. As part of the study the authors also compared the ECT to an EVH challenge (See Key Question D-4). In total 36 adults were enrolled in the study; however, only 23 (64 percent) completed both the mannitol challenge and the ECT. All participants had atopic asthma, were taking asthma medications, and had a self-reported history of EIA.

In the study by Kersten et al.⁵² the ECT was performed on a treadmill. The target workload was approximately 90 percent of predicted maximum heart rate for 6 minutes. A positive test for both the ECT and the mannitol challenge was defined as a FEV₁ fall index of 15 percent or greater. In total, 33 children were enrolled; 25 underwent both challenge tests and were included in the final analyses. All children had a history of allergic asthma and EIA.

Methodological Quality of Included Studies

Table 23 summarizes the methodological quality of the three studies. Of concern is the risk of spectrum bias in the studies by Brannan et al.⁴⁷ and Kersten et al.⁵² Participants were volunteers who had a history of EIA and are not representative of the spectrum of patients who might be tested for EIB/EIA. Blinding of the results of the ECT and the index test was not reported. There were no details about uninterpretable or indeterminate index test results in two of the three trials. All studies reported their sources of funding: Anderson et al.²³ received funding support from industry; Brannan et al.⁴⁷ and Kersten et al.⁵² were supported by government grants. The body of evidence is classified as “moderate.”

Quantitative Results

Using the threshold of a FEV₁ fall index of 10 percent or more for the ECT, 23 (100 percent) participants in the Brannan et al.⁴⁷ study were diagnosed with EIA; 22 (96 percent) were positive

on the mannitol challenge. The sensitivity was 96 percent (95 percent CI: 78, 100). Specificity could not be calculated as none of the participants tested negative on the ECT (Figure 12).

Anderson et al.²³ reported a sensitivity of 58 percent (95 percent CI: 50, 66) and a specificity of 65 percent (95 percent CI: 58, 72) (Figure 12). The ECT diagnosed 163 (44 percent) participants with EIA; 168 (45 percent) were positive on the mannitol challenge.

In the study by Kersten et al.⁵² sensitivity was 69 percent (95 percent CI: 41, 89) and specificity was 78 percent (95 percent CI: 40, 97) (Figure 12). The ECT diagnosed 16 (64 percent) participants with EIA; 13 (52 percent) were positive on the mannitol challenge. Three participants had to terminate the mannitol challenge due to persistent cough and were excluded from analysis.

Figure 12. Forest plot of sensitivity and specificity: Mannitol vs. ECT (FEV₁ fall index $\geq 10\%$ for ECT and $\geq 15\%$ for mannitol)




Table 21. Description of studies in the diagnostic test accuracy review: Mannitol vs. ECT

Author Year	Study design; Order of tests Study days; Challenges per day [N]; Time between challenges Concomitant treatment for asthma	REFERENCE STANDARD (ECT) Type; Duration (minutes) Load; Environmental conditions Follow-up time points Author definition of EIB/EIA	INDEX TEST (Mannitol) Type; Description Follow-up time points Author definition of EIB/EIA
Anderson ²³ 2009	Cross sectional (prospective); ECT first 5 visits; 1; ECT – MCH: 1-2 d; ECT – mannitol: 1-2 d; MCH – mannitol: 1 day Asthma medications withheld according to guidelines	Treadmill; 6 80-90% max HR; RH dry (compressed) air; 20-25°C 0, 5, 10, 15, 30 min post ECT ≥10% fall FEV ₁	Dose: 0, 5, 10, 20, 40, 80, 160, 160, 160 mg; Process: exhale completely, take deep breath, hold for 5 sec, exhale through mouth, remove nose clip, repeat for each dose Measured 60 sec after each dose ≥15% fall FEV ₁ or a ≥10% fall FEV ₁ between consecutive doses
Brannan ⁴⁷ 1998	Cross sectional (prospective); ECT or EVH first except for 3 participants 1 screening, 2-3 test d; 1; all completed in 35 d period NR	Bicycle ergometer; 8 90-100% max HR; NR 3, 5, 7, 10, 15, 30 min post ECT ≥10% fall FEV ₁	Dose: 0, 5, 10, 20, 40, 80, 160, 160, 160 mg; dry power inhalation; test stopped if ≥15% fall FEV ₁ or cumulative dose of 635 mg administered FEV ₁ measured at 60 sec after each dose and at 5, 10, 20, 30 min ≥15% fall FEV ₁
Kersten ⁵² 2009	Cross sectional (prospective); ECT first 2 visits; 1; within 4 wk Asthma medication withheld according to guidelines	Treadmill; 6 90% max HR; RH dry air in a skating rink; 1°C, 1, 3, 6, 9, 12, 15, 20 min post ECT ≥15% fall FEV ₁	Dose: 0, 5, 10, 20, 40, 80, 160, 160, 160 mg; dry powder inhalation; Process: with nose clip; inhaled through mouth from near functional residual capacity to near total lung capacity, held for 5 sec, exhaled through mouth, removed nose clip, repeat for each dose Measured 60 sec after each dose; lowest dose causing cough noted ≥15% fall FEV ₁ or ended when cumulative dose of 635mg mannitol reached

C = Celsius; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; EVH = eucapnic voluntary hyperpnea; FEV₁ = forced expiratory volume in 1 second; HR = heart rate; max = maximum; MCH = methacholine; mg/ml = milligram per milliliter; MVV = maximal voluntary ventilation; NR = not reported; sec = second(s)

Table 22. Description of participants in the diagnostic test accuracy review: Mannitol vs. ECT

Author Year	Participants enrolled (N); analyzed (N) Age (mean±SD) Males: N (%)	Recruitment Country Index of activity (fitness level)	History of asthma N (%); Asthma severity; Atopic status N (%); History of ICS History of EIB/EIA	Baseline lung function (FEV ₁) Baseline FEV ₁ (% predicted)
Anderson ²³ 2009	510; 375 (performed all tests) 24.3±10.2, range 6-50 182 (48.2)	Participants referred to clinic for investigation of asthma-type symptoms U.S. NR	0 (0); all had symptoms suggestive of asthma but no confirmed Dx; NAEPPII score 1.2±0.5 293 (78) NR NR	3.32±0.82 L 93.6±10%
Brannan ⁴⁷ 1998	36; 23 24.5±6.4, range 18-40 16/36 (44.4)	Volunteers recruited through advertisement in local community Australia NR	36 (100); stable; 36 (100) atopic; 16 (44.4) 36 (100) self-report	NR 83.3±13.3% (range 66 to 120.3%)
Kersten ⁵² 2009	33; 25 12.4±2.0 17/25 (68.0)	Volunteers from outpatient clinic The Netherlands NR	25 (100); clinically stable; 25 (100) allergic asthma; 15 (60) ICS; 25 (100)	NR 97.4±16.6 % (range 65-132%)

EIB/EIA = exercise-induced bronchoconstriction/asthma; Dx = diagnosis; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; L = liters; NAEPPII = National Asthma Education and Prevention Program; NR = not reported; SD = standard deviation

Table 23. Methodological quality of studies in the diagnostic test accuracy review: Mannitol vs. ECT

Author Year	Representative spectrum	Selection criteria defined	Acceptable reference standard	Timing bias avoided	Partial verification avoided	Differential verification avoided	Clear reporting of index test	Clear reporting of reference standard	Index test blinded	Reference standard blinded	Uninterpretable index test results reported	Withdrawals explained
Anderson ²³ 2009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	U	Yes	U	Yes
Brannan ⁴⁷ 1998	No	Yes	Yes	Yes	Yes	Yes	Yes	U	U	U	Yes	Yes
Kersten ⁵² 2009	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	U	U	U	Yes

U = unclear

Therapy Review

Literature Search


The search for controlled trials of the interventions targeted in this report identified 1,634 citations from electronic databases and eight by handsearching (Figure 13). Through screening of titles and abstracts, 490 references were selected for further examination. The full manuscripts of 13 citations could not be retrieved (Appendix D). Most of these were abstracts only available in supplementary conference proceedings. They were requested through interlibrary loan but did not arrive by the time this report was written. The search update identified an additional 19 citations; none met the screening criteria. We retrieved and evaluated the full-text of 477 potentially relevant articles. The application of the selection criteria resulted in 109 RCTs and CCTs being included; 368 studies were excluded.

During preliminary searches of the literature on mast cell stabilizing agents (MCS) three systematic reviews were identified. All three were published in the Cochrane Library⁷⁶⁻⁷⁸ and two were also published in journal format.^{104,161} Our search strategy included terms to identify new or additional trials that would update the existing reviews but none were identified. In consultation with AHRQ and the TEP, we made the decision to present a summary of these existing reviews (Appendix E).

The included articles addressed the following research questions: tachyphylaxis (n=9),^{53-55,57-60,62,63} leukotriene receptor agonists (n=9),^{44,64-71} inhaled corticosteroids (n=4),⁷²⁻⁷⁵ MCS (n=62),^{76-78,104,161} anticholinergics (n=18),⁷⁹⁻⁹⁶ and a refractory period (warmup/cooldown; n=7).⁹⁷⁻¹⁰³

The main reasons for excluding studies were (1) the intervention did not address one of the research questions (n=214), (2) the study was not an RCT or CCT (n=60), (3) the study was not published in English (n=38), (4) the study population did not have a confirmed a diagnosis of EIB/EIA or included only children under the age of 6 (n=32). There were 24 studies excluded for other reasons. The list of excluded studies and reasons for exclusion are identified in Appendix D.

Figure 13. Therapy for EIB/EIA: Flow diagram for study retrieval and selection



Key Question T–1: Tachyphylaxis to Short-Acting Beta-Agonists or Long-Acting Beta-Agonists

Description of Included Studies

Nine RCTs met the inclusion criteria for the review on whether people with EIB/EIA develop tachyphylaxis to long-acting beta-agonists (LABA)^{53-55,57-60} or to short-acting beta-agonists (SABA).^{62,63} Tachyphylaxis is defined as a waning or a diminishing response to prophylactic doses of a beta-agonist to attenuate or prevent EIB/EIA when these agents are also used on a continuous basis. In the case of continuous SABA use, tachyphylaxis is also defined as a diminished ability to cause bronchodilation when needed to reverse bronchoconstriction. Six trials used a crossover design^{55,57-59,62,63} and three were parallel trials.^{53,54,60} The LABA agents studied were formoterol,⁵⁴ and salmeterol.^{53,55,57-60} The duration of LABA use was every other day for 3 weeks,⁵⁸ daily use for 4 weeks,^{54,55,57,59} or daily use for 8 weeks.^{53,60}

The studies were published in peer reviewed journals between 1994 and 2009. Five were conducted in North America,^{53,55,59,62,63} three in Europe,^{54,57,58} and one in 12 different countries.⁶⁰ EIA was defined using different cutpoints of the maximum FEV₁ fall index: 15 percent or greater,^{54,55,62,63} 18 percent or greater,⁶⁰ and 20 percent or greater.⁵⁷ The exercise challenge test (ECT) was performed on a treadmill^{53,57,59,60} or bicycle ergometer.^{54,55,62,63} The characteristics of the trials are summarized in Tables 24a and 24b.

The baseline characteristics of the participants are presented in Tables 25a and 25b. The number of patients enrolled ranged from 9 to 248. Two studies^{58,59} included children only, two^{62,63} included adults only, and five^{53-55,57,60} included both adults and children. All participants had confirmed asthma; for most, their asthma was mild and stable.

Methodological Quality of Included Studies

Table 26 summarizes the methodological quality of included studies. Overall the quality of individual trials was high with a median Jadad score of 4 (IQR: 3, 4). Concealment of allocation was unclear in six trials^{54,55,57-60} and adequately reported in one.⁵³ Two trials did not report their source of funding,^{57,58} three had industry support,^{53,59,60} three had government support,^{54,62,63} and one had a combination of institution, government and private industry support.⁵⁵

Quantitative Results: SABA

Two crossover trials that involved 1 week of regular (four times daily) SABA or placebo use prior to ECTs looked for evidence of tachyphylaxis to SABA.^{62,63} The SABA agent studied was albuterol (salbutamol). Both studies compared baseline FEV₁ at the end of 1 week of use. Inman and O'Byrne⁶³ assessed the prophylactic effect on EIA of an additional prophylactic dose of SABA. Hancox et al.⁶² did not address prophylaxis; however, did assess the bronchodilator effect of SABA following the ECT. Methodological differences precluded combining the data and the two studies are described separately.

Inman and O'Byrne⁶³ randomized 10 adults with asthma and EIA (maximum percent fall FEV₁ on pre-study ECTs ranged 15 to 45 percent) to 1 week of SABA 200µg or placebo four times per day. The washout period ranged from 7 to 21 days. Additional SABA use was allowed as needed throughout study weeks and the washout period. Baseline SABA use was less than 200µg per day and no other asthma medications had been taken in the previous month. No ECT was performed on day one of treatment and no baseline lung function measures were reported.

On day 8 of each treatment week, participants performed an ECT following a dose of placebo; on day 9, all performed an ECT following 200µg SABA (participants only were blinded to the prophylactic treatment taken).

Baseline FEV₁ after 1 week of treatment. The mean (\pm SE) pre-challenge FEV₁ on day 8 of the placebo week was 3.58 \pm 0.18L compared with 3.36 \pm 0.19L on day 8 of the SABA week; the pre-challenge FEV₁ on day 9 of the placebo week was 3.58 \pm 0.17L compared with 3.34 \pm 0.20L after the SABA week. The mean difference of 230 ml between treatment weeks was statistically significant ($p=0.02$).

Post bronchodilator FEV₁. On day 9, all participants received pre-challenge SABA 200µg. There was no significant difference between the placebo and SABA groups on the post-SABA FEV₁ prior to the ECT (3.94 \pm 0.18L versus 3.83 \pm 0.18L; $p=0.06$). No comparison on the degree of bronchodilation that occurred was reported.

Effect on EIA. On day 8 after pre-treatment with placebo, both groups experienced EIA following the ECT. The mean maximum percent fall in FEV₁ after the placebo week was 24.9 \pm 4.36 percent compared with a slightly greater fall of 29.4 \pm 4.71 percent after the SABA week. The difference of 4.5 percent was not statistically significant ($p=0.12$).

On day 9 following pre-challenge SABA, both groups experienced total protection from EIA. The mean maximum percent fall in FEV₁ in the placebo group was 1.1 \pm 0.76 percent compared with a slightly greater fall of 5.1 \pm 2.03 percent in the SABA group. The difference of 4 percent was statistically significant ($p=0.05$). The post-exercise FEV₁ measures were significantly lower at all time points over the recovery period after 1 week of continuous SABA use on both the day 8 placebo challenge ($p=0.02$) and the day 9 SABA challenge ($p=0.01$).

Other outcomes. Self-reported use of additional SABA for rescue during the placebo week was lower than during the SABA week ($p>0.05$).

The authors concluded that 1 week of regular SABA use resulted in a decrease in baseline FEV₁, a decreased prophylactic effect on EIA, and more pronounced EIA.

Hancox et al.⁶² randomized eight, stable asthmatic women with EIA (maximum percent fall FEV₁ of 15 percent or more) to 6 to 10 days of SABA 200µg or placebo four times per day. There was no washout period. Baseline SABA use was not reported. All bronchodilating drugs were withheld for 8 to 36 hours pre-ECT and no prophylactic treatment was given prior to the ECT at the end of the treatment week. SABA 100 µg, 100 µg, and 200 µg were given at 5, 10, and 15 minutes post-ECT following FEV₁ measurements.

Baseline FEV₁ after 1 week of treatment. There was no significant difference between the mean pre-challenge FEV₁ after the SABA week compared with the placebo week (2.76L versus 2.80L).

Effect on EIA with no pre-treatment. At 5 minutes post-ECT the fall in FEV₁ was greater in the SABA arm and the group as a whole experienced EIA. The mean minimum absolute FEV₁ post-ECT after the SABA week was 2.28L (95 percent CI: 2.21, 2.35) compared with 2.55L (95 percent CI: 2.48, 2.62) after the placebo week ($p=0.001$). The percent fall in FEV₁ was not reported and could not be calculated. The authors reported that the magnitude of the bronchodilator response to SABA in both arms was similar (no data); however, the FEV₁ remained significantly lower in the SABA arm over the 25 minute recovery period despite administration of SABA at 5, 10, and 15 minutes.

The authors concluded that 1 week of regular SABA use results in more pronounced EIA and a suboptimal response to rescue medication.

Conclusions. The results from these two studies are equivocal on whether regular SABA use affects the baseline FEV₁ over time. The studies are consistent in presenting data that indicates that regular SABA use may lead to a greater degree of EIA. It is important to note that pre-treatment with SABA still offered complete protection to both groups in the one study.⁶³ There is some evidence to indicate tachyphylaxis develops to the bronchodilating effect of SABA as rescue medication.⁶² The body of evidence is classified as “low.”

Quantitative Results: LABA

Five studies compared regular LABA use to placebo,^{54,55,58,59} four to salmeterol,^{55,57-59} and one to formoterol.⁵⁴ Four studies reported regular LABA use for 4 weeks,^{54,55,57,59} and one⁵⁸ used LABA treatment every other day for 21 days. Four studies were crossover trials^{55,57-59} and one used a parallel group design.⁵⁴

Formoterol versus placebo. Garcia et al.⁵⁴ randomized 19 stable asthmatics with EIA (maximum percent fall FEV₁ of 15 percent or more) to 28 days of formoterol 12µg twice daily (n=10) or to a matching placebo (n=9) in a parallel group design. In the month prior to the study, SABA use was less than two doses per week and other asthma treatment remained unchanged. The primary outcome was the change in the bronchoprotection index (BI) defined as the reduction in the maximum percent fall in FEV₁ after formoterol compared with no pre-treatment on the three test days.

On days 1, 14 and 28, participants refrained from taking all asthma medications and study drugs for 12 hours and performed two bicycle ECTs, 3 hours apart. The first took place with no prophylactic treatment; the second 30 minutes after taking formoterol.

Bronchoprotection index. The BI on day 1 was similar in the formoterol and placebo groups (71.3±32.6 percent versus 69.3±30.1 percent). During the study there was a significant decrease in the degree of protection offered by formoterol as the BI dropped to 52.3±31.7 percent on day 14 (p=0.012) and then to (27.8±32.6 percent) on day 28 (p=0.06). In the placebo group, the BI increased to 88.6±19.5 percent and 84.8±21.2 percent over the test days. The authors reported that these differences were not significant.


Complete protection (maximum percent fall FEV₁ less than 10 percent). On study days 1, 14 and 28, a prophylactic dose of formoterol conferred complete protection to 9 of 10, 5 of 8, and 5 of 10 patients in the formoterol group, respectively (p=0.28). On days 1 and 14, a prophylactic dose of formoterol conferred complete protection to 8 of 9 patients, and on day 28 to 7 of 9 patients in the placebo group.

The authors concluded that twice daily formoterol over 4 weeks caused a significant reduction in bronchoprotection against EIA. Tachyphylaxis was evident by day 14 but did not progress. A single pre-exercise LABA dose in non-regular users (i.e., placebo group) maintained its efficacy.

Salmeterol versus placebo. Four crossover studies^{55,57-59} randomized groups to 3 or 4 weeks of salmeterol (50µg twice a day,^{55,57} once a day,⁵⁹ or every other day for 3 weeks⁵⁸) or to a matching placebo. Throughout the studies, the ECT was performed at 30 minutes,⁵⁵ 1 hour,⁵⁹ 6 hours,⁵⁷ and 9 hours⁵⁸ following administration of a study drug. The average fall in FEV₁ after the first ECT on day 1 in the four studies was 3.7 percent (range 5.0 to 11.9) in the LABA arms compared with 26.9 percent (range 20.5 to 36.6) in the placebo arms. The pooled difference favored the salmeterol (MD = 25.1 percent [95 percent CI: 32.3, 18.0] (Figure 14). The pooled results are presented as the MD between salmeterol and placebo at day 1, week 2 or 3, and week 4. The decreasing MD between salmeterol and placebo from day 1 to week 4 reflects the


decreasing effect of the LABA as a prophylactic EIA agent; over the same time period the placebo effect remained constant.

Figure 14. Effectiveness of LABA vs. placebo: Change from day 1 to week 3–4 weeks after the first ECT (MD in the maximum percent fall FEV₁)




Maximum percent fall in FEV₁. The mean maximum fall in FEV₁ following an ECT after 2 and 4 weeks of continuous salmeterol use plus a pre-exercise dose was greater at week 4 than at day 1 (Figure 15). In contrast, the placebo arms showed a small decrease in the degree of EIA over the same time period. At the 4 week ECT, 30 minutes post-study drug, the average fall in FEV₁ was 11.4 percent (range 4.0 to 24.0) in the LABA arms compared with 21.3 percent (range 16.0 to 32.9) in the placebo arms; however, the pooled difference still favored the LABA (MD = 10.5 percent; 95 percent CI: 14.7, 6.4) (Figure 14). The timing of the ECT following administration of the study drug (30 minutes to 9 hours) was not a factor. Onset of the bronchodilator effect of salmeterol occurs in 10 to 20 minutes and lasts for at least 12 hours.¹⁶²

Figure 15. Effects over time of LABA and placebo on the maximum percent fall in FEV₁ for the first ECT



Duration of action (maximum percent fall in FEV₁). Three studies^{55,57,59} investigated the duration of action of salmeterol. Participants underwent a second ECT on the same day; the ECT was given 9 to 12 hours after administration of the study drug. The pooled results (Figure 16) show that salmeterol continued to have a greater protective effect than placebo at 4 weeks (MD = 4.4 percent; 95 percent CI: 7.6, 1.2). However, the protective effect had decreased from day 1 when the absolute MD was 11.5 percent (95 percent CI: 14.3, 8.7).

Figure 16. Effectiveness of LABA vs. placebo: Change from day 1 after the second ECT (MD in the maximum percent fall FEV₁)



Conclusions. Three to 4 weeks of regular LABA use results in a decreased prophylactic effect on EIA and more pronounced EIA. In studies that included a second ECT given 9 to 12 hours after the first ECT, the duration of the beneficial effects of LABA waned. The body of evidence is classified as “moderate.”

LABA compared to other agents. Two studies compared regular use of salmeterol 50µg, two puffs twice daily versus a leukotriene receptor antagonist (LTRA) (montelukast 10mg) once in the evening for 8 weeks. The studies included 360 participants with stable asthma and confirmed EIA.^{53,60} Both studies were funded by industry partners. The ECTs were performed near the end of the dosing interval for each drug (Table 24A). The pooled baseline fall in FEV₁ in both groups in both studies (34.9 percent for LABA and 33.9 percent for LTRA) indicated that the participants experienced moderate to severe EIA. Both agents attenuated the EIA response after 3 days of treatment to a similar degree. The mean fall in the LABA group was reduced to 19.8 percent compared with 18.2 percent in the LTRA group; this difference was not significant (MD = 1.0 percent; 95 percent CI: -2.2, 4.2) (Figure 17). Both agents continued to be effective; however, montelukast maintained the same level of effectiveness at 4 and 8 weeks compared with a slight decrease in effect with regular use of salmeterol. At 8 weeks, the mean fall in the LABA group was 23.0 percent compared with 17.1 percent in the LTRA group; this difference was significant (MD = 5.4 percent; 95 percent CI: 2.2, 8.7). The studies also reported that a combined 52 percent of LABA participants compared with 65 percent of LTRA participants experienced falls in FEV₁ of less than 20 percent at 8 weeks.

Although indirect evidence, these results lend support to other results that indicate some degree of tachyphylaxis develops early on with regular daily use of LABA. Furthermore, regular daily use of LABA lessens its ability to attenuate EIA when prophylactic doses are taken before exercise.

Figure 17. Effectiveness of LABA vs. LTRA: Change from day 1 to week 8 (MD in the maximum percent fall FEV₁)




Table 24a. Description of trials in the therapy review: Tachyphylaxis to LABA

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre- ECT	ECT: type; duration; predicted HR; temp; RH; % Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Formoterol vs. placebo					
Garcia ⁵⁴ 2001 Spain Clinic	Journal article Fondo de Investigación Sanitaria Parallel	F: 10; P: 9 F: 10; P: 9 0	F: 12 µg/bid x 28 d; MDI; no pre-Tx and 30 min P: 2 puffs bid x 28 d; MDI; 30 min	Bicycle ergometer; 6 min; 85% 21.2°C; 48.30% RH 4 [1 screen then days 1, 14, 28] 2; 3 hr SABA, NCS, SCG, calcium antagonists, antihistamines, ipratropium bromide and study medication x 12 hr	≥15% <u>Primary</u> : max % fall FEV ₁ ; change bronchoprotection index <u>Secondary</u> : complete protection; clinical protection FEV ₁ measured at 1, 3, 5, 8, 10, 15, 20, 30, 40, 60 min post ECT NR
Salmeterol vs. placebo					
Nelson ⁵⁵ 1998 U.S. Clinic	Journal article National Heart, Lung, and Blood Institute; NIH; Glaxo Wellcome Corp. Crossover	20 20 0	Salm: 50 µg bid x 30 d; MDI; 30 and 9.5 hr P: 2 puffs bid x 30 d; MDI; 30 min and 9.5 hr	Bicycle ergometer; 4 min; 740±246 kilopond meters/min cold air (-8.5±1.3°C); NR 7 [1 screen then 1, 14 and 29 d of each study mo] 2; 9 hr ICS, methylxanthines, SABA, NS x 12 hr; methylxanthines x 24 hr	≥15% <u>Primary</u> : mean % fall FEV ₁ 10 min post-ECT; duration of action <u>Secondary</u> : FEV ₁ L; complete protection FEV ₁ measured at 10 min post ECT NR
Ramage ⁵⁷ 1994 United Kingdom Clinic	Journal article NR Crossover	12 12 0	Salm: 50 µg bid x 4 wk; MDI; 6 and 12 hr P: 1 puff bid x 4 wk; MDI; 6 and 12 hr	Treadmill; 6 min; 85% dry air; NR 5 [1 screen, and first and last day of each Tx period] 2; 6 hr SABA, SCG, methylxanthines x 8 hr; 24 hr and 24 hr	≥20% <u>Primary</u> : max % fall FEV ₁ ; difference between 1 and 4 wk dosing <u>Secondary</u> : Pre-exercise FEV ₁ L; complete protection; clinical protection FEV ₁ measured at 5, 10, 20, 30, 60 min post ECT NR

Ach = anticholinergic; AE = adverse events; AUC = area under curve; bid = twice/day; C = Celsius; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; F=formoterol; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroid; L = liter; LABA = long-acting beta-agonist; LTRA = leukotriene receptor antagonist; µg = microgram; max = maximum; m = meters; M=montelukast; MDI = metered dose inhaler; min = minute(s); mg = milligram; mo = month(s); NR = not reported; NS=nedocromil sodium; P = placebo; PEF = peak expiratory flow; RH = relative humidity; SABA = short-acting beta-agonist; SALM=salmeterol; SCG = sodium cromoglycate; temp = temperature; Tx = treatment; URTI = upper respiratory tract infection; wk = week(s)

Table 24a. Description of trials in the therapy review: Tachyphylaxis to LABA (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre- ECT	ECT: type; duration; % predicted HR temp; RH; Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Salmeterol vs. placebo					
Selvaggio ⁵⁸ 2003 Italy NR	Abstract NR Crossover	9 9 0	Salm: 50 µg every other d x 21 d; diskus; 9 hr P: 1 puff every other d x 21 d; diskus; 9 hr	NR 4 [day 1 and 21 of each Tx period]; 1 20 d NR	NR Primary: max % fall FEV ₁ Secondary: bronchoprotective effect NR
Simons ⁵⁹ 1997 Canada Clinic	Journal article Glaxo Wellcome Inc. Crossover	16 14 2	Salm: 50 µg/d x 28 d; MDI with nebulizer; chronolog; 1 and 9 hr P: 2 puffs/d x 28 d; MDI with nebulizer chronolog; 1 and 9 hr	Treadmill; 8 min; 90% 21.7-22.4°C; 46.5-53.9% RH 4; 2 8 hr SABA, pseudoephedrine x 8 hr	NR Primary: max % fall FEV ₁ ; duration of action Secondary: PEF L/min P: exacerbation=1, chest tightness=1. Salm: headache=3
Salmeterol vs. montelukast					
Edelman ⁵³ 2000 U.S. [17 sites] Clinic	Journal article Merck Parallel	Salm: 94; M: 97 Salm: 86; M: 91 Salm: 8; M: 6	Salm: 50 µg/bid x 8 wk; MDI; 9 hr M: 10 mg/d x 8 wk; tablet; 21 hr	Treadmill; 6 min; 80-90% room temp; dry air 3; 1 day 1-3, wk 4, wk 8 SABA x 6 hr	≥20% Primary: max % fall FEV ₁ Secondary: change in max % fall; FEV ₁ L; complete protection FEV ₁ measured at 0, 5, 10, 15, 30, 45, 60 min post ECT Salm vs. M: asthma 7% vs. 3%; headache 6% vs. 5%; URTI 10% vs. 14%; total AE Salm vs. M: 40% vs. 41%
Villaran ⁶⁰ 1999 25 centers in 12 countries Clinic	Journal article Merck Parallel	R=Salm: 95; M: 102; A=Salm: 88; M: 100 W=Salm: 7; M: 2	Salm: 50 µg bid x 8 wk; MDI; 8-12 hr M: 10 mg OD; tablet; 20-24 hr	Treadmill; 8 min; 80-90% room temp; compressed dry air 5 [2 screen, 3 rd d, wk 4 and 8]; 1 in evening 25-28 d SABA; antihistamines x 8 hr; 48 hr; all others 1-2 wk	≥18% Primary: max % fall FEV ₁ at 8wk; AUC Secondary: change max % fall FEV ₁ ; FEV ₁ L change from baseline; % protection FEV ₁ measured at 5, 10, 15, 30, 45, 60 min post ECT Salm vs. M: bronchoconstriction 32% vs. 24%; headache 8% vs. 10%; pharyngitis 7% vs. 8%; URTI 8% vs. 3%

Table 24b. Description of trials in the therapy review: Tachyphylaxis to SABA

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre- ECT	ECT: type; duration; temp; RH; % predicted HR Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Hancox ⁶² 2002 Canada Clinic	Journal article Father Sean O'Sullivan Research Centre; Ont Thoracic Society Crossover	9 8 1	Sal: 200 µg qid x 7 d; MDI; 8 hr P: 2 puffs qid x 7 d; MDI; 8 hr	Bicycle ergometer; incremental over 7 min; 80% NR; dry air 1; 1 NA LABA 36 hr; SABA 8 hr; IB 12 hr IB 20 µg/puff allowed for relief	≥15% <u>Primary:</u> change in bronchodilator response to Sal post-ECT <u>Secondary:</u> max % fall FEV ₁ ; FEV ₁ L; FEV ₁ measured at 1, 3, 5, 10, 15, 20, 25, 30 min Exacerbation=1 (Tx period NR)
Inman ⁶³ 1996 Canada Clinic	Journal article Ontario Thoracic Society Crossover	10 10 0	Alb: 200 µg qid x 7 d; MDI; immediate P: 2 puffs qid x 7 d; MDI; immediate	Bicycle ergometer; 5 min; 67.2±10.8% of max work rate 21.5°C; <10% RH 4; 1 24 hrs SABA x 8 hr; caffeine x 24 hr	≥15% <u>Primary:</u> max % fall FEV ₁ ; <u>Secondary:</u> FEV ₁ L FEV ₁ measured at 5, 10, 15, 30 min NR

Alb=albuterol; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; IB = ipratropium bromide; L = liter; LABA = long-acting beta-agonist; µg = microgram; max = maximum; MDI = metered dose inhaler; min = minute(s); NR = not reported; qid = four times a day; RH = relative humidity; P=placebo; SABA = short-acting beta-agonist; sal=salbuterol; temp = temperature; wk = week(s)

Table 25a. Baseline characteristics of patients in trials in the therapy review: Tachyphylaxis to LABA

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function (% predicted FEV ₁ / mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Formoterol vs. placebo							
Garcia ⁵⁴ 2001	F: 22.8±6.1 P: 25.4±5.2 F: 3/10 (30) P: 5/9 (56)	Stable x 1 mo and throughout trial	F: 104.4±19.4 P: 97.7±13.4	Control ECT F: 21.5±10.0 P: 18.11±10.0	NR	NR	F: 3/10 (30) P: 3/9 (33.3)
Salmeterol vs. placebo							
Nelson ⁵⁵ 1998	29±8.9 9/20 (45)	Stable but with mixed severity	93±13.4	Control ECT 24±8.9	Non-smokers	Mixed	6/20 (30)
Ramage ⁵⁷ 1994	25.8±5.0 8/12 (66.7)	Stable mild	105.7±20.5	Placebo ECT 34.8±17.0	Non-smokers	7/12 (58.3)	3/12 (25)
Selvaggio ⁵⁸ 2003	Range 6-16 NR	NR	NR	Placebo ECT 36.6±7.6	NR	NR	NR
Simons ⁵⁹ 1997	13.1±1.3 7/16 (43.8)	Stable	93.4±12.7	Placebo ECT 24±12	NR	16/16 (100)	16/16 (100)
Salmeterol vs. montelukast							
Edelman ⁵³ 2000	Salm: 26; range 15- 46 M: 26.5, range 15-46 Salm: 54/94 (57) M: 46/97 (47)	Stable with range of severity	Salm: 88.0±13.5 M: 87.1±11.2	Control ECT Salm: 36.6±12.3 M: 37.0±11.5	Non-smokers ≥1yr	NR	None
Villaran ⁶⁰ 1999	All: 27±5.4 Salm: 45/95 (47) M: 53/102 (52)	Stable mild	Salm: 87.2±14 M: 86.6±13.7	Control ECT Salm: 30.5±10.5 M: 33.3±12.1	Past: 170/197 (86) Never 27/197 (13.7)	NR	Salm: 6/95 (6.3) M: 14/102 (13.7)

ECT = exercise challenge test; F = formoterol; FEV₁ = forced expiratory volume in 1 second; M = montelukast; mo = month(s); NR = not reported; P = placebo; salm = salmeterol; SD = standard deviation

Table 25b. Baseline characteristics of patients in trials in the therapy review: Tachyphylaxis to SABA

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function (% predicted FEV ₁ / mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Hancox ⁶² 2002	26, range 18-44 1/9 (11.1)	Stable	FEV ₁ /FVC=83±10 % FEV ₁ =2.8 L	Placebo ECT 10%	NR	NR	1/9 (11.1)
Inman ⁶³ 1996	24.5, range 19-37 7/10 (70)	Stable	85.4±6.3	Control ECT 15- 45%	Non-smokers	10/10 (100)	None

ECT = exercise challenge test; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; NR = not reported; SD = standard deviation

Table 26. Quality assessment of trials in the therapy review: Tachyphylaxis to LABA and SABA

Author Year	Described as randomized?	Described as double-blind?	Description of withdrawals/ dropouts?	Method of randomization described and appropriate?	Method of double-blinding described and appropriate?	Method of randomization described but inappropriate?	Method of double-blinding described but inappropriate?	Overall Score: Jadad	Concealment of allocation
Edelman ⁵³ 2000	Yes	Yes	Yes	Yes	Yes	No	No	5	Adequate
Garcia ⁵⁴ 2001	Yes	Yes	Yes	No	Yes	No	No	4	Unclear
Hancox ⁶² 2002	Yes	Yes	Yes	No	Yes	No	No	4	Unclear
Inman ⁶³ 1996	Yes	Yes	Yes	No	No	No	No	3	Unclear
Nelson ⁵⁵ 1998	Yes	Yes	Yes	No	Yes	No	No	4	Unclear
Ramage ⁵⁷ 1994	Yes	Yes	Yes	No	No	No	No	3	Unclear
Selvaggio ⁵⁸ 2003	Yes	Yes	Yes	No	No	No	No	3	Unclear
Simons ⁵⁹ 1999	Yes	Yes	Yes	Yes	No	No	No	4	Unclear
Villaran ⁶⁰ 1999	Yes	Yes	Yes	Yes	Yes	No	No	5	Unclear

Key Question T–2: Leukotriene Receptor Antagonist Therapy

Description of Included Studies

Nine randomized crossover trials^{44,64-71} met the inclusion criteria for the review comparing a single dose of leukotriene receptor antagonist (LTRA) with no treatment or placebo to prevent a 10 percent or greater drop in FEV₁ compared with no treatment or placebo. The studies were published between 1999 and 2007. Six trials were conducted in North America,^{44,64,65,67,68,71} two in Europe,^{66,69} and one⁷⁰ involved multiple sites in North and South America.

The drugs studied were montelukast,^{44,64-66,68-71} zafirlukast,^{65,67} and zileuton.⁶⁵ They were administered between 2 and 24 hours prior to an ECT. The thresholds for EIB/EIA measured by the FEV₁ fall index were 10 percent or greater,^{44,66} 15 percent or greater,^{64,65,69} and 20 percent or greater.^{67,68,70,71} The ECT was performed on a treadmill,^{64,66-71} or bicycle ergometer.^{44,65} The characteristics of the trials are summarized in Table 27.

The baseline characteristics of the participants are presented in Table 28. The number of patients enrolled ranged from 10 to 62 (total 267). Three studies^{64,67,69} included children only, four^{65,66,68,70} included adults only, and two^{44,71} included both children and adults. In eight trials^{44,64-71} all participants had a confirmed diagnosis of asthma; in the remaining trial⁴⁴ 36 percent of the participants had confirmed asthma. Participants had stable asthma with lung function greater than 85 percent predicted.

Methodological Quality of Included Studies

Table 29 summarizes the methodological quality of the included studies. Overall, the quality of the nine trials was good; the median Jadad score was 3 (IQR: 3, 5). Concealment of allocation was unclear in eight trials,^{44,64-69,71} and adequately reported in one.⁷⁰ Two trials^{66,69} did not report their source of funding, five^{44,67,68,70,71} reported pharmaceutical industry support, and two^{64,65} had government/institutional support. The body of evidence is classified as “moderate.”

Quantitative Results

Pulmonary function measures. All nine trials recorded the maximum percent fall in FEV₁ on an ECT performed 2 hours or less following drug administration. The times at which later ECTs were performed varied across studies thus data were categorized into two groups: 8 to 12 hours and 24 hours.

The mean fall in FEV₁ on the placebo challenges ranged from 15.0 to 23.2 percent (average 18.5) indicative of mild EIA. The average fall in FEV₁ in the LTRA arms after the first ECT ranged from 7.6 to 13.3 percent (average 10.9). The absolute MD = 8.3 percent (95 percent CI: 6.9, 11.0) and represents clinical protection of approximately 41 percent over placebo. Substantial heterogeneity ($I^2=65$ percent) was identified (Figure 18).


Six of the trials^{64,65,68-71} recorded the mean maximum percent fall in FEV₁ on an ECT 8 to 12 hours after drug administration. The difference between groups ranged from 1.8 to 13.3 percent and all favored LTRA. The absolute MD = 6.8 percent (95 percent CI: 3.9, 9.6). Substantial heterogeneity ($I^2=70$ percent) was identified (Figure 18).

The difference in the mean fall in FEV₁ on an ECT 24 hours following drug administration was reported in three trials^{68,70,71} and ranged from 4 to 8.6 percent in favor of LTRA. The average fall in the placebo arms was 13.8 percent (range 10.7 to 16.9) compared with 8.7 percent (range 8.3 to 10) in the LTRA arms. The pooled results indicate that LTRA remained significantly more

effective than placebo in attenuating EIA (MD = 4.9 percent; 95 percent CI: 8.0, 1.8). Substantial heterogeneity ($I^2=76$ percent) was identified (Figure 18).


The source of the heterogeneity could not be explained by subgroup analyses based on age, dose of study medication, or funding source. Other subgroup analyses (e.g., ICS use, atopic status) could not be performed due to lack of data.

Figure 18. LTRA vs. placebo in pre-exercise treatment of EIB/EIA: Maximum decrease in FEV₁



Complete protection. Four trials⁶⁶⁻⁶⁹ reported the proportion of participants who received complete protection as an outcome measure. Using less than a 10 percent fall in FEV₁ as the cutpoint, the pooled estimate indicated that there was no significant difference in the number who achieved complete protection with LTRA (RR = 1.9; 95 percent CI: 0.8 to 4.6) compared with placebo. Substantial heterogeneity ($I^2=72$ percent) was identified (Figure 19).

Figure 19. LTRA vs. placebo in pre-exercise treatment of EIB/EIA: Achievement of complete protection (maximum percent fall FEV₁ is less than 10 percent)



Adverse effects. One study⁶⁹ reported that there were no adverse effects using a 5 mg dose of montelukast. Using 10 mg of montelukast, three trials reported non-serious adverse effects that included mild headache,^{68,70,71} nausea,⁶⁸ nervousness,⁶⁸ arthralgia,⁷¹ and myalgia.⁷¹ One study⁶⁷ reported dizziness, pharyngitis, fatigue and headache at a dose ranging from 5 to 40 mg of zafirlukast. The occurrence of side effects, however, was not markedly different between the treatment and placebo groups (Table 27).

Table 27. Description of trials in the therapy review: LTRA

Author Year Country Source	Publication status Funding Trial design	Randomize d [R] Analyzed [A] Withdrawal s [W]	Treatment Groups: drug; dose; delivery device; time pre-ECT (min)	ECT: type; duration (min); % predicted HR temp; RH; Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Becker ⁶⁴ 2002 Canada Clinic	Abstract Industry/Institution Crossover	19 19 0	M: 5 mg; chewable tablet 1, 2, 4, 8 hr P: NA; chewable tablet 1, 2, 4, 8 hr	Treadmill; 8; 50% 20°C; NR 3; 4 1, 2, 4 hr NR	≥15% Primary: max % fall FEV ₁ Secondary: none FEV ₁ measured at 1, 2, 4, 8 hr post ECT NR
Coreno ⁶⁵ 2000 U.S. Clinic	Journal article Government/Institute Crossover	10 10 0	M: 10 mg; oral 1, 4, 8, 12 hr Za: 20 mg; oral 1, 4, 8, 12 hr Zl: 600 mg; oral; 1, 4, 8, 12 hr P: NA; oral 1, 4, 8, 12 hr	Bicycle ergometer; 4; 790±7 kilopound m/min frigid air -5 to -16°C; NR 5 (1/wk); 4 4 hr ICS continued; BD x 24 hr; antihistamine x 72 hr	≥15% Primary: mean % fall FEV ₁ Secondary: FEV ₁ L; FEV ₁ measured at 10 min post each of 4 ECTs NR
Mastalerz ⁶⁶ 2002 Poland NR	Journal article NR Crossover	19 19 0	M: 10 mg; tablet 1 hr P: NA; tablet 1 hr	Treadmill; 6-8; 80-90% 20-25°C; ≤50% 3 d intervals; 1 3 d No; BD; NR	≥10% Primary: max % fall FEV ₁ Secondary: Complete protection FEV ₁ measured at 5, 10, 15, 20, 30 min post ECT NR
Pearlman ⁶⁷ 1999 U.S. Clinic	Journal article Zeneca Pharmaceuticals 3 way crossover; 2 independent groups; 2 doses Za, 1 P	39 36 3	G1: Za: 5 mg; 20 mg; oral, 4 hr G2: Za: 10 mg; 40 mg; oral 4 hr G1: P: NA; oral G2: P: NA; oral 4 hr	Treadmill; 6-8; 80-90% room temp; NR 4; 1 4-14 d ICS, SCG x 4wk; astemizole x 3 mo, LABA x 48 hr	≥20% Primary: max % fall FEV ₁ Secondary: complete protection (at 20%) FEV ₁ measured at 5, 10, 15, 30 min post ECT Za: dizziness=5, pharyngitis=3, fatigue=4, headache=2. P: dizziness=4, pharyngitis=3, fatigue=2, headache=3

AE = adverse events; BD = bronchodilator; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroid; L = liter; LABA = long-acting beta-agonist; M=montelukast; m = meter; max = maximum; med = medication; min = minute(s); mg = milligram; NA = not applicable; NR = not reported; P = placebo; RH = relative humidity; SABA = short-acting beta-agonist; temp = temperature; wk = week(s); za= zafirlukast; zi=zileuton

Table 27. Description of trials in the therapy review: LTRA (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre-ECT	ECT: type; duration (min); % predicted HR temp; RH; Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events (n)
Pearlman ⁶⁸ 2005 U.S. Clinic (9 centers)	Journal article Merck Research Laboratories Crossover	51 49 2	M: 10 mg; oral 2, 12, 14 hr P: NA; oral 2, 12, 24 hr.	Treadmill; 6; 80-90% NR; NR 4 (3-7 d between ECTs) 3/24 hr; 10, 12 hr ICS allowed; SABA x 8 hr	≥20% <u>Primary</u> : max % fall FEV ₁ (2 hr, 12 hr, 24 hr) <u>Secondary</u> : FEV ₁ L (% change); % protection; complete protection (at 10, 15, 20%); clinical protection FEV ₁ measured at 0, 5, 10, 15, 30, 45, 60 min post ECT No serious clinical/lab AE. M: nausea, nervousness=2; exacerbation=1, influenza=1 (these 2 withdrew)
Peroni ⁶⁹ 2002 Italy Lived in Italian Alps at high altitude	Journal article NR Crossover	19 19 0	M: 5 mg; NR 2, 12 hr P: NA; NR 2, 12 hr	Treadmill; 6; 80% 21°C; 40-50% RH 4 (3-5 d apart); 2 10 hr Meds continued; BD x 12 hr	≥15% <u>Primary</u> : max % fall FEV ₁ <u>Secondary</u> : % protection; clinical protection; FEV ₁ L; FEV ₁ measured at 1, 5, 10, 15, 20, 30 min; No AE were observed
Philip ⁷⁰ 2007a U.S., South America (Peru) Clinic (5 centers)	Journal article Merck Research Laboratories Crossover	47 45 1	M: 10 mg; oral 2, 8.5 and 24 hr P: NA; oral 2, 8.5 and 24 hr	Treadmill; 6; 80-90% room temp; dry air 5 (3-7 d between ECTs); 3/24 hr 2, 8.5, 12 hr ICS allowed, all others excluded; SABA x 8 hr	≥20% <u>Primary</u> : max % fall FEV ₁ (2 hr, 8.5 hr, 24 hr) <u>Secondary</u> : FEV ₁ L (mean % max change); mean % fall FEV ₁ FEV ₁ measured at 0, 5, 10, 15, 30, 45, 60 min No serious AE; M: 6/47; P: 7/47 (2/7 were headaches)

Table 27. Description of trials in the therapy review: LTRA (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre-ECT	ECT: type; duration (min); % predicted HR temp; RH; Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events (n)
Philip ⁷¹ 2007b U.S. NR	Journal article Merck Research Laboratories Crossover	62 53 9	M: 10 mg; oral 2, 12, 24 hr P: NA; oral 2, 12, 24 hr	Treadmill; 6; 80-90% room temp; dry air 2; 3/24 hr 10, 12 hr Meds continued; BD x 8 hr	≥20% <u>Primary</u> : max % fall FEV ₁ <u>Secondary</u> : complete protection (at 20%) FEV ₁ measured at 0, 5, 10, 15, 30, 45, 60 min post ECT; AE=7 (none discontinued); M: arthralgia and myalgia=1; P: flushing and headache=1; P: diarrhea=1, headache=1, nausea=1
Rundell ⁴⁴ 2005 U.S. College athletes (volunteers)	Journal article Merck Research Laboratories Crossover	11 11 0	M: 10 mg; oral 6-8 hr P: NA; oral 6-8 hr	Bicycle ergometer; 6; NR -3°C; 50% RH 4; 1 2-3 d None on asthma med	≥10% <u>Primary</u> : max % fall FEV ₁ <u>Secondary</u> : FEV ₁ L (% change); % protection; complete protection (at 10%); clinical protection FEV ₁ measured at 5, 10, 15 min post ECT NR

Table 28. Baseline characteristics of patients in trials in the therapy review: LTRA

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function % predicted FEV ₁ (mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status N (%)	ICS history: N (%)
Becker ⁶⁴ 2002	11.0±2.7 NR	Stable	88.6±14.4	Control ECT 21.1±9.6	NR	NR	NR
Coreno ⁶⁵ 2000	29±9.5 4/10 (40)	Stable	93±12.6	Placebo ECT 21±15.8 to 26±15.8	Non-smokers	NR	6/10 (60)
Mastalerz ⁶⁶ 2002	36.2 10/19 (52.6)	Stable	84.3 ±13.5	Placebo ECT 22.5±10.2	NR	11/19 (57.9)	17/19 (89.5)
Pearlman ⁶⁷ 1999	10.5±2.0 22/39 (56.4)	Stable	89.5±11.4	Placebo ECT 16.7±10.8	Non-smokers	NR	None
Pearlman ⁶⁸ 2005	24.5±5.9 24/51 (47)	Stable; mild to moderate	86.4±11.9	Placebo ECT 22.3±13.1	NR	NR	6/51 (12)
Peroni ⁶⁹ 2002	11.1±1.8 13/19 (68)	Stable	87.7±8.7	Placebo ECT 15.3±12.8	NR	19 (100)	19 (100)
Philip ⁷⁰ 2007a	26.0±7.9 23/47 (48.9)	Mild	87.8±11.4	Placebo ECT 27.8±6.2	Non-smokers	38/47 (81) allergic rhinitis	2/47 (2)
Philip ⁷¹ 2007b	24.4±6.9 33/62 (53.2)	Stable; mild to moderate	88.9±12.4	Placebo ECT 17.5±13.8	NR	NR	7 (11)
Rundell ⁴⁴ 2005	22.8±6.8 8/11 (72.7)	Mild	98.4±14.2	Placebo ECT 22.4±18.0	NR	NR	None

ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; NR = not reported; SD = standard deviation

Table 29. Quality assessment of trials in the therapy review: LTRA

Author Year	Described as randomized?	Described as double-blind?	Description of withdrawals/ dropouts?	Method of randomization described and appropriate?	Method of double-blinding described and appropriate?	Method of randomization described but inappropriate?	Method of double-blinding described but inappropriate?	Overall Score: Jadad	Concealment of allocation
Becker ⁶⁴ 2002	Yes	Yes	No	No	Yes	No	No	3	Unclear
Coreno ⁶⁵ 2000	Yes	No	No	No	Yes	No	No	2	Unclear
Mastalerz ⁶⁶ 2002	Yes	Yes	Yes	No	No	No	No	3	Unclear
Pearlman ⁶⁷ 1999	Yes	Yes	Yes	No	Yes	No	No	5	Unclear
Pearlman ⁶⁸ 2005	Yes	Yes	Yes	Yes	Yes	No	No	5	Unclear
Peroni ⁶⁹ 2002	Yes	Yes	Yes	No	No	No	No	3	Unclear
Philip ⁷⁰ 2007a	Yes	Yes	Yes	Yes	Yes	No	No	5	Unclear
Philip ⁷¹ 2007b	Yes	Yes	Yes	Yes	Yes	No	No	5	Adequate
Rundell ⁴⁴ 2005	Yes	Yes	Yes	No	No	No	No	3	Unclear

Key Question T–3: Inhaled Corticosteroid Therapy

Description of Included Studies

Four randomized crossover trials⁷²⁻⁷⁵ met the inclusion criteria for the review on the prophylactic use of a single dose of inhaled corticosteroid therapy (ICS) prior to an ECT. The studies were published in peer reviewed journals between 1974 and 2001 and all were conducted in Europe. The definitions of EIA as measured by the FEV₁ percent fall index were 10 percent or greater,⁷³ 15 percent or greater,^{74,75} and 20 percent or greater.⁷² The ECT was performed on a treadmill,^{73,74} bicycle ergometer,⁷⁵ or by having participants run or exercise hard.⁷² The characteristics of the trials are summarized in Table 30.

The drugs studied were betamethasone valerate,^{72,73} budesonide,⁷⁵ and fluticasone propionate.⁷⁴ The number of patients enrolled ranged from 9 to 20 (total=50). Two studies^{73,74} included children only, one included adults only,⁷⁵ and one included both adults and children.⁷² All participants had confirmed asthma; for most, their asthma was mild to moderate and stable. The baseline characteristics of the participants are presented in Table 31.


Methodological Quality of Included Studies

Table 32 summarizes the methodological quality of the included studies. Overall, the quality of the four trials was good with a median Jadad score of 3.5 (IQR: 3, 4). Concealment of allocation was unclear in three trials^{72,74,75} and inadequately reported in one.⁷³ One trial did not report their source of funding,⁷³ two had private industry support,^{72,74} and one was supported by a government grant.⁷⁵ The body of evidence is classified as “moderate.”

Quantitative Results

Pulmonary function measures. Two trials^{72,74} reported the maximum percent fall in FEV₁ and two^{73,75} reported the maximum percent fall in peak expiratory flow (PEF) post-ECT. The mean fall in FEV₁/PEF on the placebo challenges ranged from 19.2 to 36.2 percent (average 30.5). Three of the placebo groups^{72,73,75} had a mean fall in FEV₁/PEF greater than 30 percent indicating moderate to severe EIA. The average fall in FEV₁/PEF in the ICS arms ranged from 9.7 to 31.9 percent (average 25.5). The pooled MD was 5.0 percent (95 percent CI: 0.0, 9.9). The differences were not statistically significant and the results failed to identify important heterogeneity ($I^2=0$) (Figure 20).

Figure 20. Inhaled corticosteroids vs. placebo in pre-exercise treatment of EIA: MD in maximum percent fall in FEV₁ or peak expiratory flow



Clinical protection. The mean clinical protection over placebo for participants was either reported as an outcome measure or we were able to calculate it from the data. The protection index in children was 49 percent after a high dose of fluticasone,⁷⁴ and 19.6 percent after betamethasone.⁷³ A combined population of children and adults who received betamethasone⁷² did better on the placebo (clinical protection was -5.9 percent). The clinical protection index for adults who received budesonide⁷⁵ was 27.5 percent.

Complete protection. Thio et al⁷⁴ provided IPD from which we could determine that 6 of 9 participants using high dose fluticasone obtained complete protection (maximum percent fall FEV₁ less than 10 percent) compared with 4 of 9 on placebo (RR=1.5; 95 percent CI: 0.6, 3.6). This outcome was not reported in any of the other trials.

Adverse effects. None of the studies reported on adverse events.

Conclusions. We cannot conclude that ICS taken prior to exercise provides a clinical benefit to people with stable asthma who experience EIA.

Table 30. Description of trials in the therapy review: Inhaled corticosteroids

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Treatment Groups: drug; dose; delivery device; time pre-ECT (min)	ECT: type; duration; % predicted HR temp; RH; Study days; challenges/day [N]; time between challenges Withheld asthma med; class; time	Definition EIA/EIB (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Hills ⁷² 1974 United Kingdom Clinic	Journal article Glaxo Ltd. Crossover	20 18 2	BV: 0.2 mg; MDI; 15 min P: NA; MDI; 15 min	Ran or exercised sufficiently to maintain a steady level of dyspnoea; NR NR; NR 3; 1 1-2 d BD x 6-9 hr	≥20% <u>Primary:</u> FEV ₁ L <u>Secondary:</u> max% fall FEV ₁ ; mean % fall FEV ₁ ; clinical protection FEV ₁ measured at 5, 10, 15, 20 min post ECT NR
Hodgson ⁷³ 1974 United Kingdom Clinic	Journal article NR Crossover	10 10 0	BV: 0.2 mg; MDI; immediately before P: NA; MDI; immediately before	Treadmill; HR ≥160 bpm NR; NR 4; 1 NR but all at same time of d All x 12 hr	≥10% <u>Primary:</u> mean % fall PEF <u>Secondary:</u> clinical protection PEF measured at 2, 4, 6, 8, 10, 15, 20, 25, 30, 35, 40 min post ECT NR
Thio ⁷⁴ 2001 Netherlands Clinic	Journal article GlaxoWellcome Netherlands Crossover	9 9 0	FP: 1 mg; MDI with spacer 4 hr P: NA; MDI with spacer; 4 hr	Treadmill; 90% of predicted maximum NR; NR 2; 1 7-14 d BD x 12 hr; cromoglycates x 2 wk	≥15% <u>Primary:</u> mean % fall FEV ₁ <u>Secondary:</u> % protection; clinical protection FEV ₁ measured at 1, 3, 6, 9, 12, 15, 20, 25, 30 min post ECT NR
Venge ⁷⁵ 1990 Sweden Clinic	Journal article Government Crossover	13 13 0	BUD: 1 mg; MDI; 15 min P: 5 puffs; MDI; 15 min	Bicycle ergometer; 80% NR; absolute humidity=5.85±1.72; 2; 1 NR CS x 3 mo; BD/SCG; oral BD x 8 hr and 24 hr	>15% <u>Primary:</u> max % fall PEF <u>Secondary:</u> clinical protection PEF measured at 1, 3, 5, 10, 15, 20, 25, 30, 60 min post ECT; NR

BD = bronchodilator; bpm = beats per minute; BUD= budesonide; BV= betamethasone valerate; CS=corticosteroids; d = day(s); ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; FP= fluticasone propionate; hr = hour(s); HR = heart rate; L = liter; MDI = metered dose inhaler; min = minute(s); mg = milligram; mo = month(s); NR = not reported; P = placebo; PEF = peak expiratory flow; RH = relative humidity; SCG = sodium cromoglycate; temp = temperature; wk = week(s)

Table 31. Baseline characteristics of patients in trials in the therapy review: Inhaled corticosteroids

Author Year	Age yr (mean±SD) Males: N (%)	Asthma status	Pulmonary function (% predicted FEV ₁ (mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Hills ⁷² 1974	Range 5-30 9/18 (50)	5=mild; 10=moderate; 3=severe	2=normal; 3=76-90%; 10=51-75%; 3 >50%	Control ECT 49%	NR	16/18 (89)	None
Hodgson ⁷³ 1974	Children NR	Stable	>50% predicted PEF	Control ECT 35% (PEF)	NR	NR	None
Thio ⁷⁴ 2001	11.2±2.5 6 (67)	Mild to moderate (ATS)	102 ±11.8	Placebo ECT 19.2±17.3	NR	NR	None
Venge ⁷⁵ 1990	29.2±8.3 7 (53.8)	Stable	84.8±11.9 (PEF)	Control ECT 36.2±13.6	NR	9/13 (69.2)	None

ATS = American Thoracic Society; ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; NR = not reported; PEF = peak expiratory flow; SD = standard deviation; yr = year

Table 32. Quality assessment of trials in the therapy review: Inhaled corticosteroids

Author Year	Described as randomized?	Described as double-blind?	Description of withdrawals/ dropouts?	Method of randomization described and appropriate?	Method of double-blinding described and appropriate?	Method of randomization described but inappropriate?	Method of double-blinding described but inappropriate?	Overall Score: Jadad	Concealment of treatment allocation
Hills ⁷² 1974	Yes	Yes	Yes	No	Yes	No	No	4	Unclear
Hodgson ⁷³ 1974	Yes	Yes	Yes	No	Yes	No	No	4	Inadequate
Thio ⁷⁴ 2001	Yes	Yes	Yes	No	No	No	No	3	Unclear
Venge ⁷⁵ 1990	Yes	Yes	Yes	No	No	No	No	3	Unclear

Key Question T-4: Mast Cell Stabilizers

Background

With better understanding of the possible role of inflammatory mediators and mast cell degranulation in the pathogenesis of EIB/EIA, a variety of mast cell degranulation drugs have been investigated for their potential to protect against bronchoconstriction caused by exercise. Sodium cromoglycate (SCG; also referred to as "cromolyn sodium") and nedocromil sodium (NCS) are mast cell stabilizer (MCS) agents introduced in the late 1960s and early 1980s, respectively. Both are reportedly effective on a single-use basis for inhibiting bronchoconstriction due to antigens, fog, cold air, sulphur dioxide, and exercise. If effective and safe in EIB/EIA, these properties would make them attractive therapeutic options for active people.

During preliminary searches of the literature on MCS, three systematic reviews were identified. All three were published in the Cochrane Library and two were subsequently published in peer-reviewed journals. The reviews addressed the following topics: NCS to prevent EIA,^{76,104} NCS versus SCG to prevent EIA,⁷⁷ and MCS versus an anticholinergic agent, a SABA agent, or a combination of MCS and SABA agents to prevent EIA.⁷⁸ Our search strategy included terms to locate any new or additional RCTs that would add to the existing reviews. None were identified (Appendix E).

SCG is no longer available in a dry-powdered inhaler in North America; the only remaining formulations for asthma are solutions for nebulization. The evidence related to these drugs in EIB/EIA are summarized from the existing reviews.

NCS versus Placebo Review

Design issues. All the studies included in this review were randomized crossover trials.^{76,104} The ECTs were conducted on separate days and the researchers adhered to the recommended washout time of 5 to 10 times the half-life of a drug between challenges.

Objective. The objective of the review was to compare the effects of a prophylactic dose of inhaled NCS with placebo in persons with confirmed EIA. The primary outcome was a measure of the change in the percent fall index pre- or post-exercise. Secondary outcomes were the mean percent fall in FEV₁ at varying time points up to 1 hour post-ECT and the degree of clinical protection afforded by NCS over placebo. A mean protection index of 50 percent or more was considered clinically significant. The review also investigated subgroups based on dose, delivery device, timing of pre-treatment, severity of EIA, and age.

Populations. Recruitment procedures were not often described but generally seemed to be volunteers from asthma clinics or schools for asthmatic children. All had documented asthma and demonstrated reproducible EIA. All were described as having stable asthma at testing, were otherwise healthy, non pregnant, and had no respiratory comorbidity.

Exercise challenge tests. All ECTs were conducted indoors on an inclined treadmill (n=18), a bicycle ergometer (n=1), FRAST (n=1), or sport specific (n=1) (3 sprinters ran outdoors). Room temperatures ranged from 17 to 24 degrees Celsius and relative humidity ranged from 35 to 60 percent. One trial¹⁶³ conducted a trial using cold air (-18 degrees Celsius). Regardless of the challenge format, the intensity and duration demanded was sufficient to induce EIA.

Results. *Description of studies.* There were 21 RCTs included in the review (20 peer reviewed articles and one unpublished thesis). The trials all used the crossover design but did not report data by period and only one reported the treatment sequence. The reviewers analyzed the

data as though from parallel studies determining that this approach would provide a more conservative estimate of treatment effect. Data on continuous measures were pooled and reported as MD with 95 percent CI using a random effects model. In the subgroup analyses examining the effect of treatment based on baseline severity, mild EIA was defined a priori as a mean maximum percent fall in FEV₁/PEF less than 30 percent on the placebo challenge. Moderate to severe EIA was defined as a mean maximum percent fall greater than 30 percent.

Methodological quality. Using the Jadad scale for RCTs, two studies were rated “strong” (5 points), nine “very good” (4 points), with the remaining 10 studies rated as “good” (3 points). All studies were double-blinded. Two studies were rated as “adequate” concealment of allocation; the remaining studies were rated “unclear.” The body of evidence is classified as “moderate.”

Pulmonary function results. Seventeen trials measured the FEV₁ to determine the response to treatment following an ECT (total sample size=240; 11 children and 6 adult studies); seven measured the PEF (total sample size=115; 4 children and 3 adult studies). Three trials assessed the duration of effect over two or three challenges given 2 to 4 hours apart on the same day.

The maximum percent fall in either FEV₁ or PEF improved significantly following NCS indicating a statistically and clinically significant attenuation of the EIA response over placebo (MD =15.6 percent; 95 percent CI: 13.2, 18.1) (Table 33). Subgroup analyses indicated no significant differences: age (children less than 18 years; n=11), dose (low less than 4 mg, n=3; standard 4 mg, n=16; high more than 4mg, n=1), delivery system (metered dose inhaler [MDI], n=12 versus MDI with spacer device, n=5), and timing of pre-treatment (less than 30 minutes, n=10 versus 30 minutes or more, n=7). The effect of NCS appeared more pronounced in those that experienced moderate to severe EIA (i.e., a fall index 30 percent or more). In this the MD increased to 21.36 percent (95 percent CI: 25.52, 17.20).

Other outcomes. Thirteen studies compared lung function up to 30 minutes post-challenge. At each of seven time points pre-treatment with NCS resulted in significant improvements in FEV₁ and a return to within 10 percent of baseline function occurred in 10 minutes compared with 30 minutes with placebo.

In three trials that examined the duration of action on subsequent ECTs within 4.5 hours on the same day with no further medication, NCS appeared to offer benefit but of a lesser magnitude (MD=5.7 percent; 95 percent CI: 2.8, 14.2).

The trials provided no data on symptom scores, performance measures or participant preference. Subgroup comparisons by sex and corticosteroid use were not performed due to lack of data. Sensitivity analyses based on study quality, fixed versus random models, and publication status were all nonsignificant.

Adverse events. Twelve studies mentioned side effects. Seven stated that no adverse effects or symptoms attributable to NCS were observed. Minor effects reported were bad taste, throat irritation, and cough, and in one study a clinically insignificant increase in heart rate of four beats per minute.

Conclusions. In people with stable asthma that experience EIA, NCS taken 15 to 60 minutes prior to exercise reduces the severity and duration of EIA in both children and adults. The benefit appears more pronounced in those with more severe EIA.

NCS versus SCG Review

Design issues. Only crossover trials were included in this review.^{77,161} To ensure drug clearance, the challenges within each study were conducted with a minimum 24 hour break.

Objective. The objective of the review was to compare the effects on post-exercise lung function following prophylactic doses of NCS and SCG by MDI, in persons with confirmed EIA. The primary outcome was the maximum percent fall index. The review also reported the odds ratio (OR) and 95 percent CIs of *not* obtaining complete protection and clinical protection over placebo. Complete protection was not obtained if the post-exercise fall in FEV₁ exceeded either the 10 or 15 percent diagnostic cutpoints. Clinical protection was not obtained if the post-exercise fall in FEV₁ after NCS or SCG was less than 50 percent of the drop following placebo.

Population. Recruitment procedures were not well described but appeared to be healthy volunteers from either asthma clinics or schools for asthmatic children. Five studies involved children (6.5 to 15 years), three involved adults (17 to 38 years), and one study enrolled a mixed population (13 to 30 years). The majority recruited stable asthmatics with a reproducible post-exercise fall in FEV₁ of either 15 percent or 20 percent.

Exercise challenge tests. All ECTs were performed indoors on either an inclined treadmill (n=8) or a bicycle ergometer (n=1) for a duration of 6 to 8 minutes. Intensity required was reported as either a heart rate of 170 to 180 or 85 percent of predicted maximum for age. ECTs were conducted in controlled environments; however, room temperature and humidity were not reported. In all studies, the ECTs were conducted at the same time of day on different days.

Results. *Description of studies.* The review included nine RCTs (eight peer-reviewed articles and one conference abstract). As in the previous review, the data were analyzed as though they were from parallel studies. Data on continuous measures were pooled and reported as a MD with 95 percent CI, using a random effects model. Dichotomous variables for individual and pooled statistics were calculated as OR with 95 percent CI, using a random effects model. We have converted the OR of *not* obtaining complete or clinical protection to the RR of obtaining complete or clinical protection to allow comparisons to the key questions from the current review.

Subgroup analyses were performed on adults (18 years and older) versus children (under 18 years), baseline asthma severity (mild versus moderate-severe), different doses of NCS and SCG, and the timing of ECT post-treatment.

Methodological quality. Using the Jadad scale one study was rated “strong” (5 points), one “very good” (4 points), with the remaining studies rated as “good” (3 points). All studies except one were double-blinded. One study was rated as “adequate” concealment of allocation; the remaining studies were rated “unclear.” The body of evidence is classified as “moderate.”

Pulmonary function results. Seven trials reported the maximum percent fall in FEV₁ (sample size=97; 5 children, 2 adult studies). No significant differences between NCS and SCG were identified (MD=-0.88; CI: -4.50, 2.74; I²=0 percent). Subgroup analyses based on dose (NCS 4 mg versus SCG 10 mg, n=5; NCS 4 mg versus SCG 20 mg, n=1; NCS 8 mg versus SCG 4 mg, n=1) and timing of the ECT (30 minutes or less, n=7; 120 to 140 minutes, n=2; 240 minutes, n=1) failed to identify significant differences (Table 33).

Other outcomes. Six trials reported complete protection using a fall in FEV₁ of less than 10 percent and six used less than 15 percent; six also reported clinical protection over placebo. There were no significant differences between NCS and SCG by diagnostic cutpoint in providing complete or clinical protection (Table 33). The trials provided no data on symptom scores, performance measures or participant preference.

Adverse events. Three trials reported on treatment side effects (unpleasant taste N=3; sore throat N=2). No significant differences were found between NCS and SCG with respect to

unpleasant taste (RR=3.77; 95 percent CI: 1.29, 10.97) or sore throat (RR=4.96; 95 percent CI: 20.1, 9.1). Overall, the trend in both cases was for fewer side effects in the SCG group.

Conclusions. In people with stable asthma who experience EIA, both NCS and SCG provide a significant protective effect against EIA. No significant differences were evident between the two drugs on pulmonary function; however, more people experienced a sore throat or an unpleasant taste from NCS.

MCS to Prevent EIA Review

Design issues. This review⁷⁸ was restricted to full manuscripts regardless of publication status and three foreign language studies were included. All but two studies used a crossover design.

Objective. The objective of the review was to compare the effects of a prophylactic dose of either NCS or SCG (collectively called MCS) to that of atropine, ipratropium or oxitropium bromide (collectively called anticholinergics), and SABA. The review also compared the effects of a combination of SABA plus MCS to a SABA alone. The primary outcome was the percent fall in FEV₁ post-exercise. The review also reported the OR and 95 percent CIs of obtaining complete protection and clinical protection. Complete protection was obtained if the post-exercise fall in FEV₁ was less than either the 10 or 15 percent diagnostic cutpoints. Clinical protection was obtained if the post-exercise fall in FEV₁ after drug intervention was at least 50 percent less than that with placebo.

Population. Recruitment procedures were not well described but appeared to be healthy volunteers from either asthma clinics or schools for asthmatic children. Thirteen trials recruited children (6 to 13 years) and 11 recruited adults (18 years and older). Most studies documented recruiting healthy, stable, asthmatics and all of the trials required at least a 15 percent fall in FEV₁ to diagnose EIA. The populations in seven trials were considered to have mild EIA defined as a percent fall index less than 30 percent on placebo; 16 were classified moderate to severe; one did not report baseline data.

Exercise challenge tests. The ECTs involved an inclined treadmill (n=19), FRAST (n=1), bicycle ergometer (n=3), and stair climbing (n=1). Most studies reported an exercise challenge time of between 5 to 8 minutes with a target heart rate ranging from 150 to 180 beats per minute.

Results. *Description of studies.* The 24 RCTs included in the review reported data on 518 participants. The studies compared the following drug combinations: MCS versus anticholinergics (8 studies), MCS versus SABA (20 studies), and SABA versus a combination of SCG plus SABA (10 studies). The method of delivery varied across studies (8 nebulizer, 5 MDI, 3 sp inhaler, and 2 not described), with six studies comparing two or more devices. All studies required participants to abstain from taking any bronchodilator for at least 8 hours prior to a challenge; other medications were withheld for longer periods of time.

Methodological quality. Using the Jadad score, two studies were rated “strong” (5 points), five rated “very good” (4 points), nine rated “good” (3 points), and eight rated “poor” (2 points or less). Four studies were rated to have “adequate” concealment of allocation; the rest were rated “unclear.” The body of evidence is classified as “moderate.”

Pulmonary function results. Sixteen studies (9 children, 7 adult) reported the response to treatment using different FEV₁ measures (maximum percent fall FEV₁=14 studies; percent predicted=1 study; change=1 study); 8 studies (5 children, 3 adult) reported maximum percent fall PEF.

MCS versus anticholinergics: MCS provided a modest but significant advantage in post-exercise lung function over anticholinergics. Pooled results indicate MCS attenuated the fall in FEV₁ to 7.1 percent compared with 13.8 percent on anticholinergics (MD=6.7 percent; 95 percent CI: 3.3, 10.0; I²=0 percent). MCS provided more individuals with complete protection (OR=2.2; 95 percent CI: 1.3, 3.7) and clinical protection (OR=2.7; 95 percent CI: 1.1, 6.4). There were no subgroup differences based on age, severity, or study quality. No adverse effects were reported for either agent group.

MCS versus SABA: When compared with SABA, MCS were not as effective at preventing EIA. The mean maximum percent fall in FEV₁ using MCS was 11.2 percent compared with 4.3 percent on SABA (MD=6.8 percent; 95 percent CI: 4.5, 9.2; I²=20 percent). MCS provided fewer individuals with complete protection (OR=0.3; 95 percent CI: 0.2, 0.5) or clinical protection (OR=0.4; 95 percent CI: 0.2, 0.8). There were no significant subgroup differences based on age, severity, drug, delivery, or study quality.

SABA versus combination of SCG plus SABA: Combining a MCS with a SABA did not indicate significant advantages to pulmonary function over SABA alone. On average the maximum fall in FEV₁ on SABA alone was reduced to 5.3 percent compared with 3.5 percent using a combination (MD=1.3 percent; 95 percent CI: -6.3, 8.9). There were no significant differences in the number achieving complete protection (OR=0.5; 95 percent CI: 0.2, 1.4) or clinical protection (OR=0.4; 95 percent CI: 0.1 to 1.2). There were no subgroup differences. Overall, every comparison favored the combination; however, none reached statistical significance.

Other outcomes. One study measured the work effort involved during exercise. This analysis showed that SCG and SABA significantly decreased the energy cost of running, ventilation, oxygen consumption, and tidal volume which significantly increased running duration. The trials provided no data on symptom scores, performance measures or participant preference.

Adverse events. A nonsignificant difference in side effects was demonstrated with 11 percent of SABA patients experiencing side effects compared with 3 percent of those receiving MCS (OR=0.2; 95 percent CI: 0.0, 8.2). No adverse events were reported for MCS versus anticholinergics or SABA versus combinations of MCS and SABA.

Conclusions. In people with stable asthma who experience EIA, SABA, MCS, and anticholinergic agents can provide a significant protective effect against EIA with few adverse effects. On average, SABA agents were more effective than MCS, and MCS agents were more effective than anticholinergics. The combination of SABA and MCS agents did not provide significant advantages over a SABA alone; however, this approach may be appropriate for some people.

Table 33. Description of trials included in the Cochrane reviews of mast cell stabilizers

Author Year Number of trials included Country Dates published (range)	Publication status # of trials Children [C], Adults [A] Funding Trial design	Randomized [R] Sample size range [SS] Analyzed [A] Withdrawals [W]	Inclusion criteria	Intervention: drug; dose; delivery device Time pre-ECT Comparison	ECT: type Withheld asthma med	Definition EIA (% fall FEV ₁)	Outcomes: Primary Secondary Adverse events (N=studies)
Spooner ^{76,104} 2002 N=21 (20 in the MA) North America=1, Europe=18, Australia=2 1987-1995	20 journal articles; 1 unpublished thesis C: N=11 A: N=10 Funding NR All crossover trials	R=280 SS=8-24 (mean 14) A=279 W=1	Reproducible EIA Stable asthma Lung function >70% predicted; variability between challenges <10-15% N=1 Olympic athletes N=20 physical conditioning NR	NCS: 1 mg, N=1; 2 mg, N=3; 4 mg, N=20; 8 mg, N=2 MDI, N=21; MDI plus spacer, N=5 Time pre-ECT 15 min, N=3; 20 min, N=8; 30 min, N=9; 60 min, N=1; 120-150 min, N=3; 240-270 min, N=2 Placebo	Inclined treadmill N=17; FRAST N=1; Bicycle ergometer N=1; Sport specific N=1 All asthma meds stopped appropriately for 6 h to 1 wk; some allowed ICS to continue	Max % fall FEV ₁ or PEF ≥15% N=11 ≥20%: N=9	<u>Primary:</u> mean max % fall: FEV ₁ , N=17; PEF: N=7 <u>Secondary:</u> clinical protection (≥50%); mean % protection; time course analysis AE reported in 12/20 trials; 7/12 none observed; 5/12 reported bad taste, throat irritation, cough
Kelly ^{77,161} 2000 N=9 (8 in the MA) North America=1; Europe=7; Australia=1 1987-1995	8 journal articles; 1 abstract C: N=5 A: N=3 Mixed N=1 Funding NR All crossover trials	R=162 SS=8-45 A=162 W=unclear	Hx EIA Stable asthma Atopic Baseline FEV ₁ >70% predicted, and vary <10% from previous study day No URIs in last 3 wk Non-smokers	NCS: 4 mg, N=7; 8 mg, N=1 SCG: 4 mg, N=1; 10 mg, N=6; 20 mg, N=1; dose NR, N=1 MDI N=8; MDI plus spacer N=4 Time pre-ECT 15 min, N=1; 20 min, N=5; 30 min, N=2; 120 min, N=1; 140 min, N=1; 240 min, N=1	Inclined treadmill: N=8 Most meds stopped appropriately for 4 hr to 1 wk; some allowed ICS to continue	Max % fall FEV ₁ or PEF ≥15% N=7; ≥20% N=1; NR N=1	<u>Primary:</u> mean max % fall: FEV ₁ N=7 <u>Secondary:</u> clinical protection N=5; complete protection N=7 AE reported in 3/8 trials; 1/3 none observed; 2/3 observed unpleasant taste, throat irritation

AC = anticholinergic; AE = adverse events; BD = bronchodilator; ECT = exercise challenge test; EIA = exercise-induced asthma; Fen = fenoterol; FEV₁ = forced expiratory volume in 1 second; FRAST = free running asthma screening test; hr = hour(s); Hx = history; MA = meta analysis; max = maximum; MCS = mast cell stabilizers; MDI = metered dose inhaler; min = minute(s); mg = milligram; NCS = nedocromil sodium; NR = not reported; PEF = peak expiratory flow; SABA = short-acting beta-agonist; Sal = salbutamol; SCG = sodium cromoglycate; URI = upper respiratory infection; wk = week(s)

Table 33. Description of trials included in the Cochrane reviews of mast cell stabilizers (continued)

Author Year Number of trials included Country Dates published (range)	Publication status Children [C], Adults [A] Funding Trial design	Randomized [R] Sample size range [SS] Analyzed [A] Withdrawals [W]	Inclusion criteria	Intervention: drug; dose; delivery device Time pre-ECT Comparison	ECT: type Withheld asthma med	Definition EIA (% fall FEV ₁)	Outcomes: Primary Secondary Adverse events (N=studies)
Spooner ⁷⁸ 2003 24 North America =3; Europe =17; Asia=2; Australia=2 1976-1998	24 journal articles C: N=13 A: N=11 Funding NR Crossover: N=22; Parallel: N=2	R=518 SS=7-100 A=505 W=5 trials reported total of 13 withdrawals	Hx of asthma and/or EIA CS oral and inhaled use varied (never, none in past 2 mo., or currently taking) Lung function >50% predicted; variability between challenges <10- 15%	MCS N=24 SCG N=23, 2-40 mg NCS: N=1, 4 mg AC N=11 IB: N=8, 0.12–2 mg Atropine: N=2, 0.2% OB: N=1, 0.02 mg MCS vs. AC N=11 SCG vs. SABA N=20; Fen N=6, 0.1–2 mg Sal N=10, 0.2-2.5mg Terbutaline N=2 Reproterol, procaterol, isoproterenol N=1 each SCG vs. SCG plus SABA N=10 Combination doses SCG 1–20mg; Fen N=4, 0.05–0.4 mg Sal N=3, 0.2–2.5mg Terbutaline N=1, 0.5mg Reproterol N=1, 1.0mg Device Nebulizer N=8; MDI N=5; spinhaler N=3; NR N=2; ≥2 devices N=6 Time pre-ECT 10 min N=4; 15 min N=6; 15-45 min N=1; 20 min N=3; 30 min N=6; 30-45 min N=1; 60 min N=2; 120 min oral N=1	Inclined treadmill: N=19 FRAST: N=1 Bicycle ergometer: N=3 Stair climbing: N=1 Most meds stopped for 8 h to 1 wk; some allowed ICS to continue; 1 did not permit any meds throughout the trial	Max % fall FEV ₁ or PEF ≥10% N=1 ≥15% N=5 ≥20% N=13 ≥25% N=1 ≥30% N=1 NR=3	<u>Primary:</u> FEV ₁ (N=16); max % fall N=14; % predicted N=1; change N=1; max % fall PEF N=8 <u>Secondary:</u> complete protection; clinical protection AE reported in 11/24 trials; 7/11 none observed; 2/7 tremor and distress/agitation on SCG or fenoterol; 1/7 mild throat irritation on SCG

Table 34. Baseline characteristics of patients in trials included in the Cochrane reviews of mast cell stabilizers

Author Year	Age yr (mean±SD) Males: N (%)	Asthma status	Pulmonary function (% predicted FEV ₁ / mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N studies	ICS history N (%)
Spooner ⁷⁶ 2002	C: 11.3±2.2 A: 26.5±5.0 M ~ 64% Not all reported male/female mix	All stable at time of ECT	FEV ₁ >70% predicted; variability <10-15% between challenges	Mean range of EIA severity on control or placebo ECT C: 28.7 to 50.0% A: 15.00 to 40.6% Mean fall <30% N=16 Mean fall ≥30% N=5	Nonsmokers N=3; NR N=17	All atopic N=12; Mixed/NR N=8	None on ICS N=7; mixed/NR=2 3
Kelly ⁷⁷ 2002	C:11.85±4.4; A: 24±4.2 M ~ 54% Not all reported male/female mix	All stable at time of ECT	FEV ₁ >70% predicted; variability <10-15% between challenges	Mean range of EIA severity on control or placebo ECT C: 27.4 to 35.9% A: 15.00 to 33.2% Mean fall <30% N=4 Mean fall ≥30% N=4 NR N=1	Nonsmokers N=1; NR N=8	All atopic N=3; mixed/NR N=8	None N=4; mixed/NR N=5
Spooner ⁷⁸ 2003	C:11.49±3.99 A: 26.98±11.15 M ~ 48% Not all reported male/female mix	All stable at time of ECT	FEV ₁ >70% predicted; variability <10-15% between challenges	Mean range of EIA severity on control or placebo ECT C: 14.3 to 45.2% A: 15 to 47% Mean fall <30% N=7 Mean fall ≥30% N=16 NR N=1	Nonsmokers N=4; 3/18 smokers included N=1 ; NR N=19	2/49 atopic N=1; all atopic N=1; NR N=22	Unclear N=6; mixed N=4; steroid use an exclusion criteria N=9

A = adult; C = children; ECT = exercise challenge test; EIA = exercise-induced asthma; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; M = males; NR = not reported; SD = standard deviation

Key Question T–5: Anticholinergic Agents

Description of Included Studies

Eighteen randomized crossover trials⁷⁹⁻⁹⁶ met the inclusion criteria for the review of short-acting anticholinergic (SAAC) therapy. The studies were published between 1976 and 1989. All studies were conducted either in Europe^{79,82,85-90,92-94} or North America.^{80,81,83,84,91,95,96}

The drugs studied were atropine,^{84,86,91} ipratropium bromide (IB),^{79-83,85,87,88,90,93-96} and oxitropium bromide (OB).^{88,89,92} The definitions of EIA as measured by the percent fall in FEV₁ or PEF were 10 percent or greater,^{81,86,96} 15 percent or greater,^{80,83,87-89,91,95} and 20 percent or greater.^{79,85,92,93} The ECT was performed on a treadmill,^{79,83-86,89,90,92-94,96} bicycle ergometer,^{80,81,87,88,91,95} and free running (FRAST).⁸² The characteristics of the trials are summarized in Table 35.

The baseline characteristics of the participants are presented in Table 36. The number of patients enrolled ranged from 6 to 20. Seven studies^{79,80,84,86,89,91,96} included only children, eight included only adults,^{81-83,87,88,90,94,95} and three included both.^{85,92,93} All participants in these trials had a confirmed asthma status; for most, the asthma was mild and stable.


Methodological Quality of Included Studies

Table 37 summarizes the methodological quality of the included studies. Overall the quality of the 18 trials was low with a median Jadad score of 2.5 (IQR: 2, 3) (Table 37). Concealment of allocation was unclear in all the trials. Seven trials did not report their source of funding,^{79,82,85,86,91,92,94} eight received private industry support,^{80,83,87-90,93,95} and three were supported by government grants.^{81,84,96} The body of evidence is classified as “moderate.”

Quantitative Results


Pulmonary function measures. Eleven trials compared IB to placebo^{79,80,83,85,87,88,90,93-96} and reported the maximum percent fall in FEV₁ as the outcome measure; one⁸² reported the maximum percent fall in peak expiratory flow (PEF). The mean fall in FEV₁/PEF on the placebo challenges ranged from 14 to 41 percent (average 32). Seven of the placebo groups^{79,83,85,88,90,93,96} had a mean fall in FEV₁/PEF greater than 30 percent indicating they experienced moderate to severe EIA. The average fall in FEV₁/PEF in the SAAC arms ranged from 10 to 33 percent (average 21). The pooled difference favored IB over placebo (MD = 9.8 percent; 95 percent CI: 5.0, 14.6) was statistically significant (Figure 21); however, substantial heterogeneity (I²=76 percent) was identified.

Figure 21. Ipratropium vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV₁ or peak expiratory flow




Four trials compared atropine to placebo^{80,84,86,91} and all reported the maximum percent fall in FEV₁ as the outcome measure. The mean difference in the percent fall in FEV₁ ranged from 11.9 to 22.7 percent. The pooled estimate indicated that atropine was significantly more effective than placebo in attenuating EIA (MD=16.0; 95 percent CI: 10.2, 21.7) (Figure 22). Negligible heterogeneity was identified (I²=0 percent).

Figure 22. Atropine vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV₁ or peak expiratory flow




Two trials compared OB to placebo^{88,89} and both reported the maximum percent fall in FEV₁ as the outcome measure. The pooled results showed that OB was significantly more effective than placebo in attenuating EIA (MD=13.8; 95 percent CI: 6.0, 21.6) (Figure 23). Negligible heterogeneity was identified (I²=0 percent).

Figure 23. Oxitropium vs. placebo in pre-exercise treatment of EIA: Mean difference in maximum percent fall in FEV₁ or peak expiratory flow



Complete protection. Seven trials involving IB reported complete protection as an outcome measure.^{79,83,85,87,88,94,96} The proportion of patients who achieved complete protection ranged from 0 to 13 percent. The pooled estimate showed that patients are 4.5 times more likely to achieve complete protection with IB compared with placebo (RR=4.5; 95 percent CI: 1.9, 10.9) (Figure 24). Negligible heterogeneity was identified ($I^2=0$ percent).


Figure 24. Ipratropium vs. placebo in pre-exercise treatment of EIA: Achievement of complete protection (maximum fall FEV₁ less than 10 percent)



Godfrey et al.⁸⁶ found no significant difference in achieving complete protection in patients who received atropine versus placebo (RR=5.0; 95 percent CI: 0.3, 88.5). The remaining studies on atropine did not report this outcome.


The pooled estimate of RR for complete protection from the three studies^{88,89,92} comparing OB with placebo was nonsignificant (RR=4.7; 95 percent CI: 0.4, 60.3) (Figure 25). There was substantial heterogeneity ($I^2=67$ percent).

Figure 25. Oxitropium bromide vs. placebo in pre-exercise treatment of EIA: Achievement of complete protection (maximum fall FEV₁ is less than 10 percent)



Clinical protection. Six trials that examined IB reported clinical protection as an outcome measure.^{79,81,83,85,87,94} The pooled estimate showed that 60 percent (95 percent CI: 48, 72) of patients achieved clinical protection when defined as at least a 50 percent improvement in FEV₁ over placebo (Figure 26). There was negligible heterogeneity ($I^2=0$ percent).

Figure 26. Ipratropium vs. placebo in pre-exercise treatment of EIA: Achievement of clinical protection (50 percent or greater improvement over placebo in FEV₁)



In the study by Godfrey et al.⁸⁶ 29 percent (95 percent CI: 8, 64) of patients achieved clinical protection when taking atropine. The remaining studies did not report on this outcome or provide data for calculation.

Adverse effects. Overall, IB was well tolerated with seven studies reporting no adverse effects.^{79,82,87,88,93-95} Dry mouth or thirst was reported in three studies: 16 percent of patients in two studies in which the dose was 0.04 mg of IB,^{80,96} and 20 percent at a dose of 0.2 mg and 60 percent at a dose of 2 mg in the third study.⁹⁰ Other side effects included bitter taste⁹⁰ and slight tremor.⁹⁶

Larsson et al. reported no side effects with oxitropium.⁸⁸ The remaining two studies did not report on adverse effects. None of the studies that examined atropine reported on adverse effects.

Subgroup/sensitivity analyses. Subgroup analyses based on age suggest similar results for children and adults for maximum percent decrease in FEV₁. Analyses based on asthma severity did not reduce heterogeneity. Sensitivity analysis on high versus low quality studies did not reduce the heterogeneity.

Table 35. Description of trials in the therapy review: Anticholinergic therapy

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Intervention: drug; dose; delivery device; time pre-ECT	ECT: type; duration (min); % predicted HR Temp; RH; Study days; challenges/day [N]; Time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Boner ⁷⁹ 1987 Italy Residential home for asthmatics	Journal article NR Crossover	15 15 0	IB; 0.5 mg in 2 ml saline; nebulizer; 30 min P: Saline; 2 ml; nebulizer; 30 min	Treadmill; 6; 90±4% NR; NR 4; 1 24 hr BD x12 hr; SCG x 24 hr; theophylline x 1 wk	≥20% <u>Primary</u> : max % fall FEV ₁ <u>Secondary</u> : % protection; complete protection %; clinical protection FEV ₁ measured 0, 5, 10, 15, 20, 25, 30 min or until FEV ₁ started to increase No AE for any treatments
Borut ⁸⁰ 1977 U.S. Clinic	Journal article Foundation and Boehringer Ingelheim Crossover	20 20 0	IB; 0.04 mg; MDI; 45 min IB; 0.08 mg; MDI; 45 min P: NA; MDI; 45 min	Bicycle ergometer; 6-8; workload that caused the requisite degree of bronchoconstriction NR; NR 6 [1 control, 5 test]; 1 1 wk All med x 12 hr	>15% <u>Primary</u> : SGaw <u>Secondary</u> : FEV ₁ % change from 0 FEV ₁ measured at 10, 20 min Yes
Boulet ⁸¹ 1989 Canada Clinic	Journal article Government Crossover	12 11 1	IB; 0.08 mg; MDI with aerochamber; 30 min P; NA; MDI with aerochamber; 30 min	Bicycle ergometer; 6; NR NR; NR 4; 1 ≥48 hr Theophyllines x 24 hr; BD x 8 hr	≥10% <u>Primary</u> : mean % protection <u>Secondary</u> : % protection; clinical protection FEV ₁ measured at 1, 1.5, 3, min until FEV ₁ started to increase; NR

AE = adverse events; BD = bronchodilators; bpm = beats per minute; C = Celsius; cc = cubic centimeter; d = day(s); DSCG = disodium cromoglycate; ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; g/L = grams per liter; hr = hour(s); HR = heart rate; IB = ipratropium bromide; BD= bronchodilator; IM = intra muscular; L = liter; max = maximum; med = medication; MDI = metered dose inhaler; min = minute(s); mg = milligram; ml = milliliter; NA = not applicable; NR = not reported; OB = oxytropium bromide; P = placebo; PEF = peak expiratory flow; RAW = airway resistance; RH = relative humidity; rpm = revolutions per minute; SCG = sodium cromoglycate; SGaw = specific airways conductance; temp = temperature; Tx = treatment; wk = week(s)

Table 35. Description of trials in the therapy review: Anticholinergic therapy (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Intervention: drug; dose; delivery device time pre-ECT	ECT: type; duration (min); % predicted HR Temp; RH; Study days; challenges/day [N]; Time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Bundgaard ⁸² 1980 Denmark Clinic	Journal article NR Crossover	18 18 0	IB: 0.5 mg + 2 ml isotonic saline; nebulizer; 30-45 min P: saline; 4 ml; nebulizer; 30-45 min	Free running test; 6; 160 bpm after 2 min running NR; NR 6 [1 no-Tx, 5 test]; 1 24 hr All med x 24 hr	NR Primary: max % fall PEF Secondary: NR PEF measured at 0, 2, 4, 6, 8, 13, 18 min No AE on IB
Chan-Yeung ⁸³ 1977 Canada Clinic	Journal article Drugs supplied by Boehringer Ingelheim Crossover	9 9 0	IB: 0.08 mg; freon-propelled inhaler; 15 min P: lactose powder; NR; spinhaler; 15 min	Treadmill (n=6), jogging outside (n=3); 2.5-6; NR NR; NR 3; 1 3-7 d at same time of d All except oral prednisone x 6 hr	≥15% Primary: Max % fall FEV ₁ Secondary: % protection; Complete protection; Clinical protection FEV ₁ measured at 5, 10, 15, 20, 25, 30 min NR
Chen ⁸⁴ 1981 U.S. NR	Journal article Government Crossover	6 6 0	a) atropine plus 1ml IM saline; individual dosing to achieve max bronchodilation; nebulizer; 60 min b) atropine plus 1ml IM saline; double dose of a; nebulizer; 60 min P: distilled water plus 1ml IM saline; 1 ml; nebulizer; 60 min	Treadmill; 10; 180 bpm NR; NR 5; 1 5 ECT in 3 wk at same time of d Theodur, BD, SCG, ICS and prednisone every other d unchanged; testing done on d when prednisone not taken; BD x 4 hr	NR Primary: mean % change FEV ₁ Secondary: NR FEV ₁ measured at 5-10 min NR
Dorward ⁸⁵ 1982 United Kingdom Clinic	Journal article NR Crossover	7 7 0	IB: 0.12 mg; nebulizer; 60 min P: saline; 9 g/L; nebulizer; 60 min	Inclined treadmill; 8; 170-180 bpm 20-22°C; 30-50% RH 5; 1 on different d SCG and BD x 24 hr	≥25% Primary: max % fall FEV ₁ Secondary: FEV ₁ L; mean % fall FEV ₁ ; % protection; complete protection; clinical protection FEV ₁ measured at 2, 5, 10, 15, 30 min NR

Table 35. Description of trials in the therapy review: Anticholinergic therapy (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Intervention: drug; dose; delivery device; time pre-ECT	ECT: type; duration (min); % predicted HR Temp; RH; Study days; challenges/day [N]; Time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Godfrey ⁸⁶ 1976 United Kingdom Clinic	Journal article NR Crossover	7 7 0	Atropine; 0.2%; nebulizer; 5-10 min P: saline; NA; nebulizer; 5-10 min	Treadmill; 6; 170-180 bpm NR; NR 1; 2 2 hr All med x 12 hr	≥10% Primary: mean % fall PEF Secondary: complete protection; clinical protection PEF measured 2, 4, 6, 8 until 20 min NR
Hartley ⁸⁷ 1980 United Kingdom Clinic	Journal article Drugs supplied by Boehringer Ingelheim Crossover	10 10 0	a) IB: 0.1 mg; nebulizer; 90 min b) IB:1.0 mg; nebulizer; 90 min P: saline; NA; nebulizer; 90 min	Bicycle ergometer; 8; 80% 20-24°C; not controlled 3; 2 2-3 hr ICS allowed; SCG x 24 hr; BD x 12 hr	≥15% Primary: max % fall FEV ₁ ; max % fall PEF Secondary: FEV ₁ L; PEF L/min; % protection; complete protection; clinical protection FEV ₁ /PEF measured at 1, 5, 10, 15, 20, 25, 30 min No AE during study
Larsson ⁸⁸ 1982 Sweden Clinic	Journal article Boehringer Ingelheim Crossover	8 8 0	OB; 0.1 mg; MDI; 60 min IB: 0.04 mg; MDI; 60 min P: NA; MDI; 10 min	Bicycle ergometer; 6-9; load increased every min until exhaustion NR; NR 4; 1 24 hr All med x 12 hr	>15% Primary: FEV ₁ Secondary: max% fall FEV ₁ ; complete protection FEV ₁ measured at 2, 4, 6, 10, 15, 20 min No AE occurred
Neijens ⁸⁹ 1981 Netherlands Clinic	Journal article Foundation; Drugs supplied by Boehringer Ingelheim Crossover	13 13 0	OB: 0.02 mg; MDI; 20 min P: NA; MDI; 20 min	Treadmill; 6; 175 bpm 22°C; 70% RH 4 consecutive d; 2 2 hr All med x 3 d	≥15% Primary: mean % fall FEV ₁ Secondary: max% fall FEV ₁ ; % protection FEV ₁ measured at 5, 10, 15, 20 min NR
Poppius ⁹⁰ 1986 Finland Clinic	Journal article Drugs supplied by Boehringer Ingelheim; Sigrid Juselius Foundation Crossover	10 10 0	a) IB: 0.2 mg; powder capsule; 60 min b) IB 1 mg; powder capsule; 60 min c) IB: 2 mg; powder capsule; 60 min P: Powder capsule; NA; 60 min	Treadmill; 8; workload chosen to induce slight bronchoconstriction Cold air -9±7°C; water content 1.5 mg/L 4; 1 1 to 3 d All antiasthmatic meds during the trial	Not clear Primary: mean % fall FEV ₁ Secondary: mean % fall FEV ₁ FEV ₁ measured at 8, 30 min Yes

Table 35. Description of trials in the therapy review: Anticholinergic therapy (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Intervention: drug; dose; delivery device; time pre-ECT	ECT: type; duration (min); % predicted HR Temp; RH; Study days; challenges/day [N]; Time between challenges Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
Tashkin ⁹¹ 1977 U.S. Clinic	Journal article NR Crossover	15 15 0	Atropine: 1 mg; nebulizer; 10 min P: saline; 0.25 cc; nebulizer; 10 min	Bicycle ergometer; 6-8; 25-watt workload at 60 rpm NR; NR 7 [2 screen, 5 test]; 1 ≤1 wk at same time of d DSCG x 2 wk; oral/inhaled BD x 12 hr	>15% Primary: mean % change in FEV ₁ Secondary: NR FEV ₁ measured at 0, 5, 15, 20 min NR
Taytard ⁹² 1987 France Clinic	Journal article NR Crossover	10 10 0	OB: 0.3 mg; MDI; 25 min P: NA; MDI; 25 min	Treadmill; ≤8; 80% NR; NR 2; 1 48 hr Oral/inhaled BD 48 and 12 hr	≥20% Primary: RAW Secondary: complete protection FEV ₁ measured at 2, 5, 10, 15, 20 min NR
Thomson ⁹³ 1978 United Kingdom Clinic	Journal article Fison's Ltd/industry Crossover	13 13 0	IB: 2 mg; nebulizer; 20 min P: saline; 9 g/L; nebulizer; 20 min	Treadmill; 5-8; ≥170-180 bpm NR; NR 4; 1 4 ECT within 10 d SCG and BD x 24 hr	≥20% Primary: max % fall FEV ₁ Secondary: FEV ₁ L FEV ₁ measured at 2, 5, 10, 15, 20 min No AE during study
Tullett ⁹⁴ 1982 United Kingdom Clinic	Journal article NR Crossover	12 8 0	IB 0.12 mg; nebulizer; 30 min P: saline; 9 g/L; nebulizer; 30 min	Treadmill; 8; 160 bpm 20-22°C; 20-40% RH 4; 1 2-3 d SCG and BD x 24 hr	NR Primary: max % fall FEV ₁ Secondary: FEV ₁ L; % protection; complete protection; clinical protection FEV ₁ measured at 2, 5, 10, 15, 30 min Yes
Wolkove ⁹⁵ 1981 Canada Clinic	Journal article Sigrid Juselius Foundation; Drugs from Boehringer Ingelheim Crossover	8 8 0	IB: 0.04 mg; MDI; 60 min P: 2 puffs; MDI; 60 min	Bicycle ergometer; 8; 300, 600, or 900 km/min indoors 23.3±0.4°C, cold air -9.8±0.6°C; indoors=35±4%; outdoors=65±7% 4; 1 NR All med x 12 hr	≥15% Primary: FEV ₁ mean change; effect of temp Secondary: mean % fall FEV ₁ : mean fall FEV ₁ from 0 FEV ₁ measured at 5, 10, 20, 30 min No AE
Yeung ⁹⁶ 1980 Canada Clinic	Journal article Foundation Cross-over	17 17 0	IB: 0.04 mg; MDI; 45 min P: NA; MDI; 45 min	Treadmill; effort to cause a 25% fall in FEV ₁ pre-study; 170-180 bpm NR; NR 3; 1 1 to 2 d All med x 12 hrs	≥10% Primary: max % fall FEV ₁ / PEF Secondary: mean % fall FEV ₁ : complete protection; change in % predicted FEV ₁ / PEF measured at 3, 9, 15 min Yes

Table 36. Baseline characteristics of patients in trials in the therapy review: Anticholinergic therapy

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function: baseline FEV ₁ % predicted (mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Boner ⁷⁹ 1987	11.7±1.4 10/15 (66.7)	Stable	>80	Placebo ECT 40.9±17.2	NR	15/15 (100)	None
Borut ⁸⁰ 1977	13.1±2.15 18/20 (90)	Stable mild- moderate	77.9±16.01	Control ECT 20-25	NR	20/20 (100)	NR
Boulet ⁸¹ 1989	30±10.9 4/11 (57.1)	Stable	90.5±13.1	NR	NR	9/11 (81.8)	4/11 (36.4)
Bundgaard ⁸² 1980	30.5±7.6 7/18 (38.9)	Stable	NR	Placebo ECT 33.5	Never 10/18 (56); current 3/18 (17) <5/d	17/18 (94.4)	NR (none on oral corticosteroids)
Chan-Yeung ⁸³ 1977	33.1±13.8 5/9 (55.6)	Stable	90.2±12.2	Control ECT 36±15	All non-smokers	4/9 (44.4)	2/9 (22.2)
Chen ⁸⁴ 1981	13.5±1.76 5/6 (83.3)	Stable	85±10	Placebo ECT 28±14.69	NR	NR	6/6 (100) (testing done on days where no ICS taken)
Dorward ⁸⁵ 1982	24±9.5 2/7 (28.6)	Stable	2.8±0.87 L	Control ECT 47±18.4	All non-smokers	7/7 (100)	None
Godfrey ⁸⁶ 1976	8.7±2.9 13/15 (86.7)	Stable	70.3±15.1	Placebo ECT 45.2±15.5	NR	NR	NR
Hartley ⁸⁷ 1980	32; range 21-48 4/12 (40)	Stable	77.6 (53-113)	Placebo ECT 29.2±12.3	NR	8/10 (80)	3/10 (30)
Larsson ⁸⁸ 1982	44.8±10.5 5/8 (62.5)	Stable	78.61±27.32	All ≥15	NR	4/8 (50)	2/8 (25)
Neijens ⁸⁹ 1981	12.5±3.13 9/13 (69.2)	Stable mild- moderate	≥60	Control ECT 32.4±10.8	NR	NR	None
Poppius ⁹⁰ 1986	27.7±7.21 5/10 (50)	Mild	94.6±15.6	Placebo ECT 14	All non-smokers	5/10 (50)	None
Tashkin ⁹¹ 1977	11.7±1.7 14/15 (93.3)	Stable (mild airway obstruction)	79±11	Placebo ECT 18-28	NR	15/15 (100)	None

ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; ICS = inhaled corticosteroids; L = liters; NR = not reported; SD = standard deviation

Table 36. Baseline characteristics of patients in trials in the therapy review: Anticholinergic therapy (continued)

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function: baseline FEV ₁ % predicted (mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Taytard ⁹² 1987	19±4 4/10 (40)	Stable	88±16	NR	None or <5 cigarettes/d	NR	None for 1 mo
Thomson ⁹³ 1978	17-3 7/13 (53.8)	Stable	87±22.3	Control ECT 38.1±15.2	All non-smokers	13/13 (100)	None
Tullett ⁹⁴ 1982	31.2±11.3 5/8 (62.5)	Stable	3.43±0.54 L	Placebo ECT 38.1±14.1	All non-smokers	12/12 (100)	None
Wolkove ⁹⁵ 1981	28.7±5.4 4/8 (50)	Stable	62.0±16.4 to 69.8±16.7	All ≥15	NR	NR	NR
Yeung ⁹⁶ 1980	13; range 9-18 14/27 (51.9)	Stable	77.1±21.85	Placebo ECT 35.8±18.1	NR	NR	Mixed

Table 37. Quality assessment of trials in the therapy review: Anticholinergic therapy

Author Year	Described as randomized?	Described as double-blind?	Description of withdrawals/ dropouts?	Method of randomization described and appropriate?	Method of double-blinding described and appropriate?	Method of randomization described but inappropriate?	Method of double-blinding described but inappropriate?	Overall Score: Jadad	Concealment of allocation
Boner ⁷⁹ 1987	Yes	Yes	Yes	No	No	No	No	3	Unclear
Borut ⁸⁰ 1977	Yes	Yes	Yes	No	No	No	No	3	Unclear
Boulet ⁸¹ 1989	Yes	Yes	Yes	No	No	No	No	3	Unclear
Bundgaard ⁸² 1980	Yes	Yes	Yes	No	No	No	No	3	Unclear
Chan-Yeung ⁸³ 1977	Yes	No	Yes	No	No	No	No	2	Unclear
Chen ⁸⁴ 1981	Yes	No	Yes	No	No	No	No	2	Unclear
Dorward ⁸⁵ 1982	Yes	No	Yes	No	No	No	No	2	Unclear
Godfrey ⁸⁶ 1976	Yes	No	Yes	No	No	No	No	2	Unclear
Hartley ⁸⁷ 1980	Yes	No	Yes	No	No	No	No	2	Unclear
Larsson ⁸⁸ 1982	Yes	Yes	Yes	No	Yes	No	No	4	Unclear
Neijens ⁸⁹ 1981	Yes	Yes	Yes	No	No	No	No	3	Unclear
Poppius ⁹⁰ 1986	Yes	Yes	Yes	No	No	No	Yes	2	Unclear
Tashkin ⁹¹ 1977	Yes	Yes	Yes	No	No	No	No	3	Unclear
Taytard ⁹² 1987	Yes	Yes	Yes	No	No	No	No	3	Unclear
Thomson ⁹³ 1978	Yes	Yes	Yes	No	No	No	No	3	Unclear
Tullett ⁹⁴ 1982	Yes	No	Yes	No	No	No	No	2	Unclear
Wolkove ⁹⁵ 1981	Yes	Yes	No	No	No	No	No	2	Unclear
Yeung ⁹⁶ 1980	Yes	No	Yes	No	No	No	No	2	Unclear

Key Question T–6: Refractory Period (10 to 15 Minute Warmup and/or Cooldown)

Description of Included Studies

Seven trials⁹⁷⁻¹⁰³ met the inclusion criteria for the review investigating whether a defined exercise warmup protocol induces a refractory period that attenuates or prevents the EIB/EIA phenomenon within 2 hours of a subsequent ECT. Six trials used a crossover design;^{97,99-103} for one abstract the specific design could not be determined.⁹⁸ The studies were published between 1979 and 2007. Four trials were conducted in Europe,^{97,98,101,102} two in Australia^{101,103} and two in North America.^{99,100} The definition of EIB/EIA was measured by at least a 10^{98,100,101} or 15^{97,99,102} percent fall in FEV₁.

In three trials^{97,98,102} it was not clear if the ECT following the warmup met the ATS criterion of a work rate equal to 80 to 90 percent of an individually calculated maximum.¹⁶⁴ The time between warmup and ECT ranged from 1 to 49 minutes. The characteristics of the trials are summarized in Table 38.

The baseline characteristics of the participants are presented in Table 39. The number of patients enrolled ranged from 6 to 46. One study⁹⁷ included children only, three included adults only,^{99,100,102} and three included both children and adults.^{98,101,103} All participants in these trials except for one⁹⁸ had confirmed asthma; for most, their asthma was mild and stable.

Five of the seven studies investigated two or more warmup protocols. In order to capture all comparisons the protocols were categorized into three subgroups based on the intensity of the routine. Four routines involved several short sprints and are designated “interval” warmups;^{97,99,100,103} two studies involved two standardized challenges 45 minutes apart and are designated “continuous high intensity” warmups;^{102,103} three involved treadmill runs at work rates of 60 percent and are designated as “continuous low intensity” warmups.^{99,101,102} Study arms that involved drug therapy with or without a warmup are not included in this analysis.¹⁰⁰ Finally, the study by Eck et al.,⁹⁸ and one arm of the study by Schnall et al.¹⁰³ that used a continuous routine followed by an interval routine are reported separately.

Methodological Quality of Included Studies

Table 40 summarizes the methodological quality of the included studies. Overall the seven trials received low Jadad scores ranging from 1 to 2. No study described the randomization method. None stated that the assessors were blind; it was not possible to blind the participants to the type of warmup. Concealment of allocation was unclear in all the trials. The body of evidence is classified as “low.”

Quantitative Results

In all studies the mean maximum percent fall in FEV₁ or PEF was measured after a control ECT of 5 to 10 minutes and compared with the percent fall in an identical challenge after a designated warmup routine. The pooled results are presented as a MD in the maximum percent fall in FEV₁ or PEF between the two challenges. Because studies are included in more than one group, only subgroup pooled estimates were calculated.

Interval protocol. Four trials compared an interval warmup to a control challenge with no warmup.^{97,99,100,103} The protocols involved repetitive sprints of 26 to 30 seconds at 100 percent maximal oxygen consumption (VO_{2max}) or higher. The mean difference in the maximum percent

fall in FEV₁ ranged from an improvement of 4.8 to 16.1 percent over the control challenge. The pooled results showed that a series of short intense sprints attenuated the EIB/EIA response by a mean of 10.6 percent (95 percent CI: -14.7, -6.5; I²=15 percent) (Figure 27). One study reported that one of the 12 participants had falls in FEV₁ of less than 15 percent⁹⁹ and would be classified as having obtained complete protection from EIB/EIA following the interval warmup.

Continuous low intensity protocol. Three trials compared a continuous low intensity warmup that ranged from 3 minutes¹⁰¹ to 30 minutes¹⁰² to a control challenge with no warmup. Exercise intensity for the warmup was 60 percent of maximum heart rate,¹⁰¹ 60 percent of VO_{2max},⁹⁹ and reported as low intensity in the third study.¹⁰² The mean difference in the maximum percent fall in FEV₁ ranged from no improvement to 20.6 percent over the control challenge. The pooled results showed that this type of warmup attenuated the EIB/EIA response by a mean of 12.6 percent (95 percent CI: -26.7, 1.5; I²=90 percent) (Figure 27). One study also reported that 6 of the 12 participants had falls in FEV₁ of less than 15 percent and classified them as having obtained complete protection from EIB.⁹⁹

Continuous high intensity protocol. Two trials compared a continuous high intensity warmup^{102,103} to a control challenge with no warmup. Exercise intensity for the warmup was a heart rate equal to 180 beats per minute¹⁰³ and 98±2 percent of predicted maximum.¹⁰² The mean difference in the maximum percent fall in FEV₁ ranged from very little improvement (0.99) to 17.6 percent over the control challenge. The pooled results showed that this type of warmup attenuated the EIB/EIA response by a mean of 9.8 percent (95 percent CI: -26.0, 6.4) (Figure 27). Substantial heterogeneity was identified (I²=89 percent).

Combination protocols. Eck et al.⁹⁸ reported that there was no significant difference among the three protocols they investigated—one each of continuous 10 minutes of low intensity running, 10 minutes of running in intervals, and 10 minutes of exercising with increasing intensity. No data on the intensity of each warmup were reported. When combined, the three protected 79 percent (36/46) of participants from EIB/EIA (cutpoint not reported). The combined mean maximum percent fall in FEV₁ on the challenge following all warmup protocols was compared with no warmup and indicated a mean improvement of 11.0 percent (95 percent CI: 7.5, 14.6) (Figure 27).

One of three protocols in the Schnall and Landau¹⁰³ trial involved a combination of continuous and interval segments—a 6 minute treadmill run (heart rate 180 beats per minute), a 10 minute rest followed by 7 x 30 second sprints (treadmill speed increased 120 to 130 percent over first run), then a 20 minute rest before the final challenge of the same intensity as the original 6 minute run. The mean difference in the maximum percent fall in FEV₁ compared with no warmup was 10.4 percent (95 percent CI: 0.2, 21.1).

Other comparisons: One study reported no significant changes among three formats of warmup in measures of respiratory heat and water loss.⁹⁹

Figure 27. Warmup vs. no warmup in pre-exercise treatment of EIB/EIA: maximum percent decrease in FEV₁ or peak expiratory flow




Table 38. Description of trials in the therapy review: Refractory period

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Warmup protocol Description; Rest	ECT type/duration (min) following no warmup or warmup	ECT: temp; RH Number of protocols; protocols per day [N]; time between protocols Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
de Bisschop ⁹⁷ 1999 France Treatment center	Journal article NR Crossover	30 30 0	No warmup or Protocol 1: interval: 2 sets of 5 x 26 sec sprints, 1.5 min between, 5 min between sets (7.5% of the distance and 120% of the speed of FRAST) 10 min rest	FRAST: running as fast as possible x 7 min (mean distance =1,171±142 m)	4±5°C; 1.5±0.5 mmHg 2; 1; 24 hr, at mid-day SABA x 12 hr	≥15% <u>Primary</u> : mean % fall PEF <u>Secondary</u> : PEF L/min; mean % fall PEF predicted; PEF measured at post each sprint, 5, 10 min post sets, 5, 10 min post-FRAST NR
Eck ⁹⁸ 2002 Germany, Switzerland Clinic	Abstract NR Not clear	46 NR NR	No warmup or 5 min stretching, no rest, plus Protocol 1: continuous: 10 min steady training Protocol 2: interval: 10 min interval running Protocol 3: progressive: 10 min exercises with increasing intensity	Treadmill x 10 min steady running	NR; NR 4; not clear; not clear NR	≥10% <u>Primary</u> : mean % fall FEV ₁ <u>Secondary</u> : complete protection NR

AE = adverse events; AUC = area under the curve; bpm = beats per minute; C = Celsius; ECT = exercise challenge test; EIB/EIA = exercise-induced bronchoconstriction/asthma; FEV₁ = forced expiratory volume in 1 second; FRAST = free running asthma screening test; hr = hour(s); HR = heart rate; ICS = inhaled corticosteroid; km/h = kilometers per hour; L = liter; max = maximum; µg = microgram; min = minute(s); mmHg = millimeter of mercury; NR = not reported; PEF = peak expiratory flow; RH = relative humidity; SABA = short-acting beta-agonist; Sal = salbutamol; SCG = sodium cromoglycate; sec = second(s); temp = temperature; V_O₂ = oxygen consumption; wk = week(s)

Table 38. Description of trials in the therapy review: Refractory period (continued)

Author, Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Warmup Protocol Description; Rest	ECT type/duration (min) following no warmup or warmup	ECT: temp; RH Number of protocols; protocols per day [N]; Time between protocols Withheld asthma med; class; time	Definition EIB/EIA (% fall FEV ₁) Outcomes: Primary Secondary Adverse events
McKenzie ⁹⁹ 1994 Canada Volunteers	Journal article NR Crossover	12 12 0	No warmup or Protocol 1: continuous low intensity: treadmill x 15 min at 60% VO _{2max} ; 2 min rest; Protocol 2: interval: 8 x 30 sec sprints at 100% VO _{2max} separated by 1.5 min rest; 2 min rest	Treadmill x 6 min at 90% VO _{2max}	20.7±1.2°C; ambient room humidity 3; not clear (3 sessions); not clear Caffeine and exercise x 4 hr.	≥15% <u>Primary</u> : max % decrease FEV ₁ <u>Secondary</u> : complete protection FEV ₁ measured at 0.5 min, then every 2 min to 25 min; NR
Mickleborough ¹⁰⁰ 2007 U.S., United Kingdom University and local community	Journal article NR Crossover	8 8 0	No warmup or Protocol 1: Interval: 8 x 30 sec sprints with 45 sec recovery between; 15 min rest (interval intensity equal to VO _{2max}) Protocol 2: Sal 200 µg plus 8 x 30 sec sprints with 45 sec recovery between sprints; 15 min rest; Protocol 3: Sal 200 µg; 15 min rest	Treadmill x 8 min at 85-90% predicted max HR; wore a noseclip	23°C; 50% 4; 1; ≥96 hr SABA x 12 hr, caffeine/alcohol x 8 hr, exercise x 24 hr	≥10% <u>Primary</u> : max % decrease FEV ₁ ; AUC <u>Secondary</u> : NR FEV ₁ times measured at 1, 5, 10, 15 min NR
Morton ¹⁰¹ 1979 Australia Local volunteer	Journal article Foundation Crossover	19 18 1	No warmup or Protocol 1: continuous low intensity: treadmill x 3 min at 60% predicted max HR; 1 min rest;	Treadmill x 5 min at 85% predicted max HR	Room temp; NR 2; 1; ≥8 day All med and exercise x 12 hr	≥15% <u>Primary</u> : max % decrease FEV ₁ <u>Secondary</u> : FVC % change FEV ₁ times measured at 5, 10, 15, 20, 30 min 1 AE

Table 38. Description of trials in the therapy review: Refractory period (continued)

Author Year Country Source	Publication status Funding Trial design	Randomized [R] Analyzed [A] Withdrawals [W]	Warmup Protocol Description; Rest	ECT type/duration (min) following no warmup or warmup	ECT: temp; RH Number of protocols; protocols per day [N]; Time between protocols Withheld asthma med; class; time	Definition EIB/EIA Outcomes: Primary Secondary Adverse events
Reiff ¹⁰² 1989 United Kingdom Clinic Volunteers	Journal article NR Crossover	7 7 0	Protocol 1: continuous high intensity: treadmill at 15% incline; 6 km/h x 6 min; 45 min rest HR=98±2% predicted max Protocol 2: continuous low intensity: treadmill at 3% incline, 6 km/h x 30 min; 21 min rest HR=88±32% predicted max	Treadmill x 6 min at 15% incline; 6 km/h; HR=97±3% predicted max	19.9±0.7°C; 39-50±4.0% 2; 1; 2 sessions within 1 wk at same time of d ICS x 24 hr; SABA x 8 hr	≥15% <u>Primary</u> : max % decrease FEV ₁ and PEF <u>Secondary</u> : Mean % fall FEV ₁ and PEF; AUC FEV ₁ /PEF measured at every 5 min to 90 min NR
Schnall ¹⁰³ 1980 Australia NR	Journal article Government Crossover	6 6 0	Protocol 1: continuous high intensity: Treadmill x 6 min at 10% incline (HR 180 bpm), 49 min rest Protocol 2: Progressive: Treadmill x 6 min at 10% incline (HR 180 bpm); 10 min rest; 7 x 30 sec sprints with 2.5 min between (speed 120-130% of 1 st run); 20 min rest Protocol 3: Interval: 7 x 30 sec sprints with 2.5 min between (speed 120-130% of 1 st run) 20 min rest	Treadmill x 6 min at 10% incline; HR 180 bpm	21-23.5±1.2°C; 0.55 3; 1; 3 sessions in 4 wk SABA and SCG x 8 hr	NR <u>Primary</u> : max % decrease FEV ₁ and PEF <u>Secondary</u> : FEV ₁ L; PEF L/min FEV ₁ / PEF measured at 0, 2, 5, 10, 15, 25 up to 80 min Yes

Table 39. Baseline characteristics of patients in trials in the therapy review: Refractory period

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function: baseline FEV ₁ % predicted (mean±SD)	Max % fall FEV ₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
de Bisschop ⁹⁷ 1999	12; range 8-15 21/30 (70)	Stable, mixed severity	PEF: 99±15%	PEF: 37±14.5	NR	NR	≥8/30 (26.7)
Eck ⁹⁸ 2002	Range 6-19 NR	NR	NR	NR	NR	NR	NR
McKenzie ⁹⁹ 1994	26.5±7.8 3/12 (33.3)	Stable	3.42±1.05 L	>30	Non-smokers	NR	None
Mickleborough ¹⁰⁰ 2007	19.5±1.2 NR	Mild-persistent	92.4±6.12 (3.5±0.82 L)	18.25±4.01	Never smoked	NR	8/8 (100)
Morton ¹⁰¹ 1979	19.7; range 11-33 10/18 (55.6%)	Stable	100	38.1	NR	NR	NR
Reiff ¹⁰² 1989	25.4±6.6 5/7 (71.4)	Stable, mild- persistent	80.6±20.7	FEV ₁ : 46±6.9; PEF: 51±10.6	NR	7/7 (100)	2/7 (28.6)
Schnall ¹⁰³ 1980	Range 12-31 4/6 (66.7)	Stable	84.1 (2.7±0.71 L)	22.8±8.08	NR	NR	None

FEV₁ = forced expiratory volume in 1 second; L = liters; NR = not reported; PEF = peak expiratory flow; SD = standard deviation

Table 40. Quality assessment of trials in the therapy review: Refractory period

Author Year	Described as randomized?	Described as double-blind?	Description of withdrawals/ dropouts?	Method of randomization described and appropriate?	Method of double-blinding described and appropriate?	Method of randomization described but inappropriate?	Method of double-blinding described but inappropriate?	Overall Score: Jadad	Concealment of allocation
de Bisschop ⁹⁷ 1999	Yes	No	Yes	No	No	No	No	2	Unclear
Eck ⁹⁸ 2002	Yes	No	No	No	No	No	No	1	Unclear
McKenzie ⁹⁹ 1994	No	No	Yes	No	No	No	No	1	Unclear
Mickleborough ¹⁰⁰ 2007	Yes	No	Yes	No	No	No	No	2	Unclear
Morton ¹⁰¹ 1979	Yes	No	Yes	No	No	No	No	2	Unclear
Reiff ¹⁰² 1989	Yes	No	Yes	No	No	No	No	2	Unclear
Schnall ¹⁰³ 1980	Yes	No	Yes	No	No	No	No	2	Unclear

Chapter 4. Discussion

Diagnostic Test Accuracy Review

A valid test to determine if EIB or EIA is present must involve a standardized measure of effort (heart rate or ventilation rate) or dose of inhalant and be of sufficient duration to produce a response in susceptible subjects. Airway response measures must also be standardized. Testing protocols for airway constriction can be classified into direct or indirect tests. Indirect challenges such as exercise, eucapnic voluntary hyperpnea (EVH), and inhaled mannitol are thought to cause inflammatory cells to release mediators such as leukotrienes, prostaglandin, and histamine which provoke smooth muscle constriction.²⁰ In contrast, direct tests such as methacholine or histamine act directly on smooth muscle receptors to cause constriction independent of airway inflammation.¹⁹

Using a comprehensive search strategy and concerted efforts to avoid publication and selection bias, this review identified all the available evidence to assess the diagnostic test characteristics of six tests for the diagnosis of EIB/EIA. In total, we identified 27 studies that met our inclusion criteria. The number of studies available to address each of the six key questions ranged from 2 to 16.

There are many methodological considerations when undertaking a systematic review of the diagnostic literature. To determine the accuracy of a diagnostic test, a reference standard must be available for comparison. The reference test used for this report was the exercise challenge test (ECT) as detailed by the ATS.¹⁸ The guidelines cover water content and temperature of the inspired air plus work effort required for either treadmill or bicycle ergometer testing. According to the ATS criteria,¹⁸ during the ECT participants should inspire dry air at a temperature of less than 25°C with a noseclip in place to force mouth breathing. Nasal breathing decreases the water loss from the airways. Temperature and relative humidity (RH) during testing should be documented, and RH should be low (50 percent or less). It is unclear if the ambient humidity in the typical air conditioned laboratory (30 to 50 percent water vapor saturation) is less likely to induce airway narrowing as compared with perfectly dry air obtained from compressed gas (i.e., RH ~0 percent).¹⁸ However, as airway drying is the primary trigger for EIB/EIA,¹⁹ it would seem logical that tests completed with compressed air would be more sensitive for detecting EIB/EIA. In this review, many studies had the participants inspire room air as detailed in ATS guidelines, while others used compressed air during their ECT.

Among the included studies, detailed reporting of the ECT protocol varied, and in several cases it was not clear if the challenge met ATS recommendations particularly when it came to nose versus mouth breathing, effort required, and duration. Treadmill grade and speed must be individually chosen and progressively increased in the first minutes to produce 6 to 8 minutes of near maximum target heart rates (i.e., 80 to 90 percent of the predicted rate for age). Ventilation should reach 40 to 60 percent of the predicted maximum voluntary ventilation. In a bicycle ergometer challenge a target work rate is determined to achieve target ventilation and the work rate is gradually increased until the target exercise intensity is maintained for 4 to 6 minutes. With either method, the subject must reach the target heart or ventilation rate in the first 4 minutes as water loss and airway drying determine the development of EIB/EIA.¹⁸ Since the specifics of the ECTs were not consistently reported in full, some exercise challenges may not have met these standards. Furthermore, a number of studies used higher diagnostic cutpoints of a 15 or 20 percent fall in FEV₁ post-exercise instead of the ATS guideline of a 10 percent drop.

We could not always extract results for the 10 percent cutpoint. We suspect that the variability in methodology used for the reference standard ECT may be the cause of some heterogeneity in comparisons with other EIB/EIA diagnostic methods.

A key concern, which may also have contributed to the heterogeneity observed across all the diagnostic comparisons, was that of a spectrum bias. Ideally, studies should have a sample of participants who are representative of the population being examined for EIB/EIA. That is, studies should have participants that span the range from high to low likelihood of EIB/EIA so that the true positive and true negative numbers are approximately the same. Many studies included in these reviews purposely recruited participants who either had or did not have a history of EIB/EIA or asthma (asthma increases the likelihood of having EIA) or they did not mention clinical history or provide baseline data. Cumulatively, only 6 percent of studies had a representative sample and only 21 percent stated their inclusion criteria. Virtually all studies recruited volunteers who were willing to undergo the tests being compared. The lack of a representative patient spectrum limits the generalizability of the results to the target population of people with suspected EIB/EIA and therefore a pooled estimate of sensitivity and specificity is not reliable.

Table 41 and the following sections review the individual tests examined in the review.

Self-report. Since many patients present to clinicians with simply their story of breathing difficulties following exercise, the first question in this diagnostic review examined the accuracy of self-reported history or symptoms. EIB/EIA may be associated with symptoms such as shortness of breath, cough, wheeze and chest pain,¹⁸ and therefore these symptoms may lead clinicians to suspect EIB/EIA. For clinicians and patients, the diagnostic test characteristics of self-report are important to understand.

Despite extensive searching, only two studies addressed this question. While the results of one of the studies²¹ comparing post-exercise cough to an ECT are encouraging (89 percent sensitivity, 86 percent specificity), this is not sufficient evidence to conclude that self-report of symptoms is a reliable diagnostic tool for EIB/EIA (Table 41). There were too few studies to produce reliable ROC curves. Furthermore, given the complexity and variability of respiratory symptoms, recent research in chronic asthma has shown that objective lung testing is vital for a valid diagnosis¹⁶⁵ and there is no reason not to apply this to a diagnosis of EIB/EIA.

Quality of evidence. The evidence from this group of two studies was graded as “very low”. Both study designs were rated low and there are serious limitations due to the lack of a representative spectrum of participants and uncertainty whether the ECTs met the ATS guideline recommendations.¹⁸ The diagnostic thresholds differed and the sensitivity estimates are inconsistent and imprecise.

Methacholine (MCH) challenge. MCH is considered a direct challenge as it acts on smooth muscle acetylcholine receptors, causing contraction and airway narrowing.²³ It has been noted that airway responsiveness to pharmacologic agents such as MCH differs from hyper-responsiveness in response to physical stimuli such as exercise and osmotic agents.¹⁸

The review identified 16 studies that met the inclusion criteria for the diagnostic test accuracy review of the MCH challenge. Overall, the study quality varied, and there was a concern of spectrum bias in all but one study.²³ Regardless of the threshold level for MCH (8 mg/ml or 16 mg/ml), there was considerable heterogeneity across individual study estimates for sensitivity (66 to 100 percent at 8 mg/ml; 0 to 100 percent at 16 mg/ml) and specificity 0 to 100 percent at either threshold. (Table 41) Moreover, the area under the curve (AUC) of the ROC was marginally more than 0.5 for any of the FEV₁ cutpoints (10, 15, or 20 percent) or MCH

thresholds. Based on these results we cannot conclude that the MCH challenge is a valid test to diagnose EIB/EIA.

Unlike exercise challenges, a positive airway response to MCH does not infer the presence of inflammatory cells or their mediators;²⁰ therefore, it is not surprising that MCH shows variable sensitivity and specificity to detect EIB/EIA. It has been suggested¹⁸ that a positive MCH test should not be used to infer EIB/EIA and likewise, a negative MCH should not be used to exclude EIB/EIA.

Quality of evidence. The evidence from this group of 15 studies was graded as “moderate”. The study designs were rated high; however, there are serious limitations to the body of evidence as a whole. Only one study had a representative spectrum of participants and blinded the assessors to test results. It is unclear whether eight of the ECTs met the ATS guideline recommendations.¹⁸ The sensitivity estimates are reasonably consistent but are imprecise in the EIA participants. Specificity estimates are inconsistent and imprecise.

Sport or venue specific challenges. Sport or venue specific challenges refer to challenges in the specific sport (e.g., basketball, soccer) or at the venue of activity (e.g., hockey arena, swimming pool). They are advantageous in that the athlete can exercise in the conditions where they become symptomatic and the tests are reasonably inexpensive; however, coordinating the two tests and ensuring good quality control on both can be problematic.

Five studies addressed the key question of sport or venue specific exercise challenges (Table 41). Three studies focused on swim challenges and two assessed cold weather challenges. All studies involved elite athletes. The sensitivity of the field tests ranged from 0 to 100 percent. Specificity also ranged from 0 to 100 percent; however, in one study,⁴¹ all participants had a history of EIB/EIA and therefore had a high pre-test probability of testing positive on both tests. In the studies that did not have this select population, the specificity ranged from 79 to 100 percent. There were too few studies to produce reliable ROC curves. Although sport specific challenges are one of the recommended challenges for diagnosing EIB/EIA in elite athletes,³⁴ in total, only seven athletes tested positive in their own field of competition while 16 were positive on a standardized ECT. It is not clear why this occurred, although it is possible that the level of minute ventilation and differences in environmental conditions played a role. Sport specific challenges may be useful in identifying athletes who do *not* have EIB/EIA but additional testing such as a standardized ECT may be required to confirm a diagnosis.

Quality of evidence. The evidence from this group of five studies was graded as “low”. The study designs were rated high; however, there are serious limitations to the body of evidence as a whole. No study had a representative spectrum of participants or blinded the assessors to test results. It is unclear whether two of the ECTs met the ATS guideline recommendations.¹⁸ Both the sensitivity and specificity estimates are inconsistent and imprecise.

Eucapnic voluntary hyperpnea (EVH) challenge. EVH challenge is a test based on the premise that the increased minute ventilation with exercise is responsible for airway constriction in susceptible participants.¹⁹ Currently, EVH is the challenge recommended by the International Olympic Committee Medical Commission to identify EIB/EIA among Olympic athletes.⁴⁸

The stimulus for the airways to narrow in response to exercise is the water lost by evaporation from the airway surface and the osmotic and thermal effects arising from this.¹⁸ Theoretically, conditioning large volumes of cold inspired air places a greater burden on the airways to reheat and rehumidify it quickly as compared with inspiring warmer, humid air. Therefore, it is likely that additional (i.e., small) airways would be recruited to achieve the task and this would increase airway dehydration. Similarly, inspiration of cold air during EVH would

increase the likelihood of bronchoconstriction compared with EVH using room temperature air. In the study by Eliasson et al.⁴² participants performed EVH tests while inspiring air at room temperature or inspiring air cooled to between minus 18°C and minus 26°C. Despite the increased conditioning of the air required during the cold air trial, there was no difference in post-EVH FEV₁ response between the cold versus room temperature challenges.

It is worth noting that EVH challenges are likely the most technically difficult of all the EIB/EIA diagnostic tests to perform for a variety of reasons. First, minute ventilation must be measured accurately in real-time and displayed so that participants can receive feedback on their target minute ventilation. The substantial increase in minute ventilation with the challenge will cause hypocapnea, which can cause bronchoconstriction¹⁶⁶ as well as nausea and fainting. It is for this reason that EVH trials are performed with participants rebreathing a gas mixture of approximately five percent CO₂ so that arterial CO₂ levels can be maintained at resting eupneic levels. Importantly, rebreathing a gas mixture for 5 to 6 minutes may also cause hypoxemia if the gas mixture does not contain an elevated oxygen concentration. Thus, additional monitoring equipment as well as well-trained respiratory or exercise physiology staff are required to maintain CO₂ and O₂ levels within normal physiological ranges during EVH challenges.

Seven studies met the inclusion criteria to assess the diagnostic accuracy of EVH (Table 41). In general study quality raised questions of bias, in particular, there was a concern of spectrum bias in all studies. Overall, the sensitivity and specificity was heterogeneous with values ranging 25 to 100 percent, and 0 to 74 percent, respectively. It is unclear whether an EVH challenge is identifying the same people that experience a fall in FEV₁ of 10 percent or more on an ECT, particularly in a population of athletes with an unclear history of asthma. The EVH challenge resulted in a higher proportion of false positives (FP) (i.e., negative on the ECT but positive on EVH) among participants with no or unknown history of EIB/EIA. The proportion of FP ranged from 25 to 71 percent. The participants included both elite athletes (n=63) and those with unknown activity levels (n=20). Based on the available evidence, it is unclear if the EVH challenge is more sensitive to EIB/EIA, or if the mechanism that triggers the bronchoconstriction is different from that for the ECT, or if level of minute ventilation achieved on an ECT according to ATS recommendations is less than the level achieved in an EVH challenge particularly in athletes. Among participants with a history of EIB/EIA, the proportion of FPs ranged from 0 to 5 percent in participants with unknown activity levels. Among athletes, the proportion with a FP result was 27 percent. Further research is needed to determine if the EVH challenge would be an appropriate add-on test to a standardized ECT in athletes with symptoms of EIB/EIA. Based on this evidence, it is unclear whether EVH challenge is more accurate diagnostic test for EIB/EIA compared with a standardized ECT.

Quality of evidence. The evidence from this group of seven studies was graded as “low”. The study designs were rated high; however, there are serious limitations to the body of evidence as a whole. No study had a representative spectrum of participants or blinded the assessors to test results. It is unclear whether the ECTs met the ATS guideline recommendations.¹⁸ Furthermore, the sensitivity and specificity estimates are inconsistent and imprecise.

Free running asthma screening test (FRAST). Free running has often been used in screening large groups for EIB/EIA because of the ease in performing such challenges.¹⁹ Three studies met the inclusion criteria for assessing the diagnostic accuracy of the FRAST (Table 41). Participants in all the studies were children (younger than 15 years), and all tests took place indoors. Despite being able to run freely during the FRAST, the reported average heart rate during the challenge for each group was 80 percent or greater of maximum and was comparable

to the ECT. None of the studies had a representative patient spectrum. Sensitivity and specificity were modest (60 to 67 percent and 47 to 67 percent, respectively). There were too few studies to produce reliable ROC curves. While the FRAST is easy to perform, there is insufficient evidence to conclude that it accurately identifies people with EIB/EIA compared to a standardized ECT.

Quality of evidence. The evidence from this group of three studies was graded as “very low”. The study designs were rated medium; however, there are serious limitations to the body of evidence as a whole. No study had a representative spectrum of participants or blinded the assessors to test results. It is unclear whether two of the ECTs met the ATS guideline recommendations.¹⁸ The sensitivity and specificity estimates are consistent but imprecise.

Mannitol provocation test. Recently, a mannitol provocation test has been developed to examine airway hyper-responsiveness. Like exercise, mannitol is considered an indirect bronchial provocation test. Mannitol increases osmolarity, which causes the release of endogenous mediators such as prostaglandin, leukotrienes and histamine, and results in smooth muscle contraction.^{50,51} Mannitol has the advantage that it can be performed with minimal equipment (i.e., a metered-dose inhaler and spirometer).

Three studies met the inclusion criteria for the diagnostic test accuracy review of mannitol (Table 41). Sensitivity ranged from 58 to 96 percent; specificity ranged 65 to 78 percent. At this time there is insufficient evidence to conclude that the mannitol provocation test is a reliable test to diagnose EIB/EIA.

Quality of evidence. The evidence from this group of 3 studies was graded as “moderate”. The study designs were rated high; however, there is reasonable concern regarding the limitations to the body of evidence as a whole. Only one study had a representative spectrum of participants and blinded the assessors to test results. All three of the ECTs met the ATS guideline recommendations.¹⁸ The sensitivity and specificity estimates are reasonably consistent but are imprecise.

Table 41. Summary of sensitivity and specificity for the diagnostic test accuracy review

Index test	# studies, sample size	ECT type (# studies) Definition of EIB/EIA (# studies)	Sensitivity point estimate or range mean % (95% CI)	Specificity point estimate or range mean % (95% CI)	ECT +ve (≥10% fall FEV ₁) N (%)	Index test +ve N (%)	Evidence Grade
Self-report	2, N=206	Treadmill (2) ≥10% fall FEV ₁ (1) ≥15% fall FEV ₁ (1)	89% (67, 99) 36% (17, 59)	86% (64, 97) 85% (78, 90)	19 (48) 20 (13)	20 (50) 30 (18)	Very low
Methacholine	16, N=1,048	Treadmill (10) Bicycle ergometer (6) ECT: ≥8% fall FEV ₁ (1), ≥10% fall FEV ₁ (6), ≥15% fall FEV ₁ (2), ≥18% fall FEV ₁ (1), ≥20% fall FEV ₁ (5) MCH: ≥20% fall FEV ₁ at various doses MCH	≥10% fall FEV ₁ 0-100%; (MCH _{PC20} <8mg/ml) 55-100% (MCH _{PC20} <16mg/ml)	0-100% 0-100%	331 (57) 420 (53)	416 (71) 498 (63)	Moderate
Sport specific challenge	5, N=95	Treadmill (3), bicycle ergometer (2) ≥10% fall FEV ₁ (4) ≥20% fall FEV ₁ (1)	≥10% fall FEV ₁ Swim challenge 0-50%	83-100%	11 (19) 5 (14)	5 (9) 26 (70)	Low
Eucapnic voluntary hyperpnea	7, N=138	Treadmill (4), bicycle ergometer (3) ECT: ≥10% fall FEV ₁ (4), ≥20% fall FEV ₁ (1), NR (2) EVH: ≥10% fall FEV ₁ (4), NR (3)	≥10% fall FEV ₁ 25-90%	0-71%	42 (30)	74 (54)	Low
FRAST	3, N=99	Treadmill (1), bicycle ergometer (2) ≥10% fall FEV ₁ (1) ≥20% fall FEV ₁ (2)	≥10% fall FEV ₁ : 60-67% ≥20% fall FEV ₁ : 53%	47-67% 100%	13 (38) 30 (50)	18 (53) 16 (27)	Very low
Mannitol	3, N=423	Treadmill (2), bicycle ergometer (1) ECT: ≥10% fall FEV ₁ (3) Mannitol: ≥15% fall FEV ₁ (3)	≥10% fall FEV ₁ 58-96%	65-78%	202 (48)	203 (48)	Moderate

ECT = exercise challenge test; EVH = eucapnic voluntary hyperpnea; FEV₁ = forced expiratory volume in 1 second; FRAST = free running asthma screening test; MCH = methacholine; PC = provocative concentration

Limitations

In addition to the issues identified regarding ECT and index test performance, there are several limitations that need to be discussed regarding systematic reviews of diagnostic test accuracy. First, there is a possibility of publication bias. The impact of publication bias on the results of diagnostic test accuracy reviews is not well understood nor have the tools to investigate publication bias in these reviews been developed.¹⁶⁷ However, we conducted a comprehensive and systematic search of the published literature for potentially relevant studies. Search strategies included combinations of subject headings and free text words. These searches were supplemented by handsearching for gray literature (i.e., unpublished or difficult to find studies). Despite these efforts, we recognize that we may have missed some studies.

Overall, EIB/EIA literature is not indexed well and authors are not consistent in using the terms in titles or abstracts that clearly describe the scope of their research. There are also a variety of activities and sports that can potentially cause EIB/EIA. It is impossible to account for every variation and term within the search strategy. Knowing this, the search strategy was designed to be highly sensitive in order to avoid missing any potentially relevant articles and 18 electronic databases were searched in order to retrieve as many pertinent studies as possible.

There is also a possibility of study selection bias. We employed at least two independent reviewers to identify potentially relevant studies, and feel confident that the studies that were excluded from this report were done so for consistent and appropriate reasons.

A further limitation was that not all studies that seemed potentially relevant were designed as diagnostic test accuracy studies but they did compare two test methods of interest; however, the data presented were not in a useful form to evaluate the diagnostic accuracy of the comparison. In order to be included, a study had to report sufficient data to generate a 2x2 table of the reference standard and index test results based on one or more diagnostic thresholds.

Finally, we did not pool the sensitivity and specificity data in this report. A decision was made that the populations, tests, and study designs were sufficiently heterogeneous for each of the key questions that pooling would be invalid. Where appropriate we wanted to produce AUC results for ROC curves; however, given the small number of studies that addressed each of the key questions, an ROC curve was possible only for MCH versus ECT.

Conclusions

Despite exhaustive efforts to identify evidence regarding the diagnostic test characteristics of tests used to identify patients with EIB/EIA, few studies were identified. Moreover, the studies that were identified suffered from considerable test variability and spectrum bias. In all included studies, the participants were volunteers and varied from exclusively elite athletes with or without documented or suspected EIB/EIA to patients with or without documented or suspected EIB/EIA who were not trained athletes. In the many of studies physical fitness was not addressed at all. The diversity in included populations and the fact that there were not many studies comparing the same diagnostic tests precluded more detailed subgroup analysis of the issue of EIB versus EIA. However, we do not believe these limitations invalidate the results presented in the review as the reviewers analyzed the data as vigorously as it allowed. The results of this report apply to patients being screened for EIB/EIA as well as the clinicians caring for them.

On the basis of this review, there is no clear evidence to support that any of the six index tests studied are equivalent to, or better than, the standardized ECT to diagnose EIB/EIA. At this time none can be recommended to replace the ECT for diagnosing EIB/EIA in the general population. EIB/EIA remains a complex phenomenon that does not always occur in the same individual every time they under go a challenge. Combining history, symptoms, objective testing plus trial and error therapy may still be the preferred path to an active life in those that have EIB/EIA.

Therapy Review

Using a comprehensive search strategy and concerted efforts to avoid publication and selection bias, this review identified all the available evidence to assess the effectiveness of six interventions (five pharmacologic and one nonpharmacologic) to treat EIB/EIA. Overall, we identified 109 studies that met our inclusion criteria. The number of studies available to address each of the six key questions ranged from 4 to 17 involving between 40 and 272 participants.

There are many methodological considerations when undertaking a systematic review of the therapeutic literature. When determining the effectiveness of a therapy, the highest level of evidence arises from well-conducted RCTs. EIB/EIA is a unique condition. It would not exist if not triggered by vigorous exercise and, although the bronchoconstriction can be severe; it generally resolves spontaneously over the course of an hour and leaves no permanent sequelae. The therapeutic drugs used for EIB/EIA are short-acting and are rapidly cleared from the body. As a result, therapy trials for this condition lend themselves to crossover RCT methodology and the majority of trials in these reviews employed this design. The advantage of a crossover compared with a parallel group design is that all participants receive all interventions and, therefore serve as their own control. This reduces sample size requirements. However, concerns with washout periods, carryover effects, and changes over time mean trialists must design the timing and frequency of ECTs with this in mind.

Since asthma is a common chronic condition, in most countries guidelines exist for the treatment of this disease. Not surprisingly, the treatment options for EIB/EIA mirror those for symptoms in chronic asthma—mainly, bronchodilators and anti-inflammatory agents. Like an asthma attack, an EIB/EIA attack can produce symptoms such as shortness of breath, cough, wheeze and chest pain,¹⁴³ and, as in asthma, these symptoms are amenable to treatment with bronchodilators. Since many of the anti-inflammatory agents improve asthma control, clinicians and researchers have been curious to know if they also have an effect on EIB/EIA.

The following sections summarize the pharmacologic and nonpharmacologic treatments addressed in this report (Table 42 and Figure 28). The pharmacologic interventions are further divided into bronchodilating and anti-inflammatory agents.

Table 42. Prophylactic therapy for EIA: Pulmonary function results

Comparisons Intervention vs. control	N trials (SS_i vs. SS_c) MD % fall FEV₁/PEF (95% CI)*	Clinical protection ≥50% N trials (SS_i vs. SS_c) RR (95% CI) †	Mean % protection of intervention over control (95% CI)	Complete protection N trials (SS_i vs. SS_c) RR (95% CI) †	Evidence Grade
Leukotriene receptor antagonists vs. placebo	N=9 (267 vs.267) 8.9 (6.9, 11.0)	NR	NR	≤10% fall FEV ₁ N=4 (124 vs. 123) 1.87 (0.77, 4.56)	Moderate
Inhaled corticosteroids vs. placebo	N=4 (50 vs. 50) 5.0 (0.0, 9.9)	NR	BV 6%; BUD 17%; FP 49%	NR	Moderate
MCS (Nedocromil sodium) vs. placebo	N=17 (240 vs. 240) 15.6 (13.2, 18.2)	NR	51 (46, 55)	NR	Moderate
Nedocromil sodium vs. Sodium cromoglycate	N=7 (97 vs. 97) 0.9 (-2.7, 4.5)	N=6 (78 vs. 78) 1.12 (0.89, 1.40)	NR	≤10% fall FEV ₁ N=6 (78 vs. 78) 1.0 (0.7, 1.4)	Moderate
MCS vs. Anticholinergics	N=8 (183 vs. 175) 6.7 (3.3, 10.0)	N=5 (56 vs. 48) 1.35 (1.00, 1.83)	11.2 (2.4, 20.0)	≤15% fall FEV ₁ N=8 (177 vs. 169) 1.3 (1.1, 1.6)	Moderate
SABA vs. MCS	N=12 (271 vs. 272) 6.8 (4.5, 9.2)	N=6 (77 vs. 77) 1.4 (1.1, 1.7)	22.7 (11.9, 33.4)	≤15% fall FEV ₁ N=9 (225 vs. 226) 1.4 (1.2, 1.8)	Moderate
SABA + MCS vs. SABA	N=5 (40 vs. 40) 1.3 (-6.3, 8.9)	N=3 (37 vs. 37) 0.9 (0.7, 1.1)	10.3 (-27.0, 6.5)	≤15% fall FEV ₁ N=4 (44 vs. 44) 0.9 (0.5, 1.4)	Moderate
LABA vs. Placebo	N=4 (55 vs. 55) 25.1 (18.0, 32.3)	NR	86%	NR	Moderate
Anticholinergics (Ipratropium bromide) vs. placebo	N=11 (142 vs. 142) 9.8 (5.0, 19.5)	N=6 % achieved=60 (48, 72)	NR	≤10% fall FEV ₁ N=7 (74 vs. 74) 4.5 (1.2, 10.9)	Moderate
Interval warmup vs. no warmup	N=4 (56 vs. 56) 10.6 (6.5, 14.7)	NR	NR	≤15% fall FEV ₁ N=1 1/12 (8.3%)	Low
Continuous low intensity warmup vs. no warmup	N=3 (37 vs. 37) 12.6 (-1.5, 26.7)	NR	NR	≤15% fall FEV ₁ N=1 6/12 (50%)	Low
Continuous high intensity warmup vs. no warmup	N=2 (13 vs. 13) 9.8 (-6.4, 26.0)	NR	NR	NR	Low

BUD = budesonide; BV =Betamethasone valerate; FEV₁ = forced expiratory flow in 1 second; FP=fluticasone ICS = Inhaled corticosteroid; LTRA = leukotriene receptor antagonist; MCS = mast cell stabilizers; MD = mean difference; NR = not reported; PEF = peak expiratory flow; RR = risk ratio; SABA = short-acting beta-agonist; SS_i = sample size intervention; SS_c = sample size comparison

*a positive MD indicates intervention is better; † RR>1 indicates intervention is better.

Pharmacologic Interventions

Bronchodilating Agents

SABA/LABA. Beta₂-receptors on the airway smooth muscle are responsible for bronchodilation; beta₂-agonist agents attach to these receptors and are effective bronchodilators. SABA agents have been the mainstay of EIB/EIA prevention and treatment for many years. With the development and availability of LABA agents, more research has been applied to their effectiveness in EIB/EIA.

Although the evaluation of SABA or LABA versus placebo for prophylactic EIB/EIA use was not the focus of this review, results were available in some comparisons on which to base a reasonable conclusion. In the mast cell stabilizer (MCS) review⁷⁸ SABA agents were approximately 7.0 percent more effective than MCS. Using data from the SABA groups in the 12 studies in the comparison with MCS,⁷⁸ SABA reduced the maximum percent fall in FEV₁ to an average of 4.3 percent (SD±14.1; range 1.0 to 15.5) whereas as the MCS groups averaged a maximum percent fall in FEV₁ of 11.0 percent (SD±17.7; range 4.2 to 27.2).⁷⁸ The day 1 data for the four LABA groups in the tachyphylaxis review showed that LABA reduced the fall in FEV₁ to an average of 3.7 percent (SD±8.7). This indicates that LABA is also an effective agent for attenuating the bronchoconstriction that is characteristic of EIB/EIA (Figure 28).

While SABA and LABA treatments are effective, caution is advised. The data from this review support that a degree of tachyphylaxis is associated with the regular use of both beta-agonist agents. The pooled results from four LABA trials demonstrated the maximum percent fall in FEV₁ following an ECT after 4 weeks of regular LABA use was of a greater magnitude in the LABA arm than the placebo arm. Similar results were shown in the two studies that investigated SABA after only 1 week of regular use. While the results were statistically significant, there was no discussion on whether this was clinically significant or important to the participants. These data do not imply that SABA or LABA agents lose their effectiveness altogether following regular use; however, the magnitude of their effectiveness is reduced. There are no data on whether the tolerance to these agents continues to increase as duration of regular use increases to several months.

Short-acting anticholinergic (SAAC) agents. Anticholinergic agents are used in respiratory conditions to decrease mucus production and as weak bronchodilators. The original SAAC agent used in asthma was atropine; however, ipratropium bromide (IB; AtroventTM) and oxitropium bromide (OB; OxiventTM) are more commonly used. Long-acting anticholinergics such as tiotropium (Spiriva[®]) are available; however, they are more commonly used in the management of chronic obstructive pulmonary disease. SAAC agents are an intuitive addition to the treatment regimen given the concerns regarding the potential for tachyphylaxis with regular use of SABA and LABA agents.

We identified 18 trials (211 patients enrolled) that compared SAAC agents with placebo in single-dose prophylactic treatment of EIB/EIA. Twelve of the 18 researched IB and, given the worldwide availability and use of this drug, the discussion focuses on this agent.

The pooled results demonstrated a consistent benefit attributable to IB (Table 42 and Figure 28). The maximum percent fall in FEV₁ at an ECT less than 2 hours following treatment was reduced by approximately 12 percent (17 percent in PEF) compared with placebo. These clinically relevant results, however, are tempered by the presence of moderate heterogeneity.

Complete protection was achieved 4.5 times more often with IB than placebo. This conclusion is strengthened by the negligible heterogeneity ($I^2=0$ percent). Only four of 18 studies reported side effects; there were no differences identified between IB and placebo. Despite the theoretical autonomic nervous system risks associated with use of SAAC agents (e.g., dry mouth, glaucoma, confusion), there is sufficient evidence from the acute respiratory literature to suggest that a single dose of IB is safe in patients with EIA.^{168,169}

From the available evidence, it appears that when used as a pre-exercise treatment IB can be effective and safe for patients with EIB/EIA. The strength of the body of evidence is moderate.

Anti-inflammatory Agents

Mast cell stabilizers (MCS). Mast cells are important cellular contributors to the inflammatory cascade seen in asthma. MCS are asthma agents that stabilize the mast cell and prevent the release of inflammatory mediators. They are used as weak anti-inflammatory agents in mild to moderate chronic asthma. We identified three existing Cochrane reviews that addressed MCS as prophylactic treatment for EIA (Table 42 and Figure 28). The first review⁷⁶ included 21 trials that studied a single prophylactic dose of nedocromil sodium (NCS) in doses ranging from 1 mg to 8 mg, compared with a placebo. The second review⁷⁷ (9 trials) compared the effects of a single prophylactic dose of NCS, in doses ranging from 2 mg to 8 mg, to one of sodium cromoglycate (SCG), in doses ranging from 10 mg to 20 mg. The summary data from this review failed to identify differences with respect to the maximum percent decrease in FEV₁, complete protection, or the degree of clinical protection between the two drugs. Given this result, the third review⁷⁸ included trials that compared either NCS or SCG (collectively called MCS) to an anticholinergic agent (n=11), a SABA alone (n=20), or a combination of a SABA and MCS (n=10).

All studies in these three reviews included RCTs conducted on children (6 to 17 years) and adults (18 years and older) with stable asthma who experienced EIA. The majority of studies employed a crossover design with adequate time between ECTs to eliminate carryover effects but avoid period effects.

In people with stable asthma that experience EIA, NCS taken 15 to 60 minutes prior to exercise significantly reduced the severity of EIA in both children and adults. Regardless of dose, timing, delivery method, or age, NCS provided a clinically significant benefit that was 51 percent greater than placebo. The average post-exercise percent fall in FEV₁ across the 16 studies after NCS was 15.6 percent (range 10 to 29.8) compared with a fall of 30.2 (range 20.8 to 48.1) on placebo (MD=15.6 percent; 95 percent CI: 13.2, 18.1). There was substantial heterogeneity in this result that was eliminated when subgroups based on severity of EIA were compared. The benefit from NCS was more pronounced in those with severe EIA (fall in FEV₁ of 30 percent or greater).

When either NCS or SCG was compared to anticholinergics the data indicated MCS agents were somewhat more effective than anticholinergics but not as effective as SABA agents. The combination of SABA and MCS agents did not provide significant advantages over a SABA alone. Data on the safety of these agents were not routinely reported, but when it was, no serious side effects were observed. The strength of the body of evidence is moderate.

Inhaled corticosteroids (ICS). The main anti-inflammatory agents used for chronic and acute asthma management are ICS, either alone or in combination with LABA agents. ICS agents are used in respiratory conditions to decrease inflammation and reduce mucus production;

they have no direct bronchodilating effects. Contrary to systemic corticosteroids, ICS are inhaled and exert their effects locally; little of the available drug is absorbed into the systemic circulation. There are a large number of ICS agents available on the North American market (in alphabetical order): beclomethasone (QVAR™), budesonide (Pulmicort™), flunisolide (Aerobid™), fluticasone (Flovent™), and triamcinolone (Azmacort™). Agents also exist that combine ICS with LABA in one inhaler (in alphabetical order): budesonide and formoterol (Symbicort™) and fluticasone and salmeterol (Advair™). Koh et al.¹⁰⁷ published a systematic review involving six studies comparing 4 to 12 weeks of daily ICS use with placebo for prevention of EIB/EIA. The reviewers concluded that 4 or more weeks of daily ICS use attenuated the fall in FEV₁ in ranges of 7 to 14 percent over placebo. There was not enough data at that time to assess ICS used as a single-dose prophylactic for EIB/EIA. We identified four trials involving 50 children and adults that did so. Though the methodological quality of the studies was moderately good, questions remain on how adequately they were randomized and double blinded.

Although the pooled results presented here favor ICS, they failed to demonstrate a statistically or clinically beneficial reduction in the maximum percent fall in FEV₁ or PEF compared with placebo (Table 42 and Figure 28). No sound conclusions could be drawn on the complete or clinical protection provided by ICS either. None of the studies reported adverse effects. Despite the theoretical risks associated with ICS use, there is sufficient evidence from the acute respiratory literature to suggest that a single dose of ICS is safe in patients with EIB/EIA. Adverse effects such as cataracts,¹⁷⁰ adrenal suppression, osteoporosis and fractures,¹⁷¹ occur with long-term use; they are not likely an issue of concern with episodic use.

From the available evidence we cannot conclude that pre-treatment with ICS agents is an effective and safe strategy for patients with EIB/EIA. The strength of the body of evidence is moderate.

Leukotriene receptor antagonists (LTRA). Leukotrienes are produced by the cysteinyl leukotriene pathway and are implicated in both bronchoconstriction and in the inflammatory cascade leading to worsening asthma. LTRAs, which block this pathway, are available for the management of chronic and acute asthma.

We identified nine trials involving 535 patients and 10 comparisons of prophylactic treatment of EIA with LTRA compared with placebo. The methodological quality of the studies was reasonably strong. The pooled results demonstrated a consistent though modest benefit in favor of LTRAs. LTRAs were superior to placebo and reduced (i.e., improved) the percent fall in FEV₁ at the earliest measurement (usually less than 2 hours) by approximately 9 percent compared with placebo (Table 42 and Figure 28). The protective effect of this pre-treatment extended up to the 8 and 24 hour measurements of FEV₁ when there was a 7 and 5 percent improvement over placebo, respectively. It is likely that the weak anti-inflammatory effect of LTRAs is responsible for this extended action. These results are tempered by the presence of moderate heterogeneity (50 to 70 percent) in all meta-analyses. Few studies reported side effects and the data that were reported identified no differences between LTRAs and placebo; however, there is sufficient evidence from the chronic asthma literature to suggest that LTRAs are safe.¹⁷²

From the available evidence, it appears that LTRAs can be somewhat useful and safe as pre-exercise treatment for patients with EIB/EIA. The strength of the body of evidence is moderate.


Nonpharmacologic Interventions

As an alternative to drug interventions to attenuate and/or prevent EIB/EIA, many athletes, trainers and researchers advocate specific warmup exercises as a method to achieve similar results. We identified seven trials involving 128 patients that compared various forms of warmup activities to no warmup in the pre-exercise treatment of EIB/EIA. Convincing conclusions cannot be made regarding warmups because results are tempered by the methodologically poor quality of the studies and the variability in the warmup protocols studied.

Three general approaches were examined: interval, continuous high intensity (two standardized exercise challenges 45 minutes apart), and continuous low intensity (treadmill runs at work rates of 60 percent). The pooled results varied (Table 42 and Figure 28). Compared with no warmup, interval warmups attenuated the fall in FEV₁ following a subsequent ECT by a statistically significant 11 percent. For both high and low intensity continuous warmups, there was a 10 to 12 percent improvement in FEV₁ but it was not statistically significant and it was associated with substantial heterogeneity. Combinations of various warmup protocols within studies also demonstrated protection against EIB/EIA with an attenuating factor between 10 and 11 percent. Eck et al.⁹⁸ reported that 79 percent of participants achieved protection (but did not designate a cutpoint for this) when a combination of warmup activities was used as a pre-treatment for EIB/EIA. Pooling the study data was not possible due to the heterogeneity of the warmup protocols.

From this evidence, it appears that certain warmup protocols are effective at reducing the degree of airway obstruction associated with EIB/EIA. Combination warmups show promise; however, it is unclear whether continuous warmups are effective in this condition. The strength of the body of evidence is low.

Figure 28. Mean difference in the maximum percent decrease in FEV₁ following ECT with prophylactic therapy relative to placebo



NOTE: The reduction in FEV₁ post-exercise challenge with prophylactic therapy was compared with FEV₁ post-exercise challenge with placebo (i.e. placebo response - prophylactic response), and therefore negative values favor the prophylactic pre-treatment.

Limitations

In addition to the methodological issues identified previously regarding trial designs in EIB/EIA, there are several limitations that need to be discussed regarding systematic reviews. First, there is a possibility of publication bias in this systematic review. By missing unpublished and/or negative therapy studies, we may be overestimating the therapeutic benefits of certain interventions. A comprehensive and systematic search of the published literature for potentially relevant studies was conducted to avoid publication bias. This was supplemented by searching for gray literature (i.e., unpublished or difficult to find studies). Despite these efforts, we recognize that we may have missed some of these types of studies.

There is also a possibility of study selection bias. However, we employed at least two independent reviewers and feel confident that the studies that were excluded from this report were done so for consistent and appropriate reasons. Our search was comprehensive, so it is unlikely that there are many studies in press or publication that were missed.

There are several other issues with respect to populations, interventions, outcome assessments, and controls that require discussion.

Population. In general the populations involved in the therapy trials were volunteer recruits from hospital and outpatient clinics or schools for asthmatic children. All had confirmed asthma and documented EIA. The lack of reporting certain baseline data precluded more detailed subgroup analysis that would be of interest to the medical community. Larger sample sizes would help to provide more conclusive results. Overall, we do not believe these limitations invalidate the results presented in the therapy review as the reviewers analyzed the data as vigorously as was possible.

Intervention. Despite the variation in dose, delivery method, and timing of prophylactic drug treatment, these studies employed RCT methodology and standardized the drug interventions that were investigated. The major limitations are the small sample sizes and small number of trials that investigated each drug category. The interventions investigating warmup protocols were not standardized across trials. While we divided the warmup interventions into three groups based on the level of intensity required, each warmup approach varied considerably from study to study. Overall, we do not believe these limitations invalidate the results presented in the review; however, they do limit robust interpretation, drawing firm conclusions, and generalization of results.

Control. Many of the patients in the pharmacologic studies were administered placebo agents as the control treatment. These agents were often similar in appearance or delivery; however, it may have been possible for patients to detect differences among treatments, especially the bronchodilators such as SABA, LABA and SAAC agents. Also, the studies used a range of placebo devices and propellants, some of which provided significant protection to a large proportion of participants in the study. It was not possible to blind the participants to the warmup protocols in the refractory studies and it was not reported if the purpose of the intervention was known to them. Furthermore, blinding of the person conducting and assessing spirometry following the intervention and the ECT was rarely reported. It is impossible to determine how this might have affected the results. None of the included studies reported the patient's perception of treatment received. Overall, we do not believe these limitations invalidate the results presented in the review; however, they do raise questions surrounding the lack of blinding and how that may affect estimates of the overall treatment effect.¹³

Outcome. The pulmonary function outcomes reported were not standardized and comprised various forms of FEV₁ and PEF measures. Some could not be transformed or calculated from individual patient data and therefore were not included in a pooled analyses. Also, the maximum percent fall in FEV₁ cutpoints to confirm EIB/EIA ranged from a fall of 10 to 20 percent. The ATS convention is to accept a 10 percent fall in FEV₁, and that was what was employed in the majority of studies.

Outcome reporting always included a pulmonary function measure following the intervention and ECT. However, reporting other useful outcomes such as clinical and complete protection data was not consistent (Table 42). Wherever possible, we calculated these results from IPD. Few secondary outcomes were reported. For example, patient preference for the intervention, effect on performance, effect on signs and symptoms were absent. Side effect profiles were also poorly reported; however, sufficient evidence exists for the safety of many of these agents from the chronic asthma literature. Overall, we do not believe these limitations invalidate the results of the therapy review.

Finally, the comparative effectiveness of these treatments is difficult to determine. There are few direct comparisons among specific interventions for EIB/EIA treatments and this makes decisionmaking for patients and clinicians problematic. The indirect comparisons provided in Figure 28 are to be used with caution.

Conclusions

Despite exhaustive efforts to identify evidence regarding therapeutic effectiveness of various interventions used to treat people with EIB/EIA, only a small number of studies met the inclusion criteria for each key question. All of the studies recruited people with asthma and reproducible EIA. Evaluation of therapeutic effect on EIB was not possible. Many of the studies suffered from potential biases. Nonetheless, this summary represents the most comprehensive review of therapies for EIA published to date.

On the basis of this review, we can conclude that all bronchodilators that were examined are effective at attenuating and even preventing the FEV₁ drop associated with EIA (Figure 28). There is emerging evidence of the development of tachyphylaxis associated with daily use of SABA and LABA agents. This suggests that SABA and LABA agents should be used only “as required,” rather than regularly, in order to preserve their use as prophylactic agents for EIA. SAAC agents were found to be effective pre-EIA bronchodilator agents.

We can conclude that the anti-inflammatory agents examined provide mixed results. For example, MCS agents are very effective in attenuating or eliminating the FEV₁ drop associated with EIA. There is some role for LTRA in the treatment of EIA; however, the attenuation of EIA appears less than with other anti-inflammatory agents. There is limited evidence of a benefit associated with pre-treatment with ICS compounds. The long-term benefit of ICS agents in asthma is no longer questioned,¹⁰⁷ and it is possible that better control of chronic airway inflammation may benefit patients with EIA specifically.

Finally, pre-exercise interval warmup appears to be useful in significantly attenuating or eliminating the FEV₁ falls associated with EIA. This set of interventions requires further research on the relative effectiveness of various types of warmup.

Recommendations for Future Research

Efforts are needed to improve the overall quality of reporting of primary studies of diagnostic test accuracy. The STARD checklist¹⁰⁵ details 25 items that address the level of detail that should be specified within such studies including descriptions of participants, tests methods, statistical methods, and results. This could be considered as a guide for authors reporting studies that evaluate diagnostic tests and for journals that publish EIB/EIA-related research.

Studies designed to more carefully examine the methodology of the standard ATS ECT test are needed. Specifically, guidelines state that the inspired air temperature must be less than 25°C, and less than 50 percent relative humidity. Studies have used inspired air as cold as -18°C and many have used medical compressed air, which has a relative humidity of 0 percent as the air leaves the tank. Colder, drier air would result in the greatest increase in osmolarity of the airway surface and thus most likely cause EIB/EIA. Additional studies are needed to more thoroughly examine how inspired air affects EIB/EIA so that a more standardized ECT guideline can be developed.

Future purposely designed studies to compare the diagnostic characteristics of different diagnostic methods are needed. New tests such as mannitol are encouraging; however, currently there are insufficient data to allow for a strong recommendation of this test. Particular attention in future studies must be given to including a representative sample of participants with suspected EIB/EIA. Studies that prospectively recruit participants and blind the reference standard results to those who interpret the index test results are needed.

To determine if the response to diagnostic tests differs in those with EIB versus EIA, those with atopy or no atopy, or other potentially defining characteristics, appropriate populations need to be included, adequate baseline data reported, and comparative analyses by the characteristics of interest performed and reported.

With regard to the systematic review of therapy for EIA, there are several issues with respect to methodological quality, populations, interventions, outcome assessments, and controls that require discussion.

Efforts are needed to improve the quality of reporting primary studies (i.e., randomized controlled trials). The CONSORT Statement¹⁰⁶ could be considered as a guide for authors reporting trials and journals that publish EIB/EIA-related research. Most trials in this review used a crossover design. Concerns regarding crossover trials center on three factors: drug carryover effects, period effects, and statistical issues. Data should be reported in a manner that allows analyses to confirm the presence or absence of a carryover effect. Future studies should focus on complete reporting of results by period and sequence to assure readers that these concerns have been accounted for.

Population: The populations involved in the therapy trials all had stable asthma and confirmed EIA. Athletic status was not reported. This finding, coupled with the small number of studies investigating some interventions, precluded more detailed subgroup analysis of the issue of EIB/EIA in elite athletes. Additional investigations of treatment effects in patient subgroups defined by asthma severity, age, and activity level are clearly indicated.

More trials in clinically homogenous groups of patients with EIB and patients with EIA are needed to better explore and characterize differences in the efficacy of interventions between these two conditions.

Intervention: The nonpharmacologic interventions were not standardized. Although the warmup interventions were divided into similar groups, each warmup approach varied from the others. Future research exploring different standardized warmup approaches is clearly indicated.

Control: Many of the patients in the pharmacological studies were administered placebo agents as the control treatment. These agents were often similar in appearance or delivered in similar appearing devices (inhaler agents) to the active treatment; however, it may have been possible for patients to detect differences among treatments, especially the bronchodilators such as SABA, LABA and SAAC agents. It is impossible to determine how frequently this occurred since most studies did not report the patient's perception of treatment received. In addition, it was not possible to blind the participants to the warmup programs in the refractory studies. When the participant cannot be blinded, it is particularly important that the outcome assessor be blinded to all information that could bias the outcome measure or assessment (e.g., other test results, intervention given, challenge performed).

Outcome: The pulmonary function outcomes reported varied and studies used different diagnostic cutpoints ranging from a fall index of 10 to 20 percent. The ATS convention is to accept a 10 percent maximum fall in FEV₁. While outcome reporting included detailed pulmonary function measures, the format was not standardized. Data on the proportion obtaining clinical and complete protection were often missing (Table 2).

Side effect profiles were also poorly reported. While there is evidence for the safety of many of these agents from the chronic asthma literature, it would be prudent for future research to capture adverse effects in the EIB/EIA population. Future trials of interventions to prevent or attenuate EIB/EIA should include clinically relevant secondary outcomes such as patient preferences, symptom scores, and sport performance effects (e.g., changes in athletic performance or endurance). More robust outcome reporting would further inform decision-making by athletes, physicians, and sporting bodies.

References and Included Studies

1. Weiler JM, Bonini S, Coifman R, et al. American Academy of Allergy, Asthma & Immunology work group report: Exercise-induced asthma. *J Allergy Clin Immunol* 2007;119(6):1349-58.
2. Godfrey S, Bar-Yishay E. Exercise-induced asthma revisited. *Resp Med* 1993;162(87):331-44.
3. Tan RA, Spector SL. Exercise-induced asthma: diagnosis and management. *Ann Allergy Asthma Immunol* 2002;89(3):226-35.
4. Randolph C. Making the diagnosis of asthma in the athlete. *Clin Rev Allergy Immunol* 2005;29(2):113-23.
5. National Center for Health Statistics. National health interview survey, 1982-1996, 2001-2004. Atlanta: Centers for Disease Control; 2007.
6. Mehta H, Busse WW. Prevalence of exercise-induced asthma in the athlete. In: Weiler JM, ed. *Allergic and respiratory disease in sports medicine*. New York: Marcel Dekker Inc.; 1997:81-6.
7. Rundell KW JD. Exercise-induced bronchospasm in the elite athlete. *Sports Med* 2002;32(9):583-600.
8. Randolf C. Exercise-induced asthma: update on pathophysiology, clinical diagnosis and treatment. *Curr Probl Pediatr* 1997;27(2):53-71.
9. Helenius I, Haahtela T. Allergy and asthma in elite summer sports athletes. *J Allergy Clin Immunol* 2000;106:444-52.
10. Butz AM, Alexander C. Anxiety in children with asthma. *J Asthma* 1993;30:199-209.
11. Whiting J, Rutjes AW, Dinnes J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. *Health Tech Assess* 2004;8(25).
12. Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized controlled trials: is blinding necessary? *Control Clin Trials* 1996;17(1):1-12.
13. Schulz KF, Chalmers I, Hayes RJ. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273(5):408-12.
14. Altman D, Schulz K. Concealing treatment allocation in randomised trials. *Br Med J* 2001;326:446-7.
15. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008;336(7653):1106-10.
16. Owens DK, Lohr KN, Atkins D, Treadwell JR, et al. Grading the strength of a body of evidence when comparing medical interventions. Agency for Healthcare Research and Quality. 2008. [Accessed: 2009 Sep 15]; Available from: URL: http://www.effectivehealthcare.ahrq.gov/repFiles/2009_0805_grading.pdf.
17. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58.
18. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing 1999. *Am J Respir Crit Care Med* 2000;161(1):309-29.
19. Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. *J Allergy Clin Immunol* 2008;122(2):238-46.
20. Anderson SD, Holzer K. Exercise-induced asthma: is it the right diagnosis in elite athletes? *J Allergy Clin Immunol* 2000;106(3):419-28.
21. Frobese JF, Kyle JM, Hanna SD, et al. Sensitivity of post exercise cough in predicting exercise induced bronchospasm in young athletes [abstract]. *Med Sci Sports Exerc* 1992;24(5 Suppl):S143.
22. Rupp NT, Brudno DS, Guill MF. The value of screening for risk of exercise-induced asthma in high school athletes. *Ann Allergy* 1993;70(4):339-42.
23. Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. *Respir Res* 2009;10:4.
24. Avital A, Novisky N, Bar-Yishay E, et al. Sensitivity of exercise and methacholine challenge tests in the detection of bronchial hyperreactivity in asthmatic children. *Am Rev Respir Dis* 1989;139(4 Pt 2):A563.
25. Avital A, Godfrey S, Springer C. Exercise, methacholine, and adenosine 5'-monophosphate challenges in children with asthma: relation to severity of the disease. *Pediatr Pulmonol* 2000;30(3):207-14.
26. Chatham M, Bleecker ER, Smith PL, et al. A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects. *Am Rev Respir Dis* 1982;126(2):235-40.
27. Clough JB, Hutchinson SA, Williams JD, et al. Airway response to exercise and methacholine in children with respiratory symptoms. *Arch Dis Child* 1991;66(5):579-83.
28. Eggleston PA. A comparison of the asthmatic response to methacholine and exercise. *J Allergy Clin Immunol* 1979;63(2):104-10.
29. Foresi A, Mattoli S, Corbo GM, et al. Comparison of bronchial responses to ultrasonically nebulized distilled water, exercise, and methacholine in asthma. *Chest* 1986;90(6):822-6.

30. Henriksen AH, Tveit KH, Holmen TL, et al. A study of the association between exercise-induced wheeze and exercise versus methacholine-induced bronchoconstriction in adolescents. *Pediatr Allergy Immunol* 2002;13(3):203-8.
31. Kiviloog J. Bronchial reactivity to exercise and metacholine in bronchial asthma. *Scand J Respir Dis* 1973;54(6):347-58.
32. Koh YY, Lim HS, Min KU, et al. Maximal airway narrowing on the dose-response curve to methacholine is increased after exercise-induced bronchoconstriction. *J Asthma* 1996;33(1):55-65.
33. Lin CC, Wu JL, Huang WC, et al. A bronchial response comparison of exercise and methacholine in asthmatic subjects. *J Asthma* 1991;28(1):31-40.
34. Pedersen L, Winther S, Backer V, et al. Airway responses to eucapnic hyperpnea, exercise, and methacholine in elite swimmers. *Med Sci Sports Exerc* 2008;40(9):1567-72.
35. Sekerel BE, Saraclar Y, Kalayci O, et al. Comparison of four different measures of bronchial responsiveness in asthmatic children. *Allergy* 1997;52(11):1106-9.
36. Souza ACTG, Pereira CAC. Bronchial provocation tests using methacholine, cycle ergometer exercise and free running in children with intermittent asthma. *J Pediatr (Rio J)* 2005;81(1):65-72.
37. Verges S, Devouassoux G, Flore P, et al. Bronchial hyperresponsiveness, airway inflammation, and airflow limitation in endurance athletes. *Chest* 2005;127(6):1935-41.
38. Castricum A, Holzer K, Brukner P, et al. The role of the bronchial provocation challenge tests in the diagnosis of exercise induced bronchoconstriction in elite swimmers. *Br J Sports Med* 2008.
39. Dickinson JW, Whyte GP, McConnell AK, et al. Screening elite winter athletes for exercise induced asthma: a comparison of three challenge methods. *Br J Sports Med* 2006;40(2):179-82.
40. Reggiani E, Marugo L, Delpino A, et al. A comparison of various exercise challenge tests on airway reactivity in atypical swimmers. *J Sports Med Phys Fitness* 1988;28(4):394-401.
41. Rundell KW, Wilber RL, Szmedra L, et al. Exercise-induced asthma screening of elite athletes: field versus laboratory exercise challenge. *Med Sci Sports Exerc* 2000;32(2):309-16.
42. Eliasson AH, Phillips YY, Rajagopal KR, et al. Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm. *Chest* 1992;102(2):347-55.
43. Rosenthal RR. Simplified eucapnic voluntary hyperventilation challenge. *J Allergy Clin Immunol* 1984;73(5 Pt 2):676-9.
44. Rundell KW, Spiering BA, Baumann JM, et al. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. *Br J Sports Med* 2005;39(4):232-6.
45. Schmidt A, Bach-Mortensen N, Bundgaard A. Comparison of isocapnic hyperventilation and treadmill exercise in children with exercise induced asthma. *Scand J Clin Lab Invest* 1983;43(3):203-6.
46. Garcia de la Rubia S, Pajaron-Fernandez MJ, Sanchez-Solis M, et al. Exercise-induced asthma in children: a comparative study of free and treadmill running. *Ann Allergy Asthma Immunol* 1998;80(3):232-6.
47. Brannan JD, Koskela H, Anderson SD, et al. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. *Am J Respir Crit Care Med* 1998;158(4):1120-6.
48. Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. *J Allergy Clin Immunol* 2006;117(4):767-73.
49. Anderson SD, Argyros GJ, Magnussen H, et al. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction [review] [30 refs]. *Br J Sports Med* 2001;35(5):344-7.
50. Brannan JD, Gulliksson M, Anderson SD, et al. Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing. *Eur Respir J* 2006;27(5):944-50.
51. Brannan JD, Gulliksson M, Anderson SD, et al. Evidence of mast cell activation and leukotriene release after mannitol inhalation. *Eur Respir J* 2003;22(3):491-6.
52. Kersten ET, Driessen JM, van der Berg JD, et al. Mannitol and exercise challenge tests in asthmatic children. *Pediatr Pulmonol* 2009;44(7):655-61.
53. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. *Ann Intern Med* 2000;132(2):97-104.
54. Garcia R, Guerra P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. *J Investig Allergol Clin Immunol* 2001;11(3):176-82.
55. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. *N Engl J Med* 1998;339(3):141-6.
56. Pearlman D, Qaqudah P, Matz J, et al. Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. *Pediatr Pulmonol* 2009;44(5):429-35.
57. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. *Respir Med* 1994;88(5):363-8.

58. Selvaggio D, Gagliardini R, Franceschini F, et al. Intermittent administration of salmeterol does not induce tolerance to the bronchoprotective effect in exercise induced bronchoconstriction [abstract]. *Eur Respir J* 2003;22(Suppl 45):3117.
59. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. *Pediatrics* 1997;99(5):655-9.
60. Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. *J Allergy Clin Immunol* 1999;104(3):547-53.
61. Weiler JM, Nathan RA, Rupp NT, et al. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. *Ann Allergy Asthma Immunol* 2005;94(1):65-72.
62. Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. *Am J Respir Crit Care Med* 2002;165(8):1068-70.
63. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. *Am J Respir Crit Care Med* 1996;153(1):65-9.
64. Becker AB, Watson WTA, Simons FER, et al. Onset of protection from exercise-induced bronchoconstriction (EIB) by montelukast in children with asthma [abstract]. *Am J Respir Crit Care Med* 2002;165(Suppl 8):B44.
65. Coreno A, Skowronski M, Kotaru C, et al. Comparative effects of long-acting beta₂-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. *J Allergy Clin Immunol* 2000;106(3):500-6.
66. Mastalerz L, Gawlewicz-Mroccka A, Cmiel A, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. *Clin Exp Allergy* 2002;32(9):1360-5.
67. Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D₄-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. *J Pediatr* 1999;134(3):273-9.
68. Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. *Ann Allergy Asthma Immunol* 2006;97(1):98-104.
69. Peroni DG, Piacentini GL, Pietrobelli A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. *Eur Respir J* 2002;20(1):104-7.
70. Philip G, Pearlman DS, Villarán C, et al. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. *Chest* 2007;132(3):875-83.
71. Philip G, Villaran C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. *J Asthma* 2007;44(3):213-7.
72. Hills EA, Davies S, Geary M. The effect of betamethasone valerate aerosol in exercise-induced asthma. *Postgrad Med J* 1974;(50 Suppl 4):67-8.
73. Hodgson SV, McPherson A, Friedman M. The effect of betamethasone valerate aerosol on exercise-induced asthma in children. *Postgrad Med J* 1974;(50 Suppl 4):69-73.
74. Thio BJ, Slingerland GL, Nagelkerke AF, et al. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. *Pediatr Pulmonol* 2001;32(2):115-21.
75. Venge P, Henriksen J, Dahl R, et al. Exercise-induced asthma and the generation of neutrophil chemotactic activity. *J Allergy Clin Immunol* 1990;85(2):498-504.
76. Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise-induced bronchoconstriction. *Cochrane Database Syst Rev* 2002;1:CD001183.
77. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics. *Cochrane Database Syst Rev* 2000;4:CD002731.
78. Spooner CH, Spooner GH, Rowe BH. Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. *Cochrane Database Syst Rev* 2003;4:CD002307.
79. Boner AL, Antolini I, Andreoli A, et al. Comparison of the effects of inhaled calcium antagonist verapamil, sodium cromoglycate and ipratropium bromide on exercise-induced bronchoconstriction in children with asthma. *Eur J Pediatr* 1987;146(4):408-11.
80. Borut TC, Tashkin DP, Fischer TJ, et al. Comparison of aerosolized atropine sulfate and SCH 1000 on exercise-induced bronchospasm in children. *J Allergy Clin Immunol* 1977;60(2):127-33.
81. Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. *J Allergy Clin Immunol* 1989;83(5):882-7.
82. Bundgaard A, Rasmussen FV, Madsen L. Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets. *Allergy* 1980;35(8):639-45.
83. Chan-Yeung M. The effect of Sch 1000 and disodium cromoglycate on exercise-induced asthma. *Chest* 1977;71(3):320-3.

84. Chen WY, Brenner AM, Weiser PC, et al. Atropine and exercise-induced bronchoconstriction. *Chest* 1981;79(6):651-6.
85. Dorward AJ, Patel KR. A comparison of ketotifen with clemastine, ipratropium bromide and sodium cromoglycate in exercise-induced asthma. *Clin Allergy* 1982;12(4):355-61.
86. Godfrey S, Konig P. Inhibition of exercise-induced asthma by different pharmacological pathways. *Thorax* 1976;31(2):137-43.
87. Hartley JP, Davies BH. Cholinergic blockade in the prevention of exercise-induced asthma. *Thorax* 1980;35(9):680-5.
88. Larsson K. Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma. *Respiration* 1982;43(1):57-63.
89. Neijens HJ, Wesselius T, Kerrebijn KF. Exercise-induced bronchoconstriction as an expression of bronchial hyperreactivity: a study of its mechanisms in children. *Thorax* 1981;36(7):517-22.
90. Poppius H, Sovijarvi AR, Tammilehto L. Lack of protective effect of high-dose ipratropium on bronchoconstriction following exercise with cold air breathing in patients with mild asthma. *Eur J Respir Dis* 1986;68(5):319-25.
91. Tashkin DP, Katz RM, Kerschnar H, et al. Comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of exercise-induced asthma. *Ann Allergy* 1977;39(5):311-8.
92. Taytard A, Vergeret J, Guenard H, et al. Prevention of exercise-induced asthma by oxitropium bromide. *Eur J Clin Pharmacol* 1987;33(5):455-8.
93. Thomson NC, Patel KR, Kerr JW. Sodium cromoglycate and ipratropium bromide in exercise-induced asthma. *Thorax* 1978;33(6):694-9.
94. Tullett WM, Patel KR, Berkin KE, et al. Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma. *Thorax* 1982;37(10):737-40.
95. Wolkove N, Kreisman H, Frank H, et al. The effect of ipratropium on exercise-induced bronchoconstriction. *Ann Allergy* 1981;47(5 Pt 1):311-5.
96. Yeung R, Nolan GM, Levison H. Comparison of the effects of inhaled SCH 1000 and fenoterol on exercise-induced bronchospasm in children. *Pediatrics* 1980;66(1):109-14.
97. De Bisschop C, Guenard H, Desnot P, et al. Reduction of exercise-induced asthma in children by short, repeated warm ups. *Br J Sports Med* 1999;33(2):100-4.
98. Eck R, Lachtermann E, Pleyer K, et al. Effect of standardized warm-up programs on the intensity and frequency of exercise induced asthma (EIA) in children and teenagers. *Int J Sports Med* 2002;23(Suppl):S86.
99. McKenzie DC, McLuckie SL, Stirling DR. The protective effects of continuous and interval exercise in athletes with exercise-induced asthma. *Med Sci Sports Exerc* 1994;26(8):951-6.
100. Mickleborough TD, Lindley MR, Turner LA. Comparative effects of a high-intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes. *Int J Sports Med* 2007;28(6):456-62.
101. Morton AR, Fitch KD, Davis T. The effect of "warm-up" on exercise-induced asthma. *Ann Allergy* 1979;42(4):257-60.
102. Reiff DB, Choudry NB, Pride NB, et al. The effect of prolonged submaximal warm-up exercise on exercise-induced asthma. *Am Rev Respir Dis* 1989;139(2):479-84.
103. Schnall RP, Landau LI. Protective effects of repeated short sprints in exercise-induced asthma. *Thorax* 1980;35(11):828-32.
104. Spooner CH, Rowe BH, Saunders LD. Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis. *Eur Respir J* 2000;16(1):30-7.
105. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Ann Intern Med* 2003;138(1):W1-12.
106. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med* 2001;134(8):663-94.
107. Koh MS, Tee A, Lasserson TJ, et al. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. *Cochrane Database Syst Rev* 2007;(3):CD002739.
108. Virant FS. The history of exercise-induced asthma and definition of the syndrome. In: Weiler JM, ed. *Allergic and respiratory disease in sports medicine*. New York: Marcel Dekker, Inc.; 1997:65-80.
109. Global Initiative for Asthma (GINA). *Global strategy for asthma management and prevention*. <http://www.ginasthma.org>. 2007. [Accessed: 2008 May 1]; Available from: URL: <http://www.ginasthma.com/Guidelineitem.asp?l=2&l2=1&intld=1389>.
110. Randolph CC. Allergic rhinitis and asthma in the athlete. *Allergy Asthma Proc* 2006;27(2):104-9.
111. Backer V, Lund T, Pedersen L. Pharmaceutical treatment of asthma symptoms in elite athletes - doping or therapy? *Scand J Med Sci Sports* 2007;17(6):615-22.
112. Chan-Yeung MM, Vyas MN, Grzybowski S. Exercise-induced asthma. *Am Rev Respir Dis* 1971;104(6):915-23.

113. Anderson SD, Daviskas E. Pathophysiology of exercise-induced asthma: the role of respiratory water loss in allergic and respiratory disease. In: Weiler JM, ed. *Allergic and respiratory disease in sports medicine*. New York: Marcel Dekker, Inc.; 1997:87-114.
114. McFadden ER, Jr., Lenner KA, Strohl KP. Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. *J Clin Invest* 1986;78(1):18-25.
115. McFadden ER, Jr., Nelson JA, Skowronski ME, et al. Thermally induced asthma and airway drying. *Am J Respir Crit Care Med* 1999;160(1):221-6.
116. Anderson SD. Issues in exercise-induced asthma. *J Allergy Clin Immunol* 1985;76(6):763-72.
117. Deal EC, Jr., McFadden ER, Jr., Ingram RH, Jr., et al. Hyperpnea and heat flux: initial reaction sequence in exercise-induced asthma. *J Appl Physiol* 1979;46(3):476-83.
118. McFadden ER, Gilbert IA. Current concepts: exercise-induced asthma. *NEJM* 1994;330(19):1362-7.
119. Virant FS. Exercise-induced bronchospasm: epidemiology, pathophysiology, and therapy. *Med Sci Sports Exerc* 1992;24:851-5.
120. Hogshead N, Couzens G. *Asthma and exercise*. New York: Henry Holt and Company; 1989.
121. Suman OE, Beck KC, Babcock MA, et al. Airway obstruction during exercise and isocapnic hyperventilation in asthmatic subjects. *J Appl Physiol* 1999;87(3):1107-13.
122. Anderson SD. Specific problems: exercise-induced asthma. In: O'Byrne P, Thomson NC, eds. *Manual of asthma management*. London: WB Saunders Co. Ltd.; 1995:641-3.
123. Anderson SD, Schoeffel RE, Black JL, et al. Airway cooling as the stimulus to exercise-induced asthma: a re-evaluation. *Eur J Respir Dis* 1985;67(1):20-30.
124. Deal ECJ, McFadden ERJ, Ingram RHJ. Airway responsiveness to cold air and hyperpnea in normal subjects in the nose with hayfever and asthma. *Am Rev Respir Dis* 1980;121:621-8.
125. Freed AN. Models and mechanisms of exercise-induced asthma. *Eur Respir J* 1995;8(10):1770-85.
126. Mellion MB, Kobayashi RH. Exercise-induced asthma. *Am Family Physician* 1992;45:2671.
127. Proctor NH, Hughes JP, Wesenberg GL. Chlorine. In: Proctor NH, Hughes JP, eds. *Chemical hazards of the workplace*. Philadelphia: Lippincot; 1978:157-8.
128. Morton AR, Hahn AG, Fitch KD. Continuous and intermittent running in the provocation of asthma. *Ann Allergy* 1982;48(2):123-9.
129. Wilson BA, Evans JN. Standardization of work intensity for evaluation of exercise-induced bronchoconstriction. *Eur J Appl Physiol* 1981;48:189-94.
130. Hendrickson CD, Lynch JM, Gleeson K. Exercise induced asthma: a clinical perspective. *Lung* 1993;172:1-14.
131. National Center for Health Statistics. Report of final mortality statistics, 1979-1998, 1999-2003. Atlanta: Centers for Disease Control; 2007.
132. National Center for Health Statistics. National ambulatory medical care survey, 1992-2004. Atlanta: Centers for Disease Control; 2007.
133. Rupp NT. Diagnosis and management of exercise-induced asthma. *Phys Sportsmed* 1996;24(1):77-87.
134. Haahtela T, Larsson K, Bonini S. Epidemiology of asthma, allergy and bronchial hyperresponsiveness in sports. In: Carlsen K-H, Delgado L, Del Giacco S, eds. *Diagnosis, prevention and treatment of exercise-related asthma, respiratory and allergic disorders in sports*. Wakefield, UK: European Respiratory Society Journals Ltd; 2005:1-4.
135. Bjermer L, Anderson SD. Bronchial hyperresponsiveness in athletes: mechanisms for development. In: Carlsen K-H, Delgado L, Del Giacco S, eds. *Diagnosis, prevention and treatment of exercise-related asthma, respiratory and allergic disorders in sports*. Wakefield, UK: European Respiratory Society Journals Ltd; 2005:19-34.
136. Price B. The asthma experience: altered body image and non-compliance. *J Clin Nurs* 1994;3:139-45.
137. Padur JS, Rapoff MA, Houston BK, et al. Psychosocial adjustment and the role of functional status for children with asthma. *J Asthma* 1995;32:345-53.
138. Nastasi KJ, Henly TL, Blaiss MS. Exercise-induced asthma and the athlete. *J Asthma* 1995;32:249-57.
139. Becker JM, Rogers J, Rossini G, et al. Asthma deaths during sports: report of a 7-year experience. *J Allergy Clin Immunol* 2004;113(2):264-7.
140. Anderson SD, Brusasco V, Haahtela T, et al. Criteria for diagnosis of asthma, EIB and AHR for athletes: lessons from the Olympic games. In: Carlsen K-H, Delgado L, Del Giacco S, eds. *Diagnosis, prevention and treatment of exercise-related asthma, respiratory and allergic disorders in sports*. Wakefield, UK: European Respiratory Society Journals Ltd; 2005:44-66.
141. Kattan M, Keens TG, Mellis CM. The response to exercise in normal and asthmatic children. *J Pediatr* 1978;92:718-21.
142. Roca J, Whipp BJ, Agusti AGN. Clinical exercise testing with reference to lung diseases: indications, standardizations and interpretation strategies. Position document of the European Respiratory Society. *Eur Respir J* 1997;10:2662-89.

143. Crapo RO, Hankinson JL, Irvin C. Standardization of spirometry. 1994 update. The official statement of the American Thoracic Society. *Am J Respir Crit Care Med* 1994;152:1107-36.
144. Helenius IJ, Tikkanen HO, Hahtela T. Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen. *Br J Sports Med* 1998;32:125-9.
145. Rundell KW, Im J, Mayers LB, et al. Self-reported symptoms and exercise-induced asthma in the elite athlete. *Med Sci Sports Exerc* 2001;33:208-13.
146. Hurwitz KM, Argyros GJ, Roach JM, et al. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. *Chest* 1995;108:1240-5.
147. Eggleston PA. Methods of exercise challenge. *J Allergy Clin Immunol* 1984;73:666-9.
148. Godfrey S, Konig P. Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children. *Pediatrics* 1975;56(5 pt-2 suppl):930-4.
149. Joppich R. Comparison of the effects of reproterol, oxitropium bromide, disodium cromoglycate and theophylline in the prevention of exercise-induced asthma in children. *Atemwegs- und Lungenkrankheiten* 1987;13(9):453-6.
150. Shapiro GG, McPhillips JJ, Smith K, et al. Effectiveness of terbutaline and theophylline alone and in combination in exercise-induced bronchospasm. *Pediatrics* 1981;67(4):508-13.
151. Leech S, Wolfson K, Burns R. Ketotifen vs. disodium cromoglycate DSCG in the prophylaxis of exercise-induced asthma EIA. *Ann Allergy* 1983;50:352.
152. Gmur H, Scherrer M. Protection from exertion-induced bronchial asthma with disodium cromoglycate DSCG cromolyn, lomudal, intal and with ketotifen zaditen. Doubly crossed double-blind study. *Schweiz Med Wochenschr* 1979;109:881-4.
153. Tan WC, Lim TK. Double-blind comparison of the protective effect of sodium cromoglycate and ketotifen on exercise-induced asthma in adults. *Allergy* 1987;42(4):315-7.
154. Rampulla C, Bruschi C, Zoia MC. Calcium-antagonists and exercise-induced bronchoconstriction (EIB): Immediate and late effects of nifedipine, in comparison with salbuamol and DSCG. *Folia Allergologica et Immunologica Clinica* 1985;32(4):271-7.
155. Sin HL, Jae JS, Sang YL, et al. The protective effect of inhaled heparin, cromolyn, budesonide, and furosemide on exercise-induced asthma. *Zhonghua Jie He He Hu Xi Za Zhi* 1998;45(6):1188-98.
156. Novembre E, Frongia G, Lombardi E, et al. The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children. *J Allergy Clin Immunol* 1995;96(6 Pt 1):906-9.
157. Novembre E, Frongia G, Lombardi E, et al. The preventive effect of nedocromil or furosemide alone or in combination on exercise-induced asthma in children. *J Allergy Clin Immunol* 1994;94(2 Pt 1):201-6.
158. Melo RE, Sole D, Naspitz CK. Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children. *J Allergy Clin Immunol* 1997;99(2):204-9.
159. Cho MK, Bero LA. The quality of drug studies in symposium proceedings. *Ann Int Med* 1996;124:485-9.
160. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. *Systematic reviews in health care: meta-analysis in context*. 2nd ed. London: BMJ Publishing Group; 2001:285-312.
161. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate in treatment of exercise-induced bronchoconstriction: a systematic review. *Eur Respir J* 2001;17(1):39-45.
162. *Compendium of pharmaceuticals and specialties*. 9th ed. Ottawa, ON: Canadian Pharmacists Association; 2008.
163. Oseid S, Mellbye E, Hem E. Effect of nedocromil sodium on exercise-induced bronchoconstriction exacerbated by inhalation of cold air. *Scand J Med Sci Sports* 1995;5(2):88-93.
164. Palange P, Ward SA, Carlsen K-H, et al. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007;29:185-209.
165. Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. *CMAJ* 2008;179(11):1121-31.
166. Sterling GM. The mechanism of bronchoconstriction due to hypocapnia in man. *Clin Sci* 1968;34(2):277-85.
167. Leeftang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. *Ann Intern Med* 2008;149(12):889-97.
168. McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. *Cochrane Database Syst Rev* 2003;3:CD003535.
169. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. *Cochrane Database Syst Rev* 2004;3:CD003269.
170. Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataracts: a meta-analysis. *Fundam Clin Pharmacol* 2006;20(3):305-9.

171. Halpern MT, Schmier JK, Van Kerkhove MD, et al. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. *Ann Allergy Asthma Immunol* 2004;92:201-7.
172. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus antileukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. *Cochrane Database Syst Rev* 2006;4:CD003137.

Abbreviations

95% CI	95 percent confidence interval
ATS	American Thoracic Society
AUC	Area under the curve
BI	Bronchoprotection index
C	Centigrade
CCT	Clinical controlled trial
CO ₂	Carbon dioxide
ECT	Exercise challenge test
EIA	Exercise induced asthma
EIB	Exercise induced bronchoconstriction
EVH	Eucapnic voluntary hyperpnea
FEV ₁	Forced expiratory volume in 1 second
FRAST	Free running asthma screening test
GRADE	Grading of Recommendation, Assessment, Development, and Evaluation
IB	Ipratropium bromide
ICS	Inhaled corticosteroid
IPD	Individual patient data
IQR	Inter-quartile range
LABA	Long-acting beta-agonist
LTRA	Leukotriene receptor antagonist
MCH	Methacholine challenge
MCS	Mast cell stabilizer
MD	Mean difference
MDI	Metered-dose inhaler
Mg/ml	Milligrams per millilitre
mg	Milligram
MVV	Maximum voluntary ventilation
NCS	Nedocromil sodium
NSAIDS	Nonsteroidal anti-inflammatory drugs
O ₂	Oxygen
OB	Oxitropium bromide
PC ₂₀	Provocative concentration causing a 20 percent fall in FEV ₁
PEF	Peak expiratory flow
QUADAS	Quality Assessment of Studies of Diagnostic Accuracy
RCT	Randomized controlled trial
RH	Relative humidity
ROC	Receiver operating characteristic
RR	Risk ratio
SAAC	Short-acting anticholinergic
SABA	Short-acting beta-agonist
SCG	Sodium cromoglycate
SD	Standard deviation
SE	Standard error
STARD	Standard of Reporting of Diagnostic Accuracy

TEP Technical expert panel
VATAP Veterans Affairs Technology Assessment Program
VO_{2max} Maximum oxygen consumption

Appendix A. Technical Expert Panel and Peer Reviewers

Technical Expert Panel

In designing the study questions and methodology, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Due to these differences in opinion, the study questions, design, and/or methodologic approaches do not necessarily represent the views of individual technical and content experts.

Technical Expert	Affiliations/Location
Louis-Philippe Boulet, M.D., F.R.C.P.C.	Université Laval and Hôpital Laval Sainte-Foy, QC
Robert Cowie, M.D., F.C.P.(S.A.), M.Sc.	University of Calgary Calgary, AB
Andrew Gregory, M.D., F.A.A.P., F.A.C.S.M.	Vanderbilt University Medical Center Nashville, TN
Cynthia LaBella, M.D.	Children's Memorial Hospital Chicago, IL
Darcy Marciniuk, M.D., F.R.C.P.C.	University of Saskatchewan Saskatoon, SK
Kenneth Rundell, Ph.D.	Marywood University Scranton, PA

Peer Reviewers

Peer reviewer comments on a preliminary draft of this report were considered by the EPC in preparation of the final report. The synthesis presented in this report does not necessarily represent the views of individual reviewers.

Peer Reviewer	Affiliations/Location
Louis-Philippe Boulet, M.D., F.R.C.P.(C.)	Université Laval and Hôpital Laval Sainte-Foy, QC
Robert Cowie, M.D., F.C.P.(S.A.), M.Sc.	University of Calgary Calgary, AB
Andrew Gregory, M.D., F.A.A.P., F.A.C.S.M.	Vanderbilt University Medical Center Nashville, TN
Kenneth Rundell, Ph.D.	Marywood University Scranton, PA
Jeannette May	Representative, Disease Management Association of America Washington, DC
H. William Kelly, Pharm.D.	University of New Mexico Albuquerque, NM
Sheldon Spector, M.D. & Ricardo Tan, M.D.	California Allergy & Asthma Medical Group Los Angeles, CA
John Weiler, M.D.	American Academy of Asthma Allergy and Immunology Iowa City, IA

Appendix B. Literature Search Strings

Table B1. Diagnosis of EIB/EIA review – OVID Databases

Search Date: November 20, 2008 Number of Results: 3640		
Database	Years Searched	Number of Results
AMED (Allied and Complementary Medicine)	1985 to November 2008	21
PsycINFO	1806 to November Week 3 2008	14
MEDLINE®	1950 to November Week 2 2008	2321
EMBASE	1988 to 2008 Week 46)	1006
PASCAL	1987 to October 2008	179
EBM Reviews - Cochrane Central Register of Controlled Trials	4 th Quarter 2008	99
MULTIFILE STRATEGY		
<ol style="list-style-type: none"> 1. exp "Exercise Induced Asthma"/ or exp Asthma, Exercise-Induced/ 2. ("induced bronchoconstriction" or "induced asthma" or "induced bronchospasm").kw,ie,id,sh. and (exercise* or (train* and (military or army)) or fitness or "physical activity" or exertion or athlet* or sport*).mp. 3. (bronchoconstrict* or asthma* or antiasthma* or wheez* or (respiratory adj sound?) or (bronchial adj5 (spasm* or constrict*)) or bronchospas* or "bronchial hyperreactivity" or "respiratory hypersensitivity").mp. 4. ((bronchial* or respiratory or airway* or lung*) adj5 (hypersensitiv* or hyperreactiv* or allerg* or insufficiency)).mp. 5. or/3-4 6. (EIB or EIA).ti,ab. 7. ((exercise adj5 induced) or "exercised-induced" or (exercise adj5 challenge) or "exercise tolerance" or "physical exercise" or (train* and (military or army)) or fitness or "physical activity" or exertion or athlet* or sport*).mp,jn. or exp Sports/ or Exercise/ 8. or/6-7 9. and/5,8 10. or/1-2,9 11. (sensitiv* or diagnos* or predictive value* or probability).mp. 12. (accurac* or specificity).tw. 13. ((pre-test or post-test) adj probability).mp. 14. likelihood ratio*.mp. 15. di.fs. 16. *Diagnostic Accuracy/ 17. (mannitol or methacholine or MCT or EVH or eucapnic or hyperpnea* or FRAST or provocation or marker* or screen* or test*).mp. 18. or/11-17 19. 18 and 10 20. limit 19 to english language 21. limit 20 to human 22. remove duplicates from 21 		

Table B2. Diagnosis of EIB/EIA review – EBSCO Databases

Search Date: November 17, 2008		
Number of Results: 905		
Database	Years Searched	Number of Results
CINAHL® (Cumulative Index to Nursing & Allied Health Literature)	1937 to 2008	280
SPORTDiscus with Full Text	1800 to 2008	246
Academic Search Elite	1985 to 2008	379
MULTIFILE STRATEGY		
<p>S1 (DE "EXERCISE" OR DE "ABDOMINAL exercises" OR DE "AEROBIC exercises" OR DE "AQUATIC exercises" OR DE "ARM exercises" OR DE "BACK exercises" OR DE "BREATHING exercises" OR DE "BREEMA" OR DE "BUTTOCKS exercises" OR DE "CALLISTHENICS" OR DE "CHAIR exercises" OR DE "CIRCUIT training" OR DE "EXERCISE therapy" OR DE "FACIAL exercises" OR DE "FALUN gong exercises" OR DE "GYMNASTICS" OR DE "HAND exercises" OR DE "HATHA yoga" OR DE "ISOKINETIC exercise" OR DE "ISOMETRIC exercise" OR DE "LEG exercises" OR DE "LIANGONG" OR DE "METABOLIC equivalent" OR DE "MU-lan chuan" OR DE "MUSCLE strength" OR DE "PHYSICAL fitness" OR DE "PHYSICAL fitness for men" OR DE "PILATES method" OR DE "PLYOMETRICS" OR DE "QI gong" OR DE "REDUCING exercises" OR DE "RUNNING" OR DE "SCHOOLS -- Exercises & recreations" OR DE "SEXUAL exercises" OR DE "SHOULDER exercises" OR DE "STRETCHING exercises" OR DE "TAI chi chuan" OR DE "TREADMILL exercise") or (DE "SPORTS" OR DE "AERONAUTICAL sports" OR DE "AGE & sports" OR DE "AQUATIC sports" OR DE "BALL games" OR DE "BASEBALL" OR DE "BASKETBALL" OR DE "CHARITY sports events" OR DE "COLLEGE sports" OR DE "DISCRIMINATION in sports" OR DE "DOPING in sports" OR DE "ENDURANCE sports" OR DE "EXTREME sports" OR DE "FASCISM & sports" OR DE "FEMINISM & sports" OR DE "FOOTBALL" OR DE "GAELIC games" OR DE "GAY Games" OR DE "GAYS & sports" OR DE "GLBT people & sports" OR DE "GLBT rodeos" OR DE "GOLF" OR DE "GOODWILL Games" OR DE "GROUP games" OR DE "GYMNASTICS" OR DE "HOCKEY" OR DE "HOMOPHOBIA in sports" OR DE "INDIVIDUAL sports" OR DE "KNIFE throwing" OR DE "LESBIANS & sports" OR DE "LOG-chopping (Sports)" OR DE "MASCULINITY in sports" OR DE "MASS media & sports" OR DE "MILITARY sports" OR DE "MINORITIES in sports" OR DE "MOTION pictures in sports" OR DE "MOTORSPORTS" OR DE "NATIONAL socialism & sports" OR DE "NATIONALISM & sports" OR DE "OLYMPICS" OR DE "PARKOUR" OR DE "PRESIDENTS -- Sports" OR DE "PRESIDENTS -- United States -- Sports" OR DE "PROFESSIONAL sports" OR DE "PROFESSIONALISM in sports" OR DE "RACING" OR DE "RACISM in sports" OR DE "RACKET games" OR DE "ROBOTICS in sports" OR DE "RODEOS" OR DE "ROLLER skating" OR DE "SCHOOL sports" OR DE "SENIOR Olympics" OR DE "SEX discrimination in sports" OR DE "SEXUAL harassment in sports" OR DE "SHOOTING" OR DE "SHUTOUTS (Sports)" OR DE "SOCCER" OR DE "SOCIALISM & sports" OR DE "SPORT for All" OR DE "SPORTS & tourism" OR DE "SPORTS -- Collectibles" OR DE "SPORTS -- Corrupt practices" OR DE "SPORTS -- Economic aspects" OR DE "SPORTS -- Finance" OR DE "SPORTS -- Songs & music" OR DE "SPORTS for children" OR DE "SPORTS for people with disabilities" OR DE "SPORTS for women" OR DE "SPORTS forecasting" OR DE "SPORTS rivalries" OR DE "SPORTS teams" OR DE "STEREOTYPES (Social psychology) in sports" OR DE "TARGETS (Sports)" OR DE "TEAMWORK (Sports)" OR DE "TELEVISION & sports" OR DE "TOMAHAWK throwing" OR DE "TRACEURS" OR DE "VIDEO tapes in sports" OR DE "VIOLENCE in sports" OR DE "WINTER sports")</p>		
S2 (MH "Sports+") or (MH "Physical Fitness") or (MH "Exercise+")		
S3 exerc* OR train* OR fitness OR physical OR athlet* OR sport*		
S4 S3 or S2 or S1		
S5 (bronchial* OR respiratory OR airway* OR lung*) and (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency)		
S6 bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperactivity" OR "Respiratory		

Hypersensitivity"
S7 DE "BRONCHIAL spasm"
S8 (MH "Bronchoconstriction")
S9 (MH "Asthma")
S10 (bronch* AND spasm*) or (bronch* AND constrict*)
S11 S10 or S9 or S8 or S7 or S6 or S5
S12 S11 and S4
S13 DE "EXERCISE-induced asthma"
S14 (MH "Asthma, Exercise-Induced")
S15 S14 or S13 or S12
S16 diagnos* OR specificity OR accurac* OR predictive OR sensitiv* OR probability OR likelihood
S17 S16 and S15
S18
S16 and S15
<i>Limiters - Exclude MEDLINE records; Language: English</i>

Table B3. Diagnosis of EIB/EIA review – Web of Science® Institute for Scientific Information – Thomson Reuters

<p>Years/issue searched: 1900 to 2008 Search date: November 17, 2008 Number of Results: 984</p>
<p>TS=((exerc* OR train* OR fitness OR "physical activity" OR athlet* OR sport*) AND (bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperreactivity" OR "Respiratory Hypersensitivity" OR (bronch* AND spasm*) OR (bronch* AND constrict*) OR (bronchial* OR respiratory OR airway* OR lung*) AND (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency))) AND TS=(diagnos* OR sensitiv* or predictive OR accurac* OR specificity OR probability OR likelihood) AND Language=(English) AND Document Type=(Article OR Meeting Abstract OR Meeting-Abstract OR Proceedings Paper)</p>

Table B4. Diagnosis of EIB/EIA review – BIOSIS PREVIEWS® Institute for Scientific Information – Thomson Reuters

<p>Years/issue searched: 1926 to 2008 Search date: November 17, 2008 Number of Results: 1317</p>
<p>#1 Topic=(diagnos* OR sensitiv* or predictive OR accurac* OR specificity OR likelihood OR probability) #2 Topic=(exerc* OR train* OR fitness OR "physical activity" OR athlet* OR sport*) #3 TS=(bronchial* OR respiratory OR airway* OR lung*) SAME TS=(hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency) #4 TS=(bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperreactivity" OR "Respiratory Hypersensitivity" OR (bronch* SAME spasm*) OR (bronch* SAME constrict*)) #5 #3 OR #4 #6 #1 AND #2 AND #5 AND Language=(English) AND Document Type=(Article OR Book Chapter OR Meeting OR Meeting Paper OR Technical Report OR Thesis Dissertation) AND Taxa Notes=(Humans) #7 TI=COPD NOT TI=asthma* #8 #6 NOT #7</p>

Table B5. Diagnosis of EIB/EIA review – PubMed: National Library of Medicine

<p>Years/issue searched: 1950 to 2008 Search date: November 25, 2008 Number of Results: 138</p>
<p>("diagnosis"[MeSH Subheading] OR diagnos* OR sensitiv* OR predictive OR accurac* OR specificity OR probability OR likelihood OR mannitol OR methacholine) AND (((bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperreactivity" OR "Respiratory Hypersensitivity") OR (bronch* AND (spasm* OR constrict*))) OR ((bronchial* OR respiratory OR airway* OR lung*) AND (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency))) AND (exerc* OR train* OR fitness OR "physical activity" OR athlet* OR sport*) OR ((EIB OR EIA) AND (asthma* OR bronch*)) Limits: <i>added to PubMed in the last 1 year, English</i></p>

Table B6. Diagnosis of EIB/EIA review – Scopus®: Elsevier

<p>Years/issue searched: 1823 to 2008 Search date: November 14, 2008 Number of Results: 1466</p>
<p>TITLE-ABS-KEY(diagnos* OR sensitiv* OR predictive OR accurac* OR specificity OR probability OR likelihood OR methacholine OR mannitol OR screen* OR test*) AND TITLE-ABS-KEY-AUTH(exercise induced asthma) AND (LIMIT-TO(LANGUAGE, "English")) AND (LIMIT-TO(DOCTYPE, "ar") OR LIMIT-TO(DOCTYPE, "cp") OR LIMIT-TO(DOCTYPE, "ip"))</p>

Table B7. Diagnosis of EIB/EIA review – Medion database of diagnostic reviews - University of Maastricht

<p>Years/issue searched: 1967 to 2008 Search date: November 28, 2008 Number of Results: 0</p>
<p>Asthma , eia, eib, exercise</p>

Table B8. Diagnosis of EIB/EIA review – Proquest Dissertations and Theses

<p>Years/issue searched: 1861 to 2008 Search date: November 13, 2008 Number of Results: 25</p>
<p>(bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperreactivity" OR "Respiratory Hypersensitivity" OR (bronch* AND (spasm* OR constrict*))) AND TITLE(exerc* OR train* OR fitness OR "physical activity" OR athlet* OR sport*) AND (diagnos* OR sensitiv* OR predictive OR accurac* OR specificity OR probability OR likelihood OR methacholine OR mannitol OR EVH OR screen* OR test*) AND LN(EN) Look for terms in: Citation and abstract Publication type: All publication types</p>

Table B9. Therapy for EIB/EIA review – Cochrane Airways Register

<p>Years/issue searched: 1900 to 2008 Search date: November 5, 2008 Number of Results: 1601</p>
<p>The following databases are searched systematically for the Cochrane Airways Register: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and hand searching of respiratory journals and meeting abstracts.</p> <p>(exerc* OR train* OR fitness OR physical OR athlete* OR sport*) AND (bronchoconstrict* OR asthma* OR antiasthma* OR wheez* OR "Respiratory Sounds" OR "Bronchial Spasm" OR bronchospas* OR "Bronchial Hyperreactivity" OR "Respiratory Hypersensitivity" OR (bronch* AND spasm*) OR (bronch* AND constrict*).OR (bronchial* OR respiratory OR airway* OR lung*) AND (hypersensitiv* OR hyperreactiv* OR allerg* OR insufficiency)) OR EIB OR EIA</p>

Table B10. Therapy for EIB/EIA review – ClinicalTrials.Gov: National Institutes of Health

<p>Search date: November 28, 2008 Number of Results: 31</p>
<p>asthma OR eia OR eib OR exercise-induced</p>

Table B11. Therapy for EIB/EIA review – ClinicalStudyResults.Org: PhRMA Clinical Study Results Database

<p>Search date: November 28, 2008 Number of Results: 2</p>
<p>Browsed by trade and generic drug names</p>

Appendix C. Forms

Inclusion Criteria Worksheet: Diagnosis of EIB/EIA review

Reviewer ID:	Date: / /2009	Record ID:	
Criteria	Yes	No	Unclear
1. ENGLISH LANGUAGE	<input type="checkbox"/>	<input type="checkbox"/>	
2. PUBLICATION TYPE			
a. Report of primary research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. STUDY OBJECTIVE			
a. Must be to diagnose or confirm diagnosis of EIB	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. STUDY DESIGN			
a. Comparative study or...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
b. Single arm study (but results are compared to a previous standardized test (i.e. cannot just be a prevalence study))	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. POPULATION			
a. >80% patients ≥6 years who are otherwise healthy (i.e., do not have bronchitis, COPD, cystic fibrosis, bronchiectasis, etc.) NOTE: participants may have asthma or suspected EIA/EIB	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. INDEX TEST (circle the test)			
a. One of the following diagnostic tests:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
i. Self-reported history			
ii. Self-reported symptoms diary			
iii. Methacholine challenge			
iv. Sport or venue specific exercise challenges			
v. Eucapnic (or normocapnic) voluntary hyperpnea			
vi. Free running asthma screening test (FRAST)			
vii. Mannitol			
NOTE: if another testing method not listed above is used please flag as an 'other' below and keep separate from excluded pile			
7. REFERENCE STANDARD			
a. Standardized exercise challenge test (treadmill or Cycle ergometry) that resulted in a drop in FEV ₁ ≥ 10% from baseline	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. OUTCOME			
a. Numeric data sufficient to create a 2 x 2 table and/or calculation of sensitivity, specificity, positive and negative likelihood ratios.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Comments:			
REVIEWER'S DECISION : Include <input type="checkbox"/> Exclude <input type="checkbox"/> Unsure <input type="checkbox"/> Other <input type="checkbox"/>			
FINAL DECISION : Include <input type="checkbox"/> Exclude <input type="checkbox"/> Unsure <input type="checkbox"/>			
NOTE: To exclude must have said "NO" for at least one of 1-8.			

Inclusion Criteria Worksheet: Therapy for EIB/EIA review

Reviewer ID:	Date: / /2009	Record ID:	
Criteria	Yes	No	Unclear
1. ENGLISH LANGUAGE	<input type="checkbox"/>	<input type="checkbox"/>	
2. PUBLICATION TYPE			
a. Report of primary research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. STUDY DESIGN			
a. Randomized controlled trial (parallel or cross-over)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. POPULATION			
a. >80% patients ≥ 6 years who are otherwise healthy (i.e., do not have bronchitis, COPD, cystic fibrosis, bronchiectasis)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
b. Confirmed diagnosis of EIB or EIA (defined as drop in FEV ₁ or peak flow $\geq 10\%$) [EXCLUDE self-report diagnosis]	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. INTERVENTION (circle the intervention)			
Q1. One of the following <u>regular dose therapies</u> for ≥ 1 week before a standard exercise challenge (focus - testing for tachyphylaxis)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
a. SABA (see separate list of SABA agents)			
b. LABA (formoterol or salmeterol)			
OR			
One of the following <u>single dose pre-exercise therapies</u> tested by standard exercise challenge	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Q2. Leukotriene receptor antagonists (LTRA) (montelukast or zafirlukast)			
Q3. Inhaled corticosteroid (ICS) (see separate list of ICS agents)			
Q4. Mast cell stabilizers (sodium cromoglycate or nedocromil)			
Q5. Anti-cholinergics (ipratropium, oxitropium, atropine)			
OR			
Q6. A 10-15 min warmup and/or cool down prior to a standard exercise challenge (focus: checking for the effect of a refractory period)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. COMPARATOR			
a. For SABA or LABA: placebo or any standard comparator treatments for ≥ 1 week	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OR			
For other therapies: A single dose of placebo or no treatment			
7. OUTCOME			
Study reports numeric data on at least one outcome of interest (e.g., max % fall FEV ₁ from pre-exercise baseline, symptoms, presence/absence of EIA/EIB, % protection over placebo, recovery time, adverse effects).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Comments:

REVIEWER'S DECISION : Include Exclude Unsure

FINAL DECISION: Include Exclude Unsure

NOTE: To exclude must have said "NO" for at least one of 1-7.

RELEVANT TO QUESTION(S):

1. In patients with confirmed EIB/EIA, do patients using **SABA and/or LABA develop tachyphylaxis** to treatment and, if so, at what frequency compared to standard comparator treatments and/or placebo?
- 2 - 5. In patients with confirmed EIA/EIB, does pre-exercise treatment with
- 2) **leukotriene receptor antagonists (LTRA)** therapy OR
 - 3) **mast cell stabilizers (sodium cromoglycate or nedocromil)** therapy OR
 - 4) **inhaled corticosteroid (ICS)** therapy OR
 - 5) **anti-cholinergics (ipratropium)** therapy
- reduce symptoms and prevent a $\geq 10\%$ drop in FEV₁ compared to no treatment/placebo.
6. In patients with confirmed EIA/EIB, does a **refractory period (10-15 min warmup and/or cool down)** reduce symptoms and prevent a $\geq 10\%$ drop in FEV₁ compared to no treatment/placebo.

Data Extraction Form: Diagnosis of EIB/EIA review

I. CODER INFORMATION

1. Reviewer initials:	2. Time to extract (to nearest minute):
Applies to question: <input type="checkbox"/> 1 self-reported hx/symptoms diary <input type="checkbox"/> 2 methacholine challenge <input type="checkbox"/> 3 sport/venue-specific exercise <input type="checkbox"/> 4 eucapnic voluntary hyperpnea (EVH) <input type="checkbox"/> 5 free running asthma screening test (FRAST) <input type="checkbox"/> 6 mannitol	

II. PUBLICATION

3. Author:	4. Year of publication:
5. Country trial conducted in (n= ___ and complete list if >1): NR	6. Number of centres: single multi: n= NR
7. Publication Type: journal article industry reported trial abstract other (describe)	
8. Funding Government Institution Industry (describe) No funding Other (describe) NR	9. Type of study: Trial Observational other (specify) _____
	10. Design attributes prospective retrospective

III. STUDY CHARACTERISTICS

11. Study objective:	
12. Recruitment dates (mm/yy–mm/yy): NR	13. Source of participants: clinic/office school athletic team (sport/level) _____ other (describe) NR
14. No. of study days (i.e # screening/testing days)	15. No. of challenges per day
16. Time between challenges: 24 hours ≥2 days Other: _____ NR	
17. Inclusion criteria: NR	
18. Exclusion criteria: NR	
19. Definition of bronchial hyper reactivity (BHR) according to EVH or methacholine or mannitol (i.e. cut point for diagnosis): Report the reference or comments to support the cut point.	
20. Definition of EIA/EIB: ≥ 10% fall in FEV1 or PEF ≥ 15% fall in FEV1 or PEF ≥ 20 % fall in FEV1 or PEF Reproducible EIA/EIB (no definition given) Other (describe) e.g. self-report; physician diagnosed; symptoms etc. NR	
21. Please report the reference or comments made that supported the EIA/EIB definition they used (if any).	

IV. DIAGNOSTIC TESTS

Treadmill	
22. <u>Duration of challenge:</u>	6 minutes 8 minutes Other (describe) _____ NR
23. <u>% of maximal heart rate / workload:</u>	
24. <u>Relative humidity:</u>	≤50% Other (describe) _____ NR
25. <u>Air temperature:</u>	Air conditioned (ambient temp. 20-25° C) Other (describe) _____ NR
26. <u>Referenced standardized protocol:</u>	Yes No If yes, supply reference ID (if given): _____
27. <u>Follow-up time points:</u> (i.e. 1, 3, 5, 7, 30 min post challenge)	
Cycle ergometry	
28. <u>Duration of challenge:</u>	6 minutes 8 minutes Other (describe) _____ NR
29. <u>% of maximal heart rate / workload:</u>	
30. <u>Relative humidity:</u>	≤50% Other (describe) _____ NR
31. <u>Air temperature:</u>	Air conditioned (ambient temp. 20-25° C) Other (describe) _____ NR
32. <u>Referenced standardized protocol:</u>	Yes No If yes, supply reference ID (if given): _____
33. <u>Follow-up time points:</u> (i.e. 1, 3, 5, 7, 30 min post challenge)	
Self reported history/Questionnaire	
34. <u>Summary of comments from study:</u>	

Methacholine challenge	
35. <u>Dosing protocol</u>	<p>2 min tidal breathing method</p> <ul style="list-style-type: none"> ▪ 10 doubling concentrations of MCH (0.03, 0.06, 0.125, 0.25, 0.50, 1, 2, 4, 8, 16 mg/ml) ▪ Nebulizer using dry compressed air for power ▪ Perform baseline spirometry ▪ Noseclip should be worn ▪ Breathe quietly for 2 min. ▪ Measure FEV₁ 30 – 90s after nebulization of each dose ▪ Commence subsequent concentrations with ≤5 min interval <p>5 breath dosimeter method</p> <ul style="list-style-type: none"> ▪ 5 quadrupling concentrations of MCH (0.0625, 0.25, 1,4,16 mg/ml) ▪ Perform baseline spirometry ▪ Noseclip should be worn ▪ Inhale slowly & deeply from nebulizer and exhale; repeat for 5 inhalations ▪ Measure FEV₁ 30 – 90s after 5th inhalation ▪ Commence subsequent concentrations with ≤5 min interval <p>Other (specify)</p>
36. <u>Follow-up time points:</u> (i.e. 1, 3, 5, 7, 30 min post challenge)	

Sport/venue-specific exercise	
37. <u>Sport:</u>	
38. <u>Venue:</u>	
39. <u>Duration:</u>	
40. <u>Follow-up time points:</u> (i.e. 1, 3, 5, 7, 30 min post challenge)	
41. <u>Other:</u>	
EVH	
42. <u>Description:</u>	
FRAST	
43. <u>Standard test:</u>	YES NO If no, describe:
Mannitol	
44. <u>Description:</u>	
Resources used for diagnosis challenges	
45. <u>Time:</u>	
46. <u>Personnel (who, how many?):</u>	
47. <u>Cost(s) (if given):</u>	
48. <u>Patient safety:</u>	
49. <u>Other (e.g. ease of administration):</u>	

V. BASELINE CHARACTERISTICS (when possible report data post run-in/pre-test)

*Circle or describe units Indicate if no variance measure reported	
50. <u>Age</u> : years mean±SD; mean±SE; median (range); IQR	
51. <u>Males</u> : n (%)	
52. <u>Ethnicity</u> :	
53. <u>Height</u> :	
54. <u>Weight</u> :	
55. <u>BMI</u> :	
56. <u>Number of participants enrolled/randomized</u> : (n)	
57. <u>Number of participants analyzed</u> : (n)	
58. <u>Number of dropouts/withdrawals</u> : (n)	
59. <u>Reasons for dropout/withdrawal</u> :	
60. <u>History of asthma/BHR</u> :	YES NO NR If yes, how confirmed?
61. <u>Proven EIA/EIB</u> :	YES NO NR If yes, how confirmed?
62. <u>Baseline severity of asthma</u> : mild/mod/severe or stable (Report authors words) NR	
63. <u>Index of activity/fitness level</u> :	Sedentary (no activity per week) Normally active (1-3 days per week activity) Athletic (competitive athlete, 4+ days per week activity) Other NR
64. <u>Atopic status</u> : YES = to at least one allergen; NO=none were atopic Mix of atopy/no atopy (x%=yes; X%=no) (a positive skin prick test=atopic to at least 1)	
65. <u>Baseline ICS history</u> : NO = none on ICS YES = all on maintenance ICS mixed ICS use (x%= yes; X%= no) NR	
66. Which asthma medications were discontinued pre challenge and how long before challenge	
67. Baseline FEV1 (L): (mean±SD; mean±SE; median (range); IQR)	
68. Baseline FEV1 (% predicted): (mean±SD; mean±SE; median (range); IQR)	
69. Baseline PEF: (mean±SD; mean±SE; median (range); IQR)	
70. PC20 (mg/ml):	
71. Smoking Hx: never/past/current	

72. Other (describe)	
----------------------	--

VI. REPORTED OUTCOMES

		Exercise Standard		Totals
		EIB (+)	EIB (-)	
Comparator 1	EIB (+)			
	EIB (-)			
Totals				

OTHER OUTCOMES REPORTED
73. Sensitivity:
74. Specificity:

VII. ADVERSE EVENTS/SIDE EFFECTS NR Statement re: no AE observed in study

	Exercise Standard	Comparator 1	Comparator 2	Comparator 3
Total reported				

ADDITIONAL COMMENTS

75.

Data Extraction Form: Therapy for EIB/EIA review

I. CODER INFORMATION

1. Reviewer initials:	2. Time to extract (to nearest minute):
3. Applies to question: <input type="checkbox"/> 1 tachyphylaxis SABA or LABA <input type="checkbox"/> 2 i [LTRA] <input type="checkbox"/> 2 ii [ICS] <input type="checkbox"/> 2 iii [SCG / NCS] <input type="checkbox"/> 2 iv [anti-cholinergic] <input type="checkbox"/> 6 refractory period	

II. PUBLICATION

4. Author:	5. Year of publication (last two digits):		
6. Country trial conducted in (n= ___ and complete list if >1): NR	7. Number of centres: single multi: n= NR	8. Publication Type: journal article industry reported trial abstract other (describe)	
9. Funding government institution Industry (describe) No funding other (describe) NR	10. Type of trial: parallel cross-over	11. Blinding open label single blind dble blind NR	12. Other design attributes double-dummy placebo-controlled

III. STUDY CHARACTERISTICS

13. Recruitment dates (mm/yy-mm/yy): NR	14. Source of participants: clinic/office school athletic team other (describe) NR		
15. Run-in period? Yes NO [describe]			
16. No. of study days (i.e # screening/testing days)	17. No. of challenges per day		
18. Time between challenges: NR			
19. Exclusion criteria: NR			
20. Definition of EIA/EIB: $\geq 10\%$ fall in FEV1 or PEF $\geq 15\%$ fall in FEV1 or PEF $\geq 20\%$ fall in FEV1 or PEF Reproducible EIA/EIB (no definition given) Other (describe) e.g. self-report; physician diagnosed; symptoms etc. NR			
21. Please report the reference or comments made that supported the EIA/EIB definition they used (if any) we need to report this in a table for the funders.			
22. Exercise challenge: Inclined treadmill Bicycle ergometer FRAST (Free Running Asthma Sport-specific challenge Other (describe) Screening Test)	23. Duration of challenge 6 minutes 8 minutes Other (describe)		
24. Temperature Room/ambient temperature	25. Relative humidity	26. % of maximal heart rate / workload	

Cold air Other (describe)		
27. Other conditions reported		

IV. TREATMENT GROUPS

	Group A	Group B	Group C	Group D	Total
28. Number of participants enrolled/randomized (<i>n</i>)					
29. Number of participants analyzed (<i>n</i>)					
30. Number of dropouts/withdrawals (<i>n</i>)					
31. Reasons for dropout/withdrawal					
INTERVENTIONS					
32. <u>Drug 1: name</u>					
33. <u>Dose 1</u>					
34. <u>Delivery device 1:</u> Diskhaler (diskus) pMDI (MDI) Turbuhaler Spinhaler Nebulizer Other (describe)					
35. Time 1: time med taken pre exercise (minutes)					
36. <u>Drug 2: name</u>					
37. <u>Dose 2</u>					
38. <u>Delivery device 2:</u> Diskhaler (diskus) pMDI (MDI) Turbuhaler Spinhaler Nebulizer Other (describe)					
39. Time 2: time med taken pre exercise (minutes)					
40. <u>Current asthma medications allowed to continue during testing: YES NO</u>					
41. Which asthma medications were allowed					
42. Which asthma medications were discontinued pre challenge and how long before challenge					

V. BASELINE CHARACTERISTICS (when possible report data post run-in/pre-treatment)

*Circle or describe units Indicate if no variance measure reported	Group A	Group B	Group C	Group D	Total
43. <u>Age: years mean±SD;</u>					

mean±SE; median (range); IQR					
44. Males <i>n</i> (%)					
45. <u>Participants had confirmed asthma:</u> YES NO					
46. <u>Baseline severity of asthma:</u> mild/mod/severe or stable (Report authors words later we will convert to GINA guideline category) NR					
47. <u>Atopic status:</u> YES = to at least one allergen; NO=none were atopic Mix of atopy/no atopy (x%=yes; X%=no) (a positive skin prick test=atopic to at least 1)					
48. <u>Baseline ICS history:</u> NO=none on ICS YES=all on maintenance ICS mixed ICS use (x%= yes; X%= no) NR					
49. Baseline FEV1: L					
50. Baseline FEV1 % predicted					
51. mea/max % fall FEV1 control / screening challenge mean±SD / SE; median(range); IQR					
52. Severity of EIB (mild/mod/severe)					
53. mean / max % fall PEF control / screening challenge mean±SD / SE; median(range); IQR					
54. Smoking Hx: never/past/current					
55. Other (describe)					

VI. REPORTED OUTCOMES (outcomes with data reported) circle or check outcome reported

56. Primary outcome:	
OTHER OUTCOMES REPORTED	
57. FEV1: L	58. Individual patient data
59. FEV1: Max % fall	60. Adverse events (i.e.) anaphylaxis. Had to d/c challenge etc.
61. FEV1: change	62. Side effects
63. FEV1: times measured	64. Time course of EIB (graph)
65. PEF: L/min	66. Repeat tests on same day
67. PEF: max % fall	68. Symptoms
69. PEF: change	70. Rescue medication use
71. PEF: times measured	72. Other (describe)
73. % protection	74. Other (describe)
75. Complete protection:	76. Other (describe)
77. Clinical protection	78. Other (describe)

VII. ADVERSE EVENTS/SIDE EFFECTS

	Group A	Group B	Group C	Group D	Total
Total reported					

VIII. CONCLUSIONS

Describe conclusions: *(Please, also describe such as: "Compared to B and C, A----was-superior/inferior in ----", or "There were no differences between A and B in ----, but B was superior/inferior to C")*

--

ADDITIONAL COMMENTS

79.

Quality Assessment Form: Diagnosis of EIB/EIA review, QUADAS

1	The spectrum of patients was representative of the patients who would receive the test in practice.	YES	NO	UNCLEAR
2	Were selection criteria clearly defined?	YES	NO	UNCLEAR
3	Is the reference standard likely to classify the condition correctly? (Reference standard was specified as part of inclusion criteria)	YES	NO	UNCLEAR
4	Is the time period between reference standard and index test appropriate to be reasonably sure that the target condition did not change between the two tests?	YES	NO	UNCLEAR
5	Did the whole sample or a random selection of the sample, receive verification using a reference standard (partial verification bias)?	YES	NO	UNCLEAR
6	Did patients receive the same reference standard regardless of the index test results (differential verification bias)?	YES	NO	UNCLEAR
7	Was the execution of the index test described in sufficient detail to permit replication of the test?	YES	NO	UNCLEAR
8	Was the execution of the reference test described in sufficient detail to permit replication of the test?	YES	NO	UNCLEAR
9	Were the index test results interpreted without knowledge of the results of the reference standard?	YES	NO	UNCLEAR
10	Were the reference standard results interpreted without knowledge of the results of the index test?	YES	NO	UNCLEAR
11	Were the same clinical data available when index test results were interpreted as would be available when the test is used in practice? (Only applicable to self-reported history and self-reported symptoms diary)	YES	NO	UNCLEAR
12	Were uninterpretable/intermediate test results reported?	YES	NO	UNCLEAR
13	Were withdrawals from the study explained?	YES	NO	UNCLEAR

Guidelines for interpretation of QUADAS questions for EIB/EIA

1. *Was the spectrum of participants representative of the patients who would receive the test in practice?*

Answer YES if

- Unbiased recruitment methods: consecutively or randomly selected in a prospective way
- Characteristics of participants are presented: Age, comorbidity (e.g., asthma), where they were recruited from (e.g., school, clinic, sport team, etc.), all have suspected EIB

Answer NO if

- Biased recruitment methods: volunteers, retrospective selection
- Participants include those with confirmed (not suspected) EIB
- Characteristics of participants are not reported

Answer UNCLEAR if

- There is not enough relevant information to score either a Yes or No.

2. *Were selection criteria clearly defined?*

Answer YES if

- There is information on how participants were selected for inclusion including recruitment methods and inclusion/exclusion criteria (e.g., age, EIB status, setting (i.e., high school), recruitment method)

Answer NO if

- There is no information regarding recruitment methods and inclusion/exclusion criteria

Answer UNCLEAR if

- There is not enough relevant information to score either a Yes or No.

3. *Is the reference standard likely to classify the condition correctly?*

Answer YES

- Standardized exercise challenge (treadmill or cycle ergometry) that resulted in a drop of $\geq 10\%$ in FEV₁ as being acceptable.
- Age-specific heart rate achieved during exercise ($>80\%$ of predicted)
- Exercise duration ≥ 6 min

- Post exercise measure interval is approximately 2 min (i.e., 1, 3, 5, 7min)
- Answer UNCLEAR if
- The achieved age-specific HR or exercise duration are not mentioned
 - The achieved age-specific HR is mentioned but less than 80%
 - The exercise duration is mentioned but less than 6 min
 - Post exercise measure interval is longer than 2 min (i.e, 1, 4, 8m post exercise)
4. *Is the time period between reference standard and index test appropriate to be reasonably sure that the target condition did not change between the 2 tests?*
- Answer YES if
- There was an acceptable delay between the 2 tests; doesn't apply to self report and a 2nd test (mark as NA where self report is the comparison test)
 - We judged a time interval of at least 24 hours between tests as appropriate.
- Answer NO if
- If the period between the 2 tests does not fall within the time interval
- Answer UNCLEAR if
- There is not enough relevant information to score either a Yes or No.
5. *Did the whole sample or a random selection of the sample, receive verification using a reference standard (partial verification bias)?*
- Answer YES if
- All participants received the reference test **before** receiving the index test; or
 - In cases where the index test is given prior to the reference test, either all participants go on to receive the reference test or a random sample of participants receive the reference test
- Answer NO if
- Less than 90% of the participants who received the index test also received the reference test and the selection of this smaller group is based on a non-random method (such as results from the index test)
- Answer UNCLEAR if
- There is not enough relevant information to score either a Yes or No
6. *Did patients receive the same reference standard regardless of the index test results (differential verification)?*
- Answer YES if
- All participants received the same reference test
- Answer NO if
- Some participants received verification of EIB using a different reference standard or some of the participants who received the index test did not have their true disease state verified.
- Answer UNCLEAR if
- There is not enough relevant information to score either a Yes or No
7. *Was the execution of the index test described in sufficient detail to permit replication of the test?*
- Answer YES if ...
- Details are provided about duration, dose, load, environmental conditions and other items relevant to the specific index test
- Answer NO if
- There are no details about the execution of the index test.
- Answer UNCLEAR if
- There is not enough relevant information to score either a Yes or No

8. *Was the reference standard described in sufficient detail to permit replication of the test?*
 Answer YES if
- Information is reported on duration of challenge, % of maximal heart rate / workload, relative humidity, air temperature, or if a standardized protocol is referenced (i.e., AAS or similar).
- Answer NO if
- There is no information about how the exercise challenge was conducted.
- Answer UNCLEAR if
- There is not enough relevant information to score either a Yes or No
9. *Were the index test results interpreted without knowledge of the results of the reference standard?*
10. *Were the reference standard results interpreted without knowledge of the results of the index test?*
 Answer YES if
- The authors stated explicitly that the results of the index test were interpreted blind to the results of the exercise challenge, and vice versa
- Answer NO if
- If it does not seem likely that the test results were interpreted blind to the results of the other test
- Answer UNCLEAR if
- It is not reported in the study
11. *Were the same clinical data available when test results were interpreted as would be available when the test is used in practice?(Applicable only to Self reported history and Self reported symptoms diary)*
 Answer YES if
- If the interpretation of the index test is fully automated and involves no interpretation
 - If the index test is interpreted with additional clinical data in the study, while these same clinical data will also be available when the index test is performed in practice
 - If the index test is interpreted without additional clinical data, and additional clinical data will also be unavailable when the index test is performed in practice
- Answer NO if
- If the interpretation of the index test is not fully automated and involves interpretation components which can be influenced by additional clinical data
 - If the index test is interpreted with additional clinical data in the study, however, these clinical data will not be available when the index test is performed in practice
 - If the index test is interpreted without additional clinical data, however, additional clinical data will be available when the index test is performed in practice
- Answer UNCLEAR if
- Not enough relevant information to score either a Yes or No
12. *Were uninterpretable/intermediate test results reported?*
 Answer YES if
- It is clear that all test results are reported
- Answer NO if
- You suspect that uninterpretable/indeterminate/intermediate results occur but are not reported
- Answer UNCLEAR if
- There is no mention of whether such results occurred or how they were handled
13. *Were withdrawals from the study explained?*
 Answer YES if
- All the participants enrolled are accounted for (i.e., a flow chart or description of reasons for dropouts or withdrawals)
- Answer NO if
- Some participants did not receive both tests and are not accounted for
- Answer UNCLEAR if
- It is not clear whether all participants who entered the study were accounted for

Note: We did not apply Item 7 (incorporation bias) from the original QUADAS tool as it does not apply to this review.

Quality Assessment Form: Therapy for EIB/EIA review (RCTs)

Jadad scale

	YES	NO
1. Was the study described as randomized (this includes the use of words such as randomly, random and randomization)?	1	0
2. Was the study described as double-blind?	1	0
3. Was there a description of withdrawals and drop-outs?	1	0
4. Method to generate the sequence of randomization was described and was appropriate (e.g. table of random numbers, computer generated, coin tossing, etc.)	1	0
5. Method of double-blinding described and appropriate (identical placebo, active placebo, dummy)	1	0
6. Method of randomization described and it was in appropriate (allocated alternately, according to date of birth, hospital number, etc.)	-1	0
7. Method of double-blinding described but it was in appropriate (comparison of tablet vs. injection with no double dummy)	-1	0
OVERALL SCORE (Maximum 5)		

Concealment of treatment allocation – Schulz

Concealment of treatment allocation	<input type="checkbox"/> Adequate <input type="checkbox"/> Inadequate <input type="checkbox"/> Unclear
Adequate:	e.g. central randomization; numbered/coded containers; drugs prepared by pharmacy; serially numbered, opaque, sealed envelopes
Inadequate:	e.g. alternation, use of case record numbers, dates of birth or day of week; open lists
Unclear:	Allocation concealment approach not reported or fits neither above category

Appendix D. Excluded Studies

Diagnosis of EIB/EIA reviews

402 studies were excluded from the diagnostic test accuracy reviews. Reasons for exclusion include: study design (n=116), population (n=8), no reference standard (n=21), no comparison (n=46), did not diagnose EIA/EIB (n=158), insufficient data (n=26), other diagnostic tests (n=24), duplicate publication (n=2), and language (n=1). In addition, we were unable to obtain copies of 10 studies.

Study Design (n = 116)

1. Bronchial asthma. *Med Sport (Roma)* 2006;59(1):25-42.
2. No perfect screening test for asthma. *Sports Med Digest* 1999;21(6):64-5.
3. Albers M, Schermer T, Van WC. Airflow limitation as a screening tool: too relevant to ignore, too conspicuous to apply? *Chest* 2005;128(4):1898-900.
4. Amirav I. Airway response to methacholine during exercise induced refractoriness in asthma. *Thorax* 1987;42(10):831.
5. Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. *Br J Sports Med* 2001;35(5):344-7.
6. Anderson SD, Silverman M, Tai E, Godfrey S. Specificity of exercise in exercise-induced asthma. *Br Med J* 1971;4(5790):814-5.
7. Anthonisen NR. Asthma questionnaires. *Can Respir J* 2007;14(2):77-8.
8. Ashbaugh SJ, Rubino I, Rose VL. At-risk athletes should be screened for exercise-induced asthma. *Am Fam Physician* 1998;57(2):332.
9. Barbosa e Silva O, Ribeiro Saraiva LC. Exercise test indications in children and adolescents. *Rev Bras Med Esporte* 2004;10(5):420-3.
10. Berglund E. Challenging an exercise challenge protocol [comment]. *Eur Respir J* 1994;7(10):1909.
11. Berman BA, Ross RN. Exercise-induced asthma. *Cutis* 1982;30(2):176.
12. Bierman CW. Management of exercise-induced asthma. *Ann Allergy* 1992;68(2):119-22.
13. Bokulic RE. Screening for exercise-induced asthma [comment]. *J Pediatr* 2002;141(3):306-8.
14. Bonini S, Brusasco V, Carlsen KH, et al. Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. *Allergy* 2004;59(1):33-6. Erratum in: *Allergy* 2005;60(4):548.
15. Britton J. Bronchial Provocation testing. *Clin Exp Allergy* 1989;19(4):481-4.
16. Britton J, Tattersfield AE. Does measurement of bronchial hyperreactivity help in the clinical diagnosis of asthma? *Eur J Respir Dis* 1986;68(4):233-8.
17. Brown J. Asthma in childhood. *Med J Aust* 1973;1(13):654-7.
18. Bruns AS, Parsons JP. Exercise-induced bronchospasm: diagnosis and treatment. *J Clin Outcomes Manag* 2007;14(4):211-9.
19. Buckley JM. Exercise-induced 'asthma'. *Hosp Pract* 1979;14(7):118.
20. Bundgaard A. Exercise-induced asthma. *Eur J Respir Dis Suppl* 1986;143:51-6.
21. Busse WW. Exercise-induced asthma. *Am J Sports Med* 1981;9(3):194-6.
22. Cawley MJ. Exercise-induced asthma. *J Pharm Pract* 2003;16(1):59-67.
23. Chai H. Intermediary mechanisms in asthma. Some informal comments on the pathogenesis of the breathing disturbances. *Clin Pediatr* 1974;13(5):409-12.
24. Cherginets A, Cherginets V. Heterogeneity of bronchial response to exercise among children with asthma. *Allergol Int* 2001;50(2):179-87.
25. Cibor G. The diagnosis and management of exercise-induced asthma. *Sports Medicine Alert* 2001;7(8/9):49-52.
26. Cockcroft DW. Value of the diluent step in methacholine challenge tests. *Ann Allergy Asthma Immunol* 2002;89(1):4-6.
27. Colin A, Said E, Winter ST. Exercise-induced asthma in schoolchildren a pilot study in 2 Haifa districts Israel. *Isr J Med Sci* 1985;21(1):40-3.
28. Cotes JE, Reed JW. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007;29(5):1064-6.

29. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000;161(1):309-29.
30. D'Urzo AD. Hypercapnia during exercise in asthmatic subjects [comment]. *J Appl Physiol* 1995;78(1):372.
31. Addo Yobo EOD, Custovic A, Taggart SCO, safo-Agyei AP, et al. Exercise induced bronchospasm in Ghana: prevalence in urban and rural children. *Thorax* 1996;51(Suppl 3):A42.
32. de Meer G, Marks GB, Postma DS. Direct or indirect stimuli for bronchial challenge testing: what is the relevance for asthma epidemiology? *Clin Exp Allergy* 2004;34(1):9-16.
33. Dempsey JA. Challenges for future research in exercise physiology as applied to the respiratory system. *Exerc Sport Sci Rev* 2006;34(3):92-8.
34. Dickinson JW, Whyte GP, McConnell AK, Nevill AM, et al. Mid-expiratory flow versus FEV1 measurements in the diagnosis of exercise induced asthma in elite athletes. *Thorax* 2006;61(2):111-4.
35. Djukanovic R. Is airways hyperreactivity selective or nonselective? *Agents Actions* 1993;43(Suppl):231-9.
36. Duiverman EJ. Asthma and lung function. *Pediatr Pulmonol* 2001;32(Suppl 23):141-2.
37. Ernst P, Nunes F, Gerardi G, Becklake MR. Distribution and determinants of bronchial hyperresponsiveness to exercise among primary school children. *Am Rev Respir Dis* 1992;145(4 Pt 2):A537.
38. Evans TM. Exercise-induced bronchoconstriction during room temperature and cold temperature exercise and eucapnic voluntary hyperventilation Marywood University; 2005.
39. Filipe MC, Delgado J, Rodrigues J, Vaz M. Exercise-induced respiratory symptoms: the utility of a free-athletic-sport test ("FAST"). *Allergy (Copenhagen)* 1998;53(Suppl 43):146.
40. Flint SE. Exercise-induced bronchospasms. *J Pediatr Health Care* 1990;4(3):147-8.
41. Gerhard H, Schachter EN. Exercise-induced asthma. *Postgrad Med* 1996;67(3):91-102.
42. Godfrey S, Konig P. Exercise-induced bronchial lability in atopic children and their families. *Ann Allergy* 1974;33(4):199-205.
43. Godfrey S, Koenig P. Exercise induced bronchial lability in wheezy children and their families. *Pediatrics* 1975;56(5 Suppl):851-5.
44. Godfrey S, Silverman M, Anderson SD. Problems of interpreting exercise-induced asthma. *J Allergy Clin Immunol* 1973;52(4):199-209.
45. Godfrey S. Proceedings: the clinical value of exercise tests in children. *BTTA Rev* 1973;3(4):75.
46. Godfrey S, Silverman M, Anderson SD. The use of the treadmill for assessing exercise induced asthma and the effect of varying the severity and duration of exercise. *Pediatrics* 1975;56(5 Suppl):893-8.
47. Goldberg S, Schwartz S, Izbicki G, et al. Sensitivity of exercise testing for asthma in adolescents is halved in the summer. *Chest* 2005;128(4):2408-11.
48. Gordon BR. Asthma history and presentation. *Otolaryngol Clin North Am* 2008;41(2):375-85.
49. Gotshall RW. Airway response during exercise and hyperpnoea in non-asthmatic and asthmatic individuals. *Sports Med* 2006;36(6):513-27.
50. Greaves IA. Exercise and asthma. *Med J Aust* 1977;2(25):819-20.
51. Hamilton B. Diagnosis and management of asthma in athletics. [Diagnostic et gestion de l'asthme en athlétisme]. *Modern Athlete and Coach* 2003;41(2):19-20.
52. Hamilton B. Diagnosis and management of asthma in athletics [abstract]. *NSA* 2003;18(3):71.
53. Higenbottam T, Godden D. Inhalation challenge testing for asthma. Role of bronchial provocation tests in clinical practice. *Postgrad Med* 1984;76(5):161-4.
54. Holzer K, Anderson S, Douglass J. Exercise-induced bronchoconstriction in elite athletes: which diagnostic challenge test? [abstract]. *J Sci Med Sport* 2002;5(Suppl):124.
55. Holzer K, Douglass JA. Exercise induced bronchoconstriction in elite athletes: measuring the fall. [comment]. *Thorax* 2006;61(2):94-6.
56. Hosey RG, Phillips GC. Exercise-induced anaphylaxis: diagnosis and management. *Int Sport Med J* 2002;3(2):1-8.
57. Hunt CH. Exercise induced asthma. *Del Med J* 1987;59(9):609-10.
58. Hurwitz KM, Argyros GJ, Roach JM, Eliasson AH, et al. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. *Chest* 1995;108(5):1240-5.
59. Kaldmae P. Pulmonary function tests for diagnosing exercise induced airway hyperreactivity in children. *Acta Medica Baltica* 1997;4(1):36-9.
60. Kennedy MF. Exercise and children with asthma [letter]. *Can Fam Phys* 2002;48:457-8.

61. Kyle JM, Hershberger SL, Leaman JR, Melrose JK. Exercise bronchospasm in recreational athletes. *Phys Sportsmed* 1997;25(5):E30.
62. Larussa J, Feinstein RA, Wang-Dohlman A. A simple test to identify exercise induced bronchospasm (EIB) in adolescent athletes. *Pediatr Res* 1993;33(4 Pt 2):6A.
63. Leaver-Dunn D, Robinson JB, Laubenthal J. Assessment of respiratory conditions in athletes. *Athletic Ther Today* 2000;5(6):14-9.
64. Leski M. Exercise-induced asthma. *South Med J* 2004;97(9):859-60.
65. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. *Swiss Med Wkly* 2002;132(13-14):151-8.
66. Mannix ET, Farber MO. Distinguishing between exercise-induced asthma and deconditioning. *J Respir Dis* 2000;21(6):363-4.
67. Mayers LB, Rundell KW. Exercise-induced asthma. *Olympic Coach* 2000;10(3):12-4.
68. Mayol PM, Sifontes JE, Vazquez S, Rodriguez S, Jr. Exercise-induced asthma: preliminary report. *Boletin - Asociacion Medica de Puerto Rico* 1986;78(12):535-8.
69. McFadden J. Exercise-induced asthma. Recent approaches. *Chest* 1988;93(6):1282-3.
70. Meehan C. Asthma and diving screening protocols. *S Pac Underw Med Soc J* 2001;31(4):226-9.
71. Miller LC. Exercise-induced asthma. *J Indiana State Med Assoc* 1979;72(4):259-62.
72. Milne C. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction [abstract]. *New Zeal J Sports Med* 2002;30(1):22-3.
73. Munyard PF, Bush A. Exercise, a fall in peak expiratory flow rate, and asthma: what is the connection? *Clin Exp Allergy* 1992;22(8):729-30.
74. Nemet D, Wolach B, Yacobovich J, Eliakim A. Exercise in childhood asthma: provoking agent, diagnostic tool and therapeutic measure. *IMAJ* 2000;2(2):99-103.
75. Oseid S, Aas K. Exercise-induced asthma. *Allergy* 1978;33(5):227-8.
76. Owens GR. Exercise-induced asthma: optimal testing methods and preventive measures. *Consultant* 1987;27(3):23.
77. Palange P, Ward SA, Carlsen KH, et al. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007;29(1):185-209.
78. Parry DE, Lemanske RF. Exercise-induced asthma. *Athletic Ther Today* 1996;1(5):11-5.
79. Persaud Y, Lamm C, Silverman B, Schneider A. Misdiagnosis of exercise induced asthma in two patients years after surgical repair of congenital anomalies [abstract]. *J Allergy Clin Immunol* 2006;117(2 Suppl):S3.
80. Rachelefsky GS. Exercise-induced asthma. *Sports Med Digest* 1991;13(10):1-2.
81. Randolph C. The free running athletic screening test. *Ann Allergy Asthma Immunol* 1998;81(4):275a-g.
82. Randolph CC. Exercise-induced asthma, part 1: how to make the diagnosis. *J Respir Dis* 2002;23(7):387-90.
83. Randolph CC. Exercise-induced asthma, part 1: how to make the diagnosis. *J Respir Dis Pediatr* 2003;5(4):170-3.
84. Rebuck AS, Read J. Exercise-induced asthma. *Lancet* 1968;2(7565):429-31.
85. Rees J. ABC of asthma. Definition and diagnosis. *Br Med J (Clin Res Ed)* 1984;288(6427):1370-2.
86. Rund DA. Asthma. *Phys Sportsmed* 1990;18(1):143-4.
87. Rundell KW, Wilber RL, Szmedra L, Wang D. Laboratory EIA screening unreliable for elite athletes. *Phys Sportsmed* 2000;28(6):26.
88. Rundell KW. Screening elite winter athletes for exercise induced asthma: a comparison of three challenge methods: commentary. *Br J Sports Med* 2006;40(2):179-82.
89. Rupp NT. Diagnosis and management of exercise-induced asthma. *Phys Sportsmed* 1996;24(1):77-87.
90. Santilli G. Pulmonary function evaluation and physical activity. *Med Sport (Roma)* 2006;59(1):1.
91. Saranz R, Del Giacco GS, Croce VH, Del Giacco SR. Exercise-induced asthma: an update. *Eur J Inflamm* 2004;2(1):5-16.
92. Schoene ML. Conventional testing methods incapable of detecting breathing problems among elite athletes. *Sports Med Digest* 1999;21(6):61.
93. Schoene ML. Respiratory symptoms no indication of asthma among elite athletes. *Sports Med Digest* 2000;22(8):85-7.
94. Shapiro GG, Bierman CW. Exercise-induced asthma. *J Asthma* 1983;20(5):383-9.
95. Shapiro GG. Methacholine challenge - relevance for the allergic athlete. *J Allergy Clin Immunol* 1984;73(5 Suppl II):670-5.
96. Simons E. Repeat exercise normalizes the gas-exchange impairment induced by a previous exercise bout in asthmatic subjects: commentary. *Pediatrics* 2006;118(Suppl 1):S28-S29.

97. Simonsson BG, Skoogh BE, Ekstrom-Jodal B. Exercise-induced airway constriction. *Thorax* 1969;24(4):506.
98. Simpson G. Mannitol bronchial challenge testing and scuba diving. *Diving and Hyperbaric Medicine* 2006;36(4):231.
99. Slater JB, Slater EG. Exercise induced asthma. *Sports Medicine Update* 1996;11(3):26-9.
100. Souhrada JF, Zeballos RJ, Chai H, Souhrada M. Two types of responses to exercise and isocapnic hyperventilation in asthmatics. *Eur J Respir Dis Suppl* 1983;128(Pt 1):246-52.
101. Spector SL, Chai H. Bronchial exercise and oral challenge procedures. *Bull N Y Acad Med* 1981;57(7):572-81.
102. Stephens J, Paridon SM. Exercise testing in pediatrics. *Pediatr Clin North Am* 2004;51(6):1569-87.
103. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. *Eur Respir J Suppl* 1993;6(16):53-83.
104. Sterk PJ, Martinez Fernando J, Celli Bartolome R. Bronchoprovocation testing. Pulmonary function and exercise testing. *Semin Respir Crit Care Med* 1998;19(4):317-24.
105. Stoloff SW. The role of history taking in the diagnosis of asthma. *Hosp Pract* 1996;31(10):155-6.
106. Storms WW. Exercise-induced asthma: diagnosis and treatment for the recreational or elite athlete. *Med Sci Sports Exerc* 1999;31(1):S33-8.
107. Storms WW. Exercise-induced asthma: diagnosis and treatment for the recreational or elite athlete. *American Swimming* 1999;(3):28-32.
108. Sukanich AC, Rogers KD, Fireman P. Free-running test for asthma screening in school children. *Pediatr Res* 1989;25(4 Pt 2):105A.
109. Svenonius E, Lecerof H, Lilja B, et al. The volume of trapped gas: a new and sensitive test for the detection of exercise-induced bronchospasm in children. *Acta Paediatr Scand* 1978;67(5):583-9.
110. Terblanche E, Stewart RI. The prevalence of exercise-induced broncho-constriction in Cape Town school children. *S Afr Med J* 1990;78(12):744-7.
111. Volcheck GW. In-office diagnosis of exercise-induced asthma. *Postgrad Med* 2000;107(2):48.
112. Weaver J, Denegar CR, Hertel J. Exercise-induced asthma. *Athletic Ther Today* 2000;5(3):38-42.
113. Weinstein R. Exercise-induced asthma. *Ear Nose Throat J* 1984;63(2):57-8.
114. Wheeler LS, Boyle S. Attempting to use a district-wide asthma case identification system for asthma prevalence. *J Sch Health* 2006;76(6):219-22.
115. Winslow DH. Exercise induced asthma. *J Ky Med Assoc* 1978;76(6):271-4.
116. Wolanczyk-Medrała A, Dor A, Szczepaniak W, Tomkowicz T, et al. Exercise-induced bronchospasm among athletes in Lower Silesia Province. *J Sports Sci* 2008;26(13):1467-71.

Population (n = 8)

1. Belcher NG, Lee TH, Rees PJ. Airway responses to hypertonic saline, exercise and histamine challenges in bronchial asthma. *Eur Respir J* 1989;2(1):44-8.
2. Bundgaard A, Ingemann-Hansen T, Schmidt A, Halkjaer-Kristensen J. The importance of ventilation in exercise-induced asthma. *Allergy* 1981;36(6):385-9.
3. Glanville AR, Gabb GM, Theodore J, Robin ED. Bronchial responsiveness to exercise after human cardiopulmonary transplantation. *Chest* 1989;96(2):281-6.
4. Mapp CE, Boniotti A, Papi A, Maggi CA, et al. Effect of bumetanide on toluene diisocyanate induced contractions in guinea pig airways. *Thorax* 1993;48(1):63-7.
5. Reiff DB, Choudry NB, Pride NB, Ind PW. The effect of prolonged submaximal warm-up exercise on exercise-induced asthma. *Am Rev Respir Dis* 1989;139(2):479-84.
6. Stark RD, Gambles SA, Chatterjee SS. An exercise test to assess clinical dyspnoea: estimation of reproducibility and sensitivity. *Br J Dis Chest* 1982;76(3):269-78.
7. Vilozni D, Bentur L, Efrati O, et al. Exercise challenge test in 3- to 6-year-old asthmatic children. *Chest* 2007;132(2):497-503.
8. Waffler-Kammermann N, Lacorcchia RS, Wettstein M, et al. A new standardized treadmill walking test requiring low motor skills in children aged 4-10 years. *Pediatr Pulmonol* 2008;43(2):187-95.

No Reference Standard (n = 21)

1. Bavarian B, Mehrkhani F, Ziaee V, et al. Sensitivity and specificity of self-reported symptoms for exercise-induced bronchospasm diagnosis in children. *Iran J Pediatr* 2009;19(1):47-51.
2. Capao-Filipe M, Moreira A, Delgado L, et al. Exercise-induced bronchoconstriction and respiratory symptoms in elite athletes. *Allergy* 2003;58(11):1196.
3. Choi IS, Chung SW, Koh YI, et al. Airway hyperresponsiveness to hypertonic saline as a predictive index of exercise-induced bronchoconstriction. *Korean J Intern Med* 2005;20(4):284-9.
4. De Fuccio MB, Nery LE, Malaguti C, et al. Clinical role of rapid-incremental tests in the evaluation of exercise-induced bronchoconstriction. *Chest* 2005;128(4):2435-42.
5. Drobnic F, Casan P, Banquells M, et al. Cough after exercise in the elite athlete. *Sports Med Train Rehabil* 1996;6(4):309-15.
6. Durand F, Kippelen P, Ceugniet F, et al. Undiagnosed exercise-induced bronchoconstriction in ski-mountaineers. *Int J Sports Med* 2005;26(3):233-7.
7. Erhabor GE, Awotedu AA, Balogun MO. Exercise induced bronchoconstriction in Nigerian asthmatics. *Afr J Med Med Sci* 1993;22(2):33-7.
8. Fernandez-Nieto M, Rodriguez-Nieto M, Aguado E, et al. Airway inflammation after mannitol challenge in elite athletes. *Allergy (Oxford)* 2009;64(Suppl 90):196.
9. Haby MM, Anderson SD, Peat JK, et al. An exercise challenge protocol for epidemiological studies of asthma in children: comparison with histamine challenge *Eur Respir J* 1994;7(1):43-9.
10. Hallstrand TS, Curtis JR, Koepsell TD, et al. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. *J Pediatr* 2002;141(3):343-8.
11. Hammerman SI, Becker JM, Rogers J, et al. Asthma screening of high school athletes: identifying the undiagnosed and poorly controlled. *Ann Allergy Asthma Immunol* 2002;88(4):380-4.
12. Kaynar H, Akgun M, Saglam L, et al. The prevalence of exercise-induced bronchoconstriction among symptomatic sportsmen. *Asian Pac J Allergy Immunol* 2004;22(4):191-6.
13. Koh YI, Choi IS, Lim H. Atopy may be related to exercise-induced bronchospasm in asthma. *Clin Exp Allergy* 2002;32(4):532-6.
14. Mannix ET, Manfredi F, Farber MO. A comparison of two challenge tests for identifying exercise-induced bronchospasm in figure skaters. *Chest* 1999;115(3):649-53.
15. Randolph C, Mattasavage C, Fraser B. Screening of high school athletes for exercise asthma by free running test. *J Allergy Clin Immunol* 1996;97(1 Pt 3):378.
16. Randolph C, Fraser B, Matasavage C. The free running athletic screening test as a screening test for exercise-induced asthma in high school. *Allergy Asthma Proc* 1997;18(2):93-8.
17. Rundell KW, Spiering BA, Evans TM, et al. Baseline lung function, exercise-induced bronchoconstriction, and asthma-like symptoms in elite women ice hockey players. *Med Sci Sports Exerc* 2004;36(3):405-10.
18. Rundell KW, Anderson SD, Spiering BA, et al. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. *Chest* 2004;125(3):909-15.
19. Spiering B, Rundell K, Anderson S, et al. Diagnosing exercise-induced bronchoconstriction in elite athletes: exercise vs. eucapnic voluntary hyperventilation [abstract]. *Med Sci Sports Exerc* 2003;35(5 Suppl):S10.
20. Stenfours N. A comparison of inhaled mannitol, metacholine provocation and eucapnic voluntary hyperventilation as diagnostic tests for exercised induced bronchoconstriction in cross country skiers [abstract]. *European Respiratory Society Annual Congress, Berlin, Germany, October 4-8 2008:P1094.*
21. Stensrud T, Mykland KV, Gabrielsen K, et al. Bronchial hyperresponsiveness in skiers: field test versus methacholine provocation? *Med Sci Sports Exerc* 2007;39(10):1681-6.

No Comparison (n = 46)

1. Identifying asthma in young athletes. *Phys Sportsmed* 1996;24(6):42i.
2. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. *Am J Respir Crit Care Med* 1997;156(3):758-65.
3. Arbour K, Provost-Craig M, Sestili D, et al. Incidence of exercise-induced asthma in figure skaters [abstract]. *Med Sci Sports Exerc* 1993;25(5 Suppl):S180.
4. Balla K, Mezei G, Gyene I, et al. The running fitness of young asthmatic patients. *Int Rev Allergol Clin Immunol* 2007;13(2-3):38-43.
5. Bierman CW, Spiro SG, Petheram I. Characterization of the late response in exercise-induced asthma. *J Allergy Clin Immunol* 1984;74(5):701-6.
6. Boner A, Niero E, Antolini I, et al. Biphasic (early and late) asthmatic responses to exercise in children with severe asthma, resident at high altitude. *Eur J Pediatr* 1985;144(2):164-6.
7. Braback L, Kalvesten L, Sundstrom G. Prevalence of bronchial asthma among schoolchildren in a Swedish district. *Acta Paediatr Scand* 1988;77(6):821-5.
8. Carlsen KH, Engh G, Mork M. Exercise-induced bronchoconstriction depends on exercise load. *Respir Med* 2000;94(8):750-5.
9. Dahlen B, O'Byrne PM, Watson RM, et al. The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements. *Eur Respir J* 2001;17(4):581-8.
10. Eggleston PA, Guerrant JL. A standardized method of evaluating exercise-induced asthma. *J Allergy Clin Immunol* 1976;58(3):414-25.
11. Estela D, Sienna-Monge J, de la Paz H. Determinate the sensitivity and specificity exercise challenge on forced expiratory volume 1 second in obese and non obese children compared with asthmatic children [abstract]. *J Allergy Clin Immunol* 2003;111(2 Suppl):S140.
12. Falcao H, Almeida S, Gomes E. Treadmill exercise test in children: difficulties and relevance. *Allergy (Oxford)* 2007;62(Suppl 83).
13. Feinstein RA, Hains CS, Hemstreet MP, et al. A simple "step-test" protocol for identifying suspected unrecognized exercise-induced asthma (EIA) in children. *Allergy Asthma Proc* 1999;20(3):181-8.
14. Field J, Allegra J, Trautlein J, et al. Evaluation of exercise-induced bronchospasm in the adult asthmatic. *J Allergy Clin Immunol* 1976;58(5):575-80.
15. Freeman W, Weir DC, Sapiano SB, et al. The twenty-metre shuttle-running test: a combined test for maximal oxygen uptake and exercise-induced asthma? *Respir Med* 1990;84(1):31-5.
16. Hagan J, Millward D, Paul S, et al. The diagnosis of exercise induced bronchospasm and asthma in NCAA Division I athletes. *Clin J Sport Med* 2008;18(2):186.
17. Inbar O, Winstein Y, Daskalovic Y, et al. The effect of prone immersion on bronchial responsiveness in children with asthma. *Med Sci Sports Exerc* 1993;25(10):1098-102.
18. Jones NL. New tests to assess lung function. Exercise testing in pulmonary evaluation: clinical applications. *New Engl J Med* 1975;293(13):647-50.
19. Kable S, Henry R, Sanson-Fisher R, et al. Childhood asthma: can computers aid detection in general practice? *Br J Gen Pract* 2001;51(463):112-6.
20. Kannisto S, Korppi M. Bronchial lability index in the diagnosis of asthma in children. *Pediatr Asthma Allergy Immunol* 1999;13(3):141-8.
21. Kannisto S, Vanninen E, Remes K, et al. Interrupter technique for evaluation of exercise-induced bronchospasm in children. *Pediatr Pulmonol* 1999;27(3):203-7.
22. Kippelen P, Caillaud C, Coste O, et al. Asthma and exercise-induced bronchoconstriction in amateur endurance-trained athletes. *Int J Sports Med* 2004;25(2):130-2.
23. Kukafka DS, Lang DM, Porter S, et al. Exercise-induced bronchospasm in high school athletes via a free running test: incidence and epidemiology. *Chest* 1998;114(6):1613-22.
24. Lumme A, Haahtela T, Ounap J, et al. Airway inflammation, bronchial hyperresponsiveness and asthma in elite ice hockey players. *Eur Respir J* 2003;22(1):113-7.
25. Lumme A, Haahtela T, Ounap J, et al. Airway inflammation, bronchial hyperresponsiveness, and asthma in elite ice hockey players. *Med Sci Sports Exerc* 2003;35(5 Suppl).
26. Nicklaus TM, Burgin WW Jr., Taylor JR. Spirometric tests to diagnose suspected asthma. *Am Rev Respir Dis* 1969;100:153-9.

27. Nicolaescu VV, Bozianu E, Manicatide MA, et al. Value of exercise test for the detection of bronchial asthma during field surveys in children. *Rev Roum Med Intern* 1974;11(2):207-13.
28. Nowak D, Kuziek G, Jorres R, et al. Comparison of refractoriness after exercise- and hyperventilation-induced asthma. *Lung* 1991;169(2):57-67.
29. Ogston J, Butcher JD. A sport-specific protocol for diagnosing exercise-induced asthma in cross-country skiers. *Clin J Sport Med* 2002;12(5):291-5.
30. Pearlman D, Anderson S, Charlton B, et al. Concordance of results from repeat exercise challenges. *J Allergy Clin Immunol* 2008;121(2 Suppl 1):S209.
31. Pierson WE, Bierman CW, Stamm SJ. Cycloergometer-induced bronchospasm. *J Allergy* 1969;43(3):136-44.
32. Pierson WE, Bierman CW. Free running test for exercise induced bronchospasm. *Pediatrics* 1975;56(5 Suppl):890-2.
33. Powell CV, White RD, Primhak RA. Longitudinal study of free running exercise challenge: reproducibility. *Arch Dis Child* 1996;74(2):108-14.
34. Rodriguez CH, Pimm PE, Shephard RJ, et al. Use of isovolume flow curves in the detection of exercise-induced bronchospasm. *Respiration* 1981;41(2):82-9.
35. Rosenthal RR, Laube BL, Jaeger JJ, et al. Methacholine sensitivity is unchanged during the refractory period following an exercise or isocapnic challenge. *Am Rev Respir Dis* 1984;129(4 Suppl):A250.
36. Rundell KW, Im J, Mayers LB, et al. Self-reported symptoms and exercise-induced asthma in the elite athlete. *Med Sci Sports Exerc* 2001;33(2):208-13.
37. Rupp NT, Brudno DS, Wagner JM, et al. Correlation of spirometric measures in the diagnosis of exercise induced asthma. *J Allergy Clin Immunol* 1992;89(1):232.
38. Schachter EN, Kreisman H, Littner M, et al. Airway responses to exercise in mild asthmatics. *J Allergy Clin Immunol* 1978;61(6):390-8.
39. Scott GC, Kung M, Nsari SJ. The reproducibility of paired spirometry following exercise-induced bronchoconstriction. *Chest* 1986;89(6 Suppl):499S.
40. Tsanakas JN, Milner RD, Bannister OM, et al. Free running asthma screening test. *Arch Dis Child* 1988;63(3):261-5.
41. Turcotte H, Langdeau JB, Bowie DM, et al. Are questionnaires on respiratory symptoms reliable predictors of airway hyperresponsiveness in athletes and sedentary subjects? *J Asthma* 2003;40(1):71-80.
42. Vacek L. Incidence of exercise-induced asthma in high school population in British Columbia. *Allergy Asthma Proc* 1997;18(2):89-91.
43. Varga EM, Eber E, Zach MS. Cold air challenge for measuring airway reactivity in children: lack of a late asthmatic reaction. *Lung* 1990;168(5):267-72.
44. Vichyanond P, Anuraklekha P, Ruengruk S. Exercise-induced asthma among Thai asthmatic children. *J Med Assoc Thailand* 2002;85(Suppl 2):S579-S585.
45. Wagner JM, Rupp NT, Brudno DS, et al. Length of post-exercise assessment in the determination of exercise induced asthma. *J Allergy Clin Immunol* 1992;89(1 Pt 2):233.
46. Williams D, Bruton J, Wilson I. Screening a state middle school for asthma using the free running asthma screening test. *Arch Dis Child* 1993;69(6):667-9.

Did Not Diagnose EIA/EIB (n = 158)

1. Ahad A, Sandila MP, Siddiqui NA, et al. Exercise-induced bronchospasm in male athletes at Karachi. *J Ayub Med Coll Abbottabad* 2003;15(4):29-33.
2. Ahad A, Sandila MP, Siddiqui NA. Prevalence of exercise-induced bronchospasm in national hockey players of Pakistan. *J Pak Med Assoc* 2004;54(2):96-9. Erratum in: *J Pak Med Assoc*. 2004 Apr;54(4):231
3. Amin R, Faezi A, Kashef S, et al. Assessment of exercise induced asthma in asthmatic children. *Allergy (Oxford)* 2009;64(Suppl. 90).
4. Amirav I, Dowdeswell R, Webster T, et al. Exercise, regardless of induced bronchoconstriction or inspired air conditions, does not alter airway reactivity. *Chest* 1993;104(1):171-4.
5. Anderson SD, McEvoy JD, Bianco S. Changes in lung volumes and airway resistance after exercise in asthmatic subjects. *Am Rev Respir Dis* 1972;106(1):30-7.
6. Anderson SD, Schoeffel RE. Respiratory heat and water loss during exercise in patients with asthma. Effect of repeated exercise challenge. *Eur J Respir Dis* 1982;63(5):472-80.
7. Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. *J Allergy Clin Immunol* 2003;111(1):45-50.
8. Argyros GJ, Roach JM, Hurwitz KM, et al. The refractory period after eucapnic voluntary hyperventilation challenge and its effect on challenge technique. *Chest* 1995;108(2):419-24.
9. Avital A, Springer C, Bar-Yishay E, et al. Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. *Thorax* 1995;50(5):511-6.
10. Barnes PJ, Brown MJ, Silverman M, et al. Circulating catecholamines in exercise and hyperventilation induced asthma. *Thorax* 1981;36(6):435-40.
11. Barnes PJ, Brown MJ. Venous plasma histamine in exercise- and hyperventilation-induced asthma in man. *Clin Sci* 1981;61(2):159-62.
12. Ben Dov I, Amirav I, Shochina M, et al. Effect of negative ionisation of inspired air on the response of asthmatic children to exercise and inhaled histamine. *Thorax* 1983;38(8):584-8.
13. Ben Dov I, Gur I, Bar-Yishay E, et al. Refractory period following induced asthma: contributions of exercise and isocapnic hyperventilation. *Thorax* 1983;38(11):849-53.
14. Berkman N, Avital A, Breuer R, et al. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. *Thorax* 2005;60(5):383-8.
15. Berto JM, Lopez C, Pina JM, et al. Lung function and bronchial response to methacholine in young adults who had asthma in childhood. *Ann Allergy* 1993;70(1):40-3.
16. Bhagat RG, Grunstein MM. Comparison of responsiveness to methacholine, histamine, and exercise in subgroups of asthmatic children. *Am Rev Respir Dis* 1984;129(2):221-4.
17. Bollinger MB. A school-based case identification process for identifying inner city children with asthma: The Breathmobile program. *Pediatrics* 2005;116(2):560-1.
18. Bolme P, Eriksson M, Freyschuss U, et al. The effects of pharmacological treatment on pulmonary function in children with exercise-induced asthma. *Acta Paediatr Scand* 1980 Mar;69(2):165-72.
19. Bonini M, Lapucci G, Petrelli G, et al. Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. *Allergy* 2007;62(10):1166-70.
20. Boulet LP, Turcotte H. Comparative effects of hyperosmolar saline inhalation and exercise in asthma. *Immunol Allergy Pract* 1989;11(3):23-30.
21. Boulet LP, Morin D, Turcotte H. Variations of airway responsiveness to methacholine and exercise in asthmatic and normal subjects over a 12-month period. *Clin Invest Med* 1990;13(2):60-6.
22. Bremberg SG, Kjellman NIM. Children with asthma: how do they get along at school. *Acta Paediatr Scand* 1985;74(6):833-40.
23. Buckley JM, Souhrada JF. A comparison of pulmonary function tests in detecting exercise induced bronchoconstriction. *Pediatrics* 1975;56(5 Suppl):883-9.
24. Buckley JM, Souhrada JF, Kopetzky MT. Detection of airway obstruction in exercise-induced asthma. *Chest* 1974;66(3):244-51.
25. Burr ML, Eldridge BA, Borysiewicz LK. Peak expiratory flow rates before and after exercise in schoolchildren. *Arch Dis Child* 1974;49(12):923-6.

26. Carlsen KH, Engh G, Mork M, et al. Cold air inhalation and exercise-induced bronchoconstriction in relationship to metacholine bronchial responsiveness: different patterns in asthmatic children and children with other chronic lung diseases. *Respir Med* 1998;92(2):308-15.
27. Carlsten C, Aitken ML, Hallstrand TS. Safety of sputum induction with hypertonic saline solution in exercise-induced bronchoconstriction. *Chest* 2007;131(5):1339-44.
28. Chai H, Purcell K, Brady K, et al. Therapeutic and investiatinal evaluation of asthmatic children. *J Allergy* 1968;41(1):23-36.
29. Corris PA, Nariman S, Gibson GJ. Nifedipine in the prevention of asthma induced by exercise and histamine. *Am Rev Respir Dis* 1983;128(6):991-2.
30. Cox AJ, Gleeson M, Pyne DB, et al. Clinical and laboratory evaluation of upper respiratory symptoms in elite athletes. *Clin J Sport Med* 2008;18(5):438-45.
31. Daga MK, Ahuja VM, Bajaj SK, et al. Bronchial responsiveness in normal first-degree relatives of asthmatics and patients of allergic rhinitis. *JIACM* 2007;8(1):36-41.
32. De Baets F, Bodart E, Dramaix-Wilmet M, et al. Exercise-induced respiratory symptoms are poor predictors of bronchoconstriction. *Pediatr Pulmonol* 2005;39(4):301-5.
33. Demissie K, White N, Joseph L, et al. Bayesian estimation of asthma prevalence, and comparison of exercise and questionnaire diagnostics in the absence of a gold standard. *Ann Epidemiol* 1998;8(3):201-8.
34. Elbiaze M, Rahimi H, El ghazi K, et al. Exercise induced asthma in schoolchildren of Fes city (Morroco) [abstract]. *Allergy (Oxford)* 2008;63(Suppl 88):P184.
35. Erhabor GE, Adedoyin RA, Abayomi SO, et al. Evaluation of energy expenditure using three different exercise protocols in asthmatic subjects. *Fizyoterapi Rehabilitasyon* 2004;15(2):55-60.
36. Evans TM, Rundell KW, Beck KC, et al. Cold air inhalation does not affect the severity of EIB after exercise or eucapnic voluntary hyperventilation. *Med Sci Sports Exerc* 2005;37(4):544-9.
37. Fallon K. Commentary. *Br J Sports Med* 2007;41(10):695.
38. Feyilola AO, Erhabor GE, Osagbenworhue OD, et al. Exercise-induced asthma in Nigerian adults: a comparison between step test, free running, and bicycle ergometer [abstract]. *Chest* 2007;132(4 Suppl S):508S.
39. Finnerty JP, Polosa R, Holgate ST. Repeated exposure of asthmatic airways to inhaled adenosine 5'-monophosphate attenuates bronchoconstriction provoked by exercise. *J Allergy Clin Immunol* 1990;86(3 Pt 1):353-9.
40. Fitch KD, Morton AR. Specificity of exercise in exercise-induced asthma. *Br Med J* 1971;4(5787):577-81.
41. Foucard T, Sjoberg O. A prospective 12-year follow-up study of children with wheezy bronchitis. *Acta Paediatr Scand* 1984;73(5):577-83.
42. Freedman S, Lane R, Gillett MK, et al. Abolition of methacholine induced bronchoconstriction by the hyperventilation of exercise or volition. *Thorax* 1988;43(8):631-6.
43. Frischer T, Meinert R, Urbanek R, et al. Bronchial response to exercise in a cohort of primary school children: a longitudinal study. *Eur Respir J* 1994;7(Suppl 18):124S.
44. Frischer T, Kuhr J, Meinert R, et al. Relation between response to exercise and diurnal variability of peak expiratory flow in primary school children. *Thorax* 1993;48(3):249-53.
45. Fruchter O, Yigla M. Response to bronchodilators after exercise challenge predicts bronchial hyperreactivity. *J Asthma* 2008;45(5):353-6.
46. Game AB, Voaklander D, Syrotuik DG, et al. Incidence of exercise-induced bronchospasm and exercise-induced hypoxaemia in female varsity hockey players. *Res Sports Med* 2003;11(1):11-21.
47. Gauvreau GM, Ronnen GM, Watson RM, et al. Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma. *Am J Respir Crit Care Med* 2000;162(4):1302-7.
48. Gerald LB, Redden D, Turner-Henson A, et al. A multi-stage asthma screening procedure for elementary school children. *J Asthma* 2002;39(1):29-36.
49. Godfrey S, Springer C, Noviski N, et al. Exercise but not methacholine differentiates asthma from chronic lung disease in children. *Thorax* 1991;46(7):488-92.
50. Golish JA. The BODE index predicted death in chronic obstructivepulmonary disease. *ACP Journal Club* 2004;141(2):53.
51. Granerus G, Simonsson BG, Skoogh BE, et al. Exercise-induced bronchoconstriction and histamine release. *Scand J Respir Dis* 1971;52(3):131-6.
52. Gruchalla RS, Gan V, Roy L, et al. Results of an inner-city school-based asthma and allergy screening pilot study: a combined approach using written questionnaires and step testing. *Ann Allergy Asthma Immunol* 2003;90(5):491-9.

53. Gursel G, Turktas H. Air trapping as a predictor of exercise induced asthma. *Eur Respir J Suppl* 1996;9(23):82S.
54. Haas F, Pasierski S, Levine N, et al. Effect of aerobic training on forced expiratory airflow in exercising asthmatic humans. *J Appl Physiol* 1987;63(3):1230-5.
55. Haas F, Haas A. Maximum expiratory flow volume curves in the diagnosis of exercise induced broncho spasm. *Physiologist* 1981;24(4):29.
56. Haas F, Axen K, Pineda H, et al. Relative sensitivities of a step-wise exercise protocol and a fixed work load protocol in provoking exercise-induced bronchospasm. *Am Rev Respir Dis* 1982;125(4):251.
57. Hahn AG, Nogrady SG, Tumilty DM, et al. The role of histamine depletion in the refractory period after exercise-induced asthma. *Aust N Z J Med* 1984;14(4 Suppl 2):540-1.
58. Hamielec CM, Manning PJ, O'Byrne PM. Airway responsiveness to methacholine and histamine during the refractory period following exercise-induced asthma. *Am Rev Respir Dis* 1987;135(4 Pt 2):A314.
59. Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. *Am J Respir Crit Care Med* 2002;165(8):1068-70.
60. Haugaard L, Iversen M, Dahl R. A comparative study of four different bronchial challenge tests. *Allergy* 1992;47(2):138-42.
61. Haverkamp H, Dempsey J, Miller J, et al. Repeat exercise normalizes the gas-exchange impairment induced by a previous exercise bout in asthmatic subjects. *J Appl Physiol* 2005;99(5):1843-52.
62. Heaton RW, Henderson AF, Costello JF. Cold air as a bronchial provocation technique. Reproducibility and comparison with histamine and methacholine inhalation. *Chest* 1984;86(6):810-4.
63. Hedlin G, Freyschuss U. Cardiac output and blood pressure in asthmatic children before and during induced asthma. *Acta Paediatr Scand* 1984;73(4):441-7.
64. Henriksen JM, Nielsen TT. Effect of physical training on exercise-induced bronchoconstriction. *Acta Paediatr Scand* 1983 Jan;72(1):31-6.
65. Higenbottam T, Stokes T, Jamieson S, et al. A comparison of exercise, hyperventilation with cold air and warm air, and the inhalation of "fog" in the provocation of asthma. *Eur J Respir Dis Suppl* 1983;128(Pt 2):421-3.
66. Inbar O, Alvarez D, X, Lyons HA. Exercise induced asthma: a comparison between 2 modes of exercise stress. *Eur J Respir Dis* 1981;62(3):160-7.
67. Inman MD, Watson RM, Killian KJ, et al. Methacholine airway responsiveness decreases during exercise in asthmatic subjects. *Am Rev Respir Dis* 1990;141(6):1414-7.
68. Joerres R, Boerger S, Voigt P, et al. Influence of 0.25 ppm nitrogen dioxide on exercise-induced bronchoconstriction and airway responsiveness to methacholine in asymptomatic asthmatics. *Am Rev Respir Dis* 1988;137(4 Pt 2):168.
69. Jones RS. Clinical value of exercise tests in childhood asthma. *Thorax* 1970;25(2):258.
70. Joyner BL, Fiorino EK, Matta-Arroyo E, et al. Cardiopulmonary exercise testing in children and adolescents with asthma who report symptoms of exercise-induced bronchoconstriction. *J Asthma* 2006;43(9):675-8.
71. Katz I, Moshe S, Levin M, et al. Does exercise cause asthma? *Occup Med* 2008;58(7):480-4.
72. Kiers A, Van der Mark TW, Woldring MG, et al. Changes in functional residual capacity during exercise in patients with exercise-induced asthma. *Bull Eur Physiopathol Respir* 1981;17(6):869-78.
73. Killian KJ, Summers E, Watson RM, et al. Factors contributing to dyspnoea during bronchoconstriction and exercise in asthmatic subjects. *Eur Respir J* 1993;6(7):1004-10.
74. Kinnula VL, Sovijarvi AR. Hyperventilation during exercise: independence on exercise-induced bronchoconstriction in mild asthma. *Respir Med* 1996;90(3):145-51.
75. Kivity S, Argaman A, Onn A, et al. Eosinophil influx into the airways in patients with exercise-induced asthma. *Respir Med* 2000;94(12):1200-5.
76. Kivity S, Solomon A, Schwarz Y, et al. Evaluation of asymptomatic subjects with low forced expiratory ratios (FEV1/VC). *Thorax* 1994;49(6):554-6.
77. Knopfli BH, Luke-Zeitoun M, Von Duvillard SP, et al. High incidence of exercise-induced bronchoconstriction in triathletes of the Swiss national team. *Br J Sports Med* 2007;41(8):486-91.
78. Kobayashi H, Minoguchi K, Kohno Y, et al. Exercise challenge in patients with asthma whose peak expiratory flow values are controlled within the green zone. *Allergol Int* 1999;48(2):145-8.
79. Kojima N, Takeda Y, Akashi M, et al. Educational asthma summer camp including exercise challenge test improved adherence [abstract]. *J Allergy Clin Immunol* 2007;119(1 Suppl 1):S286.
80. Koskela HO, Hyvarinen L, Brannan JD, et al. Responsiveness to three bronchial provocation tests in patients with asthma. *Chest* 2003;124(6):2171-7.

81. Koskela HO, Rasanen SH, Tukiainen HO. The diagnostic value of cold air hyperventilation in adults with suspected asthma. *Respir Med* 1997;91(8):470-8.
82. Lara M, Duan N, Sherbourne C, et al. Differences between child and parent reports of symptoms among Latino children with asthma. *Pediatrics* 1998;102(6):E68.
83. Lazo-Velasquez JC, Lozada AR, Cruz HM. Evaluation of severity of bronchial asthma through an exercise bronchial challenge. *Pediatr Pulmonol* 2005;40(5):457-63. Erratum in: *Pediatr Pulmonol* 2006;41(1):102.
84. Lee C, Corren J. Effects of nasal allergen challenge upon airway responsiveness to exercise [abstract]. *J Allergy Clin Immunol* 2008;121(2 Suppl 1):S260.
85. Lee SY, Kim HB, Kim JH, et al. Eosinophils play a major role in the severity of exercise-induced bronchoconstriction in children with asthma. *Pediatr Pulmonol* 2006;41(12):1161-6.
86. Magnussen H, Reuss G, Jorres R. Airway response to methacholine during exercise induced refractoriness in asthma. *Thorax* 1986;41(9):667-70.
87. Makker HK, Walls AF, Goulding D, et al. Airway effects of local challenge with hypertonic saline in exercise-induced asthma. *Am J Respir Crit Care Med* 1994;149(4):1012-9.
88. Makker HK, Holgate ST. Hypertonic saline responsiveness relates to exercise-induced asthma symptoms rather than to histamine or methacholine reactivity. *Am Rev Respir Dis* 1992;145(4 Pt 2):A730.
89. Makker HK, Carroll M, Gratziau C, et al. Local endobronchial hypertonic challenge in patients with exercise-induced asthma. *Am Rev Respir Dis* 1992;145(4 Pt 2):A729.
90. Mashalane MB, Stewart A, Feldman C, et al. Prevalence of exercise-induced bronchospasm in Thokoza school children. *S Afr Med J* 2006;96(1):67-70.
91. Mays W, Knecht SK, Forment YM, et al. Age specific treadmill protocol for the evaluation of exercise induced bronchospasm (EIB) in pediatric patients. *Med Sci Sports Exerc* 2004;36(5 Suppl S):S209-S210.
92. Mcfadden ER Jr., Stearns DR, Ingram RH Jr., et al. Relative contributions of hypocarbia and hyperpnea as mechanisms in postexercise asthma. *J Appl Physiol* 1977;42(1):22-7.
93. McNeill RS, Nairn JR, Millar JS, et al. Exercise-induced asthma. *Q J Med* 1966;35(137):55-67.
94. Mihalyka M, Wong J, James AL, et al. The effect on airway function of inspired air conditions after isocapnic hyperventilation with dry air. *J Allergy Clin Immunol* 1988;82(5):842-8.
95. Mildon A, Leroux M, Hutcheon M, et al. The site of airways obstruction in exercise-induced asthma. *Am Rev Respir Dis* 1974;110(4):409-14.
96. Mirav I, Plit M. Airway response to inhaled histamine in asthmatic children 40-60 minutes after exercise. *Am Rev Respir Dis* 1988;137(4 Pt 2):336.
97. Molis WE, Bagniewski S, Weaver AL, et al. Timeliness of diagnosis of asthma in children and its predictors. *Allergy* 2008;63(11):1529-35.
98. Morton AR, Lawrence SR, Fitch KD, et al. Duration of exercise in the provocation of exercise-induced asthma. *Ann Allergy* 1983;51(5):530-4.
99. Morton AR, Fitch KD, Davis T. The effect of "warm-up" on exercise-induced asthma. *Ann Allergy* 1979;42(4):257-60.
100. Munoz PA, Gomez FP, Manrique HA, et al. Pulmonary gas exchange response to exercise. *J Appl Physiol* 2008;105(5):1477-85.
101. Nagakura T, Obata T, Shichijo K, et al. GC/MS analysis of urinary excretion of 9alpha, 11beta-PGF2 in acute and exercise-induced asthma in children. *Clin Exp Allergy* 1998;28(2):181-6.
102. Nichols DJ, Longsworth FG. Prevalence of exercise-induced asthma in schoolchildren in Kingston, St. Andrew and St. Catherine, Jamaica. *West Indian Med J* 1995;44(1):16-9.
103. Nickerson BG, Bautista DB, Namey MA, et al. Running improves fitness in asthmatic children without changing airway reactivity or ventilatory muscle function. *Clin Res* 1981;29(1):149A.
104. Ninan TK, Russell G. Is exercise testing useful in a community based asthma survey? *Thorax* 1993;48(12):1218-21.
105. Nishio K, Odajima H, Motomura C, et al. Exhaled nitric oxide and exercise-induced bronchospasm assessed by FEV1, FEF 25-75% in childhood asthma. *J Asthma* 2007;44(6):475-8.
106. Nowak D, Templin K, Jorres R, et al. Comparison of airway responsiveness to prostaglandin D2 and histamine, methacholine or exercise in healthy and asthmatic subjects. *Ann New York Acad Sci* 1991;629:442-5.
107. Nowak D, Jorres R, Magnussen H. Influence of exercise-induced bronchoconstriction on refractoriness. *Lung* 1992;170(2):75-84.
108. Nystad W, Stensrud T, Magnus P, et al. The association between BHR measured by metacholine and exercise challenge and their relation to atopy in school children. *Eur Respir J Suppl* 1997;10(25):344S.
109. Patricio L, Quarema R, Didenko I, et al. Exercise induced-asthma in high school adolescents from Setubal. *Allergy (Oxford)* 2007;62(Suppl 83):423-4.

110. Pedersen R. Use of exhaled nitric oxide (eNO) as a marker for anti-inflammatory dose response of beclomethasone extrafine aerosol (Q) dosed once daily (50-100ug) in children with exercise induced asthma [abstract]. *Eur Respir J* 2003;(Suppl)..
111. Pedrosa M, Botello M, Caminoa M, et al. Comparative study between bronchial challenges with methacholine and adenosine in asthma diagnosis [abstract]. *J Allergy Clin Immunol* 2009;123(2 Suppl S):S206.
112. Pohjantahti H, Laitinen J, Parkkari J. Exercise-induced bronchospasm among healthy elite cross country skiers and non-athletic students. *Scand J Med Sci Sports* 2005;15(5):324-8.
113. Porsbjerg C, Rasmussen L, Thomsen SF, et al. Response to mannitol in asymptomatic subjects with airway hyper-responsiveness to methacholine. *Clin Exp Allergy* 2007;37(1):22-8.
114. Poswell C, V, Primhak R. Longitudinal study of free running exercise testing: is it a reproducible screening test for undiagnosed asthma? *Eur Respir J* 1994;7(Suppl 18):124A.
115. Potts JE. Adverse respiratory health effects of competitive swimming: the prevalence of symptoms, illnesses, and bronchial responsiveness to methacholine and exercise [dissertation]. University of British Columbia (Canada); 1994.
116. Quigley PM, Browning IB, Muelenaer AA, et al. The relationship of desaturation to exercise induced bronchospasm in a pediatric population. *Am Rev Respir Dis* 1989;139(4 Pt 2):A594.
117. Ragan J, King T. Exercise-induced hyperresponsiveness to methacholine: is it asthma. *Am Rev Respir Dis* 1988;137(4 Pt 2):510.
118. Riccioni G, D'Orazio N, Di Ilio C, et al. Bronchial hyperresponsiveness and quality of life in asthmatics. *Respiration* 2003;70(5):496-9.
119. Rice SG, Bierman CW, Shapiro GG, et al. Identification of exercise-induced asthma among intercollegiate athletes. *Ann Allergy* 1985;55(6):790-3.
120. Roecker K, Wolters R, Niess A, et al. Uncontrolled expiratory peak-flow during intensive exercise in cold air: diagnostic criterion for exercise-induced asthma? [abstract]. *Med Sci Sports Exerc* 2002;34(5 Suppl):S52.
121. Rosenthal RR, Laube BL, Hood DB, et al. Analysis of refractory period after exercise and eucapnic voluntary hyperventilation challenge. *Am Rev Respir Dis* 1990;141(2):368-72.
122. Rundell K, Im J, Wilber R, et al. Mid expiratory flow rates of cold weather athletes with exercise-induced asthma. *Med Sci Sports Exerc* 2001;33(5 Suppl):512.
123. Salazar-Schicchi J, Reggiani JL, Haas F, et al. Maximum expiratory flow-volume (MEFV) curves in the diagnosis of exercise-induced bronchospasm (EIB). *Am Rev Respir Dis* 1990;141(4 Pt 2):A221.
124. Sanchez AAS, Gerald A, Jiao Q, et al. The relationship of forced expiratory volume in one second and maximum mid-expiratory flow rate in the diagnosis of exercise induced asthma [abstract]. *Chest* 2005;128(4):188S.
125. Sandsund M, Reinertsen RE, Holand B, et al. Thermoregulatory and respiratory responses in asthmatic and nonasthmatic subjects breathing cold and warm air during exercise in the cold. *J Therm Biol* 2007;32(5):246-54.
126. Schoeffel RE, Anderson SD, Gillam I, et al. Multiple exercise and histamine challenge in asthmatic patients. *Thorax* 1980;35(3):164-70.
127. Schoene RB, Giboney K, Schimmel C, et al. Spirometry and airway reactivity in elite track and field athletes. *Clin J Sport Med* 1997;7(4):257-61.
128. Schwindt CD, Zaldivar F, Nemet D, et al. Leukocyte profiles during and after exercise challenge in asthmatic children [abstract]. *Med Sci Sports Exerc* 2004;36(5 Suppl S):S150.
129. Scollo M, Zanconato S, Ongaro R, et al. Exhaled nitric oxide and exercise-induced bronchoconstriction in asthmatic children. *Am J Respir Crit Care Med* 2000;161(3):1047-50.
130. Shin HW, Schwindt CD, Aledia AS, et al. Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry. *Am J Physiol Regul Integr Comp Physiol* 2006;291(6):R1741-8.
131. Shin Y, Lee Y, Jung Y, et al. Exercise challenge test in relation to methacholine challenge test in young asthmatics [abstract]. *J Allergy Clin Immunol* 2008;121(2 Suppl 1):S78.
132. Silverman M, Anderson SD. Standardization of exercise tests in asthmatic children. *Arch Dis Child* 1972;47(256):882-9.
133. Skadberg B, Halvorsen T, Heimdal JH, et al. Exercise induces stridor - visualising the problem [abstract]. *Rev Port Cien Desp* 2003;3(2):53-4.
134. Smeeton NC, Rona RJ, Oyarzun M, et al. Agreement between responses to a standardized asthma questionnaire and a questionnaire following a demonstration of asthma symptoms in adults. *Am J Epidemiol* 2006;163(4):384-91.
135. Smith CM, Anderson SD. Inhalational challenge using hypertonic saline in asthmatic subjects: a comparison with responses to hyperpnoea, methacholine and water. *Eur Respir J* 1990;3(2):144-51.

136. Soferman R, Kivity S, Marcus B, et al. Comparison between bronchial response to inhaled hypoosmolar and isoosmolar solutions of sodium cromoglycate after exercise challenge. *Ann Allergy* 1990;64(2 Pt 1):143-6.
137. Soifer MM, Barboriak JJ, Chyssanthopoulos C, et al. Metabolic changes in exercise-induced and methacholine-induced bronchoconstriction. *J Allergy Clin Immunol* 1976;57(6):576-81.
138. Song DJ, Woo CH, Kang H, et al. Applicability of interrupter resistance measurements for evaluation of exercise-induced bronchoconstriction in children. *Pediatr Pulmonol* 2006;41(3):228-33.
139. Spada E, Donner CF, Meriggi A, et al. The exercise broncho provocation test: 2 different procedures in treadmill running challenge. *Clin Respir Physiol* 1982;18(Suppl 4):233-8.
140. Stensrud T, Berntsen S, Carlsen KH. Exercise capacity and exercise-induced bronchoconstriction (EIB) in a cold environment. *Respir Med* 2007;101(7):1529-36.
141. Stensrud T. Maximal oxygen uptake testing, a comparison of two test protocols [abstract]. *Proc Am Thorac Soc* 2005;2(Abstracts Issue):B65.
142. Sudhir P, Prasad CE. Prevalence of exercise-induced bronchospasm in schoolchildren: an urban-rural comparison. *J Trop Pediatr* 2003;49(2):104-8.
143. Sue-Chu M, Henriksen AH, Bjermer L. Non-invasive evaluation of lower airway inflammation in hyper-responsive elite cross-country skiers and asthmatics. *Respir Med* 1999;93(10):719-25.
144. Sue-Chu M, Bjermer L. Non invasive estimation of bronchial inflammation in "skiers asthma". *Eur Respir J* 1997;10(Suppl 25):10S.
145. Sukanich A, Osterhus N, Fireman P. One mile run asthma screening in school children. *J Allergy Clin Immunol* 1999;103(1 Pt 2):S10.
146. Suzuki S, Chonan T, Sasaki H, et al. Time-course of response in exercise-induced bronchoconstriction. *Ann Allergy* 1984;53(4):341-6.
147. Svenonius E, Kautto R, Arborelius M Jr. Improvement after training of children with exercise-induced asthma. *Acta Paediatr Scand* 1983;72(1):23-30.
148. Szczeklik A, Sanak M, Nizankowska E, et al. Provocation tests in asthma: relationship between urinary cysteinyl-leukotrienes response and leukotriene C4 synthase genetic polymorphism. *Eur Respir J* 1998;12(Suppl 29):71S.
149. Tateishi K, Motojima S, Kushima A, et al. Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. *Ann Allergy Asthma Immunol* 1996;77(3):229-37.
150. Taylor IK, Wellings R, Taylor GW, et al. Urinary leukotriene E4 excretion in exercise-induced asthma. *J Appl Physiol* 1992;73(2):743-8.
151. Wekesa M, Langhof H, Sack P. The asthma six-minute provocation test and mountain climbing in children. *East Afr Med J* 1994;71(1):51-4.
152. West JV, Robertson CF, Roberts R, et al. Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys. *Thorax* 1996;51(6):590-5.
153. Wilson BA, Evans JN. Standardization of work intensity for evaluation of exercise-induced bronchoconstriction. *Eur J Appl Physiol* 1981;47(3):289-94.
154. Wrzyszc M, Medrala W, Liebhart E, et al. Serum eosinophil cationic protein concentration in patients with exercise-induced asthma. *Int Rev Allergol Clin Immunol* 1996;2(3):89-92.
155. Young YK, Hyung SL, Kyung UM. Airway responsiveness to allergen is increased 24 hours after exercise challenge. *J Allergy Clin Immunol* 1994;94(3):507-16.
156. Zhang L, Liang YJ, Lei H, et al. Evaluation of exercise response in asthmatics: impulse oscillometry in measurement of respiratory impedance. *J Clin Rehabilitative Tissue Eng Research* 2007;11(31):6311-4.
157. Zielinski J, Chodosowska E, Radomyski A. Plasma catecholamines during exercise-induced bronchoconstriction in bronchial asthma. *Thorax* 1980;35(11):823-7.
158. Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, et al. Changes in RANTES and beta-thromboglobulin after intensive exercise in patients with allergic asthma. *Int Arch Allergy Immunol* 2008;148(1):31-40.

Insufficient Data (n = 26)

1. Anderson S, Brannan J, Koskela H, et al. Inhaled mannitol: a bronchial provocation test (BPT) to identify exercise-induced bronchoconstriction (EIB). *J Allergy Clin Immunol* 1998;101(1 Pt 2):S117.
2. Arias IJ. Mild to moderate asthmatics and free running. *J Investig Allergol Clin Immunol* 1999;9(1):50-4.
3. Boner AL, Sette L, Piacentini G, et al. Exercise-induced biphasic responses and methacholine reactivity in asthma. *Ann Allergy* 1990;65(4):284-6.
4. Brown LL, Martin BL, Morris MJ. Airway hyperresponsiveness by methacholine challenge testing following negative exercise challenge. *J Asthma* 2004;41(5):553-8.
5. Brown LL, Martin BL, Morris MJ. Airway hyperresponsiveness in methacholine challenge following negative exercise challenge. *J Allergy Clin Immunol* 2001;107(2):S303.
6. Charpin-Kadouch C, Ercoli J, Quralt J, et al. Is spirometry a better tool than measurement of peak flow for monitoring a run-test for screening exercise-induced asthma? *J Allergy Clin Immunol* 2007;119(1 Suppl 1):S89.
7. Chmelik F. The degree of exercised induced asthma EIA comparing eucapnic voluntary hyperventilation EVH vs treadmill exercise TM. *Ann Allergy* 1990;64:82.
8. Dor A. Comparison of exercise and histamine provocation tests in patients with bronchial asthma. *Pneumonol Alergol Pol* 2009;67(1-2):22-7.
9. Eggleston PA. The cycloergometer as a system for studying exercise-induced asthma. *Pediatrics* 1975;56(5 Pt 2 Suppl):899-903.
10. Evans TM, Rundell KW, Beck KC, et al. Impulse oscillometry is sensitive to bronchoconstriction after eucapnic voluntary hyperventilation or exercise. *J Asthma* 2006;43(1):49-55.
11. Horie T, Enomoto S, Inazawa T, et al. Bronchial hyper sensitivity in exercise induced asthma. *Jpn J Med* 1982;21(4):317.
12. Kivity S, Souhrada JF. Hyperpnea: the common stimulus for bronchospasm in asthma during exercise and voluntary isocapnic hyperpnea. *Respiration* 1980;40(4):169-77.
13. Koh YI, Choi S. Blood eosinophil counts for the prediction of the severity of exercise-induced bronchospasm in asthma. *Respir Med* 2002;96(2):120-5.
14. Lara ME, Sherbourne C, Halfon N, et al. Evaluating exercise induced symptoms in children with asthma: should we ask parents, children, or do peak flows? *J Invest Med* 1996;44(1):156A.
15. Martin-Vivaldi F, Fernandez E, Moreno R, et al. A comparison of two treadmill exercise tests for the diagnosis of exercise induced bronchospasm (EIB). *Eur Respir J* 1994;7(Suppl 18):326S.
16. Novoy HS, Wilson AF, Surprenant EL, et al. Early ventilation-perfusion changes in asthma. *J Allergy* 1970;46(4):221-30.
17. Panditi S, Silverman M. Perception of exercise induced asthma by children and their parents. *Arch Dis Child* 2003;88(9):807-11.
18. Pedersen L, Lund TK, Barnes PJ, et al. Airway responsiveness and inflammation in adolescent elite swimmers. *J Allergy Clin Immunol* 2008;122(2):322-7.
19. Pierson WE, Shapiro GG, Furukawa CT, et al. Methacholine sensitivity in allergic patients with and without exercise-induced bronchospasm. *J Allergy Clin Immunol* 1980;65(3):207.
20. Rosenthal RR, Laube B, Jaeger JJ, et al. Methacholine sensitivity is unchanged during the refractory period following an exercise or isocapnic challenge. *J Allergy Clin Immunol* 1984;73(1 Pt 2):179.
21. Rupp NT, Guill MF, Brudno DS, et al. The value of screening for risk of exercised induced asthma in high school athletes. *J Allergy Clin Immunol* 1991;87(1 Pt 2):165.
22. Seear M, Wensley D, West N. How accurate is the diagnosis of exercise induced asthma among Vancouver schoolchildren?. *Arch Dis Child* 2005;90(9):898-902.
23. Shapiro GG, Pierson WE, Furukawa CT, et al. A comparison of the effectiveness of free-running and treadmill exercise for assessing exercise-induced bronchospasm in clinical practice. *J Allergy Clin Immunol* 1979;64(6 Pt 2):609-11.
24. Shield S, Wang-Dohlman A. Incidence of exercise-induced bronchospasm (EIB) in high school football players. *J Allergy Clin Immunol* 1991;87(1 Pt 2):166.
25. Vecchio C, Donner CF, Ioli F, et al. Comparative study between free-running and a new treadmill running procedure in exercise bronchoprovocation challenge. *Respiration* 1984;46(Suppl 1):65.

26. Wiens L, Sabath R, Scagliotti D, et al. The frequency of exercise-induced asthma presenting as

chest pain in children. *J Allergy Clin Immunol* 1991;87(1 Pt 2):295.

Other Diagnostic Tests (n = 24)

1. Bar-Yishay E, Gur I, Inbar O, et al. Differences between swimming and running as stimuli for exercise-induced asthma. *Eur J Appl Physiol* 1982;48(3):387-97.
2. Buchvald F, Hermansen MN, Nielsen KG, et al. Exhaled nitric oxide predicts exercise-induced bronchoconstriction in asthmatic school children. *Chest* 2005;128(4):1964-7.
3. ElHalawani SM, Ly NT, Mahon RT, et al. Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. *Chest* 2003;124(2):639-43.
4. Feinstein RA, LaRussa J, Wang-Dohlman A, et al. Screening adolescent athletes for exercise-induced asthma. *Clin J Sport Med* 1996;6(2):119-23.
5. Holzer K, Anderson SD, Douglass J. Exercise in elite summer athletes: Challenges for diagnosis. *J Allergy Clin Immunol* 2002;110(3):374-80.
6. Holzer K, Anderson SD, Chan HK, et al. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. *Am J Respir Crit Care Med* 2003;167(4):534-7.
7. Holzer K, Anderson S, Douglass J. Methacholine has a low sensitivity to identify elite athletes with a positive response to eucapnic voluntary hyperpnea. *Med Sci Sports Exerc* 2002;34(5 Suppl).
8. Horie T, Enomoto S, Inazawa T, et al. Comparison of airway responsiveness to exercise and histamine inhalation in asthmatics. *Jpn J Med* 1983;22(1):26-30.
9. Hurwitz KM, Roach JM, Argyros GJ, et al. Refractory period during provocation with eucapnic hyperventilation and methacholine. *Am J Respir Crit Care Med* 1994;149(6):1452-6.
10. Inbar O, Dotan R, Dlin RA, et al. Breathing dry or humid air and exercise-induced asthma during swimming. *Eur J Appl Physiol* 1980;44(1):43-50.
11. Kilham H, Tooley M, Silverman M. Running, walking, and hyperventilation causing asthma in children. *Thorax* 1979;34(5):582-6.
12. LaRussa J, Feinstein R, Wang-Dohlman A. A simple exercise test to identify exercise induced bronchospasm in adolescent athletes. *Clin Res* 1992;40(4):775A.
13. Manning PJ, Watson RM, O'Byrne PM. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms. *Am Rev Respir Dis* 1993;148(4):950-4.
14. Mellis CM, Kattan M, Keens TG, et al. Comparative study of histamine and exercise challenges in asthmatic children. *Am Rev Respir Dis* 1978;117(5):911-5.
15. Patricio L, Didenko I, Campos L, et al. Detecting exercise-induced asthma using adenosine 5'-monophosphate or methacholine challenges [abstract]. *Allergy (Oxford)* 2008;63(Suppl 88):285.
16. Soferman R, Spierer Z, Topilsky M. Small airway responsiveness to exercise as an objective measure of exercise-induced asthma in children. *Pediatr Asthma Allergy Immunol* 2003;16(2):77-84.
17. Strauss RH, Haynes RL, Ingram RH Jr., et al. Comparison of arm versus leg work in induction of acute episodes of asthma. *J Appl Physiol* 1977;42(4):565-70.
18. Sylvester KP, O'Connor BJ, Farebrother HM, et al. Cold air and exercise challenge — influence of minute ventilation. *J Asthma* 2007;44(2):143-7.
19. Tancredi G, Quattrucci S, Scalercio F, et al. 3-min step test and treadmill exercise for evaluating exercise-induced asthma. *Eur Respir J* 2004;23(4):569-74.
20. Tweeddale PM, Godden DJ, Grant IW. Hyperventilation of exercise to induce asthma? *Thorax* 1981;36(8):596-8.
21. Van Den ELSH, Van HC, Molema J, et al. Exercise-induced bronchoconstriction (EIB) detected with the forced oscillation technique. *Am Rev Respir Dis* 1990;141(4 Pt 2):A834.
22. Webner D, Disabella V. Exercise-induced asthma (EIA): a diagnosis of inclusion? [abstract]. *Clin J Sport Med* 2005;15(4):281.
23. Young RP, Holst PE. A simple exercise test in assessment of asthma. *New Zealand Med J* 1988;101(854):600-1.
24. Zeballos RJ, Shturman-Ellstein R, McNally JF Jr., et al. The role of hyperventilation in exercise-induced bronchoconstriction. *Am Rev Respir Dis* 1978;118(5):877-84.

Duplicate Publication (n = 2)

1. Kiviloog J. The correlation between exercise induced bronchoconstriction and bronchial methacholine sensitivity in asthma. *Pediatrics* 1975;56(5 Suppl):908-9.
2. Kiviloog J. Variability of bronchial reactivity to exercise and metacholine in bronchial asthma. *Scand J Respir Dis* 1973;54(6):359-68.

Language (n = 1)

1. Varray A, Mercier J, Ramonatxo M, et al. L'exercice physique maximal chez l'enfant asthmatique: limitation aerobie et compensation anaerobie? *Science & Sports* 1989;4(3):199-207. French.

Unable to Retrieve (n = 10)

1. Ames J. Exercise induced bronchospasm. *Sports Med Clinic Newsletter* 1986;1-2.
2. Garfinkel SK, Kesten S, Chapman KR, Rebuck AS. Physiologic and nonphysiologic determinants of aerobic fitness in mild to moderate asthma. *Am Rev Respir Dis* 1992;145(4:Pt 1):741-5. Erratum in: *Am Rev Respir Dis* 1992;146(1):269.
3. Hay JM. Exercise induced asthma & the athlete. *Sports Physical Therapy Section* 1999;3.
4. Hoher K. Prevalence of exercise-induced bronchoconstriction (eib) in young athletes identified by eucapnic voluntary hyperpnea (evh). *Respirology* 2001;6(Suppl 1):A10.
5. Irnell L, Kiviloog J, Strom G. Variation of maximal expiratory flow at exercise test in patients with bronchial asthma. *Bronches* 1968;18(6):506-9.
6. Laitinen LA. Histamine and metacholine challenge in the testing of bronchial reactivity. *Scand J Respir Dis Suppl* 1974;86:1-48.
7. Mcfadden ER Jr. Exercise performance in the asthmatic. *Am Rev Respir Dis* 1984;129(2 Pt 2):S84-7.
8. Roksund OD, Nja F, Svidal B, Carlsen KH. Sensitivity and specificity of a standard exercise challenge test in asthmatic and healthy school children. *Am J Respir Crit Care Med* 1999;159(3):A673.
9. Tower J. Office testing for exercise-induced asthma. *Alaska Med* 1978;20(5):70-1.
10. Zohar O. Exercise induced asthma. *Aust J Physiother* 1996;42(1):3-5.

Therapy for EIB/EIA review

368 studies were excluded from the review. Reasons for exclusion include: study design (n=60), population (n=32), intervention (n=214), no comparison (n=2), outcome (n=1), language (n=38), insufficient data (n=12), and duplicate publication (n=9). We were not able to retrieve the reports of 15 studies.

Study Design (n = 60)

1. Levalbuterol for asthma. *Med Lett Drugs Ther* 1999;41(1054):51-3.
2. Allegra J, Field J, Trautlein J, et al. Oral terbutaline sulfate—amelioration of exercise-induced bronchospasm. *J Clin Pharmacol* 1976;16(7):367-70.
3. Anderson S, Rodwell L, Toit J, Young I. Salmeterol, a novel beta-adrenoceptor agonist, provides longer protection against exercise-induced asthma EIA compared with salbutamol. *Aust N Z J Med* 1991;21:644.
4. Anderson SD, Bye PT, Schoeffel RE, et al. Arterial plasma histamine levels at rest, and during and after exercise in patients with asthma: effects of terbutaline aerosol. *Thorax* 1981;36(4):259-67.
5. Atkinson DC, Torres M. Comparison of two bronchodilator inhalers in adolescents and adults with exercise-induced asthma. [Internet] 2004 Jun. [cited 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00085774>
6. Bierman CW, Shapiro GG, Furukawa CT, et al. Double-blind cross-over study of theophylline and terbutaline in exercise-induced bronchospasm. *J Allergy Clin Immunol* 1979;63(3):No. 75.
7. Boner AL, Niero E, Grigolini C, et al. Inhibition of exercise-induced asthma by three forms of sodium cromoglycate. *Eur J Respir Dis* 1985;66(1):21-4.
8. Bundgaard A. Exercise-induced asthma - laboratory observations. *Eur J Respir Dis Suppl* 1983;128(Pt 1):253-7.
9. Bundgaard A. Pretreatment of exercise-induced asthma with beta-2 agonists inhaled from RV to TLC or at TLC. A preliminary report. *Eur J Respir Dis Suppl* 1983;128(Pt 2):518-20.
10. Cavallo A, Cassaniti C, Glogger A, Magrini H. Action of nedocromil sodium in exercise-induced asthma in adolescents. *J Investig Allergol Clin Immunol* 1995;5:286-8.
11. Ceugniet F, Cauchefer F, Fragneaud C, Evano-Celli I. Prophylactic treatment of exercise-induced asthma in children: salmeterol or sodium cromoglycate single dose before exercise? *Ann Pediatr (Paris)* 1997;44(9):625-34.
12. Chung JT, Jones RS. Bronchodilator effect of sodium cromoglycate and its clinical implications. *Br Med J* 1979;2(6197):1033-4.
13. Comerford M. The use of nedocromil sodium in the prevention of exercise-induced bronchoconstriction. *Pediatr Nurs* 2000;26(5):523-5.
14. D'Alonzo GE. Efficacy of inhaled salmeterol in the treatment of asthma. *Eur Respir Rev* 1995;5(27):128-32.
15. Davies SE. Effect of disodium cromoglycate on exercise-induced asthma. *Br Med J* 1968;3(618):593-4.
16. De Benedictis FM, Tuteri G, Alunni F, et al. Combination drug therapy for the prevention of exercise-induced asthma in children [abstract]. *Eur Respir J Suppl* 1995;8(Suppl 19):518S.
17. Ferres J, Guasch E, Garcia MP, Julia A. Assessing the efficacy of nedocromil sodium in exercise induced asthma [abstract]. *Eur Respir J Suppl* 1990;3(Suppl 10):385S.
18. Ferres J, Recoder O, Ferres RM, et al. Formoterol in the prevention of exercise induced asthma in children five hours before a free running test [abstract]. *Eur Respir J Suppl* 1996;9(Suppl 23):286S.
19. Ferres J, Recoder O, Andrew MA, et al. Prevention of exercise induced asthma by prior administration of sodium nedocromil with spacer [abstract]. *Eur Respir J Suppl* 1993;6 (Suppl 17):355S.
20. Gaile S, Philip G, Pearlman DS, et al. Reduction of the severity and duration of exercise-induced bronchoconstriction by single-dose montelukast or salmeterol [abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA.
21. Higgs CM, Laszlo G. The duration of protection from exercise-induced asthma by inhaled salbutamol, and a comparison with inhaled reproterol. *Br J Dis Chest* 1983;77(3):262-9.
22. Holmes TH, Morgan BA, Wolff CR. The effect of disodium cromoglycate on plasma 17-hydroxycorticoid concentration during exercise. *Am Rev Respir Dis* 1972;106(4):610-3.

23. Ienna TM, McKenzie DC. The asthmatic athlete: metabolic and ventilatory responses to exercise with and without pre-exercise medication. *Int J Sports Med* 1997;18(2):142-8.
24. Knopfli BH, Bar-Or O, Araujo CG. Effect of ipratropium bromide on EIB in children depends on vagal activity. *Med Sci Sports Exerc* 2005;37(3):354-9.
25. Konig P, Jaffe P, Godfrey S. Effect of corticosteroids on exercise-induced asthma. *J Allergy Clin Immunol* 1974;54(1):14-9.
26. Lenney W, Milner AD, Tyler RM. BRL10833 in inhibiting exercise-induced bronchoconstriction in asthmatic children. *Br J Dis Chest* 1978;72(3):225-30.
27. Lund T. Elite sport and development of asthma. [Internet] 2005 Dec. [Cited 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00262587>
28. Markham A, Faulds D. Montelukast. *Drugs* 1998;56(2):251-6.
29. McCarthy OR. The prevention of exercise induced asthma. *Br J Dis Chest* 1972;66(2):133-40.
30. McNeill RS, Nairn JR, Millar JS, Ingram CG. Exercise-induced asthma. *Q J Med* 1966;35(137):55-67.
31. Melo RE, Sole D, Naspitz CK. Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children. *J Allergy Clin Immunol* 1997;99(2):204-9.
32. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. *J Allergy Clin Immunol* 2003;111(2):301-7.
33. Merck. An approved drug to study a new indication in exercise-induced bronchospasm. [Internet] 2004 Aug. [Cited 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00090142>
34. Merck. An investigational drug to prevent exercise-induced bronchospasm. [Internet] 2005 Oct. [Cited 2009 Aug 31]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT00245570>
35. Mihalyka MS, Anderson SD, Corte P. Nedocromil sodium in exercise-induced asthma EIA [abstract]. *Aust N Z J Med* 1987;17(Suppl 12):524.
36. Muijsers RBR, Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. *Paediatr Drugs* 2002;4(2):123-39.
37. Nathan RA, Dorinsky P, Rosenzweig JRC, et al. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. *J Asthma* 2003;40(7):815-822.
38. Nsouli SM. Efficacy of montelukast, a leukotriene receptor antagonist for the treatment of exercise induced bronchoconstriction. *Ann Allergy Asthma Immunol* 1999;82:100.
39. Patel KR, Kerr JW. The dose-duration effect of sodium cromoglycate in exercise-induced asthma. *Clin Allergy* 1984;14(1):87-91.
40. Peroni DG, Piacentini GL, Loiacono A, et al. Efficacy of single-dose montelukast on exercise-induced bronchoconstriction in children. *Eur Respir J* 2001;18(Suppl 33):495S.
41. Philip G, Pearlman DS, Villaran C, et al. Protection against exercise-induced bronchoconstriction by single-dose montelukast or salmeterol [abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA.
42. Philip G, van Adelsberg J, Pearlman DS, et al. Randomized, placebo-controlled studies of onset and duration of single-dose protection against exercise-induced bronchoconstriction [abstract]. *Eur Respir J* 2005;26(Suppl 49):Abstract 1730.
43. Pichaipat V, Tongpenyai Y, Nerntong T, Sriprapachiranont C. The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children. *J Med Assoc Thai* 1995;78(10):505-8.
44. Poppius H, Muittari A, Kreuz KE, et al. Exercise asthma and disodium cromoglycate. *Br Med J* 1970;4(731):337-9.
45. Rebic P, Petrovic V, Savic J, et al. Protective effect of fenoterol, cromolyn, and their combination on exercise-induced asthma: comparison between young and adult patients [abstract]. *Eur Respir J Suppl* 1994;7(Suppl 18):112s.
46. Ringel KP, El Nur AR, Karg F. FPL 52758 and disodium cromoglycate (INTAL) in exercise-induced infantile bronchoconstriction. *Z Erkr Atmungsorgane* 1982;159(1):50-6.
47. Rohr AS, Siegel SC, Katz RM, et al. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. *Ann Allergy* 1987;59(2):107-9.
48. Russo GH, Bellia CA, Bodas AW. Exercise-induced asthma (EIA): its prevention with the combined use of ipratropium bromide and fenoterol. *Respiration* 1986;50(Suppl 2):258-61.
49. Scherrer M, Gmur H. Protection against exercise-induced asthma. *Allergologie* 1981;4(1):46-7.

50. Selcow JE. Cromolyn therapy in children. *J Asthma* 1983;20(5):361-8.
51. Silverman M, Tooley M. Oxatomide and exercise-induced asthma in children: the value of serial exercise tests. *Clin Allergy* 1981;11(5):421-8.
52. Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L. Effects of montelukast on cardiopulmonary ergonomy and physical performance during exercise in adult asthmatics with exercise-induced bronchoconstriction. *Am J Respir Crit Care Med* 2001;163(5 Suppl):429.
53. Stemmann EA, Kosche F. A comparison of the effects of Sch 1000 MDI, sodium cromoglycate and beta-adrenergic drugs on exercise-induced asthma in children. *Postgrad Med J* 1975;51 S:105-6.
54. Svenonius E, Arborelius M Jr., Wiberg R, Ekberg P. Prevention of exercise-induced asthma by drugs inhaled from metered aerosols. *Allergy* 1988;43(4):252-7.
55. Vidal C, Fernandez OE, Eiro J, et al. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol* 2001;86(6):655-8.
56. Waalkens HJ, van Essen Zandvliet EE, Gerritsen J, et al. The effect of an inhaled corticosteroid budesonide on exercise-induced asthma in children. Dutch CNSLD Study Group. *Eur Respir J* 1993;6(5):652-6.
57. Wallace D, Grieco MH. Double-blind, cross-over study of cromolyn sodium inhibition of exercise-induced bronchospasm in adults. *Ann Allergy* 1976;37(3):153-63.
58. Warner JO. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. *Allergy* 2001;56:22-9.
59. Woolley MJ. The duration of action of terbutaline and sodium cromoglycate alone and in combination on exercise-induced asthma EIA [abstract]. *Aust N Z J Med* 1988;18(3 Suppl 2):538.
60. Yergen U, Till D, Ziehmer B, Kottakis J. Formeterol (foradil, aerolizer) protects against exercise induced bronchoconstriction [abstract]. *J Allergy Clin Immunol* 2003;111(2 Suppl):S144.

Population (n = 32)

1. Albazzaz MK, Neale MG, Patel KR. Dose-response study of nebulised nedocromil sodium in exercise induced asthma. *Thorax* 1989;44(10):816-9.
2. Albazzaz MK, Neale MG, Patel KR. Dose duration of nebulized nedocromil sodium in exercise-induced asthma. *Eur Respir J* 1992;5(8):967-9.
3. Bigby B, Boushey H. Effects of nedocromil sodium on the bronchomotor response to sulfur dioxide in asthmatic patients. *J Allergy Clin Immunol* 1993;92(1 Pt 2):195-7.
4. Butz AM. Nebulizer intervention for minority children with asthma. [Internet] 2005 Sept. [Cited 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00218816>
5. Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control. *Respiration* 2004;71(6):594-601.
6. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. *Thorax* 1993;48(12):1205-10.
7. Freeman W, Packe GE, Cayton RM. Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma. *Thorax* 1989;44(11):942-7.
8. Freeman W, Javaid A, Cayton RM. Ipratropium bromide and maximum exercise performance in asthmatic subjects [abstract]. *Eur Respir J Suppl* 1990;3(Suppl 10):439S.
9. GlaxoSmithKline. A study measuring asthma control in pediatric and adolescent subjects whose asthma is worsened by activity or exercise. [Internet] clinicaltrials.gov 2006.
10. Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. *Clin Ther* 2006;28(6):906-20.
11. Jokic R, Swystun VA, Davis BE, Cockcroft DW. Regular inhaled salbutamol: effect on airway responsiveness to methacholine and adenosine 5'-monophosphate and tolerance to bronchoprotection. *Chest* 2001;119(2):370-5.
12. Kreisman H, Frank H, and GM. The effect of ipratropium on exercise-induced asthma [abstract]. *J Allergy Clin Immunol* 1979;63(3):153.
13. Langton HS, Hobbs J, Connett G, Lenney W. Salmeterol in the prevention of exercise-induced bronchospasm in preschool children. *Eur Respir J Suppl* 1994;7(Suppl 18):451S.

14. Leech S, Wolfson K, Burns R. Ketotifen vs. disodium cromoglycate DSCG in the prophylaxis of exercise-induced asthma EIA. *Ann Allergy* 1983;50:352.
15. Maesen FP, Nakratzas G, Bantje TA, et al. Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients. *Chest* 1992;102(5):1544-9.
16. Magnussen H, Nowak D, Wiebicke W. Effect of inhaled ipratropium bromide on the airway response to methacholine, histamine, and exercise in patients with mild bronchial asthma. *Respiration* 1992;59(1):42-7.
17. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. *Respir Med* 1990;84(4):293-5.
18. Molema J, van Herwaarden CL, Folgering HT. Effects of long-term treatment with inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with allergic asthma. *Eur Respir J* 1989;2(4):308-16.
19. Morton AR, Turner KJ, Fitch KD. Protection from exercise-induced asthma by pre-exercise cromolyn sodium and its relationship to serum IGE levels. *Ann Allergy* 1973;31(6):265-71.
20. Nelson H, Kemp JP, Bieler S, et al. Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered-dose inhaler in asthma. *Chest* 1999;115(2):329-35.
21. Noonan M, Corren J, Leflein J. Safety of mometasone furoate dry powder inhaler and comparison with beclomethasone dipropionate in children with asthma previously maintained on inhaled corticosteroids (ICS) [abstract]. *Chest* 2004;126(4 Suppl):912S.
22. Patel KR. Bronchodilator activity of a new inhaled betasub 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. *Br J Clin Pharmacol* 1986;21(2):234-7.
23. Pflieger A, Eber E, Weinhandl E, Zach MS. Effects of nedocromil and salbutamol on airway reactivity in children with asthma. *Eur Respir J* 2002;20(3):624-9.
24. Raissy HH. Exercise induced bronchospasm in children. [Internet] 2006 Jan. [Cited: 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00273689>
25. Rundell KW, Spiering BA, Baumann JM, Evans TM. Bronchoconstriction provoked by exercise in a high-particulate-matter environment is attenuated by montelukast. *Inhal Toxicol* 2005;17(2):99-105.
26. Sanguinetti CM, Gasparini S, Bonifazi F, Vennarucci LS. Exercise-induced asthma diagnosis and prevention with a metered dose aerosol formulation of sodium cromoglycate. *Respiration* 1982;43(2):132-41.
27. Silverman M, Andrea T. Time course of effect of disodium cromoglycate on exercise-induced asthma. *Arch Dis Child* 1972;47(253):419-22.
28. Speelberg B, Verhoeff NP, van den Berg NJ, et al. Nedocromil sodium inhibits the early and late asthmatic response to exercise. *Eur Respir J* 1992;5(4):430-7.
29. Sue-Chu M, Sandsund M, Helgerud J, et al. Salmeterol and physical performance at -15 degrees C in highly trained nonasthmatic cross-country skiers. *Scand J Med Sci Sports* 1999;9(1):48-52.
30. Telenga ED, Kerstjens HA. Effect of inhaled hyaluronic acid (HA) on exercised induced bronchoconstriction (EIB). *Pulm Pharmacol Ther* 2008;21(2):430.
31. Unnithan VB, Thomson KJ, Aitchison TC, Paton JY. Beta 2-agonists and running economy in prepubertal boys. *Pediatr Pulmonol* 1994;17(6):378-82.
32. von Berg A, Berdel D. Efficacy of formoterol metered aerosol in children. *Lung* 1990;168(Suppl 1):90-8.

Intervention (n = 214)

1. Adelman A. Montelukast for mild and exercise-induced asthma. *J Fam Pract* 1998;47(5):335.
2. Adelroth E, Inman MD, Summers E, et al. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. *J Allergy Clin Immunol* 1997;99(2):210-5.
3. Allegra J, Field J, Trautlein J, et al. The pharmacologic effect of aerosolized terbutaline sulfate in exercise-induced bronchospasm. *J Clin Pharmacol* 1976;16(8-9):444-7.
4. Alvarez D, Rodriguez V, Fernandez S, et al. Comparison of the protective effect on exercise induced bronchospasm between albuterol and albuterol+ipratropium bromide in pediatric asthma patients [abstract]. *Am J Respir Crit Care Med* 2002;165(8 Suppl):A740.
5. Alvarez J, Rosales M, Sanchez LC, et al. Effect of nedocromil sodium compared to budesonide as prevention of bronchospasm induced by exercise test and methacoline test in asthma patients. *Eur Respir J Suppl* 1996;9 Suppl 23:34S.

6. Anderson SD, Rozea PJ, Dolton R, et al. Inhaled and oral bronchodilator therapy in exercise induced asthma. *Aust N Z J Med* 1975;5(6):544-50.
7. Anderson SD, Lambert S, Brannan JD, et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. *Med Sci Sports Exerc* 2001;33(6):893-900.
8. Becker A, Kumar R, Stewart L, et al. Chronobiology of exercise-induced bronchoconstriction (EIB) in pediatric asthma: response to montelukast [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A194.
9. Belcher NG, Rees PJ, Clark TJ, et al. A comparison of the refractory periods induced by hypertonic airway challenge and exercise in bronchial asthma. *Am Rev Respir Dis* 1987;135(4):822-5.
10. Ben D, I, Gur I, Bar YE, et al. Refractory period following induced asthma: contributions of exercise and isocapnic hyperventilation. *Thorax* 1983;38(11):849-53.
11. Berkowitz R, Schwartz E, Bukstein D, et al. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate. *Pediatrics* 1986;77(2):173-8.
12. Blake K, Pearlman DS, Scott C, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. *Ann Allergy Asthma Immunol* 1999;82(2):205-11.
13. Boner AL, Vallone G, Brighenti C, et al. Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children. *Pediatr Pulmonol* 1988;4(4):197-200.
14. Boner AL, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. *Am J Respir Crit Care Med* 1994;149(4 Pt 1):935-9.
15. Bonsignore MR, La Grutta S, Cibella F, et al. Effects of exercise training and montelukast in children with mild asthma. *Med Sci Sports Exerc* 2008;40(3):405-12.
16. Brannan JD, Anderson SD, Freed R, et al. Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects. *Am J Respir Crit Care Med* 2000;161(6):2096-9.
17. Brodde OE, Petrasch S, Bauch HJ, et al. Terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. *J Cardiovasc Pharmacol* 1992;20(3):434-9.
18. Bronsky EA, Spector SL, Pearlman DS, et al. Albuterol aerosol versus albuterol Rotacaps in exercise-induced bronchospasm in children. *J Asthma* 1995;32(3):207-14.
19. Bronsky EA, Kemp JP, Zhang J, et al. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. *Clin Pharmacol Ther* 1997;62(5):556-61.
20. Bronsky EA, Yegen U, Yeh CM, et al. Formoterol provides long-lasting protection against exercise-induced bronchospasm. *Ann Allergy Asthma Immunol* 2002;89(4):407-12.
21. Bronsky EA, Pearlman DS, Pobiner BF, et al. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices. *Pediatrics* 1999;104(3 Pt 1):501-6.
22. Bronsky F, Yegen U, Yeh CM, et al. Foradil provides rapid and long acting protection against exercise-induced bronchospasm [abstract]. *Ann Allergy Asthma Immunol* 1998;80:129.
23. Bundgaard A, Ingemann-Hansen T, Halkjaer-Kristensen J, et al. Short-term physical training in bronchial asthma. *Br J Dis Chest* 1983;77(2):147-52.
24. Busse WW, Dahiya GG, Yancey SW. Single doses of salmeterol provide protection against exercise-induced bronchospasm (EIB) for 12 hours. *Ann Allergy* 1994;72:95.
25. Capristo AF, del Giudice MM, Maiello N, et al. Montelukast for the treatment of exercise induced asthma in children, mid term study. *Eur Respir J Suppl* 1999;14(Suppl 30):362.
26. Carlsen KH, Roksund O, Olsholt K, et al. Overnight protection by inhaled salmeterol on exercise-induced asthma in children. *Eur Respir J* 1995;8(11):1852-5.
27. Cavagni G, Caffarelli C, Manni PL, et al. Salbutamol administered through a new spacer device to prevent exercise-induced asthma. *Adv Ther* 1993;10(5):207-16.
28. Cavagni G, Monici Preti PA, Caffarelli C, et al. Salbutamol administered via a new spacer device in preventing exercise-induced asthma [abstract]. *Eur Respir J Suppl* 1993;6(Suppl 17):353S.
29. Clark RA, Reid PC, Taak NK. A comparison of the duration of protection against exercise induced bronchoconstriction following single and chronic dosing with salmeterol and sodium cromoglycate in children [abstract]. *Eur Respir J Suppl* 1995;8(Suppl 19):517S.
30. Colice GL, Klinger NM, Ekholm BP, et al. Proventil HFA prevents exercise-induced bronchoconstriction in children. *J Asthma* 1999;36(8):671-6.

31. Corren J, Firriolo K, Ghannam A, et al. The effect of add-on therapy with montelukast or salmeterol on exercise-associated asthma exacerbation and recovery following rescue short-acting beta-agonist. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23 2001.
32. Dahlen B, Roquet A, Inman MD, et al. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. *J Allergy Clin Immunol* 2002;109(5):789-93.
33. Dahlen B, Roquet A, Inman M, et al. The contribution of histamine and leukotrienes to exercise induced airway obstruction in asthmatics [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A613.
34. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. *Eur Respir J* 1993;6(7):1018-26.
35. Dal CG, Martinati L, Mingoni S, et al. Salbutamol powder, administered via a multidose and a single-dose powder inhaler, in the prevention of exercise-induced asthma in children. *Pediatr Asthma Allergy Immunol* 1995;9(3):165-71.
36. Das S, Gunawardena K, Palmer P. Protection against exercise-induced asthma: a sensitive method to compare long acting β_2 -agonist inhalers [abstract]. American Thoracic Society 99th International Conference; Seattle, WA, May 16-21, 2003;B036.
37. Daugbjerg P, Nielsen KG, Skov M, et al. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. *Acta Paediatr* 1996;85(6):684-7.
38. De Benedictis FM, Tuteri G, Pazzelli P, et al. Combination drug therapy for the prevention of exercise-induced bronchoconstriction in children. *Ann Allergy Asthma Immunol* 1998;80(4):352-6.
39. De Benedictis FM, del Giudice MM, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. *Eur Respir J* 2006;28(2):291-5.
40. De Benedictis FM, Tuteri G, Solinas LF, et al. Salmeterol in the prevention of exercise-induced asthma in children: comparing two doses [abstract]. *Eur Respir J Suppl* 1995;8 Suppl 19:519S.
41. Debelic M. Comparison of inhaled formoterol and fenoterol in prevention of exercise-induced asthma. *Eur Respir J* 1988;1(Suppl 2):381S.
42. Del Col G, Spezia E, Richelli C, et al. Assessment of a new spacer device (Jet) for use with inhaled beta2-agonists in children with exercise-induced asthma. *Pediatr Asthma Allergy Immunol* 1993;7(2):119-26.
43. Del BN, Quartieri F, Vibelli C. Aerosolized clenbuterol NAB 365 and salbutamol in exercise-induced asthma. *Curr Med Res Opin* 1979;6(4):237-43.
44. Del BN, Quartieri F, Brembilla E. Effect of tiaramide hydrochloride Thc on exercise-induced asthma eia. *Curr Ther Res Clin Exp* 1981;30 (Pt 4):578-86.
45. Del BN, Quartieri F, Vibelli C. Intravenous NAB 365 clenbuterol and terbutaline in exercise-induced bronchospasm EIB. *Clin Allergy* 1979;9(3):277-82.
46. Del CG, Mingoni S, Martinati LC, et al. Salbutamol administered via two different powder inhalers in the prevention of exercise induced asthma (EIA) in children [abstract]. *Eur Respir J Suppl* 1995;8(Suppl 19):519S.
47. Dessanges JF, Prefaut C, Taytard A, et al. The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. *J Allergy Clin Immunol* 1999;104(6):1155-61.
48. Dinh Xuan A, Lebeau C, [Roche R](#), [Ferriere A](#), [Chaussain M](#). Inhaled terbutaline administered via a spacer fully prevents exercise-induced asthma in young asthmatic subjects: a double-blind, randomized, placebo-controlled study. *J Int Med Res* 1989;17(6):506-13.
49. Djaballah K, Dessanges JF, Patalano F, et al. Protective effect of inhaled iralukast (a new LTD4 antagonist) on exercise-induced bronchospasm. *Eur Respir J Suppl* 1996;9 Suppl 23:272S.
50. Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. *Ann Allergy* 1997;79(1):85-8.
51. dos Santos JM, Costa H, Stahl E, et al. Bricanyl Turbuhaler and Ventolin Rotahaler in exercise-induced asthma in children. *Allergy* 1991;46(3):203-5.
52. Duong M, Subbarao P, Otis J, et al. Relationship between exercise-induced bronchoconstriction and sputum eosinophilia during ciclesonide treatment in asthmatics [abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, CA 2005;B35.
53. Edelman JM, Turpin JA, DeLucca PT, et al. Comparison of oral montelukast, a leukotriene antagonist and inhaled salmeterol in exercise induced asthma (EIA) [abstract]. *Eur Respir J* 1998;12(Suppl 29):18S.
54. Eggleston PA, Bierman CW, Pierson WE, et al. A double blind trial of the effect of cromolyn sodium on exercise-induced bronchospasm. *J Allergy Clin Immunol* 1972;50(1):57-63.

55. Eggleston PA, McMahan SA. The effects of fenoterol, ephedrine and placebo on exercise-induced asthma. *Chest* 1978;73(6 Suppl):1006-8.
56. Eggleston PA, Bierman CW, Pierson WE, Stamm SJ, Van Arsdel PP. Pharmacologic modulation of exercise asthma: the role of Cromolyn Sodium. *J Allergy* 1971;47:96.
57. Emtner M, Johansson H, Holmback J. A randomised controlled trial of the effects of the quality of life physical capacity and exercise in adults with asthma after short term intervention [abstract]. *Eur Respir J* 2005;26(Suppl 49):Abstract 1172.
58. Ferrari M, Segattini C, Zanon R, et al. Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before a cycloergometric test. *Respiration* 2002;69(6):509-12.
59. Ferrari M, Balestrieri F, Baratieri S, et al. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. *Respiration* 2000;67(5):510-3.
60. Ferres J, Ma FR, Sanchez del RT, et al. Formoterol in the prevention of exercise induced asthma in children five hours before a running test [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):222S.
61. Ferres J, Recoder O, Gispert J, et al. Two months treatment with beclomethasone 500 or 1000µg in exercise induced asthma in children [abstract]. *Eur Respir J Suppl* 1995;8(Suppl 19):468S.
62. Filipoviã M, Pljastiã-Kamenov S, Kekovoã P, et al. Action of salmeterol in exercise induced asthma in adolescents and young adults [abstract]. *Eur Respir J* 1998;12(Suppl 29):20S.
63. Filipovic MD, Cekic SS, Dimitrijevic OB. Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB) [abstract]. *Eur Respir J Suppl* 2002;20(Suppl 38):abstract 1924.
64. Finnerty JP, Wood BR, Thomson H, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. *Am Rev Respir Dis* 1992;145(4 Pt 1):746-9.
65. Fitch KD, Morton AR. Specificity of exercise in exercise-induced asthma. *Br Med J* 1971;4(787):577-81.
66. Foreza N, del Giudice MM, Decimo F, et al. Overtime effect of montelukast in asthmatic children with exercise-induced bronchoconstriction [abstract]. *Eur Respir J* 2005;26(Suppl 49):Abstract 1061.
67. Francis PW, Krastins IR, Levison H. Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm. *Pediatrics* 1980;66(1):103-8.
68. Freezer NJ, Croasdell H, Doull IJ, et al. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. *Eur Respir J* 1995;8(9):1488-93.
69. Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study. *Eur Respir J* 1993;6(4):527-30.
70. Giustina A, Malerba M, Bresciani E, et al. Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. *J Endocrinol Invest* 1995;18(11):847-52.
71. Goldberg JB, Böhning WS. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison. *Respir Med* 2000;94(10):948-53.
72. Golice G, Klinger N, Ekholm B, et al. Prevention of exercise-induced asthma by salbutamol formulated in HFA-134a propellant. *Aust N Z J Med* 1998;28:259.
73. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. *Arch Dis Child* 1992;67(8):1014-7.
74. Gronnerod TA, von Berg A, Schwabe G, et al. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. *Respir Med* 2000;94(7):661-7.
75. Grzelewski T, Jerzynska J, Stelmach I. Budesonide and montelukast once daily inhibits exercise induced bronchoconstriction in 6 to 18 year old children with asthma [abstract]. *J Allergy Clin Immunol* 2006;117(2 Suppl 1):S93.
76. Guerin JC, Germain M, Febvre N, et al. Protective effect of formoterol on exercise-induced bronchoconstriction 10 hours after inhalation [abstract]. *Eur Respir J Suppl* 1993;6(Suppl 17):201S.
77. Gunawardena K, Palmer P, Das S, et al. Comparison of long acting B2 agonist inhalers for treatment of exercise induced bronchoconstriction (EIB) [abstract]. *Eur Respir J* 2003;22(Suppl 45):Abstract 1987.
78. Hartley JP, Charles TJ, Seaton A. Betamethasone valerate inhalation and exercise-induced asthma in adults. *Br J Dis Chest* 1977;71(4):253-8.

79. Haverkamp HC, Eldbridge MW, Miller JD, et al. Treatment of airway inflammation improves arterial blood gas status during exercise in habitually active asthmatics [abstract]. American Thoracic Society 2005 International Conference; May 20-25 2005; San Diego, California;B19.
80. Haverkamp HC, Dempsey JA, Pegelow DF, et al. Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects. *J Allergy Clin Immunol* 2007;120(1):39-47.
81. Hawksworth RJ, Sykes AP, Faris M, et al. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol* 2002;88(5):473-7.
82. Helenius I, Lumme A, Ounap J, et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. *Allergy* 2004;59(1):39-44.
83. Hendeles L, Erb TA, Bird S, et al. Post-exercise response to albuterol after addition of montelukast or salmeterol to inhaled fluticasone [abstract]. *J Allergy Clin Immunol* 2004;113(2 Suppl):S34.
84. Henriksen JM. Effect of inhalation of corticosteroids on exercise induced asthma: randomised double blind crossover study of budesonide in asthmatic children. *Br Med J (Clin Res Ed)* 1985;291(6490):248-9.
85. Henriksen JM, Dahl R. Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. *Am Rev Respir Dis* 1983;128(6):993-7.
86. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. *J Allergy Clin Immunol* 1992;89(6):1176-82.
87. Hermansen MN, Nielsen KG, Buchvald F, et al. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. *Chest* 2006;129(5):1203-9.
88. Hills EA, Davies S, Geary M. Salmefamol and salbutamol in exercise-induced asthma in children. *Br J Dis Chest* 1976;70(2):78-82.
89. Ho Chu JY, Tuazon O, Martinez C, et al. Comparison of the protective efficacy of inhaled and oral procaterol on exercise-induced asthma [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A345.
90. Hodges ANH, Lynn BM, Koehle MS, et al. Effects of inhaled bronchodilators and corticosteroids on exercise induced arterial hypoxaemia in trained male athletes. *Br J Sports Med* 2005;39(12):917-20.
91. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. *Pediatr Pulmonol* 2000;29(6):415-23.
92. Hofstra WB, Sterk PJ, Neijens HJ, et al. Short term treatment with zafirlukast, sodium cromoglycate or placebo in reducing exercise-induced bronchoconstriction in adolescent asthmatics [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):220S.
93. Horn CR, Jones RM, Lee D, et al. Bronchodilator effect of disodium cromoglycate administered as a dry powder in exercise induced asthma. *Br J Clin Pharmacol* 1984;18(5):798-801.
94. Ioli F, Donner CF, Fracchia C, et al. A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. *Int J Clin Pharmacol Res* 1986;6(5):389-96.
95. Jonasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. *Eur Respir J* 1998;12(5):1099-104.
96. Jonasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. *Pediatr Allergy Immunol* 2000;11(2):120-5.
97. Jonasson G, Carlsen KH. Low dose inhaled budesonide in exercise induced asthma. *Eur Respir J* 1999;14(Suppl 30):194S.
98. Jones RS, Blackhall MI. Role of disodium cromoglycate ("Intal") in treatment of childhood asthma. *Arch Dis Child* 1970;45(239):49-53.
99. Kalmanova E, Chuchalin A, Knyageskaya N, et al. Influence of long acting beta-2 agonist and sustained-release theophylline on exercise and resting metabolism in asthmatic patients [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):350S.
100. Katsunuma T, Akashi K, Shibata A, et al. Effect of short-term treatment with low-dose of fluticasone on exercise-induced bronchoconstriction in children with asthma [abstract]. American Thoracic Society International Conference, San Diego, CA, May 19-24 2006;A157.
101. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. *J Pediatr* 1998;133(3):424-8.
102. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. *Am J Respir Crit Care Med* 1994;150(6 Pt 1):1612-5.

103. Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. *Pediatr Pulmonol* 2005;39(2):162-6.
104. Kivity S, Onn A, Greif Y, et al. Nedocromil and exercise-induced asthma: acute and chronic effects. *Isr Med Assoc J* 1999;1(2):92-4.
105. Konig P, Eggleston PA, Serby CW. Comparison of oral and inhaled metaproterenol for prevention of exercise-induced asthma. *Clin Allergy* 1981;11(6):597-604.
106. Kumar AS. Salmeterol in exercise induced asthma. *Indian Pediatr* 1998;35(7):681-2.
107. La Grutta S, Cibella F, Morici G, et al. Beneficial effects of aerobic training montelukast in children with mild to intermittent asthma [abstract]. *Eur Respir J* 2005;26(Suppl 49):Abstract 1050.
108. Laube BL, Edwards AM, Creticos PS, et al. Optimizing the acute protective effect of sodium cromoglycate aerosol in patients with allergen-induced and exercise-induced asthma. *Eur Respir J Suppl* 1996;9(Suppl 23):352S.
109. Lecheler J, Pfannebecker B, Ellers-Lenz B, et al. Prevention of exercise induced bronchoconstriction (EIB) by a fixed combination of disodium cromoglycate plus reproterol compared to montelukast [abstract]. *Eur Respir J* 2004;24(Suppl 48):443S.
110. Lecheler J, Pfannebecker B, Nguyen DT, et al. Prevention of exercise-induced asthma by a fixed combination of disodium cromoglycate plus reproterol compared with montelukast in young patients. *Arzneimittelforschung* 2008;58(6):303-9.
111. Leff JA, Bronsky EA, Kemp J, et al. Montelukast (MK-0476) improves patient global assessment and decreases beta-agonist requirements in patients with mild asthma and exercise-induced bronchoconstriction (EIB) [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):438S.
112. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med* 1998;339(3):147-52.
113. Lockhart A, Djaballah K, Dessanges JF, et al. The protective effect of zafirlukast against exercise-induced asthma [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):419S.
114. Lopes DSJM, Costa H, Stahl E, et al. Bricanyl R Turbuhaler R and Ventolinrho Rotahaler R in exercise-induced asthma in children. *Allergy* 1991;46(3):203-5.
115. Magnussen H, Rabe KF. The protective effect of low-dose inhaled fenoterol against methacholine and exercise-induced bronchoconstriction in asthma: a dose-response study. *J Allergy Clin Immunol* 1992;90(5):846-51.
116. Mahomedy YA, Cowling CGD, Boeree B. A comparison of the effects of orally administered M&B 22,948 Zaprinst and placebo on changes in ventilatory function in patients with exercise-induced bronchial asthma: a pilot study. *Curr Ther Res Clin Exp* 1986;40(4):750-60.
117. Makker HK, Lau LC, Thomson HW, et al. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. *Am Rev Respir Dis* 1993;147(6 Pt 1):1413-8.
118. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. *N Engl J Med* 1990;323(25):1736-9.
119. Manning PJ, Watson RM, Margolskee DJ, et al. The effect of a leukotriene D-receptor antagonist, MK-571, on exercise-induced bronchoconstriction [abstract]. *Eur Respir J Suppl* 1990;3(Suppl 10):203S.
120. McFadden ER Jr., Lenner KA, Strohl KP. Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. *J Clin Invest* 1986;78(1):18-25.
121. McFadden ER Jr., Mills R. Prevention of exercise-induced bronchospasm with aerosolized albuterol. *Curr Ther Res Clin Exp* 1986;39(1):112-8.
122. Melo RE, Sole D, Naspitz C. Montelukast (MK) prevents immediate and late asthmatic responses to exercise [abstract]. *J Allergy Asthma Immunol* 2002;109(Suppl 1):242-3.
123. Meltzer EO, Baena-Cagnani CE, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. *Pediatr Asthma Allergy Immunol* 2007;20(2):67-81.
124. Merck. Two investigational drugs in the prevention of airway constriction brought on by exercise in asthmatic patients. [Internet] 2005 June. [Cited 2009 Aug 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00127166>
125. Millqvist E, Bengtsson U, Whagen O. Combining a beta2-agonist with a face mask to prevent exercise-induced bronchoconstriction. *Allergy* 2000;55(7):672-5.
126. Miraglia del GM, Forenza N, Capristo A, et al. Time effect of montelukast in the prevention of exercise-induced bronchoconstriction in children. *Eur Respir J* 2001;18(Suppl 33):119S.

127. Molimard M, Martinat Y, Rogeaux Y, et al. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. *Respir Med* 2005;99(6):770-8.
128. Morse JL, Jones NL, Anderson GD. The effect of terbutaline in exercise-induced asthma. *Am Rev Respir Dis* 1976;113(1):89-92.
129. Morton AR, Hahn AG, Fitch KD. Continuous and intermittent running in the provocation of asthma. *Ann Allergy* 1982;48(2):123-9.
130. Morton AR, Scott CA, Fitch KD. Rimiterol and the prevention of exercise-induced asthma. *J Allergy Clin Immunol* 1989;83(1):61-5.
131. Morton AR, Papalia SM, Morton PS, et al. The efficacy of the nebulizer method of administration of terbutaline sulphate in the prevention and amelioration of exercise induced asthma. *Aust J Sci Med Sport* 1992;24(4):103-6.
132. Netzer N, Steinacker JM, Schuell K, et al. Protective effect of oral montelukast (M) in a fixed drug combination of inhaled sodium cromoglycate and reproterol (SCG+R) on exercise induced asthma (EIA). *Am J Respir Crit Care Med* 2000;161(3 Suppl):A613.
133. Newnham DM, Ingram CG, Earnshaw J, et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. *Respir Med* 1993;87(6):439-44.
134. Nicolaescu V, Racoveanu C, Manicatile M. Effects of exercise on practolol-treated asthmatic patients. *Eur J Clin Pharmacol* 1973;6(1):3-8.
135. Novembre E, Frongia G, Lombardi E, et al. The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children. *J Allergy Clin Immunol* 1995;96(6 Pt 1):906-9.
136. Orgel HA, Meltzer EO, Kemp JP. Flunisolide aerosol in treatment of steroid-dependent asthma in children. *Ann Allergy* 1983;51(1 Pt 1):21-5.
137. Ostrom NK, Larsen JS, Miller CJ, et al. Sustained attenuation of exercise-induced bronchoconstriction by Zafirlukast when administered with food. *J Allergy Clin Immunol* 2001;107(2):S112.
138. Patakas D, Louridas G, Sehletidis L. Effect of beclomethasone dipropionate inhalation on exercise induced bronchospasm. *IRCS Med Sci Cardiovasc Syst* 1978;6(11):448.
139. Patalano F, Tidmann U, Radermecker M. Foradil® (formoterol fumarate) 12 micrograms single dose prevents exercise induced bronchospasm over a period of 12 hours. *Ann Allergy Asthma Immunol* 1998;80:87.
140. Patalano F, Tidmann U, Radermecker M. Foradil® (formoterol fumarate) 12 micrograms single dose prevents exercise induced bronchospasm over a period of 12 hours. *Ann Allergy Asthma Immunol* 1998;80:87.
141. Patel K, Kerr R, MacDonald W, et al. The effect of thymoxamine and cromolyn sodium on postexercise bronchoconstriction in asthma. *J Allergy Clin Immunol* 1976;57(4):285-92.
142. Patessio A, Podda A, Carone M, et al. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. *Eur Respir J* 1991;4(3):296-300.
143. Pavord ID, Wisniewski A, Tattersfield AE. Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids. *Thorax* 1992;47(10):797-800.
144. Pearlman D, Milgrom H, Andriano K, et al. Comparison of formoterol (Aerolizer®), albuterol (MDI) and placebo in the prevention of exercise-induced bronchospasm in pediatric patients [abstract]. *Chest* 2002;122(4 Suppl):114S.
145. Pearlman D, Qaqudah P, Matz J, et al. Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. *Pediatr Pulmonol* 2009;44(5):429-35.
146. Pearlman DS, Rees W, Schaefer K, et al. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm. *J Asthma* 2007;44(9):729-33.
147. Pederson R, Agertoft L, Pederson S. Use of exhaled nitric oxide (eNO) as a marker for anti-inflammatory dose response of beclomethasone extrafine aerosol (Q) dosed once daily (50-100ug) in children with exercise induced asthma [abstract]. *Eur Respir J* 2003;22(Suppl 45):Abstract 1984.
148. Petersen R, Agertoft L, Pedersen S. Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma. *Eur Respir J* 2004;24(6):932-7.
149. Petheram IS, Bierman CW, Cobley A, et al. Oral prophylaxis of exercise induced asthma: a study of two new drugs. *Br J Dis Chest* 1980;74:319-20.
150. Petrovic V, Rebic P, Savic J, et al. Protective effect of fenoterol, cromolyn and their combination on exercise-induced asthma [abstract]. *Eur Respir J Suppl* 1995;8(Suppl 19):260S.
151. Pflieger A, Eber E, Weinhandl E, et al. Comparison of the preventive effects of nedocromil and salbutamol on the bronchial response to cold dry air challenge in children with exercise-induced asthma [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A38.

152. Pin L, Bozel P, Ceugniet F, et al. Effect of 2 physical training programmes on oxygen consumption and exercise-induced asthma in asthmatic teenagers [abstract]. *Eur Respir J Suppl* 1993;6(Suppl 17):613S.
153. Pohl WR, Vetter N, Zwick H, et al. Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. *Respir Med* 2006;100(3):551-60.
154. Poppius H, Salorinne Y. Comparative trial of salbutamol and an anticholinergic drug, SCH 1000, in prevention of exercise-induced asthma. *Scand J Respir Dis* 1973;54(3):142-7.
155. Rabe KF, Jorres R, Magnussen H. The effect of 10, 50 and 200 micrograms inhaled fenoterol on exercise induced asthma. *Clin Exp Allergy* 1993;23(5):440-5.
156. Raissy HH, Harkins M, Kelly F, et al. Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. *Pharmacotherapy* 2008;28(3):287-94.
157. Ramage L, Ingram C, Cree IA, et al. Chronic dosing with inhaled salmeterol in exercise induced asthma. *Scott Med J* 1992;37(5):155.
158. Reinhardt D, Ludwig J, Braun D, et al. Effects of the antiallergic drug ketotifen on bronchial resistance and beta-adrenoceptor density of lymphocytes in children with exercise-induced asthma. *Dev Pharmacol Ther* 1988;11(3):180-8.
159. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. *Thorax* 1997;52(12):1030-5.
160. Riccioni G, Ballone E, D'Orazio N, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. *Int J Immunopathol Pharmacol* 2002;15(2):149-55.
161. Richter K, Janicki S, Jorres RA, et al. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. *Eur Respir J* 2002;19(5):865-71.
162. Richter K, Janicki S, Jörres RA, Magnussen H. The acute effects of formoterol, salmeterol and terbutaline on airway tone and protection against exercise-induced asthma [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A613.
163. Robertson W, Simkins J, O'Hickey SP, et al. Does single dose salmeterol affect exercise capacity in asthmatic men? *Eur Respir J* 1994;7(11):1978-84.
164. Robuschi M, Scuri M, Spagnotto S, et al. The protective effect of transdermal broxaterol on exercise-induced bronchoconstriction. *Eur J Clin Pharmacol* 1995;47(5):465-6.
165. Sanguinetti CM, De Luca S, Gasparini S, Massei V. Evaluation of Duovent in the prevention of exercise-induced asthma. *Respiration* 1986;50(Suppl 2):181-5.
166. Schaanning J, Vilsvik J, Henriksen AH, et al. Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol* 1996;76(1):57-60.
167. Schaanning J, Vilsvik J, Henriksen AH. The efficacy of salmeterol in protecting against exercise induced bronchoconstriction: a double blind placebo control cross-over study comparing the effect of placebo and salmeterol at 4, 8 and 12 hours after medication [abstract]. *Eur Respir J Suppl* 1994;7(Suppl 18):113S.
168. Schmidt A, Diamant B, Bundgaard A, et al. Ergogenic effect of inhaled beta 2-agonists in asthmatics. *Int J Sports Med* 1988;9(5):338-40.
169. Sepracor Inc. Efficacy study of single-dose levalbuterol tartrate hydrofluoroalkane (HFA) metered dose inhaler (MDI) versus placebo in prevention of exercise-induced bronchospasm (EIB) in subjects 18 years of age and older with exercise-induced bronchospasm. [Internet] 2005 Dec. [Cited 2009 Sep 3]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT00268723>
170. Shapiro GG, McPhillips JJ, Smith K, et al. Effectiveness of terbutaline and theophylline alone and in combination in exercise-induced bronchospasm. *Pediatrics* 1981;67(4):508-13.
171. Shapiro GG, Kemp JP, DeJong R, et al. Effects of albuterol and procaterol on exercise-induced asthma. *Ann Allergy* 1990;65(4):273-6.
172. Shapiro GS, Yegen U, Xiang J, et al. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. *Clin Ther* 2002;24(12):2077-87.
173. Sheppard D, Nadel JA, Boushey HA. Inhibition of sulfur dioxide-induced bronchoconstriction by disodium cromoglycate in asthmatic subjects. *Am Rev Respir Dis* 1981;124(3):257-9.
174. Shostakovich-Koretskaya L, Cherginets A. Effect of long-term treatment with inhaled furosemide and nedocromil sodium on exercise-induced broncho-obstruction in asthmatic children. *Eur Respir J* 2001;18(Suppl 33):495S.
175. Sichletidis L, Daskalopoulou E, Kyriazis G, et al. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. *J Int Med Res* 1993;21(2):81-8.
176. Sly RM, O'Brien SR. Effect of oral terbutaline on exercise-induced asthma. *Ann Allergy* 1982;48(3):151-5.

177. Sly RM, Schlumbrecht L. Exercise-induced bronchospasm: comparison of bronkephrine and epinephrine. *Ann Allergy* 1968;26(9):493-8.
178. Sly RM, Puapan P, Ghazanshahi S, et al. Exercise-induced bronchospasm: evaluation of albuterol aerosol. *Ann Allergy* 1975;34(1):7-14.
179. Smolenov IV, Stakhanova SA, Ogorodova LM, et al. Prevention of exercise-induced bronchospasm in children with asthma: a comparison of different anti-inflammatory combination therapy [abstract]. *Eur Respir J Suppl* 2002;20(Suppl 38):abstract 2402.
180. Snijders D, Panizzolo C, Galesso P, et al. Urinary leukotriene E4 after training exercise in children with asthma [abstract]. *Eur Respir J* 2006;28(Suppl 50):478S.
181. Soferman R, Kivity S, Marcus B, et al. Comparison between bronchial response to inhaled hypoosmolar and isoosmolar solutions of sodium cromoglycate after exercise challenge. *Ann Allergy* 1990;64(2 Pt 1):143-6.
182. Steinshamn S, Sandsund M, Sue-Chu M, et al. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. *Scand J Med Sci Sports* 2002;12(4):211-7.
183. Steinshamn SL, Sandsund M, Sue-Chu M, et al. Effects of montelukast on cardiopulmonary ergonomy and physical performance during exercise in adult asthmatics with exercise-induced bronchoconstriction: a comparative study with salmeterol [abstract]. *Chest* 2002;122(4):185S.
184. Stelmach I, Grzelewski T, Majak P, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. *J Allergy Clin Immunol* 2008 Feb;121(2):383-9.
185. Stensrud T, Nordahl B, Vilberg A, et al. Maximal oxygen uptake testing, a comparison of two test protocols [abstract]. *American Thoracic Society 2005 International Conference*; May 20-25; San Diego, California 2005;B65.
186. Sturani C, Schiavina M, Tosi I, et al. Comparison of inhaled fenoterol and salbutamol in the prevention of exercise-induced asthma. *Eur J Respir Dis Suppl* 1983;128(Pt 2):526-8.
187. Subbarao P, Duong M, Otis J, et al. Ciclesonide attenuates exercise-induced bronchoconstriction over time in asthmatic subjects [abstract]. *American Thoracic Society 2005 International Conference*; May 20-25; San Diego, California 2005;B35.
188. Subbarao P, Duong M, Adelroth E, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. *J Allergy Clin Immunol* 2006;117(5):1008-13.
189. Subbarao P, Duong M, Pedersen S, et al. Once daily ciclesonide protects against exercise-induced bronchoconstriction [abstract]. *XIX World Allergy Organization Congress*, June 26-July 1, Munich, Germany 2005.
190. Subbarao PJ, Duong M, Otis J, et al. Ciclesonide is effective in protecting against exercise-induced bronchoconstriction [abstract]. *J Allergy Clin Immunol* 2005;115(2 Suppl):S1.
191. Sue-Chu M, Karjalainen EM, Laitinen A, et al. Placebo-controlled study of inhaled budesonide on indices of airway inflammation in bronchoalveolar lavage fluid and bronchial biopsies in cross-country skiers. *Respiration* 2000;67(4):417-25.
192. Svenonius E, Arborelius M, Wiberg R, et al. A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon CFC inhaler in children with exercise-induced asthma. *Allergy* 1994;49(6):408-12.
193. Tammivaara R. The efficacy of terbutaline and fenoterol aerosols on adult exercise-induced asthma. *Scand J Respir Dis Suppl* 1979;103:212-3.
194. Tan WC, Lim TK. Double-blind comparison of the protective effect of sodium cromoglycate and ketotifen on exercise-induced asthma in adults. *Allergy* 1987;42(4):315-7.
195. Thomson NC, Green AG, Kerr JW. Effect of FPL57787 in exercise-induced asthma. *Clin Allergy* 1980;10(1):43-6.
196. Tsoy AN, Cheltzov VV, Zaseyeva OV, et al. Preventive effect of formoterol aerosol in exercise-induced broncho-constriction [abstract]. *Eur Respir J Suppl* 1990;3(Suppl 10):235S.
197. Tullett WM, Patel KR. Isosorbide dinitrate and isoxsuprine in exercise induced asthma. *Br Med J (Clin Res Ed)* 1983;286(6382):1934-5.
198. Turcotte H, Archambault F, Rigali F, et al. Influence of a low dose of BDP-HFA on methacholine or exercise-induced lung hyperinflation in mild asthma [abstract]. *Eur Respir J* 2005;26(Suppl 49):Abstract 3317.
199. Turpin JA, Edelman JM, DeLucca PT, et al. Chronic administration of montelukast (MK-476) is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction (EIB). *Am J Respir Crit Care Med* 1998;157(3 Suppl):A456.
200. Vige R, Carlsen K-H, Ingjer F. The effect of the leukotriene receptor antagonist Montelukast on endurance performance in healthy non-asthmatic endurance trained athletes. *Eur Respir J* 2001;18(Suppl 33):491S.
201. Vilsvik J, Schaanning J, Stahl E, et al. Comparison between Bricanyl Turbuhaler and Ventolin metered dose inhaler in the treatment of exercise-induced asthma in adults. *Ann Allergy* 1991;67(3):315-8.

202. Vilsvik J, Ankerst J, Palmqvist M, et al. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. *Respir Med* 2001;95(6):484-90.
203. Vilsvik J, Ankerst J, Palmqvist M, et al. Protection against exercise-induced bronchoconstriction during regular treatment with formoterol turbuhaler® B.I.D in adult asthmatics. *Eur Respir J Suppl* 1999;14(Suppl 30):1085S.
204. Vilsvik J, Schaanning J, Stahl E, et al. Exercise-induced asthma in adult patients: a comparison between Bricanyl, Turbuhaler and Ventolin metered dose inhaler (MDI) [abstract]. *Eur Respir J Suppl* 1990;3(Suppl 10):71S.
205. Walker SB, Bierman CW, Pierson WE, et al. Bitolterol mesylate in exercise-induced asthma. *J Allergy Clin Immunol* 1986;77(1 Pt 1):32-6.
206. Ward FG, Gomes S, McNeill RS. Disodium cromoglycate in exercise-induced asthma. *Br Med J* 1969;3(663):176-7.
207. Weiler JM, Nathan RA, Rupp NT, et al. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. *Ann Allergy Asthma Immunol* 2005;94(1):65-72.
208. Weinberg EG. The effect of terbutaline sulphate on exercise-induced asthma in children. *S Afr Med J* 1982;61(16):587-9.
209. Weinbren I, Bound J, Capper L. A double-blind trial of disodium cromoglycate in bronchial asthma with assessment by four observers. *Br J Dis Chest* 1969;63(3):155-64.
210. Wilson N, Dixon C, Silverman M. Bronchial responsiveness to hyperventilation in children with asthma: inhibition by ipratropium bromide. *Thorax* 1984;39(8):588-93.
211. Yazigi R, Sly RM, Frazer M. Effect of triamcinolone acetonide aerosol upon exercise-induced asthma. *Ann Allergy* 1978;40(5):322-5.
212. Yegen U, Shapiro G, Xiang X, et al. Foradil aeroliser provides rapid and long acting protection against exercise-induced bronchospasm. *Am J Respir Crit Care Med* 1998;157(3 Suppl):A92.
213. Zimmermann T, Viel K. An open randomized cross-over study to assess protection of salmeterol vs dinatriumcromoglycat in children with exercise induced asthma. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23 2001.
214. Zimmermann T, Gulyas A, Bauer CP, et al. Salmeterol versus sodium cromoglycate for the protection of exercise induced asthma in children-a randomised cross-over study. *Eur J Med Res* 2003;8(9):428-34.

Comparison (n = 2)

1. Almahroos G, Watts TP, Joshi RC. Ketotifen and disodium cromoglycate in the prevention of exercise induced asthma [abstract]. *Clin Sci* 1986;71(Suppl 15):9P.
2. Lilja G, Graff-Lonnevig V, Bevegard S. Comparison of the protective effect of ketotifen and disodium cromoglycate on exercise-induced asthma in asthmatic boys. *Allergy* 1983;38(1):31-5.

Outcome (n = 1)

1. Grove A, McFarlane LC, Lipworth BJ. Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. *Thorax* 1995;50(2):134-8.

Language (n = 38)

1. [Tolerance for salmeterol in exercise-induced asthma]. *Geneesmiddelenbulletin* 1999;33(2):20-1.
2. Aebischer JC, Benoit RC, Scherrer M. [Pirbuterol and salbutamol aerosol for exercise-induced bronchoconstriction]. *Schweiz Med Wochenschr* 1984;114(46):1660-4. German.
3. Agostini M, Barlocco G, Mastella G. [Protection against exercise induced asthma in children. Double blind controlled clinical trial with fenoterol spray, fenoterol plus ipratropium and oral clenbuterol]. *Riv Ital Pediatr* 1983;9(4):347-52. Italian.
4. Battistini A, Grzincich GL, Gorni A, Baroni AL. Asthma and bronchodilator drugs. Evaluation of a newly developed betasub 2-agonist: Clenbuterol. [Asma da sforzo e broncodilatatori. Valutazione strumentale di un nuovo Beta2 stimolante: il clenbuterolo]. *Riv Ital Pediatr* 1980;6(3):313-9. Italian.
5. Bauer C, P. [Therapy of exercise-induced asthma with Cromoglicinic acid disodium salt DNCG]. *Padiatrische Praxis* 1984;30:597-601. German.
6. Bauer CP, Emmrich P. [Effect of nedocromil sodium on the hyperreactivity of the bronchial system in young asthmatic patients]. *Monatsschr Kinderheilkd* 1988;136(12):810-4. German.
7. Baur X. [Bronchial asthma induced by exercise]. *Dtsch Med Wochenschr* 1981;106(10):301-4. German.
8. Boner AL, Zamo CR, Marchiori MM, et al. [Comparison of nebulized ipratropium, salbutamol and cromoglicate solutions, cromoglicate inhaled powder, theophylline elixir and placebo in exercise induced asthma of the children]. *G Ital Mal Torace* 1984;38(6):395-9. Italian.
9. Boye NP. Disodium cromoglycate and exercise induced airway obstruction. *Tidsskr Nor Laegeforen* 1973;93(12):840-2.
10. Corrias A, Pelosi U, Corona GB, et al. [Efficacy of broxaterol vs salbutamol in asthma induced by physical exercise in children]. *Pediatr Med Chir* 1989;11:161-3. Norwegian.
11. Cropp GJ, A. [Relative effectivity of inhalation of Isoprenalalin and Disodium Chromoglycicum on exercise-induced asthma]. *Monatsschr Kinderheilkd* 1976;124:234-7. German.
12. Dal CG, Martinati L, Mingoni S, et al. [Salbutamol powder, administered via a multidose and a single-dose powder inhaler, in the prevention of exercise-induced asthma in children]. *Rev Bras Med* 2002;59(6):462-6. Portuguese.
13. Debelic M, Stechert R. [Exercise-induced asthma—protection with disodium cromoglycate alone and in combination with fenoterol]. *Monatsschr Kinderheilkd* 1988;136(8):448-52. German.
14. Delnitz D, Rozniecki J, Grabski W. [Comparative evaluation of the effects of sodium cromoglycate and ketotifen on exercise-induced bronchospasm in patients with asthma]. *Pneumonol Pol* 1985;53(4):192-4. Polish.
15. Delnitz D, Rozniecki J. [Pharmacological prevention of exercise-induced bronchospasm in patients with asthma]. *Pneumonol Pol* 1985;53(4):185-91. Polish.
16. Fu YX, Ye ST, Xia LY. [The effect of sodium cromoglycate in the prevention of exercise-induced asthma]. *Zhonghua Jie He He Hu Xi Za Zhi* 1985;24(10):577-9. Chinese.
17. Gehrke I, Bohm E, Sybrecht GW. [Stress-induced asthma—placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two]. *Prax Klin Pneumol* 1986;40(4):129-34. German.
18. Gmur H, Scherrer M. [Protection from exertion-induced bronchial asthma with disodium cromoglycate DSCG cromolyn, lomudal, intal and with ketotifen zaditen. Doubly crossed double-blind study]. *Schweiz Med Wochenschr* 1979;109:881-4. German.
19. Guerin JC, Flandrois R. [A study of berodual protector effect on asthma induced by exercise, by placebo and disolic cromoglycate comparison]. *Rev Mal Respir* 1989;6(Suppl 1):R37. French.

20. Guerin JC, Brambilla C, Godard P, et al. [Prolonged effect against exercise-induced bronchospasm: salmeterol versus sodium cromoglycate]. *Rev Mal Respir* 1992;9(Suppl 1):R27-R30. French.
21. Hertz B, Fuglsang G, Holm EB. [Exercise-induced asthma in children and oral terbutaline. A dose-response relationship study]. *Ugeskr Laeger* 1994;156(39):5693-5. Danish.
22. Jenssen AO. [Broncholytic effects of salbutamol and isoprenaline aerosol given to asthmatics before exercise]. *Tidsskr Nor Laegeforen* 1972;92(16):1104-7. Norwegian.
23. Joppich R. [Comparison of the effects of reproterol, oxitropium bromide, disodium cromoglycate and theophylline in the prevention of exercise-induced asthma in children]. *Atemwegs- und Lungenkrankheiten* 1987;13(9):453-6. German.
24. Koenig P, Abramov A, Godfrey S. [Exercise-induced asthma as an objective criterion for assessing response to disodium cromoglycate]. *Harefuah* 1971;81(3):127-30. Hebrew.
25. Lecheler J, Biberger A, Seligmann C, et al. [Sports therapy in the treatment of pediatric bronchial asthma. Comparison of interval and continuous training]. *Prax Klin Pneumol* 1988;42(7):475-8. German.
26. Magnussen H, Reuss G. [Blockade of exercise-induced bronchial asthma by fenoterol]. *Klin Wochenschr* 1984;62(4):168-74. German.
27. Negele K, Stein D, Grubl A, Bauer CP. [Value of Montelukast in comparison to Nedocromil-NA in exercise-induced Asthma]. *Klin Padiatr* 2000;212(5):S80. German.
28. Petrov VI, Smolenov IV, Alikova OA, et al. [Step-by-step management of bronchial asthma children: step up or step down?] *Pulmonology* 2000;2(C). Russian.
29. Rampulla C, Bruschi C, Zoia MC. [Calcium-antagonists and exercise-induced bronchoconstriction (EIB): immediate and late effects of nifedipine, in comparison with salbutamol and DSCG]. *Folia Allergologica et Immunologica Clinica* 1985;32(4):271-7. Italy.
30. Scherrer M, Zeller C, Kyd K, Geiser M. [Budesonide Pulmicort and exertion-induced asthma]. *Schweiz Med Wochenschr* 1986;116(23):775-81. German.
31. Sienna Monge JJ, Bermejo Guevara MA, Espinola RG, et al. [Effect of heating on FEV-1 in children with asthma challenged with exercise]. *Rev Alerg Mex* 2000;47(2):75-9. Spanish.
32. Sin HL, Jae JS, Sang YL, et al. [The protective effect of inhaled heparin, cromolyn, budesonide, and furosemide on exercise-induced asthma]. *Zhonghua Jie He He Hu Xi Za Zhi* 1998;45(6):1188-98. Korean.
33. Spada EL, Donner CF, Meriggi A, Vecchio C. [Pharmacologic prevention of exercise-induced asthma]. *Minerva Pneumol* 1985;24(2):159-64. Italy.
34. Stemann EA, Weihermann D, Schachoff R. [Prophylactic treatment of exercise-induced asthma]. *Med Welt* 1981;32(24):981-4. German.
35. Todaro A, Rossi A. [Formoterol for the treatment of the asthmatic athletes]. *Med Sport (Roma)* 2002;55(3):189-94. Italian.
36. Vazquez C, Fidalgo I, Virto MC, et al. [Effectiveness of disodium cromoglycate, salbutamol, and ipratropium bromide in the inhibition of exercise-induced bronchospasm]. *An Esp Padiatr* 1984;20(8):756-62. Spanish.
37. Viallat JR, Razzouk H, Boutin C. [A double-blind study of sodium chromoglycate preventive effect of sodium chromoglycate on children with post-exercise asthma]. *Rev Mal Respir* 1985;2(2):111. French.
38. von Berg A, Albrecht B, Darlath W, et al. [Intraindividual randomised double-blind comparison between sodium cromoglycate and reproterol to assess the protective effect of the single drugs and their combination in children with exercise induced asthma]. *Allergologie* 2002;25(11):557-64. German.

Insufficient Data (n = 12)

1. Cekic SS, Filipovic MD, Dimitrijevic OB. Comparison of salbutamol, nedocromil sodium and disodium cromoglycate (DSCG) protective effects in patients with exercise induced bronchoconstriction (EIB). *Eur Respir J* 2002;20(Suppl 38):306S.
2. Coreno AJ, Skowronski ME, Kotaru C, et al. Comparative effects of single doses of anti-leukotrienes and long acting b2- agonists on exercise induced asthma (EIA) [abstract]. *Am J Respir Crit Care Med* 2000;161(3 Suppl):A613.

3. Filipovic M, Kamenov S, Kamenov B, et al. Comparative efficacy of cromolyn and salbutamol in exercise induced asthma. *Eur Respir J Suppl* 1999;14(Suppl 30):1385.
4. Hartley JPR, Davies BH, Nogrady SG. The effect of anticholinergic and H1 receptor blockade on exercise-induced asthma. *Br J Dis Chest* 1980;74:315-6.
5. Johnson CE, Belfield PW, Davis S, et al. Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol. *Thorax* 1986;41(4):290-4.
6. Kendall MJ. The Problem of salmeterol. University Hospital Birmingham NHS Trust 2001 Mar 14;14/03/2002 End date(Unknown):Complete.
7. Lee T, Mant T, Amin D, et al. A single dose (4 mg) of CFC-free nedocromil sodium is effective against exercise-induced bronchoconstriction (EIB) in asthmatic volunteers [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):128S.
8. Ostrom N, Bronsky E, Pearlman D, et al. Effects of the leukotriene-receptor antagonist zafirlukast on exercise-induced asthma in pediatric subjects [abstract]. *Eur Respir J Suppl* 1997;10(Suppl 25):276S.
9. Pearlman D, Greos L, Olson G, et al. A single-dose efficacy comparison of albuterol-HFA-BOI and albuterol-HFA-MDI in adolescents and adults with exercise-induced bronchospasm (EIB) [abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005;B36.
10. Pearlman DS, Ostrom NK, Bronsky EA, et al. Efficacy and safety of zafirlukast (Accolate®) in pediatric patients with exercise-induced asthma. *Ann Allergy Asthma Immunol* 1997;78:113.
11. Shapiro GG, DuHamel TR, Wighton TG, et al. The childhood asthma management program (CAMP): design, rationale, and methods. *Control Clin Trials* 1999;20(1):91-120.
12. Weiner P, Greif J, Fireman E, et al. Bronchodilating effect of cromolyn sodium in asthmatic patients at rest and following exercise. *Ann Allergy* 1984;53(2):186-8.

Duplicate Publication (n = 9)

1. De Benedictis FM, Tuteri G, Niccoli A, et al. The protective effect and the duration of action of cromolyn and nedocromil sodium on exercise-induced asthma in children [abstract]. *Eur Respir J Suppl* 1994;7(Suppl 18):140S.
2. Godfrey S, Konig P. Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children. *Pediatrics* 1975;56(5 suppl):930-4.
3. Hancox RJ, Subbarao P, Kamada D, et al. Beta-agonist tolerance and exercise-induced bronchospasm. *Am J Respir Crit Care Med* 2002;165(Suppl 8):A185.
4. Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. *Am J Respir Crit Care Med* 2002;165(8 Suppl):A185.
5. Johnson O, van Adelsberg J, Pearlman DS, et al. Onset and duration of single-dose protection of montelukast against exercise-induced bronchospasm [abstract]. *J Allergy Clin Immunol* 2005;115(2 Suppl):S11.
6. Patel KR, Tullett WM, Neale MG, et al. Plasma concentrations of sodium cromoglycate given by nebulisation and metered dose inhalers in patients with exercise-induced asthma: relationship to protective effect. *Br J Clin Pharmacol* 1986;21(2):231-3.
7. Pearlman DS, Philip G, Johnson O, et al. Protection against exercise-induced bronchospasm by a single dose of montelukast [abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005;B36.
8. Peroni DG, Piacentini GL, Ressa M, et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. *Pediatr Allergy Immunol* 2002;13(6):434-7.
9. Rachelefsky GS, Tashkin DP, Katz RM, et al. A Comparison of aerosolized atropine, isoproterenol, atropine plus isoproterenol, disodium cromoglycate and placebo in the prevention of exercise-induced asthma. *Chest* 1978;73(6 Suppl):1017-9.

Unable to Retrieve (n = 13)

1. Bach-Mortensen N, Bundgaard A, Schmidt A. Ipratropium (Atrovent) treatment (alone and in combination) in children with exercise-induced asthma. *Postgrad Med J* 1987;63(Suppl 1):11A.
2. Cooper DM, Atlas AB. Effectiveness of single dose pre-exercise treatment with montelukast in children with exercise induced asthma [abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando 2004;A53.
3. Dinh Xuan AT, Campagnon A, Summerton L, et al. Attenuation of exercise-induced asthma but not exercise induced increases in exhaled oxide output by zafirlukast (Accolate™) [abstract]. *Am J Respir Crit Care Med* 1998;157(3 Suppl):A624.
4. Flynn D. Proposal for a series of n of 1 trials of the bronchodilator effect of the Leucotriene receptor antagonist (LTRA) montelukast (ML) in childhood asthma. Barking, Havering and Redbridge Hospitals NHS Trust 2003.
5. GlaxoSmithKline. A study to determine the duration of action of inhaled salmeterol during exercise challenge tests in asthmatic children. [Internet] 2005 July. [Cited 2009 Sept 3]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT00118690>.
6. Gronnerod TA, Hamre HS, Oepen G, et al. Protective effect of single doses of formoterol turbuhaler® 4.5 microgramm and 9 microgramm in children with exercise-induced bronchoconstriction. *Eur Respir J Suppl* 1999;14(Suppl 30):352.
7. Kim JH, Kim BS, Choi SO, et al. Clinical and bronchoprotective effects of montelukast in children with exercise-induced asthma [abstract]. American Thoracic Society 99th International Conference 2003;B036.
8. Morgan M. A comparison of the efficiency of Salmeterol xinafoate with oral salbutamol controlled release against exercise induced asthma in adult asthmatics. University Hospitals of Leicester NHS Trust 1994.
9. Pearlman DS, Rees W, Huang H, et al. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm [abstract]. *Chest* 2006;130(4):163S.
10. Richter K, Jorres RA, Janicki S, et al. Protection against exercise-induced asthma by the inhaled leukotriene D4-receptor antagonist bay X7195 [abstract]. *Am J Respir Crit Care Med* 1998;157(3 Suppl):A409.

11. Silverman M. Management of asthma in schoolchildren: role of montelukast and salmeterol at step 3 of the BTS guidelines: a double blind randomised controlled trial using exercise induced asthma as outcome. To compare the efficacy of two medications currently used for persistent exercise induced asthma in school children 2000.
12. Thio BJ, Slingerland GLM, Nagelkerke AF, et al. Single high dose inhaled fluticasone propionate (FP) reduces exercise induced bronchial obstruction (EIB). *Am J Respir Crit Care Med* 1998;157(3 Suppl):A710.
13. West J. A secondary care based study to examine the effect of salmeterol vs. salbutamol in exercise induced asthma in children 1998.

Appendix E. Studies Investigating Mast Cell Stabilizing Agents

The following 44 studies were included in three systematic reviews and two subsequent publications that investigated mast cell stabilizing agents.⁷²⁻⁷⁵ Six of the studies in this list addressed one or more of the other key questions of this current report; they have been marked with an asterisk (*). Nine studies did not meet the inclusion criteria for this current report; most were excluded because they were not published in English or were not randomized controlled trials. These studies have been marked with a †.

1. Boner AL, Vallone G, Bennati D. Nedocromil sodium in exercise-induced bronchoconstriction in children. *Ann Allergy* 1989;62(1):38-41.
2. Boner AL, Miglioranza P, Piacentini G, et al. Effects of nedocromil sodium pressurized aerosol on exercise challenge using a spacer device and the normal adapter. *Pediatr Asthma Allergy Immunol* 1988;2(3):207-15.
- *3. Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. *J Allergy Clin Immunol* 1989;83(5):882-7.
4. Bundgaard A, Enehjelm SD, Schmidt A. A comparative study of the effects of two different doses of nedocromil sodium and placebo given by pressurized aerosol in exercise-induced bronchoconstriction. *Allergy* 1988;43(7):493-6.
- *5. Bundgaard A, Rasmussen FV, Madsen L. Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets. *Allergy* 1980;35(8):639-45.
6. Bundgaard A, Buch D, Schmidt A, et al. Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder. *Eur J Respir Dis Suppl* 1983;130:36-41.
7. Bundgaard A, Schmidt A. Pretreatment of exercise-induced asthma by disodium cromoglycate and fenoterol. *Eur J Respir Dis Suppl* 1983;128(Pt 2):521-5.
8. Bundgaard A. Exercise-induced asthma. *Eur J Respir Dis* 1980;68(Suppl 143):51-6.
9. Chudry N, Correa F, Silverman M. Nedocromil sodium and exercise induced asthma. *Arch Dis Child* 1987;62(4):412-4.
10. Clarke PS, Ratowsky DA. Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. *Ann Allergy* 1990;64(2 Pt 2):187-90.
11. Comis A, Valletta EA, Sette L, et al. Comparison of nedocromil sodium and sodium cromoglycate administered by pressurized aerosol, with and without a spacer device in exercise-induced asthma in children. *Eur Respir J* 1993;6(4):523-6.
12. De Benedictis FM, Tuteri G, Niccoli A, et al. The effect of cromolyn sodium and nedocromil sodium administered by a pressurized aerosol with a spacer device on exercise-induced asthma in children. *Mediators Inflamm* 1994;3(Suppl 1):S35-7.
13. De Benedictis FM, Tuteri G, Bertotto A, et al. Comparison of the protective effects of cromolyn sodium and nedocromil sodium in the treatment of exercise-induced asthma in children. *J Allergy Clin Immunol* 1994;94(4):684-8.
14. De Benedictis FM, Tuteri G, Pazzelli P, et al. Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children. *J Allergy Clin Immunol* 1995;96(4):510-4.
- †15. De Benedictis FM, Tuteri G, Pazzelli P, et al. Combination drug therapy for the prevention of exercise-induced bronchoconstriction in children. *Ann Allergy Asthma Immunol* 1998;80(4):352-6.
16. Debelic M. Nedocromil sodium and exercise-induced asthma in adolescents. *Eur J Respir Dis* 1986;69(Suppl 147):266-7.
17. Debelic M, Hertel G, Konig J. Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma. *Ann Allergy* 1988;61(1):25-9.
- *18. Dorward AJ, Patel KR. A comparison of ketotifen with clemastine, ipratropium bromide and sodium cromoglycate in exercise-induced asthma. *Clin Allergy* 1982;12(4):355-61.
- †19. Gehrke I, Bohm E, Sybrecht GW. [Stress-induced asthma--placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two]. *Prax Klin Pneumol* 1986;40(4):129-34. German.

- †20. Godfrey S, Konig P. Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children. *Pediatrics* 1975;56(5 Suppl):930-4.
- *21. Godfrey S, Konig P. Inhibition of exercise-induced asthma by different pharmacological pathways. *Thorax* 1976;31(2):137-43.
22. Henriksen JM. Effect of nedocromil sodium on exercise-induced bronchoconstriction in children. *Allergy* 1988;43(6):449-53.
23. Konig P, Hordvik NL, Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma EIA in adults. *J Allergy Clin Immunol* 1987;79(1):64-8.
24. Morton AR, Ogle SL, Fitch KD. Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise-induced asthma. *Ann Allergy* 1992;68(2):143-8.
- *25. Neijens HJ, Wesselius T, Kerrebijn KF. Exercise-induced bronchoconstriction as an expression of bronchial hyperreactivity: a study of its mechanisms in children. *Thorax* 1981;36(7):517-22.
26. Novembre E, Frongia G, Lombardi E, et al. The preventive effect of nedocromil or furosemide alone or in combination on exercise-induced asthma in children. *J Allergy Clin Immunol* 1994;94(2 Pt 1):201-6.
27. Novembre E, Frongia GF, Veneruso G, et al. Inhibition of exercise-induced asthma EIA by nedocromil sodium and sodium cromoglycate in children. *Pediatr Allergy Immunol* 1994;5(2):107-10.
28. Obata T, Matsuda S, Akasawa A, et al. Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. *Ann Allergy* 1993;70(2):123-6.
29. Oseid S, Mellbye E, Hem E. Effect of nedocromil sodium on exercise-induced bronchoconstriction exacerbated by inhalation of cold air. *Scand J Med Sci Sports* 1995;5(2):88-93.
- †30. Pichaiapat V, Tongpenyai Y, Nerntong T, et al. The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children. *J Med Assoc Thai* 1995;78(10):505-8.
31. Roberts JA, Thomson NC. Attenuation of exercise-induced asthma by pretreatment with nedocromil sodium and minocromil. *Clin Allergy* 1985;15(4):377-81.
- †32. Rohr AS, Siegel SC, Katz RM, et al. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. *Ann Allergy* 1987;59(2):107-9.
33. Shaw RJ, Kay AB. Nedocromil, a mucosal and connective tissue mast cell stabilizer, inhibits exercise-induced asthma. *Br J Dis Chest* 1985;79(4):385-9.
34. Sinclair DG, Winfield CR. Attenuation of exercise induced asthma by nedocromil sodium and sodium cromoglycate. *J R Army Med Corps* 1990;136(2):105-6.
- †35. Spada EL, Donner CF, Meriggi A, et al. [Pharmacologic prevention of exercise-induced asthma]. *Minerva Pneumol* 1985;24(2):159-64. Italian.
- †36. Svenonius E, Arborelius M, Wiberg R, et al. A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon CFC inhaler in children with exercise-induced asthma. *Allergy* 1994;49(6):408-12.
37. Thomson NC, Roberts JA. Nedocromil sodium attenuates exercise-induced asthma. *Eur J Respir Dis* 1986;69(Suppl 147):297-8.
- *38. Thomson NC, Patel KR, Kerr JW. Sodium cromoglycate and ipratropium bromide in exercise-induced asthma. *Thorax* 1978;33(6):694-9.
39. Todaro A, Faina M, Alippi B, et al. Nedocromil sodium in the prevention of exercise-induced bronchospasm in athletes with asthma. *J Sports Med Phys Fitness* 1993;33(2):137-45.
- *40. Tullett WM, Patel KR, Berkin KE, et al. Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma. *Thorax* 1982;37(10):737-40.
- †41. Vazquez C, Fidalgo I, Virto MC, et al. [Effectiveness of disodium cromoglycate, salbutamol, and ipratropium bromide in the inhibition of exercise-induced bronchospasm]. *An Esp Pediatr* 1984;20(8):756-62. Spanish.
42. Vilsvik J, Schaanning J. A comparative study of the effect of three doses of nedocromil sodium and placebo given by pressurized aerosol to asthmatics with exercise-induced bronchoconstriction. *Ann Allergy* 1988;61(5):367-70.
43. Woolley M, Anderson SD, Quigley BM. Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma. *Chest* 1990;97(1):39-45.
44. Zanconato S, Baraldi E, Santuz P, et al. Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children. *Pediatr Pulmonol* 1990;8:240-4.

The following 33 studies investigated mast cell stabilizing agents but were not included in three previous systematic reviews.

1. Bar-Yishay E, Gur I, Levy M, et al. Duration of action of sodium cromoglycate on exercise induced asthma: comparison of 2 formulations. *Arch Dis Child* 1983;58(8):624-7.
2. Bauer CP. The protective effect of nedocromil sodium in exercise-induced asthma. *Eur J Respir Dis* 1986;69(Suppl 147):252-4.
3. Ben-Dov I, Bar-Yishay E, Godfrey S. Heterogeneity in the response of asthmatic patients to pre-exercise treatment with cromolyn sodium. *Am Rev Respir Dis* 1983;127(1):113-6.
4. Bianco S, Moavero E, Robuschi M, et al. Prevention of PGF2alpha induced bronchoconstriction by disodium cromoglycate in asthmatic patients. *IRCS Med Sci Clin Med* 1976;4(4):147.
5. Brooks CD, Nelson AL, Metzler C. Attenuation of protection with repeated cromolyn dosing before exercise challenge in subjects with asthma. *J Clin Pharmacol* 1986;26(2):91-6.
6. Bundgaard A, Bach-Mortensen N, Schmidt A. The effect of sodium cromoglycate delivered by Spinhaler and by pressurized aerosol on exercise-induced asthma in children. *Clin Allergy* 1982;12(6):601-5.
7. Calvayrac P, Leophonte P, Fuseiller A, et al. Reduction of bronchial hyperreactivity and exercise-induced bronchospasm in children treated for one month with a pressurized sodium cromoglycate aerosol. *Curr Ther Res Clin Exp* 1991;49(3):422-35.
8. Corkey C, Mindorff C, Levison H, et al. Comparison of three different preparations of disodium cromoglycate in the prevention of exercise-induced bronchospasm: a double-blind study. *Am Rev Respir Dis* 1982;125(6):623-6.
9. Dahl R, Henriksen JM. Effect of oral and inhaled sodium cromoglycate in exercise-induced asthma. *Allergy* 1980;35(4):363-5.
10. Dahl R, Henriksen JM. Inhibition of exercise-induced bronchoconstriction by nebulised sodium cromoglycate in patients with bronchial asthma. *Scand J Respir Dis* 1979;60(2):51-5.
11. De Cree J, Verhaegen H, Geukens H, et al. Exercise-induced asthma. The comparative acute effects of oxatomide, placebo and sodium cromoglycate. *Clin Trials J* 1980;17(3):84-91.
12. De Fuccio MB, Neder JA, Dal CS, et al. Rapidly-incremental versus constant work rate protocols to investigate exercise-induced bronchospasm [abstract]. *American Thoracic Society 99th International Conference* 2003;B118.
13. Fu YX, Ye ST, Xia LY. The effect of sodium crompromate in the prevention of exercise-induced asthma. *Asian Pac J Allergy Immunol* 1985;3(2):147-50.
14. Jones RM, Horn CR, Lee DV, et al. Bronchodilator effects of disodium cromoglycate in exercise-induced bronchoconstriction. *Br J Dis Chest* 1983;77(4):362-9.
15. Morton AR, Ogle SL, Fitch KD. A comparison of nedocromil sodium, sodium cromoglycate and a placebo in the prevention of exercise induced asthma. *Sports Med News* 1991;9(1):4-5.
16. Morton AR, Fitch KD. Sodium cromoglycate BP in the prevention of exercise-induced asthma. *Med J Aust* 1974;2(5):158-62.
17. Patel KR, Wall RT. Dose-duration effect of sodium cromoglycate aerosol in exercise-induced asthma. *Eur J Respir Dis* 1986;69(4):256-60.
18. Patel KR, Berkin KE, Kerr JW. Dose-response study of sodium cromoglycate in exercise-induced asthma. *Thorax* 1982;37(9):663-6.
19. Patel KR. Sodium cromoglycate and verapamil alone and in combination in exercise induced asthma. *Br Med J (Clin Res Ed)* 1983;286(6365):606.
20. Rasmussen FV, Madsen L, Bundgaard A. Combined effect of an anticholinergic drug ipratropium bromide and disodium cromoglycate in exercise induced asthma. *Scand J Respir Dis Suppl* 1979;103:159-62.
21. Robuschi M, Riva E, Fucella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist SK&F 104353. A double-blind study versus disodium cromoglycate and placebo. *Am Rev Respir Dis* 1992;145(6):1285-8.
22. Schoeffel RE, Anderson SD, Lindsay DA. Sodium cromoglycate as a pressurised aerosol vicrom in exercise-induced asthma. *Aust N Z J Med* 1983;13(2):157-61.

23. Shaw RJ, Kay AB. Nedocromil sodium, a mucosal and connective tissue mast cell stabilizer, inhibits exercise-induced asthma. *Eur J Respir Dis* 1986;69(Suppl 147):294-6.
24. Silverman M, Turner WM. Exercise induced asthma: response to disodium cromoglycate in skin-test positive and skin-test negative subjects. *Clin Allergy* 1972;2(2):137-42.
25. Silverman M, Connolly NM, Balfour-Lynn L, et al. Long-term trial of disodium cromoglycate and isoprenaline in children with asthma. *Br Med J* 1972;3(823):378-81.
26. Sly RM. Effect of cromolyn sodium on exercise-induced airway obstruction in asthmatic children. *Ann Allergy* 1971;29(7):362-6.
27. Storms W. Double-blind, placebo-controlled study of single doses of chlorofluorocarbon (CFC) and CFC-free cromolyn sodium for exercise-induced bronchoconstriction. *Curr Ther Res Clin Exp* 1999;60(12):629-37.
28. Tullett WM, Tan KM, Wall RT, et al. Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma. *Thorax* 1985;40(1):41-4.
29. Umeno E, Nishima S. Investigation of the inhibiting mechanism of disodium cromoglycate in exercise-induced bronchospasm. *Arerugi* 1985;34(5):320-8.
30. Valero A, Garrido E, Malet A, et al. Exercise-induced asthma prophylaxis in athletes using inhaled nedocromil sodium. *Allergol Immunopathol (Madr)* 1996;24(2):81-6.
31. Viallat JR, Razzouk H, Edmond F. Double-blind study of the preventive action of sodium cromoglycate on the exercise induced bronchospasm in children. *Rev Fr Allergol Immunol Clin* 1986;26(3):121-4.
32. Vidgren M, Silvasti M, Vidgren P, et al. Physical properties and clinical efficacy of two sodium cromoglycate inhalation aerosol preparations. *Acta Pharm Nord* 1991;3(1):1-4.
33. Weiner P, Saaid M, Reshef A. Isotonic nebulized disodium cromoglycate provides better protection against methacholine- and exercise-induced bronchoconstriction. *Am Rev Respir Dis* 1988;137(6):1309-1.